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ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS 
WITH MULTIPLE SCLEROSIS IN THE OUTPATIENT SETTING: A 
MIXED METHODS STUDY 
HELEN WILLIS 
September 2018 
Health-related quality of life (HRQoL) is often adversely affected in multiple sclerosis 
(MS). It has been extensively researched but to date there is little published describing 
its assessment in routine clinical practice. This study examines whether there is a role 
for the assessment of HRQoL in patients with MS in daily clinical practice. The 
research was undertaken at two NHS hospital outpatient departments in the UK. 
The first phase of this explanatory sequential mixed methods study was designed to 
gather information on the physical and psychological dimensions of HRQoL using the 
Multiple Sclerosis Impact Scale version 2 (MSIS-29v2) in a longitudinal prospective 
panel study of 311 patients. The impact of interventions on HRQoL was measured 
through subsequent assessments. In the second phase, a grounded theory-based 
approach was followed. Information concerning the views and experiences of fifteen 
patient-participants and two healthcare professionals of using a HRQoL measure 
within a routine outpatient consultation was gathered through semi-structured 
interviews and explored with thematic analysis. 
The results support the use of the MSIS-29v2 in the outpatient setting as a means of 
facilitating the discussion of HRQoL issues for which interventions may be offered, 
and heightening healthcare professionals’ awareness of patient problems. Shared 
decision-making was promoted and an awareness of the different levels of 
involvement patients wanted in their care revealed. Those interviewed valued the use 
of the MSIS-29v2, describing how they became more aware of the impact that MS 
was having on them; subsequently many reported that they became more active 
participants in the management of their MS. A change in HRQoL following 
interventions was not consistently demonstrated, possibly due to the heterogeneity of 
MS and short time scale of the research. However, the research demonstrates the value 
to both patients and healthcare professionals of using a HRQoL measure in daily 
clinical practice. 
Keywords: Multiple sclerosis, Quality of life, Health-related quality of life, Health-
related quality of life measures. 
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1.1 PERSONAL AND PROFESSIONAL EXPERIENCE 
As a clinical nurse specialist for multiple sclerosis (CNS MS) I have always 
endeavoured to give high quality patient-centred care to my patients. On commencing 
work as a CNS MS in 2007, within an acute care setting, I had minimal knowledge of 
multiple sclerosis (MS). Over the last eleven years I have attended courses, 
conferences and extensively read around the subject to develop my knowledge of MS. 
When exploring topics for this research it was important to select a topic of interest to 
both myself and my colleagues. It is my belief that healthcare should aim to optimise 
health-related quality of life (HRQoL). Hence, I came to this project with a particular 
set of experiences which have informed this research. Reflecting on my practice whilst 
working in the field of MS, I recognised that the experiences of patients living with 
MS and the impact of the condition are not always easily explored during outpatient 
appointments. My clinical expertise, as suggested by Edwards and Chalmers (2002) 
was the very reason that I initiated this topic of research. 
When selecting the area for my research, I considered there to be a gap in my 
professional practice and in that of the neurology department where I work. Despite 
assessment of patients during an outpatient consultation, no formal appraisal of 
HRQoL is made; research suggests such assessments are essential to determine the 
impact of a disease as well as potential effects of treatment interventions (Visschedijk, 
et at., 2004; Solari, 2005; Amato and Portaccio, 2007; Turpin, et al., 2007; 
Baumstarck, et al., 2013). During an outpatient appointment most patients 
communicate their health needs and problems; following discussions of possible 
treatment options an informed decision is reached by the patient concerning their 
future health care. Some patients however divulge little or no information which can 
make it difficult to determine whether they have any issues for which interventions 
could be considered and appropriate care offered. Consequently, I believed some 
clinic appointments were not as effective and structured as they could be and that I 
was not always offering the best care to my patients. Thus, I determined I wished to 
explore whether the use of an appropriate HRQoL measure could potentially have a 
positive impact on the care and support of patients with MS and improve the patient 
experience. 
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1.2 RATIONALE & BACKGROUND INFORMATION 
The chronic progressive condition multiple sclerosis is characterised by numerous 
symptoms, all of which can adversely affect the health-related quality of life of both 
patients and their families. As one of the leading causes of neurological disability in 
young adults, Wu, et al. (2007) suggest that MS has enormous implications for the 
current and future health-related quality of life of people diagnosed with this condition. 
It is well documented that many people who live with a long-term illness, such as 
rheumatoid arthritis or multiple sclerosis, may experience a decline in their quality of 
life (Rudick, et al., 1992; Somerset, Sharp and Campbell, 2002; Mackenzie, et al., 
2014). 
Health-related quality of life is considered to be an important measure of health and 
disease impact in patients with multiple sclerosis as MS symptoms affect many aspects 
of everyday living. In 1988 Slevin, et al. (1988) suggested that inclusion of HRQoL 
assessment in routine care should be considered essential, as health professionals often 
underestimate the difficulties people have with activities of daily living and social 
routines. This view was reiterated by Bandari, et al. (2010) who proposed that, as MS-
specific HRQoL tools have the potential to discern true changes in an MS patient’s 
HRQoL, they should be routinely included in the healthcare programme of every 
patient, the information obtained influencing the health of the patient through targeted 
healthcare interventions. Beiske, et al. (2012) also recognised measurement of HRQoL 
as an important consideration in the assessment and management of patients with MS, 
describing how instruments have been developed to help healthcare providers 
accurately and completely assess an MS patient’s HRQoL, particularly when 
determining disease-related aspects likely to impact on patients’ lives. I would argue 
that assessing HRQoL is an essential part of a comprehensive evaluation of a patient. 
Within the literature many views are presented concerning the goals of healthcare in 
long-term conditions. Brunet, et al. (1996), Lankhorst, et al. (1996), Solari, et al. 
(1999) and Rotstein, et al. (2000) describe how in the management of incurable 
chronic conditions, such as multiple sclerosis, the goal of healthcare is often to 
optimise a patient’s health-related quality of life and improve patients’ well-being. 
Carr, Gibson and Robinson (2001) go further suggesting that a primary aim of 
treatment in chronic disease should be the enhancement of quality of life by 
minimising the impact of the disease, a view echoed by Miller (2002) who also 
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suggests that the goal of treatments for MS should be to reduce disease impact on 
patients’ lives and to assure that interventions do no harm. Wu, et al. (2007) suggest 
that this may be achieved by maximising function, thereby enhancing satisfaction with 
life. However, Bandari, et al. (2010) who advocate that long-term preservation of 
HRQoL should be considered a critical marker of therapeutic success, and Beiske, et 
al. (2012) who describe how maintenance of patients’ HRQoL is an important 
treatment goal, are arguably more realistic in their views due to the chronic progressive 
nature of MS. Alternatively, Kuspinar, Rodriguez and Mayo (2012) suggest that the 
management of MS is rehabilitative or palliative as the condition is incurable. Given 
these different points of view it is apparent that HRQoL as an outcome measure may 
be used to determine both clinical success and also as a palliative goal. 
Quality of life is a subjective concept and thus Skevington (1999) argues the best 
person to assess it is the individual themselves. A measure of the success in reaching 
any of the goals described above can only be made with direct information from 
patients about how they experience the illness and the effects of treatments (Miller, 
2002). This view is corroborated by Riazi, et al. (2003a) who describes an increasing 
recognition that health care should be evidence-based and that healthcare evaluations 
should incorporate the patient’s perspective. HRQoL measurement allows this as such 
assessments are multidimensional and include physical, psychological, social 
functioning, and well-being components (Santana and Feeny, 2009). 
Whilst Mitchell, et al. (2005) and Solari (2005) asserted that measures of HRQoL were 
being used with increasing frequency in the assessment of multiple sclerosis in routine 
clinical practice as an outcome measure for assessing disease progression, evaluating 
treatment and managing care, current literature indicates that their use in clinical 
practice as opposed to research is still uncommon. This is despite the extent of the 
evidence which demonstrates that the use of a measure of health-related quality of life 
in routine clinical practice has the potential to improve the quality of healthcare and 
outcomes by promoting detection of physical and psychological problems and, 
monitoring disease and treatment (Greenhalgh and Meadows, 1999; Lohr and 
Zebrack, 2009; Santana and Feeny, 2009). In 2012, the work of Snyder, et al. (2012) 
described how patients’ reports on their functioning and well-being were still only 
rarely collected in a standardised fashion in routine clinical practice. Indeed, the 
current paucity of literature regarding assessment of HRQoL of patients with MS 
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during routine clinical practice and also on patients’ views concerning such 
assessments highlights the existence of a theory/practice gap in nursing knowledge 
regarding the quality of life of patients with MS. 
The growing numbers of individuals suffering from MS highlights the need for further 
research to gain a greater understanding of this condition. At a time when no cure has 
been developed, the best option for optimising health-related quality of life is by 
ensuring that patients are offered appropriate treatments and interventions thereby 
enabling them to successfully adjust to and cope with living with MS. Research aimed 
at identifying the impact of MS on people with the disease, and subsequently offering 
successful interventions to optimise quality of life, is therefore timely and important. 
This study has the potential to demonstrate that using a HRQoL measure in routine 
clinical practice can improve the care of patients with MS. 
1.3 ORIGINALITY 
For many years there has been increasing interest in the use of health-related quality 
of life assessment in daily clinical practice (Detmar, et al., 2002) to determine the 
significance of the impact of MS on the lives of patients. Many authors including Gray, 
McDonnell and Hawkins (2009) suggest that various generic and disease-specific 
measures may be used to measure HRQoL in patients. Whilst van Winsen, et al. (2010) 
describe how the ability to detect improvement using HRQoL measures is sparsely 
studied, Bandari, et al. (2010) suggest that further research is needed to better 
understand the limitations of MS-specific HRQoL tools in clinical research and 
practice. Baumstarck, et al. (2013, p.4) state that, ‘to our knowledge there are no 
studies that have explored the effect of assessing QoL in MS care management’. This 
research explores these issues from the perspective of both those with MS and 
healthcare professionals in the outpatient setting of a district hospital. 
Although there are a growing number of studies concerning the area of assessment of 
HRQoL in patients with MS these predominantly focus on the psychometric properties 
of HRQoL measures or factors affecting HRQoL. However, there appears to be no 
published work describing the benefit to patients with MS, from their perspective, of 
using such instruments in routine clinical practice, and little research concerning 
longitudinal assessment of HRQoL in routine clinical practice. Thus, I determined 
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there to be scope for clinically relevant research into the assessment of HRQoL and 
its value to people with MS, leading in part, to better overall care and optimised 
HRQoL for those with MS. No qualitative studies collecting information from the 
perspective of people with MS were retrieved. Such studies could offer an insight into 
the advantages and disadvantages of assessment of HRQoL, helping guide both 
researchers and clinicians when deciding whether to include a measure in routine care. 
This gap provided a rationale for the second phase of this research, when the 
perspective of patients with MS was explored. This study is the first to consider the 
assessment of HRQoL in MS from a patient perspective. It is unique in its focus on an 
in-depth investigation into the patient experience of HRQoL assessment. 
1.4 AIMS AND OBJECTIVES OF THE STUDY 
The aim of this study was to explore and subsequently understand and evaluate 
whether there is a role for assessment of HRQoL in patients with MS in daily clinical 
practice. 
The objectives were: 
• To determine if it is feasible to assess HRQoL in daily practice in the outpatient 
setting. 
• To determine if the results of HRQoL assessment can be used to inform 
therapeutic interventions. 
• To assess the impact of interventions on HRQoL in patients with MS through 
the assessment of HRQoL. 
• To explore patients’ opinions about HRQoL assessment during an outpatient 
appointment. 
These objectives gave rise to the research questions listed below. 
1.5 RESEARCH QUESTIONS 
The research questions are broad as the literature review identified a lack of evidence 
concerning the use of a measure for assessing HRQoL in daily clinical practice, and 
the patient perspective of such an assessment. 
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The key question for this research is: 
• Is there a role for the assessment of health-related quality of life in patients 
with multiple sclerosis in daily clinical practice? 
This gives rise to the following: 
• Is assessment of HRQoL in patients with MS feasible in daily clinical practice? 
• Can the results of HRQoL assessment be used to inform therapeutic 
interventions? 
• Can a HRQoL measure detect change in HRQoL after the implementation of 
interventions? 
• Does assessment of HRQoL with an appropriate measure make a meaningful 
difference to patients? 
1.6 THESIS STRUCTURE 
This chapter provides the background to the thesis, describes its originality and lists 
the research questions. As not everyone is familiar with MS and its ramifications an 
overview of this condition is given in chapter 2. Within chapter 3, the literature 
pertaining to the research is presented thereby providing context for assessment of 
HRQoL in the outpatient setting. As a result of my literature review, I discuss my 
underlying conceptual framework. Chapter 4 describes the methodology, and 
subsequently the methods for the two phases of this mixed methods study. The results 
of the two phases are presented and discussed in chapters 5 and 6. Subsequently, in 
chapter 7 the findings are drawn together and discussed in relation to the research 
questions. Finally, conclusions are presented in chapter 8. 
.
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2.1 INTRODUCTION 
Within this chapter key information about multiple sclerosis is presented and 
discussed. Firstly, a definition of multiple sclerosis is given, the prevalence of MS 
identified and the different aetiological theories for why individuals develop the 
condition considered. Additionally, the process of diagnosis is described and some of 
the difficulties patients encounter in receiving a diagnosis highlighted. The different 
types of multiple sclerosis are discussed, symptoms described, and a brief introduction 
to the impact of MS given. Finally, treatment options are presented. Thus, this chapter 
introduces the research, highlighting key information about MS essential for 
understanding the development, design and implementation of this research. 
2.2 DEFINITION OF MULTIPLE SCLEROSIS 
Multiple sclerosis is an acquired chronic immune-mediated inflammatory condition of 
the central nervous system, affecting both the brain and spinal cord (NICE CG186, 
2014). It is an incurable progressive condition and is the most common disabling 
condition affecting young adults (Noseworthy, et al., 2000; Compston and Coles, 
2002; Morales-Gonzáles, et al., 2004). 
2.3 PREVALENCE 
Linked with both the genetic and environmental risk factors, the prevalence of MS 
varies around the world. It is found most commonly in countries populated by those 
of primarily European ancestry, such as Ireland, the United Kingdom, South East 
Australia, New Zealand, Sweden, Finland and Southern Canada/Northern United 
States (Compston and Coles, 2008). MS is also more common in countries that are 
further away from the equator. Migration from low-risk region to high-risk regions 
before the age of fifteen is associated with an increased risk (Compston and Coles, 
2008). Whilst there are approximately 100,000 people with MS in the UK (MS 
Society, 2017; MS Trust, 2017), it is estimated that more than 2.5 million people are 
affected worldwide (Compston and Coles, 2008). These numbers are increasing, with 
more than 100 people being diagnosed per week in the UK (MS Society, 2018). About 
1 in 600 people in the UK will develop MS (MS Trust, 2017). The average prevalence 
across the UK is approximately 125 per 100 000 (Giovannoni, 2004). 
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MS is most often diagnosed between the ages of 20 and 40 (Simone, et al., 2002) but 
can be diagnosed in both younger and older people, including children. It is more 
common in women than men, with research suggesting that the MS prevalence ratio 
of women to men has increased markedly during the last decades (2.3–3.5:1), 
indicating a true increase in MS among women but not men (Compston and Coles, 
2002; Confavreux and Compston, 2005; Orton, et al., 2006; Ahlgren, Odén, and 
Lycke., 2011). 
2.4 WHO DEVELOPS MS 
Although MS is not strictly a hereditary disease, there is an increased chance of MS 
developing in close relatives of affected people. For example, a person with a mother 
or father with a diagnosis of MS has a 1 in 67 chance of developing MS (MS Trust, 
2017); someone with a brother or sister with MS has a risk of 1 in 37 of developing 
MS (MS Trust, 2017). These figures compare with a risk of 1 in 600 in the general 
population. 
2.5 AETIOLOGY AND PATHOPHYSIOLOGY 
Whilst the aetiology of MS is unknown, and its parthenogenesis poorly understood, 
research suggests that a combination of genetic, infectious and environmental factors 
may play a role in its development (Noseworthy, et al., 2000; Burgess, 2010a; 
Giovannoni, Foley and Brandes, 2012). 
MS is characterised by the development of demyelinating lesions (destruction of 
myelin around the nerve fibres) as shown in Figure 1 in the brain and spinal cord, 
which ultimately result in long-term disability. An auto-immune response causes 
inflammation and subsequently demyelination along the axon of neurons, leading to 
axonal loss and brain atrophy (Compston and Coles, 2002). As damage to the neurons 
can occur anywhere throughout the central nervous system, people with MS 
experience a wide variety of symptoms and often marked physical disability. 
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Figure 1 Damage to the myelin sheath 
(Natural Knowledge 24/7, 2018) 
It is not known why some people develop MS whilst other do not. It is believed that 
in those people genetically predisposed to MS, an abnormal immune response to 
environmental triggers results in immune-mediated acute, and then chronic, 
inflammation. The initial phase of inflammation is followed by a phase of progressive 
degeneration of the affected cells in the nervous system. There is increasing evidence 
that low levels of vitamin D and smoking are two of the environmental factors that 
may result in the development of MS. 
2.6 DIAGNOSIS 
Multiple sclerosis can be difficult to diagnose as it is a complex condition with many 
different symptoms. There is no single definitive test for MS (Calabresi, 2004). 
Diagnosis is primarily one of exclusion as all the symptoms of MS may also be 
symptoms of other conditions. Diagnosis involves taking a medical history from the 
patient to identify past and present symptoms and performing a clinical examination. 
Diagnostic tests including an MRI scan, blood tests and possibly a lumbar puncture 
are carried out. Diagnosis is dependent on identifying multiple central nervous system 
lesions over time using an MRI scan. The white spots in Figure 2 indicate lesions in 
the brain. 
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Figure 2 Brain MRI showing active lesions 
(Pietrangelo, 2017) 
 Diagnostic Difficulties 
The onset of MS may be insidious or sudden (Calabresi, 2004). It is often hard to 
pinpoint exactly when MS begins, as the early signs and symptoms can be very minor, 
such that a person may not consider seeking medical advice. Hence, it is not 
uncommon for a definitive diagnosis to take several months, or even longer. 
Sometimes a ‘watch and wait’ approach is required to see how symptoms develop as 
this can help distinguish MS from the other possibilities. This can be very frustrating 
and worrying for patients. Sufferers often describe a confusing and short-lived array 
of symptoms, which often cannot be observed directly by health professionals. 
Furthermore, these symptoms can fluctuate rapidly. The differing symptoms may have 
been experienced over many years and have often reduced or settled. For some people 
the symptoms may have seemed unimportant. Sometimes there seem to be other very 
reasonable explanations. For example, being incredibly tired could be due to a new 
baby in the family; stumbling more could be due to getting older or wearing in a new 
pair of shoes. This may lead to misdiagnosis. For other people there will be a sudden 
more severe attack which demands hospital attention; a diagnosis of MS may follow 
very quickly, perhaps within days. Some people will be told that the cause of their 
symptoms cannot be found. This can be hard to accept, and it may be years before the 
correct diagnosis of MS can be given. The use of magnetic resonance imaging has 
however enabled the diagnosis of MS to become quicker and more accurate. 
Lesions 
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2.7 CLASSIFICATION OF MS 
For the purposes of this research MS was classified into four groups: relapsing-
remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS 
(PPMS) and benign MS. Each of these groups is described below. Rapidly evolving 
severe relapsing-remitting multiple sclerosis (RES) is briefly discussed as having this 
type of MS influences the choice of drugs for which patients may be eligible. 
 Relapsing-Remitting MS (RRMS) 
Approximately 80-85% of people with MS are diagnosed with relapsing-remitting MS 
(Weinshenker, et al., 1989b; Noseworthy, et al., 2000; Confavreux and Vukusic, 2006; 
Compston and Coles, 2008; Tremlett, et al., 2010). RRMS is generally diagnosed 
between the ages of 20 and 40. Approximately three times as many women as men are 
diagnosed with RRMS. It is characterised by episodes of acute neurological 
dysfunction (relapses, attacks or exacerbations) followed by by periods of good or 
complete recovery - a remission (Figure 3). The Association of British Neurologists 
(ABN, 2009) guidelines define a relapse: 
‘A relapse is defined as the onset of new symptoms or the worsening of 
pre-existing symptoms attributable to demyelinating disease lasting for 
more than 24 hours and preceded by improving or stable neurological 
status for at least 30 days from the onset of the previous relapse in the 
absence of infection, fever or significant metabolic disturbance’. 
The symptoms of neurological dysfunction increase over a few days to several weeks 
before reaching a maximum. Relapses may persist for weeks or months and can vary 
in their level of intensity. Remission occurs once the symptoms settle down. A relapse 
may or may not result in disability; typically, recovery is most rapid and complete in 
the early stages of the disease. 
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Figure 3 Pattern of relapsing-remitting MS 
(MS Trust, 2018) 
The frequency of relapses, the severity of symptoms experienced and the length of 
time between attacks are unpredictable. It can be difficult to determine what is a 
fluctuation in symptoms (a day-to-day worsening or improvement) and what is a 
relapse. The rate of relapses rarely exceeds 1.5 per year (Compston and Coles, 2008). 
Although recovery from relapses may become less complete over time as some 
residual damage to the myelin may result (Compston and Coles, 2002) the level of 
disability will remain largely stable between relapses. 
 Secondary Progressive MS (SPMS) 
Approximately 58% of people with RRMS will eventually enter a progressive phase 
known as secondary progressive MS (SPMS) (Weinshenker, et al., 1989a; Confavreux 
and Vukusic, 2006). The median time to develop SPMS is nineteen years from 
diagnosis (Tremlett, Zhao and Devonshire, 2008). SPMS is characterised by 
increasing disability, rather than by relapses followed by recovery as shown in Figure 
4 (Weinshenker, et al., 1989a; Lublin and Reingold, 1996). Most people with 
secondary progressive MS don't tend to recover completely from a relapse. People's 
experience of SPMS can vary widely. Some people find that the increase or 
progression of disability is very gradual, whilst for others it can occur more quickly. 
SPMS can be hard to diagnose; neurologists will look for at least six months of clear 
progression before they use the term ‘secondary progressive’. 
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Figure 4 Disability progression in secondary progressive MS 
(MS Trust, 2018) 
A small number of people are diagnosed with secondary progressive MS from the 
outset (MS Society, 2018); these people may have experienced relapses in the past 
which were either mild or their significance missed. Alternatively, they may have 
lesions in areas of the brain or spinal cord that do not give rise to any symptoms. 
 Rapidly Evolving Severe Relapsing-Remitting MS (RES) 
This is a less common form of relapsing-remitting MS in which a person with MS has 
two or more disabling relapses in one year and evidence of increasing numbers of 
lesions on two consecutive MRI scans. The term is used in relation to the eligibility 
for two disease-modifying drugs Natalizumab (Tysabri) and Fingolimod (Gilenya). 
 Primary Progressive MS (PPMS) 
Approximately 10-20% of people with MS are diagnosed with primary progressive 
MS which is characterised by a gradual progressive clinical course; disability 
increases from the outset (Noseworthy, et al., 2000). 
PPMS is typically diagnosed in people in their forties or fifties but can be diagnosed 
earlier or later than this. There is a similar incidence among men and women 
(Noseworthy, et al., 2000). From onset individuals experience a continual worsening 
of symptoms with no distinct relapses or remissions (Figure 5), the patient’s symptoms 
may eventually level off; in others, they may continue to worsen (MS Trust, 2017). 
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Figure 5 Typical pattern of primary progressive MS 
(MS Trust, 2018) 
People with PPMS often experience many of the same symptoms as those with RRMS. 
PPMS is associated with chronic, debilitating symptoms that often affect the 
individual’s most productive years and everyday life (Compston and Coles, 2008; 
Zwibel and Smrtka, 2011). 
 Benign MS 
Benign MS is a form of relapsing-remitting MS with very mild attacks separated by 
long periods with no symptoms. Between 5% to 40% of patients with MS have a 
benign course with little or no disability after 15-25 years of follow-up (Hawkins and 
McDonnell, 1999). The phrase ‘benign MS’ is sometimes used inaccurately to 
describe a period with few or no symptoms following diagnosis. However, as the 
defining characteristic of benign MS is the long-term absence of symptoms, it can only 
be diagnosed retrospectively after ten or more years. This type of MS does not 
progress, and neurological symptoms remain unchanged long after diagnosis. Even 
patients diagnosed with benign MS experience MS-related problems and a relapse can 
still occur even after many years of the illness being inactive (Jopson and Moss-
Morris, 2003). The term should be used with caution and can only describe an 
individual's past experience of MS. 
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2.8 SYMPTOMS OF MS 
The two main types of symptoms associated with MS- physical and psychological are 
discussed below. 
 Physical Symptoms 
2.8.1.1 Primary Symptoms 
Regardless of the disease type, patients with MS commonly experience multiple 
symptoms including spasticity, muscle weakness, movement disorders, fatigue, 
bladder, bowel and sexual dysfunction, pain, visual disturbances, changes in cognitive 
function, abnormal sensations and dysphagia (Mohr, et al., 1999; Noseworthy, et al., 
2000; Calabresi, 2004). These are known as primary symptoms of MS and occur as a 
direct result of demyelination. Some of these disabling symptoms are invisible to the 
observer but all have the potential to reduce quality of life. The occurrence of these 
symptoms varies within and between patients based on the extent and location of the 
lesions and on MS relapses and progression. The symptoms may fluctuate in severity 
on a daily basis. Common symptoms in MS are interrelated; one symptom can 
exacerbate another or can be caused by the treatment of another symptom. For 
example, neuropathic pain relief medication can adversely affect cognitive function. 
Neurological impairments and disabilities may thus vary considerably in nature and 
severity. In addition, patients with MS can also experience a number of secondary 
symptoms. 
2.8.1.2 Secondary Symptoms 
Secondary symptoms occur as an indirect result of the primary symptoms of MS. For 
example, patients with bladder dysfunction, often experience urinary tract infections. 
Inactivity can result in loss of muscle tone and weakness (not necessarily related to 
demyelination) and lack of mobility can result in the development of pressure sores. 
Although secondary symptoms can often be treated, neurologists and health 
professionals often aim to avoid them completely by treating the primary symptoms 
(National MS Society, 2017). 
2.8.1.3 Tertiary Symptoms 
As a direct consequence of experiencing primary and/or secondary symptoms, people 
with MS may develop social, vocational and emotional problems, known as tertiary 
symptoms. Tertiary symptoms can be considered to be the ‘trickle down’ effects of 
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the disease on life (National MS Society, 2017). For example, if a patient is no longer 
able to drive or walk, they may not be able to hold down a job. Additionally, the stress 
and strain of dealing with MS often alters social networks and sometimes fractures 
relationships. Problems with bladder control, tremor or swallowing may cause people 
to withdraw from social interactions and become isolated. 
 Psychological Symptoms 
People with MS may also experience a range of psychological symptoms: e.g. 
depression, anxiety, hopelessness, and suicide ideation. Depression is one of the most 
common symptoms of MS and occurs in as many as 50-60% of patients (Bakshi, et 
al., 2000; Feinstein, 2011). It is three times more common among people with MS than 
in the general population or in persons with many other chronic disabling conditions. 
Depression may be both a primary and a tertiary symptom as it can be caused by the 
disease process itself and/or triggered by challenges such as those discussed above. 
Emotional changes also occur in some people with MS. These can be a reaction to the 
stresses of living with MS as well as the result of neurological changes. Bouts of 
depression, mood swings, irritability, and episodes of uncontrollable laughter and 
crying pose significant challenges for people with MS and their families. 
 
Thus, it is evident that as a potentially highly disabling disorder with considerable 
personal, social and economic consequences, MS can profoundly affect individuals on 
both a physical and psychological level. These physical and psychological factors, 
both dimensions of HRQoL, may be modified through interventions and/or treatments 
potentially resulting in an improved health-related quality of life. A definition of 
health-related quality of life and a discussion of how it is affected in people with MS 
is provided in chapter 3. 
2.9 THE IMPACT OF MS 
The effect each of the types of MS can have on patients’ lives varies markedly. 
Individuals with benign MS may live relatively unaffected by the condition, however 
the course of relapsing-remitting, secondary progressive and primary progressive 
course is likely to have severe consequences for both the patient and their family. Even 
patients who have been diagnosed with the same type of MS can be affected 
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differently, since the course of the illness and symptoms varies from individual to 
individual; Lublin and Reingold (1996) describe the disease course of MS as ‘highly 
variable’. Also, the type of MS may change over time. Individuals are therefore faced 
with high levels of uncertainty and unpredictability which is reinforced by the wide 
and confusing number of symptoms associated with MS, some of which may be 
transitory. It is therefore unsurprising that MS can potentially have a considerable 
impact on all areas of the patient’s life, including their HRQoL This is an important 
area of focus for my research particularly if care management is to optimise HRQoL. 
People with MS can live for many years after diagnosis with significant impact on 
their ability to work, as well as an adverse and often highly debilitating effect on their 
quality of life and that of their families. Emotional and psychological adjustment to 
MS can be difficult because of the diversity of symptoms, absence of a cure, limited 
availability of medical treatment, and uncertainty about the future effect of one’s 
physical disabilities (Lublin, et al., 2014). McCabe, Stokes and McDonald (2009) 
propose that the ways in which a person with MS copes with the condition would also 
be expected to impact on HRQoL. Despite this, MS has little effect on longevity 
(Weinshenker, 1995; Ragonese, et al., 2008). 
The extent to which MS can affect each aspect of a person’s life is determined largely 
by both the physical and psychological symptoms of the condition (described in 
sections 2.8.1 and 2.8.2), many of which are subjective and therefore difficult to 
measure (Ford, et al., 2001a). The number and severity of physical symptoms 
experienced often places a variety of limitations on the patient’s day-to-day activities. 
Furthermore, the psychological impact of living with MS can have considerable 
implications for everyday life. The impact of MS can influence future, self-confidence 
and self-esteem, families and employment prospect (Edwards, Barlow and Turner, 
2008). I would suggest that only by considering the symptoms and uncertainty from 
the patient’s perspective can effective management strategies be considered. I would 
propose that this could be achieved using an appropriate HRQoL measure, thereby 
forming the basis of part of this research. 
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2.10 TREATMENTS 
Once an individual receives a confirmed diagnosis of MS they are faced with the 
reality that there is no available cure for this condition. Before 1993, MS treatments 
were directed towards symptom management (Keenan, 2002; Newsome, et al., 2016). 
However, there are now many drug treatments available which either aim to reduce 
relapse rates (disease modifying therapies) or help to manage and alleviate specific 
symptoms. Many views are portrayed in the literature concerning treatment aims; 
Schwartz and Frohner (2005) suggest that the main goal of treatment is to delay 
progression, relieve symptoms, and optimise quality of life, a view with which Miller 
and Allen (2010) concur. They also propose that enhancing coping strategies to 
improve HRQoL should be a major components of MS care, and that quantitative 
methods measuring HRQoL can be an important part of assessing a patient’s treatment 
needs. Hadgkiss, et. al. (2012) suggest that maintenance of function and HRQoL 
should be the focus of treatment. 
 Symptom Management 
The dominant view in the literature reviewed is that there should be a multi-
disciplinary approach to the care of people with MS. Noseworthy, et al. (2000) suggest 
that as patients with multiple sclerosis face enormous prognostic uncertainty, they 
must become well informed about their illness, this being best accomplished with a 
multi-disciplinary approach. Tappenden, et al. (2001) describe how management 
involves the multi-disciplinary team and includes physiotherapy, psychiatric and 
social support and disability aids, whilst Crayton and Rossman (2006) suggest that 
optimal management of MS symptoms is clinically challenging, requiring a 
comprehensive multimodal and individualised approach. They suggest that both 
pharmacologic and non-pharmacologic modalities are recommended, with the goals 
of improving or maintaining function and preserving quality of life. Smrtka, et al. 
(2010) discuss how a team of coordinated, skilled and expert healthcare clinicians are 
essential to the delivery of timely and appropriate care. This approach is expanded 
upon by Papeix, et al. (2015) who suggest that as the clinical presentation of MS is 
often complex, with motor symptoms, ataxia, cognitive difficulties, bladder 
dysfunction, pain, visual deficits, depression and fatigue, a multi-disciplinary 
approach of care with different MS specialists and allied health professionals is 
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frequently needed. Additionally, the NICE Guideline, ‘Multiple sclerosis in adults: 
management’ (CG186, 2014) describes how MS care should be patient-centred and 
follow a coordinated multidisciplinary approach. Potential members of the multi-
disciplinary team involved in the long-term care of people with MS are shown in 
Figure 6 below. 
The majority of treatment for MS involves managing the individual symptoms and 
related complications. Depending on the symptom, management may involve drug 
therapy, input from therapists and/or the development of self-management strategies. 
A number of drugs are available to treat the specific symptoms of MS. For example, 
Amitriptyline is often used to relieve neuropathic pain such as burning sensations, pins 
and needles or stabbing pains while Oxybutynin is given for bladder dysfunction. The 
impact of chronic disease on a patient’s health-related quality of life can be minimised, 
or even improved, by helping them adjust their expectations and adapt to their changed 
clinical status. This may be done by encouraging the use assistive devices such as 
walking sticks, wheelchairs, and scooters. Other treatment options include exercise, 
cognitive therapy, and complementary and alternative therapies.  
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Figure 6 Multi-disciplinary patient-centred approach to the care of the person 
with MS 
 Disease Modification 
Over the last 15 years the management of MS has changed from one of symptom 
control to one of disease modification (Shaw, 2008). Disease modifying therapies 
(DMT) are predominantly licensed for use in patients with relapsing-remitting MS, 
although the use of some may be continued in patients who develop secondary 
progressive MS. These drugs aim to decrease the frequency of clinical relapses and 
reduce the accumulation of physical disability. However, some of these treatments 
(interferon beta-1a {Avonex and Rebif}, interferon beta-1b {Betaferon} and 
glatiramer acetate {Copaxone}) have only a modest benefit on the course of the 
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disease (Filippini, Munari, and Incorvaia, 2003). Teriflunomide (Aubagio) and 
peginterferon beta-1a (Plegridy) also have a modest effect on the reduction of relapse 
rate. More recent disease modifying therapies, such as alemtuzumab (Lemtrada), 
dimethyl fumarate (Tecfidera), fingolimod (Gilenya), and natalizumab (Tysabri) 
reduce the number of relapses considerably and delay disease progression. 
 Treatment Choice 
Because of the variety of drugs available to either reduce the number of relapses or 
ameliorate symptoms there is a large variation in how people choose to treat their 
condition. Some patients do not take any medication, either DMT or symptomatic 
relief, simply persevering with their symptoms, whereas others can find themselves 
taking many drugs, each with their own side effects. Patients may find the side effects 
of individual drugs intolerable and chose to live with the symptoms untreated. Hence, 
whilst drug therapy is important in the care of people with MS, the comprehensive 
care of the individual requires a multi-disciplinary approach, where patients are 
appropriately managed by effectively addressing the course of the disease and its 
resultant symptoms (Newsome, et al., 2016). 
As members of the multi-disciplinary team, clinical nurse specialists for MS play a 
key role in providing holistic care to a person with MS (PwMS). Only by 
understanding the disease and disease process can the patient and their family 
participate actively in making informed decisions about their treatment. Through 
assessment of HRQoL it is likely that there will be a greater shared understanding of 
symptoms, potentially resulting in the initiation of appropriate interventions which 
links to this research. 
2.11 SUMMARY 
As a chronic progressive disease, which may be difficult to diagnose, receiving a 
diagnosis of MS can be difficult for some people to cope with. The uncertainty for the 
future coupled with the numerous symptoms, treatments options and lack of cure all 
require consideration with regards the care of a person with MS. The impact of 
physical and psychological symptoms on daily life varies from person to person but 
may be assessed using a HRQoL measure and appropriate care strategies proposed. A 
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patient-centred multi-disciplinary approach is central to the management of this 
chronic condition. 
The following chapter focuses on the assessment of health-related quality of life. A 
literature review is used to present and discuss the concepts surrounding this wide 
topic, with a choice of measure for assessment in the outpatient department resulting 
from the review. 
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3.1 INTRODUCTION 
Health-related quality of life in patients with multiple sclerosis is a much-researched 
topic, the literature frequently indicating the profound effect this condition can have 
on the lives of people with MS. Within this chapter, a description of the current 
literature pertaining to the assessment of health-related quality of life in MS is 
presented providing the background and justification for this thesis. Establishing the 
status quo within the current MS health-related quality of life literature allowed the 
two phases to develop from the work of others. By obtaining a detailed knowledge of 
the topic, it was possible to design relevant studies to fill the literature gaps. 
A description of the concepts of quality of life and health-related quality of life sets 
the scene. Subsequently the impact of multiple sclerosis on health-related quality of 
life is described. 
The process of an outpatient appointment is key to delivering high quality care. Only 
by considering patient choice and patient expectations of health care, through an 
effective consultation when patient views are respected and preferences considered, 
can this be achieved. Models of consultation, and the role of patient involvement and 
patient activation in decision making are examined and the concept of patient-centred 
care related to these, thereby enabling an understanding of how individual patients 
may interact during an appointment when the assessment of HRQoL is discussed and 
interventions proposed. 
The background to the assessment of health-related quality of life in MS and reasons 
for such assessments are considered within this chapter. The effectiveness of the use 
of HRQoL measures in routine clinical practice in improving the process and 
outcomes of patient care is discussed and related to patient-centred care. Barriers to 
the use of such measures are examined. 
Health-related quality of life may be measured using both generic and disease-specific 
tools. Throughout this chapter, the various requirements of the measure for this 
research are introduced and measures included for consideration or discounted 
accordingly. Subsequently, the rationale for the chosen HRQoL measure for this 
research is presented. 
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3.2 SEARCH STRATEGY 
A narrative stance was taken for the literature review of this research. As such the 
literature review was less focused but wider ranging in scope than a systematic review 
as described by Bryman (2008). The preliminary literature review indicated the 
importance of assessing HRQoL in daily clinical practice but suggested that it was not 
routinely measured. No information was found concerning the relevance of such an 
assessment to people with MS, from their perspective. 
A multiple search strategy was adopted to identify literature related to the assessment 
of health-related quality of life in multiple sclerosis. Additionally, literature pertaining 
to communication and models of consultation, patient involvement in consultations, 
patient-centred care, and types of decision-making was identified through the Athens 
search tool using the following databases: British Nursing Index (BNI), Cumulative 
Index to Nursing and Allied Health Literature (CINAHL), the Cochrane Library, 
EMBASE, MEDLINE, PsycINFO, NICE and the HTA (Health Technology 
Assessment) reports. 
The electronic database search strategy was developed using keywords, including 
‘multiple sclerosis’, ‘quality of life’, ‘health-related quality of life’, ‘assessment’, 
‘intervention’, ‘efficacy of treatment’ and ‘longitudinal study’. These terms were 
combined; truncated versions of the key words were also used. Author searching, 
snowballing, hand searching and scrutinising reference lists of the included papers 
also occurred. The main search covered the period January 1980-August 2018 
however older papers of interest were also included. A large time frame was used as 
interest in health-related quality of life in MS first began in the 1980s. 
Email alerts of the ‘table of contents’ from relevant journals were registered for by the 
author and reviewed as received. The following journals were monitored: Applied 
Research in Quality of Life, British Journal of Nursing, International Journal of MS 
Care, Journal of Mixed Methods Research, Journal of Neuroscience Nursing, Multiple 
Sclerosis and Related Disorders, Multiple Sclerosis International, Multiple Sclerosis 
Journal, and Quality of Life. 
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3.3 QUALITY OF LIFE AND HEALTH-RELATED QUALITY OF 
LIFE 
To begin to be able to understand health-related quality of life from the perspective of 
a person with multiple sclerosis, an understanding of the concepts of quality of life 
and health-related quality of life is required. Both concepts are explored in the 
following text. Health-related quality of life is subsequently related to multiple 
sclerosis, thereby providing context for the following literature review where the 
rationale for assessing health-related quality of life and subsequently planning care to 
optimise or maintain it is developed. 
3.3.1 Quality of Life 
Quality of life (QoL) as a concept is derived from the social and behavioural sciences. 
QoL is a universally recognised term but its meaning is difficult to define. The 
WHOQOL Group (1995, p.1405) defines quality of life as: 
‘…an individuals’ perception of their position in life in the context of 
the culture and value systems in which they live and in relation to their 
goals, expectations, standards and concerns.’ 
WHOQOL Group (1995) describe QoL as a broad ranging concept which is affected 
in a complex way by a person's physical health, psychological state, level of 
independence, social relationships, personal beliefs and their relationship to salient 
features of their environment. In 1996 Brunet, et al. (1996) suggested that QoL is 
difficult to conceptualise as it is affected by economic, political, cultural and spiritual 
factors, which are not generally considered to fall under the purview of healthcare 
professionals. The WHOQOL definition highlights the view that quality of life is 
subjective, includes both positive and negative facets of life and is multi-dimensional, 
a point which aligns with Slevin, et al. (1988) who suggest that what constitutes quality 
of life is a personal and individual question, this lending itself to a philosophical rather 
than a scientific approach. 
Whilst Cella, et al. (1996) describe QoL as a person’s subjective sense of wellbeing 
or global satisfaction with important aspects of life, Calman (1984) suggests that 
quality of life is determined by the extent to which our hopes and ambitions are 
matched by experience. Calman (1984) also suggests that a key aim of health care 
should be to ‘narrow the gap between a patient’s hopes and aspirations and what 
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actually happens’. In a chronic condition, such as MS, I believe that this indicates 
management of expectations thereby maximising wellbeing rather than health is the 
key to success; I would suggest this could potentially be achieved through structured 
appointments when the patient’s opinion of how MS impacts on them is considered. 
As an observation from the literature review, the dominant view of ‘quality of life’ is 
that it refers to an individual’s total wellbeing and includes all emotional, social and 
physical aspects of the individual’s life. It can only be described and measured by that 
individual. Major factors that contribute to QoL are the ability to perform daily 
activities and the level of well-being and satisfaction with life (Arnoldus, et al., 2000). 
When the term ‘quality of life’ is used in relation to medicine and healthcare it is 
termed ‘health-related quality of life’. HRQoL is distinguished from QoL because it 
is based on health domains which can be measured and quantified. 
3.3.2 Health-Related Quality of Life 
Health-related quality of life (HRQoL) is a discrete component of QoL. HRQoL is 
conceptualised as those aspects of life quality or function which are influenced by 
health status, i.e. it focuses on the impact health status has on quality of life (Morales-
Gonzáles, et al., 2004). This is broadly compatible with the World Health Organisation 
definition of health, namely that health is ‘a state of complete physical, mental and 
social well-being and not merely the absence of disease or infirmity’ (WHO, 1946). 
This definition proposes that health is a dynamic multidimensional concept that 
captures these domains of well-being simultaneously. 
Many definitions of health-related quality of life are given in the literature, these being 
broadly similar. Rothwell, et al. (1997) suggest that HRQoL focuses on the patient as 
a whole and encompasses several important domains of health, including general well-
being, social function, and psychological function which, whilst not directly related to 
neurological impairment or disability, are considered by patients to be more important 
determinants of their health status than impaired physical function alone. HRQoL is 
also considered to be a multidimensional construct that includes aspects of life quality 
or function affected by health status, such as physical health and symptoms, 
psychosocial factors, and psychological and emotional dimensions of one’s well-being 
(Vickrey, et al.; 1995; Benito-León, et al., 2003; Mitchell, et al., 2005; Buchanan, 
Huang and Kaufman, 2010). As a term, HRQoL refers to an individual’s assessment 
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of how a health problem and its treatment affect his/her ability to perform activities 
and roles the she/he values (Cella, et al., 1996; Fischer, et al., 1999). Carr, Gibson and 
Robinson (2001, p.1240) consider that ‘health-related quality of life is the gap between 
our expectations of health and our experience of it’. Bandari, et al. (2010) describe 
HRQoL as the distillation of almost every aspect of the patient’s existence, including 
perception of treatment benefit and functional decrements of disease progression, a 
definition which I would suggest is particularly pertinent to this research. 
It is evident from the literature that many years of research have led to a consensus 
notion of HRQoL as a multidimensional concept which usually investigates four 
health-related domains; psychological functioning (well-being and emotional status), 
social functioning, physical status and, disease and treatment-related symptoms. The 
psychological domain deals with the emotional concomitants of illness whilst the 
social domain considers the impact of illness on social interactions with the family, 
friends, work colleagues and within the community. The physical/biological domain 
is concerned with the effects of illness on a person’s ability to carry out their normal 
day-to-day activities (Chadwick, Baker and Jacoby, 1993). The work of Wilson and 
Cleary (1995) also describes how most conceptualisations of HRQoL include the 
dimensions of physical, social and role-functioning as well as mental health and 
general health perceptions with important concepts such as vitality, pain and cognitive 
function subsumed under these broader categories. 
There are a number of potential determinants of HRQoL. These include disease related 
variables such as disability status (Lobentanz, et al., 2004; Fernández, et al., 2011), 
disease duration (Benito-León, et al., 2002), fatigue (Janardhan and Bakshi, 2002; 
Pittion-Vouyovitch, et al., 2006), depression (Amato, et al., 2001a; Lobentanz, et al., 
2004), cognition (Fernández, et al., 2011), sociodemographic variables including age 
and sex (Pfaffenberger, et al., 2006; Turpin, et al., 2007), and marital status (Wu, et 
al., 2007; Fernández, et al., 2011). Fernández, et al. (2011) also identified educational 
level and time since last relapse as determinants of HRQoL in a large sample of 
patients with MS representing all the major subtypes of the disease. More recently 
Lysandropoulos and Havrdova (2015) described how HRQoL in patients with MS is 
determined by several factors including coping with the MS diagnosis, understanding 
the disease and the disease process, dealing with the hidden symptoms such as fatigue, 
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cognitive impairment and sexual function and managing the many associated personal 
challenges such as social isolation, family issues and working difficulties. 
The determinants of HRQoL may interact with each other; Janardhan and Bakshi 
(2002), Mitchell, et al. (2005) and Hoogs, et al. (2011) all suggest that HRQoL has 
both physical and psychological components that interact with each other. Ford, et al. 
(2001a) describe how endogenous factors (such as coping skills, gender, ethnicity, 
religious beliefs) interact with an individual’s health status to determine the overall 
impact of the disease on HRQoL. HRQoL is also influenced by psychosocial 
characteristics, a key aspect of which is patient activation, defined as ‘the patients’ 
ability to take an active role in managing their health’ (Mosen, et al., 2007). Mosen, et 
al. (2007) add that the interplay between the patients’ social circumstances and their 
psychological ability to cope with chronic illness is reflected in their ability 
(knowledge, skills and confidence) for self-management, which is important in 
behavioural dimensions of chronic disease management such as healthy lifestyle (diet 
and exercise), self-care and medication adherence. 
A critical element of HRQoL is that it reflects the patient’s assessment of the impact 
of their illness, not the healthcare professional’s perspective (Hobart, 1997). 
Visschedijk, et al. (2004) agree suggesting that HRQoL essentially reflects an 
evaluation of health and well-being from the patient’s perspective. It refers to how an 
individual perceives their illness and associated treatments to be impacting on their 
ability to live life in the way that they wish. 
In most studies, the HRQoL of patients with MS is measured in terms of physical 
symptoms, mobility, emotional life and social interaction (Hakim, et al., 2000; Miller, 
et al., 2003). However, as a concept, Bowling (2014) suggests health-related quality 
of life can be complex to analyse as it is mediated by several inter-related variables, 
including self-related constructs such as self-efficacy, self-esteem and perceived 
control over life. Cognitive mechanisms such as expectations of life, level of optimism 
or pessimism and aspirations can also affect subjective evaluations. The highly 
variable nature of MS and response shift will also affect the measurement and analysis 
of HRQoL. 
As an observation, the terms QoL and HRQoL are often used interchangeably within 
much of the literature reviewed but typically relate to the health-related quality of life 
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of a patient. As HRQoL appears to have become the dominant term in much of the 
literature I have used this term throughout. 
Within the following section, the concept of HRQoL is related specifically to multiple 
sclerosis. The clinical context of MS was described in chapter 2. 
3.3.3 Impact of Multiple Sclerosis on Health-Related Quality of 
Life 
The concept of HRQoL has been applied to numerous conditions such as epilepsy 
(Edefonti, et al., 2011), Parkinson’s disease (Soh, et al., 2013) and cancer (Detmar, et 
al., 2002). It has been particularly useful for capturing the patient perceptions of these 
conditions in daily life and is especially useful in chronic conditions. In this section I 
review how the concept is considered in relation to MS. 
The impact of multiple sclerosis on health-related quality of life has been studied 
extensively over the last thirty years. MS has been found to have a significant impact 
on health-related quality of life for individuals at all stages of the disease (Miller and 
Allen, 2010).The long-term neurodegenerative effects of MS can impact on physical, 
cognitive, psychological, emotional and social functioning (Vickrey, et al., 1995; 
Rothwell, et al., 1997; Compston and Coles, 2008), each having the potential to reduce 
health-related quality of life (Benito-León, et al., 2003; Morales-Gonzáles, et al., 
2004; Buchanan, Huang and Kaufman, 2010; Buhse, Banker and Clement, 2014). 
The impact of MS on HRQoL is widely recognised. Vickrey, et al. (1995), Hermann, 
et al. (1996), Rothwell, et al. (1997), Nortvedt, et al. (1999), Janardhan and Bakshi 
(2002), Benedict, et al. (2005), Mitchell, et al. (2005), and Buhse, Banker and Clement 
(2014) all describe how health-related quality of life is adversely affected by MS, 
suggesting that it is substantially impaired compared with the general population. 
These findings are further described by McCabe and McKern (2002) who found that, 
when comparing quality of life between patients with MS and people in the general 
population, those with MS experienced lower levels of quality of life in the objective 
and subjective dimensions of the domains of physical health, psychological 
adjustment, social relationships and environmental adjustment. Studies have also 
shown that people with MS have lower HRQoL scores than populations with other 
chronic conditions such as rheumatoid arthritis (Rudick, et al., 1992), inflammatory 
bowel disease, (Rudick, et al., 1992), diabetes and epilepsy (Hermann, et al., 1996), 
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and Parkinson’s disease (Riazi, et al., 2003a). The lower scores may be due to the 
unique pattern of symptoms of MS and in particular the hidden symptoms such as 
fatigue and stamina. Devins, et al. (1993) describes a greater impact of illness 
intrusiveness in MS than in rheumatoid arthritis; I would propose that this could be 
affecting overall HRQoL in MS. 
The symptoms of MS are individual, the range of functional, psychological and 
cognitive limitations varying from one individual to another. Numerous authors 
describe the influence of MS symptoms on patients. For example, Morales-Gonzáles, 
et al. (2004) suggest that the core symptoms of MS impact considerably upon the 
activities of daily living of patients. Lobentanz, et al. (2004) describe reduced physical 
functioning in people with MS compared to the general population. Whilst Hadgkiss, 
et al. (2012) suggest that the impact of MS on employment status, social and family 
relationships, sexual satisfaction, enjoyment of life, and emotional well-being can be 
profound, White (2012) describes how MS has a significant effect on patients’ lives 
affecting many areas of functioning. 
The psychological impact of living with MS can have considerable implications for 
everyday life. Depressive symptoms, difficulties with ambulation and employment 
limitations due to health are considered the main indicators of reduced quality of life 
in patients with MS (Vickrey, et al., 1995; Aronson, 1997). People with MS are more 
likely to suffer with fatigue (Amato, et al., 2001a; Lobentanz, et al., 2004) and 
depression (Amato, et al., 2001a; Montel and Bungenert, 2007) than the general 
population, and are more likely to be unemployed (Aronson, 1997; Ford, et al., 2001b). 
More than 75% of people with MS are unemployed within ten years of onset (Tripoliti, 
et al., 2007). 
In 2000 Rätsep, et al. (2000) discussed the importance of acknowledging the numerous 
individual differences in emotional and psychological adjustment to disease, even 
when severely impaired. The ways in which quality of life is affected by disabilities is 
not solely determined by the disabilities themselves but also by their impact or 
importance for a patient. Whilst stress, depression and feelings of isolation may all 
occur as a consequence of the disease and associated treatments, mood, coping ability, 
self-efficacy, autonomy, independence, dignity and future plans will all be impacted-
on by a diagnosis of MS, thereby influencing a patient’s HRQoL (Mitchell, et al., 
2005). Hence, it is evident that a diagnosis of MS will affect people in differing ways. 
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Lysandropoulos and Havrdova (2015) describe how whilst some people with MS may 
be well-treated and free from current symptoms, they have a poor HRQoL due to 
patient-centred factors such as depression, inability to work and relationship issues. 
However, others with a high degree of physical disability may continue to participant 
fully in life and consequently view their HRQoL more positively. Thus, it is possible 
for someone with considerable disability to perceive themselves as having a good 
quality of life, and vice versa. These patients demonstrate adaptation to their condition. 
From the patient’s perspective, it appears that the psychosocial components may be of 
more concern than physical factors in terms of their HRQoL (Aronson, 1997; 
Rothwell, et al., 1997; Shawaryn, et al., 2002; Somerset, Sharp and Campbell, 2002). 
Employment, day-to-day functioning including ability to work and drive, maintain and 
enjoy social relationships and recreational activities can all be affected adversely by 
physical and cognitive deficits (Rao, et al., 1991b; Schultheis, Garay, DeLuca, 2001; 
Kobelt, et al., 2006), leading to a reduced HRQoL for patients, their family and carers 
(Patti, 2009). Rudick, et al. (1992), Benito-León, et al. (2003) and Aymerich, 
Guillamón and Jovell, (2009) also found that whilst not only the HRQoL of patients 
with MS, but also their caregivers was notably affected, both having lower HRQoL 
than the general population, the HRQoL for patients was significantly lower. 
The poorer health-related quality of life of some people with MS may also be 
attributed to the unpredictable and unstable course of the disease, the variable and 
sometimes hidden symptoms and absence of a cure (Amato, et al., 2001a; Benito-
León, et al., 2002; Miller, et al., 2003; Mitchell, et al., 2005). Bueno, et al. (2015) 
suggest that the impact of such a high degree of clinical heterogeneity on HRQoL is 
poorly understood. 
In the following section the concepts of partnerships in care, patient choice and, patient 
involvement in decision making, including informed decision-making and shared 
decision-making are discussed. The influence of communication and the style of the 
consultation on these concepts is considered. Without an understanding of the different 
roles and expectations of both the patient and healthcare professional an effective 
consultation cannot occur and ultimately the opportunity to discuss various clinical 
interventions which could optimise HRQoL might be missed. 
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3.4 MANAGEMENT OF CARE IN MS 
Within western health care there has been a paradigm shift from paternalistic medicine 
toward patient autonomy both legally and ethically (Rieckmann, et al., 2015; Spatz, 
Krumholz and Moulton, 2016). Recent health policies and guidance (e.g. NICE 
clinical guideline:138, ‘Patient experience in adult NHS services’ CG138, 2012) 
emphasise informed choice, patient-centred medicine, and patient participation in 
medical decision-making. The literature reviewed for chapter 2 also conclusively 
indicated the need for a multidisciplinary approach to the care of those with MS. This 
assertion is reiterated in NICE clinical guideline 186: ‘Multiple sclerosis in adults: 
management’, (CG186, 2014), which offers best practice advice on the care of adults 
with MS, describing how treatment and care should take into account individual needs 
and preferences and involve the multidisciplinary team. Also, patients should have the 
opportunity to make informed decisions about their care and treatment, in partnership 
with healthcare professionals (CG186, 2014). CG138 (2012) also includes 
recommendations on patient care, indicating that patients value HCPs acknowledging 
the unique way that each person experiences a condition and its impact on their life; I 
would propose that the impact can be more fully understood with a HRQoL 
assessment. Similarly to CG186 (2014), CG138 (2012) also acknowledges that 
healthcare services should be tailored to each patient, an individualised approach being 
adopted, and patients’ views, and preferences respected. Patients should be 
empowered to actively participate in their own care if they so wish. The 
recommendations of these guidelines can all be addressed with good communication 
skills, patient-centred care and the practice of shared decision-making. 
Guidance for care provision is also provided within the domains of the NHS Outcomes 
Framework. The overarching indicator of Domain 2 (NHS Outcomes Framework, 
2016-2017), ‘Enhancing quality of life for people with long-term conditions’ is 
‘Health-related quality of life for people with long-term conditions’; one of the areas 
listed for improvement is ‘Ensuring people feel supported to manage their condition’. 
It is now widely recognised that the successful management of chronic illness depends 
on the active behavioural involvement of the patient. Domain 4 (NHS Outcomes 
Framework, 2016-2017), ‘Ensuring that people have a positive experience of care’ 
improvement area lists as an area for improvement ‘Improving people’s experience of 
outpatient care’. These two areas link with this research, I would propose that a 
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HRQoL assessment could potentially contribute to the achievement of both these 
targets. 
Caring for people with MS requires a comprehensive health care team with the MS 
nurse as an integral part. Halper (2009) describe the MS nurse as one who assists, 
enlightens, refers, helps establish reasonable expectations, offers encouragement, 
prepares the patient and provides explanation. The many roles of the MS nurse are 
also described by Smrtka, et al. (2010) and include symptom manager, patient and 
family advocate, collaborator, counsellor and educator. It is likely that these 
responsibilities will be more effectively fulfilled if trust has developed between the 
MS nurse and the patient and that open and honest communication is occurring (Caon, 
et al., 2013). 
In the UK, clinical nurse specialists for MS play an important part in educating patients 
and their families about MS, symptoms, treatments and possible side effects (MS 
Society 2017; MS Trust 2017). They are responsible for answering patients’ questions 
as well as providing emotional and practical support to patients and their carers. 
Managing patients’ needs, goals, and expectations can be difficult. Treatment options 
must be discussed effectively so that appropriate informed decisions can be made by 
patients. The level of involvement a patient wishes for in their care should be 
considered and must be respected at all times. Some patients may be considered 
experts as they have gained a great deal of knowledge about MS and how to manage 
it. 
An experienced nurse with a broad knowledge of MS, excellent communication skills 
and a working knowledge of consultation models who recognises the importance of 
patient-centred care and shared decision-making should be able to assess HRQoL 
using a questionnaire, evaluate the responses and suggest clinical interventions, 
potentially maintaining or improving HRQoL whilst offering holistic care. Prior to the 
start of this study, neither the clinical nurse specialists for MS nor  the consultant 
neurologists, at the Acute NHS Trust of this research routinely used any HRQoL 
instrument in clinical practice. However, there is anecdotal evidence from my practice 
that clinical interventions can make a difference to patients. For example, patients may 
be referred to the continence service for assessment and management of bladder 
symptoms; whilst some patients describe the outcome as life-changing and would 
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potentially demonstrate an improved quality of life if assessed, others do not find they 
benefit. 
The following sections address these considerations which all impact on treatment 
decisions and therefore will potentially affect HRQoL of patients. 
3.4.1 The Communication Process and its Role in Consultations 
Communication is an important aspect in human interaction; as a healthcare 
professional, it is essential to understand the key role of communication when 
providing care and supporting patients in their decision-making. Kurtz, (2002) 
describes communication as a basic clinical skill. As well as a series of learned skills 
communication is also a set of procedures for improving outcomes of care (Kurtz, 
2002). Communication skills comprise content skills, process skills and perceptual 
skills, all of which should be used during a consultation and are key components of 
patient-centred care; content skills include the substance of the questions asked and 
the responses derived, the information gathered and given, and treatments discussed; 
process skills are those which relate to the way a healthcare professional 
communicates with a patient, how their history is learnt, how information is given, the 
verbal and non-verbal skills used, the manner in which the relationship is developed 
with the patient and the way the communication is structured. Perceptual skills relate 
to the internal decision-making of a healthcare professional and include their clinical 
reasoning and problem solving-skills, attitudes and intentions, values and beliefs, 
awareness of their thoughts and feelings about the patient, about the illness and other 
issues that may be concerning them and, their awareness of their own self-concept and 
confidence and internal biases. These three skills are intricately linked and should not 
be considered in isolation (Kurtz, Silverman and Draper, 2005). 
Patients need to be able to understand the content of the consultation and recall 
information provided during the consultation. Good communication produces a more 
effective consultation for both the healthcare professional and the patient as effective 
communication significantly improves accuracy, efficiency, supportiveness and, 
health outcomes for patients in the form of improved adherence or concordance, 
symptom relief and physiological outcome, satisfaction for both the healthcare 
professional and the patient and, the therapeutic relationship (Kurtz, Silverman and 
Draper, 2005). 
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Effective doctor-patient communication is a central requirement in building a 
therapeutic doctor-patient relationship (Ha and Longnecker, 2010). I would propose 
that effective communication is also essential to the development of a therapeutic 
nurse-patient relationship. Indeed, McCabe (2004) suggests that patient-centred 
communication can contribute towards a positive nurse-patient relationship 
developing, this being essential for quality nursing care. Whilst appropriate effective 
communication reduces conflict by preventing misunderstandings from arising 
between healthcare professionals and patients, and thus may improve outcomes for 
patients, poor communication can result in the breakdown of the clinician-patient 
relationship and adversely affect patient outcomes. 
It is acknowledged in the literature that clinician communication is not always good. 
Whilst the review of Ha and Longnecker (2010) suggests that doctors tend to 
overestimate their abilities in communication resulting at times in complaints from 
patients, McCabe (2004) found that patients attributed poor communication to the 
nurses being ‘too busy’. The findings of McCabe’s study (2004) also indicated that 
nurses ‘can’ communicate well when using a patient-centred approach. 
The literature reveals various ways that communication can be improved. Detmar, et 
al. (2002) found that physician communication was improved using a HRQoL measure 
during a consultation and that patient issues and needs, which required supportive 
intervention were more readily identified. Newsome, et al. (2016) suggest that a 
multidisciplinary patient-centred team approach promotes communication and 
optimal care. 
I would suggest that a dynamic approach within effective communication allows for 
flexibility, responsiveness and patient engagement; what may be considered 
appropriate for one situation may not be appropriate for another as patients’ needs 
often change. Cultural differences in styles and patterns of communication may also 
have a significant impact on the communication process. Good communication skills 
also support a patient-centred approach resulting in a collaborative partnership 
whereby the healthcare professional enhances the patient’s ability to become more 
involved in the consultation and to take part in a more balanced relationship, this being 
an interactive process. Thus, partnerships in care, patient involvement in decision 
making and communication may be considered to be inextricably linked. 
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The relevance of communication skills to the consultation process is discussed in the 
following section. 
3.4.2 The Consultation 
The consultation is the central act of medicine, and as such it deserves to be 
understood. 
(Pendleton, et al., 1984, p.1) 
Hastings, et al. (2003) define a consultation as a meeting between practitioner and 
patient. Within this literature review I consider a consultation to describe the 
interaction between a patient and healthcare professional in the outpatient department, 
when the patient’s condition is reviewed, and their beliefs and expectations identified 
and managed. 
A patient may attend a consultation for a regular review. Willcox and Munson (2007) 
propose that health-promoting forms of consultations are used for patients with an 
existing condition in an effort to prevent a deterioration in health. I would suggest that 
this type of model is relevant to those with MS for whom optimising HRQoL is 
essential. Patients also attend for urgent reviews when they are experiencing a 
deterioration of their symptoms or are in relapse. Lawal (2007) suggests that with 
chronic conditions, each consultation is part of a journey that may continue for many 
months or years. This is particularly true for patients with MS who may be diagnosed 
in their early 20’s and will potentially access healthcare for the remainder of a normal 
lifespan. Generally, people with MS only cease to attend appointments at the Trust of 
this research when they are no longer able to access the hospital or move away. 
However, some patients who have moved away from the immediate locality of the 
Trust of this research continue attending appointments, attributing this to a relationship 
of trust which has built up over many years. 
A successful consultation occurs when there is integration of technical knowledge and 
skills on the part of the doctor or healthcare professional, together with competent 
interpersonal communication, which enables an understanding and appropriate 
engagement of both the consulter and the consulted, to manage the problem. 
Communication is an important part of such a consultation (Illingworth, 2010). Whilst 
Kurtz, Silverman and Draper (2005) suggest that the medical interview is central to 
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clinical practice and is a few critical minutes for the doctor to help the patient with 
their problems, Main, et al. (2010) describe how patient beliefs and expectations lie at 
the heart of the consultation process as they potentially influence adherence and are 
pre-cursors of behaviour change and mediators of outcome. I would argue that these 
opinions relate to all healthcare professionals. One of the primary roles of the clinical 
nurse specialist is that of consultant; success in this role depends on both expert 
knowledge of the specialty area and an in-depth knowledge of the consultation process 
(Hodges, Poteet, and Edlund, 1985). 
The Calgary-Cambridge model (Figure 7) is one of many models of consultation. It is 
widely recognised as providing a basis for consultations. It may be applied in most 
clinical settings and helps health professionals achieve good communication with 
patients. As a model, it is patient-centred and promotes shared decision-making, both 
of which are important in the care of those with MS. In addition to its five stages, there 
are two ‘threads’ that run throughout the consultation as shown in Figure 7. The 
content, process and perceptual skills described earlier in section 3.4.1 are potentially 
all utilised when conducting a consultation using the enhanced Calgary-Cambridge 
Guide (Kurtz, et al., 2003). The framework identifies the objectives to be achieved 
during a consultation. 
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Figure 7 The Enhanced Calgary-Cambridge Framework 
(Kurtz, et al., 2003) 
Main, et al. (2010) describe the key principles behind the Calgary-Cambridge 
approach as blending the biomedical (disease) perspective with the patient (illness) 
perspective within the context of background medical, personal, and social history. I 
suggest that information relating to HRQoL may be determined if these three 
perspectives are fully explored. Information is elicited in an efficient manner within a 
patient-centred approach, designed to facilitate patient engagement, thereby enhancing 
satisfaction and improving clinical outcomes. I would propose that the way the 
information is gained is circular and reflective indicating the two-way nature of the 
elicitation process. However, whether these points are achieved is dependent upon the 
patient, the person using the model and the training they have received. 
The Calgary-Cambridge model is described as useful a guide within a consultation by 
Munson and Willcox (2007) because it acknowledges the importance of individual 
patient concerns. I would suggest that it is important to discuss what the patient wishes 
to address during a consultation; the highly individual needs and perspectives of each 
patient need to be understood. Throughout a consultation I encourage patients to share 
their experiences, thus enabling me to tailor my clinical advice and approach to their 
individual needs. The model also promotes a healthcare professional/patient 
partnership (Denness, 2013) which is essential for the delivery of high quality care. 
During an outpatient appointment, the particular model of consultation used, the way 
information is presented and the degree of involvement a patient wishes to have in 
their care can significantly influence understanding and decision-making among 
patients and clinicians. My consultations are based on the Calgary-Cambridge 
enhanced framework which I have found to be extremely effective. 
Over time the consultation process has changed and evolved. The medical or 
paternalistic approach to a consultation is based on two fundamental concepts, disease 
and diagnosis. Within this approach, the doctor’s authority is emphasised; the 
physician dominates the medical encounter, using their skills to diagnose and 
recommend tests and treatments for the patient (Charles, Gafni and Whelan, 1997). 
The clinician decides what care is in the patient’s best interest and expects the patient 
to be compliant with the treatment recommended (Frosch and Kaplan, 1999). In this 
model I would suggest that the doctor is considered the expert. 
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Since the paternalistic approach arose, the requirement to discover the patient’s 
beliefs, concerns and expectations about their problem has been recognised and the 
value of patient-centred care, shared decision-making and informed decision-making 
has been realised. Within the informed model, the patient’s right to exercise their 
autonomy is emphasised. The shared decision-making model lies between the 
paternalistic and informed model and relies on a relationship developing between the 
patient and the healthcare professional. Within a shared decision-making model, the 
clinician elicits the patient’s values and preferences about their care, has an evidence-
based discussion of treatment options and then the patient and clinician arrive at a 
treatment decision together (Frosch and Kaplan, 1999; Barry and Edgman-Levitan, 
2012; Armstrong, et al., 2016). Barry and Edgman-Levitan (2012) consider shared 
decision-making to be the pinnacle of patient-centred care. Indeed, shared decision-
making has been shown to be particularly useful in preference-sensitive conditions 
(Armstrong, et al., 2016) in which there exist a number of available treatment options 
of similar efficacy, with differences in risks and benefits. MS is one such condition. 
Informed decision-making and shared decision-making lie at opposite ends of a 
continuum when decision-making is considered. Both have relevance in the 
consultation, the type chosen being influenced by the patient. 
3.4.3 Clinical Contexts for Partnership Relationships 
The clinician–patient relationship may be considered central to the practice of 
healthcare and is essential for the delivery of high quality health care, the quality of 
the relationship being important to both parties. Respect and understanding from both 
sides are required to develop a trusting relationship. Such a partnership may be 
immensely rewarding for both the parties. Charles, Whelan and Gafni, (1999) suggest 
that the need for a healthcare professional/patient partnership is most compelling when 
a patient presents with a serious illness. 
For those with MS, sickness is not a temporary status; rather the long-term chronic 
illness becomes a permanent part of their identity and status. For these people, the 
healthcare professional/patient relationship is potentially a long-term one. This 
relationship starts to develop when a patient and/or significant others is reviewed for 
the first time at an outpatient appointment. Subsequently, if a patient is admitted to 
hospital, in relation to their MS or otherwise, as a clinical nurse specialist I will visit, 
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appropriately offering expert advice to the clinicians caring for that patient, thereby 
further developing my relationship with that patient. 
Whilst establishing a relationship, the type of involvement a patient would prefer in 
the process of making decisions about treatment should be explored, thereby ensuring 
that a patient feels that their preferences have been listened to and that they feel 
confident with their role in decision-making. If decisions are made by the patient with 
which they feel confident they are more likely to adhere to treatment plans; it is 
probable that their quality of life could improve or at least be maintained as a 
consequence. 
3.4.4 Patient Involvement in Decision-making 
Bowling (2014) suggests that the active participation of patients in shared decision-
making about their health care is an important dimension of contemporary models of 
patient-centred care and of doctor-patient decision-making. By assessing how engaged 
a patient is in their own care, healthcare professionals can build an individualised 
approach that will ultimately lead to greater self-management. Patient activation 
embodies a developmental process of patients’ willingness and ability to manage their 
health and healthcare; four progressive levels of competency have been described, 
ranging from patients being relatively passive and not seeing themselves as playing an 
active role in their health to patients having the knowledge and confidence to self-
manage health behaviours and seek additional support when needed (Hibbard, et al., 
2004). Patient activation helps patients to gain the knowledge, skills and confidence 
to manage their own condition. Some may then take a more active role in their care 
management, asking questions and making informed decisions. However, although 
patient activation can empower some patients to make decisions, others may prefer to 
rely on healthcare professional to make decisions for them. 
Frosch and Kaplan (1999) reviewed a number of studies concerning whether patients 
wished to participate in medical decision-making; they found that younger patients 
have a greater desire to participate in treatment decision-making than older patients. 
When studying patient preference in MS, Heesen, et al. (2007) found that 91% of 
patients preferred to make an autonomous or shared-decision, as opposed to only 9% 
who wished the physician to make a decision for them. These patients are passive and 
avoid receiving information. Only by discovering the patient’s perspective can the 
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type of involvement that the patient wishes be ascertained. Bowling (2014) describes 
how whilst most patients wish to be informed about their condition, only a proportion 
want to participate in clinical decisions about their treatment. 
Of the patients reviewed by the clinical nurse specialists for MS during outpatient 
consultations, some consider the options in a perfunctory manner and immediately 
prefer one option, others weigh up the pros and cons before making a decision, some 
wish the consultant/nurses to decide- they may be anxious about making the ‘right’ 
decision and so surrender the decision to the us, others demand a treatment, some 
cannot decide and, others review the options, consider the doctor’s recommendation 
and their personal preference, before choosing a certain treatment. How patients make 
their choice is a fluid concept which shifts according to patient preferences and their 
condition at the time. This may be due to psychological vulnerability which makes it 
difficult for some to participate in treatment decision-making regardless of how well 
informed they may feel. 
The degree of involvement that patients want in their care decisions will vary over 
time, and thus one has to assess where the patient wants the healthcare professional to 
be at any one time on a continuum ranging from paternalistic to autonomy (Lawal, 
2007). An autonomous patient could be considered to be an expert in their own 
condition. Through patient activation, the person with MS may become more involved 
in making decisions concerning their care and management over time. Michie, Miles 
and Weinman (2003), Hibbard, et al. (2004, 2007) and Mosen, et al. (2007) describe 
how higher levels of patient activation have been associated with better adherence to 
treatment, improved medical outcomes and greater satisfaction with care. This point 
is supported by Hadgkiss, et al. (2015) who suggest that patients who are proactive in 
their health may achieve better outcomes than those who are more passive. However, 
the work of Shay and Lafata (2015) demonstrated that the link between shared 
decision-making and patient adherence to medical therapy or improved outcomes had 
yet to be established. 
Both self-efficacy and patient activation have positive associations with HRQoL 
(Mosen, et al., 2007). For people with MS increasing self-efficacy has been found to 
predict improvement in the physical and psychological impact of MS (Riazi, 
Thompson and Hobart, 2004) and better quality of life (Stepleman, et al., 2010). 
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3.4.5 Patient-Centred Care 
Since the 1970s an extensive body of literature has been published advocating a 
patient-centred approach to medical care, this focusing on the patient as a whole, rather 
than just their disease and diagnosis. Patients are no longer regarded as passive 
recipients of services (Donaldson, 2007). They should be able to determine how much 
information they want and how much they want to participate in decision making and 
self-care. 
As a concept, Illingworth (2010) suggests that the term patient–centred is difficult to 
define as it means different things to different people. The Department of Health 
(DOH, 2004) definition confers two dimensions to the concept: Patient-centred is a 
philosophy of care that encourages: (a) a focus in the consultation on the patient as a 
whole person who has individual preferences situated within social contexts, and; (b) 
shared control of the consultation, decisions about interventions or management of 
health problems with the patient. 
In patient-centred care, a holistic approach is taken when discovering the patient’s 
perspective; the patient is seen as a person whose disease is experienced individually 
as an illness, who has thoughts and feeling about the illness, and who needs to be 
regarded within their social setting (Stewart, et al., 2003). Michie, Miles and Weinman 
(2003), Donaldson (2007) and Illingworth (2010) suggest that patient-centredness has 
two components. Firstly, they describe how the healthcare professional discovers and 
takes account of the patient’s perspective, their beliefs, views and feelings. The 
patient’s perspective includes the effect of their illness and treatment on their 
functionality, the stages of the illness, type of illness, and their expectations of the 
doctor or healthcare professional. Consequently, these should be explored with the 
patients to discover their preferences. However, the behaviour of the professional, 
their knowledge of the condition and their relationship with the patient will also affect 
patient-centredness. This aspect of patient-centred care promotes patient satisfaction 
which in turn may increase adherence to advice given within the consultation. 
Michie, Miles and Weinman (2003) and Illingworth (2010) suggest that the second 
component of patient-centredness is the ability to activate the patient to take shared 
control in the consultation and/or in the management of their illness; self-management 
is promoted and health-outcomes are better. These sentiments are echoed in the work 
of Stewart, et al. (2003) who also describe the need for a sharing, participative, and 
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equal approach with the patient, including shared power which underpins shared 
control and finding common ground to lead to a mutual decision. Through shared 
control of a consultation, shared decision-making can be achieved. However, as 
described earlier not all patients want to be involved in decision-making and their 
choice must be respected. 
A patient-centred approach is increasingly regarded as crucial for the delivery of high-
quality care by doctors (Mead and Bower, 2000). I would argue that this approach to 
care is crucial to the delivery of high-quality care by all healthcare professionals and 
is especially important for patients with MS and their care, as will be demonstrated 
throughout this work. 
More recently the term ‘person-centred care’ has been advocated instead of patient-
centred care as the later term has come to symbolise the dependency that 
personalisation aims to overcome (Scammell, 2017). The Health Foundation (2014) 
describes how the word ‘person’ is used to emphasise a holistic approach to care, that 
considers the whole person, not a narrow focus on their condition or symptoms but 
also their preferences, wellbeing and wider social and cultural background. This view 
appears identical to the descriptions of Stewart, et al. (2003), Michie, Miles and 
Weinman (2003), Donaldson (2007) and Illingworth (2010) presented earlier in this 
section. 
Within the care of people with MS different types of decision-making contexts arise. 
Emergency treatment may be necessary, long-term adherence to medications is 
required, and the treatment of new symptoms as they develop are all integral to the 
effective management of the condition. Different types of decision-making will be 
more appropriate or feasible in specific contexts. 
3.4.6 Informed Decision-Making 
Whilst healthcare providers often possess better knowledge regarding the expected 
effectiveness of healthcare in improving health status, patients potentially know best 
how the improvements in health status will affect their well-being and quality of life. 
Thus, by combining both of these types of information, effective care that results in 
health status improvements valued by patients can be provided. In the informed 
decision-making model, this is achieved by increasing the patient’s knowledge of the 
risks, benefits and clinical effectiveness of different treatment options, thereby 
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enabling them to make decisions that reflect both their preferences and the best 
scientific knowledge available. Whilst the patient is left outside the decision-making 
process in the paternalistic model, the healthcare professional is theoretically excluded 
in the informed decision-making model, their role being limited to one of information 
transfer. Charles, Gafni and Whelan (1997) suggest that an informed patient may 
prefer to make a decision themselves, to share the decision-making process, or to 
delegate the responsibility to the physician. 
Throughout any decision-making process, as already described in section 3.4.2, the 
expertise of the patient should be considered. Many patients have lived with MS for a 
considerable period of time and are extremely well-informed about their condition and 
treatment options. They have learnt to manage this chronic illness themselves, calling 
on health professionals only in times of crisis or when new treatments become 
available for which they would like to be considered. These patients can be considered 
to be expert patients i.e. someone who feels confident and in control of their life, aims 
to manage their condition and its treatment in partnership with healthcare 
professionals, communicates effectively with professionals and is willing to share 
responsibility for treatment, is realistic about how their condition affects them and 
their family and, uses their skills and knowledge to lead a full life (DOH, 2001). 
3.4.7 Shared Decision-Making 
The shared decision-making approach is part of a wider initiative to promote patient-
centred care and increase patient involvement in clinical decisions (Madsen and 
Fraser, 2015). As a model of joint decision making, shared decision-making has been 
linked with positive patient outcomes such as satisfaction and improvements in 
functional status (Charles, Gafni and Whelan, 1997). 
Frosch and Kaplan (1999) describe shared decision-making as a process by which the 
healthcare professional and patient consider available information about the medical 
problem in question, including treatment options and consequences, and then consider 
how these fit with the patient’s preferences for health states and outcomes. Health 
professionals provide expert knowledge on treatment choices and their benefits and 
drawbacks, whilst patients are experts on their own needs and priorities. It is important 
that the values and preferences of the patient are determined and respected, especially 
as the patient will bear the consequences of whatever treatment is implemented. It is 
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likely however that the patient may feel vulnerable and not give any indication of their 
values and preferences, particularly in early consultations. Thus, Charles, Whelan and 
Gafni (1999) suggests that it is the responsibility of the healthcare professional to 
initiate such a discussion. Only by getting to know a patient can appropriate care for 
that patient be initiated. Newsome, et al. (2016) suggest that shared decision-making 
among people with MS and healthcare providers should be encouraged, and that 
partners should also be included in the conversation, with patient permission, when 
treatment decisions are made. This is because partners and close family members 
experience the consequences of treatment decisions. 
There are many decision points during the disease course of MS that are well suited 
for shared decision-making, including whether to take steroids for an acute relapse, 
whether to initiate disease-modifying therapy drugs, or whether to have a child after 
being diagnosed with MS. These are all preference-sensitive issues, where the 
patient’s values and preferences can and should contribute to the ultimate decision 
(Colligan, Metzler and Tiryaki, 2016). Shared decision-making is particularly 
important in the shared consultant/nurse encounter when possible treatments are 
initially discussed, firstly because many treatment options exist with differing efficacy 
and side effect profiles, and secondly because there is no right or wrong treatment to 
choose. Thirdly treatments will vary in their impact on the patient’s physical and 
psychological well-being. The patient will decide, with the help of the HCP, which of 
the treatment options is most consistent with their preferences. Achieving this goal 
requires the active participation of both the patient and the healthcare professional. 
Within shared decision-making it is implicit that there is a relationship between the 
healthcare professional and the patient, a partnership relationship. Charles, Gafni and 
Whelan (1997) suggest that for shared decision-making to occur, it is important the 
relationship which develops between the patient and the healthcare providers enables 
a conducive environment in which the patient feels that they are being listened to and 
their views valued and respected. For shared decision-making to occur, there needs to 
be complementary role-expectations and behaviour between the healthcare 
professional and the patient. If the patient wants to participate but the healthcare 
professional is not willing to let them, then shared decision-making will not occur. 
Information sharing is essential for shared decision-making. As a minimum, the 
healthcare professional should discuss treatment options and their potential 
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consequences for the patient in order to obtain informed consent (Charles, Gafni and 
Whelan, 1997). The patient may also bring information to the consultation derived 
from outside sources. Donaldson (2007) suggests that using patient-reported HRQoL 
information implies shared decision-making because it allows both patients and HCPs 
to be knowledgeable about the effects of the disease and treatment and to jointly decide 
which intervention may be useful. Patient preferences need to be elicited so that any 
treatment options discussed will be compatible with their lifestyle; one of the disease 
modifying therapies is not suitable for patients who are Jehovah’s Witnesses, others 
are not appropriate for vegetarians. Also, the nurse should help the patient to evaluate 
the risks and benefits in light of their pre-existing knowledge, thereby ensuring that 
their treatment choices are based on fact and not misconception. Additionally, within 
the shared decision-making process, the healthcare professional should share their 
treatment recommendations with the patient and affirm the patient’s treatment 
preference. Care needs to be taken to ensure that the healthcare professional does not 
impose their values about treatments onto the patient. As earlier discussed, although 
patients often have high preferences for information about their illness and its 
management, many do not engage in treatment decision-making. Thus, although 
information is given, its potential value as an aid to decision-making is not always 
realised. Rather it may be that the information provides psychological reassurance or 
reduced uncertainty at a time of stress or vulnerability. 
Finally, within the shared decision-making process a treatment decision is made and 
both the healthcare professional and the patient agree to that decision. Occasionally, 
no decision is made, or an agreement cannot be reached. If a shared decision occurs, 
both the healthcare professional and the patient agree on the treatment option. This 
does not mean that both parties are convinced that this is the best possible treatment 
option for the patient; rather they agree to it as the treatment option to implement. The 
healthcare professional may believe that it would be more beneficial for the patient to 
receive another treatment but agrees to endorse the patient’s choice as part of a 
negotiated agreement in which the patient’s views count. Thus, through mutual 
acceptance, the responsibility for the final decision is shared. An example of this 
occurred when the consultant suggested one particular therapy for a patient, but due 
to religious beliefs the patient was not able to proceed with this treatment. Thus, an 
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alternative was discussed, considered and, following extensive discussion, agreed 
upon. 
In summary, the shared decision-making approach lies between the paternalistic 
approach which is characterised by healthcare professional dominance of the decision-
making process and the informed decision-making approach which limits the role of 
the healthcare professional to one of transferring information, thereby enhancing the 
patient’s ability to make decisions autonomously with ultimate control but also with 
responsibility for the treatment choice. Whilst shared decision-making enables 
patients to have a say in their treatment without total responsibility, it provides 
healthcare professional the opportunity to participate in but not dominate the decision-
making process. 
Shared decision-making in relation to HRQoL assessment and treatment choices and 
decisions will be discussed in more detail later in this chapter, section 3.8.4. 
3.5 CONCEPTUAL FRAMEWORK 
Conceptual frameworks are the system of concepts, assumptions, expectations, beliefs 
and theories that support and inform research (Maxwell, 1996). This definition is 
expanded upon by Leshem and Trafford (2007) who describe a conceptual framework 
as a tool that helps researchers structure their theorising and ideas and brings a sense 
of ‘coherence’ to their research. Conceptual frameworks are pivotal in nursing and 
social research as they clarify and integrate the philosophical, methodological and 
pragmatic aspects of the doctoral thesis (Durham, et al., 2015). I started to consider 
the conceptual framework for this research once I had read around the extensive body 
of literature concerned with health-related quality of life in multiple sclerosis and its 
assessment. As suggested by Trafford and Leshem (2008) this framework was also 
influenced by my own experiences and observations. 
The emergent framework (Figure 8) relates to the concept that assessment of HRQoL 
is a complex process consisting of a web of interlinking relationships. The framework 
portrays four related variables. Only when all these variables come together is it likely 
that a tangible benefit of assessment of HRQoL will be evident to patients and thus a 
role for assessment of HRQoL in routine practice be confirmed or refuted. 
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Whilst realising that there was a gap in the literature as the benefits of assessment of 
HRQoL has not been documented from the patient perspective, I was aware that the 
feasibility of such an assessment in everyday practice is poorly documented in the 
field of MS. The benefits of assessment of HRQoL in other fields is much written 
about and includes improved communication and detection of patient issues for which 
interventions may be considered (Detmar, et al., 2002; Janse, et al., 2004; Fayers and 
Machin, 2016). I was curious to know if the patients I work with were aware of the 
potential benefits and if so did they consider such an assessment to be a valuable part 
of their outpatient consultation. I also wished to investigate how assessment of 
HRQoL affected MS care management. Through subsequent re-assessment of HRQoL 
changes may be revealed, as shown in the conceptual framework of Figure 8, where 
the effect of assessing HRQoL on MS care management is demonstrated. 
Once I started the quantitative data collection I realised that I would need to explore 
the thoughts, feelings and perceptions of both staff and patient-participants about the 
assessment of HRQoL. This qualitative stage became a way of exploring some of the 
relationships between the concept of HRQOL, communication and consultation styles, 
patient activation and the various types of decision-making that underpin the 
framework. I propose that the mutual understanding of a patient’s HRQoL is essential 
if it is to be influenced and either maintained, optimised or improved through 
communication using an appropriate patient-based assessment measure during an 
outpatient consultation when shared decision-making is practiced. 
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Figure 8 Conceptual framework: Effect of assessing HRQoL on MS care 
The conceptual framework in Figure 8 acts as the foundation for my research. It 
highlights how the sharing of knowledge and information can result in optimisation of 
HRQoL. As previously discussed, within healthcare there has been a shift from a 
paternalistic approach to care towards a more patient-centred paradigm and greater 
awareness of chronic illness. The concept of HRQoL and its assessment is linked to 
this paradigm shift. The health-related quality of life of a person with MS lies at the 
heart of this conceptual framework. The outpatient consultation is central to the 
assessment of HRQoL, the clinician interpreting the responses of a HRQoL measure 
with the participant, and a questionnaire providing guidance for determining clinical 
interventions during the consultation. The influence of communication and its style 
and the nature of the consultation including the expertise of the patient and the 
relationship between the patient and the health professional all require due 
consideration. Patient-centered care and the type of decision-making will all influence 
the outcome of the consultation and ultimately the care choices made and their success. 
At all stages, the expertise of the patient should be considered. 
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3.6 WAYS OF ASSESSING HRQOL 
Health-related quality of life may be assessed or measured in several ways in routine 
clinical practice. The typical question asked at the beginning of an outpatient 
appointment, ‘How are you feeling?’ may be viewed as a global inquiry into the 
patient’s QoL (Detmar and Aaronson, 1998) as can the question ‘How is your quality 
of life’ (Kuspinar, Rodriguez and Mayo, 2012). More commonly, however, HRQoL 
is measured using a self-reported questionnaire made up of a series of items or 
questions (Kuspinar, Rodriguez and Mayo, 2012). Measures of HRQoL record 
patients’ perceptions of their overall health and how their health affects their daily 
lives (Buchanan, et al., 2010). Patient reported outcome measures (PROMs) which are 
defined as ‘any report of a patient’s health condition that comes directly from the 
patient, without interpretation of the patient’s response by a clinician or anyone else’ 
(FDA, 2009) are frequently used to measure HRQoL. PROMs include validated 
questionnaires that assess the impact of the disease and the treatment from the patient 
perspective (Solari, 2005; Fayers and Machin, 2000). PROMs and HRQoL measures 
cover a range of health dimensions including physical, psychological and social 
functioning and aim to assess a variety of broader constructs such as impairment, 
disability, handicap and quality of life. 
The patients’ perceptions of their experience whilst receiving care can be measured 
using patient-reported experience measures (PREMs). As questionnaires these are 
indicators of the quality of patient care (Kingsley and Patel, 2017). For this study I 
chose to focus on MS-specific tools to measure HRQoL as I wished to explore how 
the use of such an instrument could aid the understanding of the impact of MS and the 
management of symptoms. HRQoL may also be assessed using interviews and/or 
conversational analysis. As this research was concerned with the assessment of 
HRQoL in clinical practice these two methods were rejected as too time consuming. 
The history behind the assessment of HRQoL in MS is presented in the following 
section. Subsequently the rationale for measuring HRQoL is discussed. 
3.7 HISTORICAL PERSPECTIVE 
In 1998 Rothwell described how there had been an upsurge in interest in HRQoL in 
the medical literature. Since 1989 there has been increasing interest in the development 
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and application of patient-based measures of health in healthcare (Greenhalgh and 
Meadows, 1999). Addington-Hall and Kalra (2001) suggested that the growing 
recognition of the importance of understanding the impact of healthcare interventions 
on patients’ lives rather than just their bodies was one of the main reasons behind the 
rapid development of quality of life measures in health care. Since the mid-1990s a 
number of MS-specific HRQoL instruments have been developed; these are critiqued 
in relation to this research in section 3.12. Subsequently many papers have been 
written as interest in measuring HRQoL in MS has grown (Gruenewald, et al., 2004). 
Interest has continued and was commented on by Mitchell, et al. (2005, p556) who 
stated that ‘HRQoL has been more intensively studied in MS than any other 
neurological disorder’. I would suggest that this is because of the profound impact MS 
can have on the life of a person with MS. Indeed, HRQoL is now recognised as an 
essential measure to determine the impact of a disease as well as the potential effects 
of treatment interventions. For patients with chronic disabling conditions, such as MS, 
where there is little realistic hope of cure, I would consider that this is especially 
important. 
The growing recognition that the global well-being of patients with chronic 
neurological disease is an important outcome in both research and clinical practice 
(Benito-León, et al., 2003) is reflected in NICE CG186 (2014). Certainly, the patients’ 
perception of their own HRQoL is now increasingly being recognised as important to 
clinicians, researchers and health care policy makers (Miller, 2012). 
3.8 RATIONALE FOR MEASURING HRQOL 
Traditionally in MS care any change in a patient’s condition or success of an 
intervention has been assessed using clinical history, neurological examination, and 
laboratory or clinical tests. These could be an MRI scan, psychometric testing, visual 
evoked responses or an Expanded Disability Status Scale (EDSS) assessment. These 
tests give important information about the condition, focusing on physical 
dysfunction, but lend no personal or social context. It is these additional aspects which 
may be captured using health-related quality of life measures. Fitzpatrick, et al. (1998) 
and Hobart et al. (2001) describe how HRQoL questionnaires gain information about 
health, illness and the effects of healthcare interventions from the perspective of the 
patient. 
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Higginson and Carr (2001) suggest that in the outpatient setting QoL measures may 
be used to prioritise problems, facilitate communication, screen for potential 
problems, identify preferences, and monitor changes or response to treatment. Rapkin 
and Schwartz (2004) expand further describing how HRQoL measurement is relevant 
for assessing symptoms, side effects of treatment, disease progression, satisfaction 
with care, quality of support services, unmet needs, and appraisal of health and 
healthcare options. These views are echoed by Solari (2005) who describes how 
assessing HRQoL using an appropriate instrument can: facilitate the detection of 
aspects of the disease that might otherwise go unrecognised; help clinicians appreciate 
patient priorities especially in terms of treatment goals; facilitate patient-physician 
communication, and; ultimately promote shared decision-making. 
It is thus evident that assessment of the HRQoL of patients with MS provides both 
unique and beneficial information for patients and clinicians (Ghaem, et al., 2007), 
enabling an understanding of the impact of the disease and its treatment on the 
person’s emotional, physical and social functioning and lifestyle. These views are 
reiterated by Amato, et al. (2001a) who acknowledges that quality of life instruments 
can help to provide a broader measure of the disease impact and to develop a care 
program tailored to the patient’s needs. Also, identification of patient HRQoL may 
help predict future difficulties of patients, and prevent further deterioration in HRQoL 
(Devy, et al., 2013). Turpin, et al. (2007) suggest that as MS has enormous 
implications for the current and future quality of life of young adults diagnosed with 
this condition, determining how the illness impacts on the quality of life of people with 
MS in the early stages of the illness is critical for effective and efficient patient care. 
Identifying modifiable factors by measuring HRQoL and implementing clinical 
interventions can also have a massive impact on a patient’s HRQoL, and potentially 
on the QoL of their family and carers. 
Through focusing on how individuals appraise their health status and level of 
functioning within their own personal and social context, the patients’ perceptions of 
how their health affects their daily lives is recorded. Thus, routine HRQoL assessment 
should help physicians understand and address the factors that negatively impact 
patients (Benedict, et al., 2005; Bandari, et al., 2010). Accordingly, Solari (2005) 
suggests that it may be considered that the ultimate aim of measuring HRQoL is to 
provide a comprehensive assessment of patients’ health status from their perspective, 
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to serve as a baseline from which to tailor interventions, pharmacological or otherwise, 
and assess their effectiveness, both in the clinical trial setting and in routine care. 
Following consideration of the rationale for measuring HRQoL and the role of HRQoL 
measures in the care of patients with MS, the dominant views in the literature 
regarding the various reasons for assessing health-related quality of life are presented 
in more detail in the following sections with the aim of justifying the use of an 
appropriate measure in daily clinical practice. 
3.8.1 To Facilitate Communication 
The process of communication during the outpatient consultation was discussed earlier 
in this chapter (section 3.4.1). Greenhalgh and Meadows (1999) suggest that the use 
of the use of a patient-based measure could facilitate doctor-patient communication. 
This was demonstrated in the study of Detmar, et al. (2002) who described various 
applications of HRQoL measures in clinical practice; they demonstrated how 
completion of a HRQoL measure by patients prior to their encounter with the clinician, 
and feedback of the results to clinicians, was effective in improving patient-clinical 
communication. Subsequently Bandari, et al. (2010) determined that communication 
between patients and healthcare providers is enhanced through HRQOL assessment 
allowing the main concerns of the patient to be focused on. 
3.8.2 To Promote Detection of Patient Issues and Needs 
It has been said that clinicians often underestimate the difficulties their patients 
experience as a consequence of a disabling condition (Anonymous, 1991). Lankhorst, 
et al. (1996) believe that the use of a comprehensive questionnaire can be an effective 
way to overcome this underestimate; they are of the opinion that QoL assessments are 
important for clinical assessments, where the needs of individual patients are identified 
and then translated into healthcare interventions. Whilst Rothwell, et al. (1997) found 
that the problems patients believe to be affecting their quality of life are very different 
from those perceived by clinicians, Detmar and Aaronson (1998) suggest that the use 
of a measure might form a useful basis for identifying issues of concern to patients 
and thereby provide physicians with potential topics to discuss during medical 
consultations. I would suggest this is applicable to all healthcare professionals. Benito-
León, et.al. (2003) suggested that incorporating HRQoL assessment into routine 
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clinical practice should result in an increasing recognition of neuropsychiatric 
symptoms of MS. Social complications are also detected as well as traditional 
impairment and disability domains that form part of the total burden experienced by 
patients with MS. Benito-León, et al. (2003) describe how such an assessment helps 
clinicians plan and implement a care programme. Through integrating HRQoL 
assessment into clinical practice, HCPs can become aware of the patients’ perception 
of their HRQoL, which can be helpful in optimising treatment (Janse, et al., 2004). 
Donaldson (2007) suggests that HRQoL assessment is as least as efficient and perhaps 
more effective than asking open-ended questions such as ‘How are you doing?’ 
because it can identify priority areas for attention. HRQoL instruments can reveal 
aspects of illness that are not reflected by standard clinical instruments and can 
highlight areas of particular concern to the patient which can then be addressed 
(Aymerich, Guillamón and Jovell, 2009). In the clinical setting, Fallowfield (2009) 
suggests that very few clinicians make explicit, objective assessments about HRQoL 
when treating a patient; most clinicians depend on informal appraisal in the clinical 
setting as they believe that clinical judgement is superior to formal assessment. 
Potentially, symptoms may be overlooked, patient concerns left unaddressed and side 
effects of therapies unidentified (Ross, et al., 2012). Hence, a thorough assessment, 
identifying the actual needs of the patient as opposed to clinician perceived ones, 
would make it possible to suggest interventions potentially able to maintain or improve 
the HRQoL of patients. 
In a busy clinic it is likely that some factors which influence HRQoL in MS patients 
may be overlooked (Lysandropoulos and Havrdova, 2015). I would suggest that the 
use of a HRQoL measure in routine practice is likely to promote detection of such 
factors. Whilst medicine tends to focus on symptom relief as an outcome measure, 
Fayers and Machin (2016) describe how studies have demonstrated that using QoL 
measures may reveal other issues that are equally or more important to patients. 
Detmar, et al. (2002) found that oncologists who administered HRQOL tests were 
more likely to identify moderate-to–severe health problems, and to provide 
suggestions for managing them. Bandari, et al. (2010) were unable to find a similar 
study involving MS patients but was of the opinion that the same benefits could apply 
and called for further research in this area. 
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3.8.3 To Aid Decision-Making 
As a consequence of determining the elements that are impacting on the health-related 
quality of life of a person with MS, decision-making in the form of planning of 
interventions, treatments and services aimed at optimising or enhancing HRQoL may 
be facilitated (Rothwell, 1998). However, it is only when HRQoL measures are used 
as an integral part of care planning and evaluation that they are likely to influence 
clinical decision-making. Boyce, Browne and Greenhalgh (2014) conducted a 
systematic review of qualitative research concerning the experiences of professionals 
with using information from patient-reported outcome measures to improve the quality 
of healthcare. They concluded that professionals value PROMs when they are useful 
for clinical decision-making. 
3.8.4 To Promote Patient-Centred Care and Shared Decision-
Making 
Within the field of MS care many treatment decisions involve a trade-off between 
therapeutic effects and side effects. Rothwell, et al. (1997) describe how patients and 
clinicians often have different priorities regarding the aims of treatment or the effects 
of illness on their lives with different patients attaching differing values to the potential 
outcomes. By involving patients in the decision-making process, they are empowered 
to make appropriate decisions for themselves and ultimately are more likely to be 
satisfied with their care and adhere to treatment plans. In addition, the patient’s 
perspective on the effectiveness of the interventions can be monitored. Detmar and 
Aaronson (1998) conclude that the form, content and quality of the consultation using 
a HRQoL measure may influence decisions about treatment. Miller (2002) agrees 
suggesting that if clinicians were to routinely use a HRQoL measure, it would allow 
them to review patient functioning and concerns, quickly and systematically, and help 
patients to become active participants in their care. It was proposed that patient-based 
measures of health could promote shared decision-making by Greenhalgh and 
Meadows (1999). Subsequently Santana, et al. (2015) describe how several authors 
did indeed find that using PROMs supported shared decision-making. 
Donaldson (2007) also discusses the effects of inclusion of HRQoL measures in 
routine care and its role in patient-centred care, suggesting that the use of HRQOL 
measures allowed the patient and the clinician to share information, helped both to be 
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more knowledgeable about the effects of the disease and its treatment and, promoted 
the involvement of patients in the decision-making process. 
3.8.5 To Assess the Effectiveness of Clinical Interventions 
The requirement to assess the effectiveness of clinical interventions or therapeutic 
response from the patient perspective is widely documented in the literature. Indeed, 
Florence Nightingale was one of the first clinicians to insist on measuring the outcome 
of routine care to evaluate treatment (Higginson and Carr, 2001). 
Hobart, Lamping and Thompson (1996) suggest that, as MS is generally a progressive 
condition, measurement of HRQoL is important in the evaluation of therapeutic 
efficacy. This belief is reiterated by Solari, et al. (1999) who describe how HRQoL 
measures may be used to monitor the impact of disease and its treatment on individual 
patients in clinic when the needs of individual patients have been identified and 
translated into healthcare interventions. Skevington (1999, p.449) demonstrates 
agreement when stating, ‘quality of life is an important outcome measure in the 
evaluation of treatments for a wide range of chronic physical and psychological 
disorders’. For a complete assessment of the benefits of an intervention Garratt, et al. 
(2002) suggest that it is essential to provide evidence of the impact on the patient in 
terms of health status and health-related quality of life. By assessing HRQoL the 
effectiveness of treatment may be assessed, the need for further interventions 
determined, and consideration given as to whether the interventions were as effective 
from the patient’s perspective as clinicians believed they should be (Janse, et al., 2004; 
Mitchell, et al., 2005), a point concurred with by Fernández, et al. (2011) who describe 
how the measurement of HRQoL is an important part of treatment evaluation and care-
management. Thus, it would seem that there is increasing recognition of the 
importance of assessing the effectiveness of clinical interventions. 
As MS and its treatments have numerous effects on HRQoL any treatments offered 
should have at least a neutral effect and hopefully a positive impact on HRQoL in the 
long term. This is illustrated by di Fabio, et al. (1997) who demonstrated an 
improvement in physical and emotional health following a rehabilitation programme 
using the SF-36 and MSQoL-54, two HRQoL measures. However, unfortunately, 
some treatments used in MS are associated with a number of side effects which have 
been shown to negatively impact on HRQoL. Whether these treatments should be 
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offered then becomes debatable. Rothwell (1998) describes how HRQoL assessment 
allows HCPs to measure the overall balance between the benefit derived from the 
treatment and the harm caused by the side effects and constraints of the treatment. 
These issues are of concern to MS patients and healthcare professionals and may 
influence decisions in relation to receiving or prescribing treatments (Freeman, et al., 
2001). Hence, the assessment gives the patient the opportunity to consider a wider 
range of issues relating to the impact of the treatment on their MS, than would perhaps 
be discussed by the clinical team. An assessment of HRQoL thus enables an effective 
evaluation of treatments and determination of the appropriateness of continuation of 
therapy. 
3.8.6 To Monitor Progress over Time 
Multiple sclerosis is known to be associated with marked impairments in HRQoL 
(section 3.3.3). One-off assessments of HRQoL can help to identify problems that have 
otherwise gone undetected but provide no information on the patient’s outcomes over 
time. Longitudinal assessment, however, allows both healthcare professionals and 
patients to follow the progress of individual patients over time and evaluate the impact 
of MS on their lives (Gutteling, et al., 2008b; Ahmed, et al., 2011; Boucekine, et al., 
2013). Systematically collected HRQoL information can provide feedback to patients 
about their progress and help in exploring their goals and expectations (Donaldson, 
2007). Donaldson (2007) also suggests that simply listening to patients’ concerns, 
even when no remedies are available may result in improved HRQoL, a point with 
which I concur. Physical disability does not generally improve over time in MS and is 
often not the primary concern of patients with MS; thus Noble, et al. (2012) suggest 
measuring factors such as involvement in everyday activities, and psychological and 
emotional well-being and their improvements after interventions is of equal or more 
importance. Bowling (2014) demonstrates agreement describing how any quality of 
life measure used in research on health or healthcare should be able to inform the 
investigator of the effects of the condition on the patient’s daily as well as long-term 
life. However, it must be remembered that people with MS continually adapt to their 
condition and so evaluations of change in HRQoL should account for this adjustment. 
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3.8.7 To Maintain or Optimise Health-Related Quality of Life 
Motl, et al. (2013) discuss how, as a consequence of realising the effect of MS 
symptoms on HRQoL, researchers and clinicians have become interested in improving 
the HRQoL of people with MS. By assessing HRQoL those factors which are 
impacting negatively may be determined, the patient’s specific health needs explored, 
and interventions suggested to address the issues, thereby influencing the health of 
that patient through accurately targeted healthcare interventions. For example, a 
referral may be made to the wheelchair services for someone who is socially isolated 
because of severely reduced mobility. This should contribute to improving or at least 
maintaining their HRQoL. These actions could be considered an important part of the 
role of the clinical nurse specialist. Many treatments aim to improve HRQoL with a 
reduction in relapses, delayed disease progression and symptomatic relief. Therefore, 
it is highly desirable that we should be able to measure HRQoL in patients with MS 
simply and with confidence. 
It is evident that there is an overwhelmingly large body of evidence emphasising the 
benefits of assessment of HRQoL for patients. Anecdotal evidence is also available 
for the use of measures in various neurology centres throughout the country. For 
example, a patient who is also under the care of a London hospital was given the 
MSIS-29v2 by his MS care team in London; he brought it completed to his outpatient 
appointment at the place of this research. The London hospital staff had asked him to 
complete it at home prior to a follow-up telephone appointment. He described how 
using the MSIS-29v2 had prompted discussion with his wife concerning symptoms 
and issues he had. He had found the assessment to be of benefit to him and was able 
to discuss the results on the telephone. Some of his concerns were further addressed 
at the outpatient appointment with me. 
In summary, health-related quality of life measures have many roles in the care and 
support of patients with multiple sclerosis in the clinical setting. They may be used to: 
stimulate better communication, promote shared decision-making, describe the burden 
of disease, highlight previously unrecognised health problems, assess the effectiveness 
of different treatment plans and monitor disease progression. 
Within the literature there is debate about whether using HRQoL measures actually 
improves care. This thesis aims to further address this debate. 
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3.9 DO HRQOL MEASURES IMPROVE CARE? 
The evidence supporting the effectiveness of PROMs in contributing to improvements 
in the quality of healthcare is heterogeneous. Greenhalgh and Meadows (1999) 
conducted a literature review of the effectiveness of the use of patient-based measures 
of health in routine practice in improving the process and outcomes of patient care. At 
this time, they determined that although the information from patient-based measures 
of health was seen as valuable in the overall assessment of patients by clinicians, and 
that its feedback to clinicians increased the detection of psychological and functional 
problems, there was little evidence to suggest that their use substantially changed 
patient management or improved patient outcomes. Latterly, Boyce and Browne 
(2013) suggest that it has been difficult to draw definitive conclusions about their 
impact on patient care. The work of Boyce and Browne (2013) describes how 
professionals identified that the use of PROMs in practice had the potential to improve 
the process of care by enhancing communication, increasing patient education, 
promoting joint decision-making, screening for health issues, monitoring changes in 
disease severity and response to treatment, and stimulating better care planning. 
However, they found little evidence that PROMs feedback to healthcare professionals 
changed care management or improved patient outcomes. 
The effectiveness of HRQoL measurement in clinical practice has been demonstrated 
in several cancer studies including that of Detmar, et al. (2002); using a HRQoL 
measure enabled more frequent discussion and identification of HRQoL related 
problems, improved emotional functioning, improved HRQoL, and resulted in a 
decrease in depression, a decrease in debilitating symptoms, and an expressed interest 
in continued use of the information by both physicians and patients. From this work, 
I would surmise that an improvement in outcomes would be likely in MS care, 
although this might not always be detectable due to the fluctuating nature of MS. 
Whether measuring HRQoL can demonstrate an improvement in patient care, optimise 
HRQoL and make a meaningful difference to those with MS will potentially influence 
whether an appropriate measure is incorporated into the routine clinical practice of the 
neurology service at the Acute Trust of this research, and possibly other areas where 
patients with MS are cared for. From my perspective, the need to demonstrate evidence 
of effectiveness as a consequence of incorporating a HRQoL measure into routine 
clinical practice is key to this research. 
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3.10 BARRIERS TO THE USE OF HRQOL INSTRUMENTS 
Despite the increasing evidence that HRQoL measures are more reliable indicators of 
the positive and negative impact of disease and treatment than clinical opinion, and 
also the increasing body of evidence that there are a number of potential benefits for 
both patients and clinicians, as described earlier in this chapter, clinicians still do not 
routinely assess HRQoL in clinical practice. The challenge remains to encourage 
clinicians to use them outside the research setting. Greenhalgh and Meadows (1999) 
suggested that there were several practical, methodological and attitudinal barriers to 
the use of patient-based measures in healthcare. These barriers were described again 
by Solari in 2005 and are related to feasibility, acceptability, lack of psychometrically 
tested measures, lack of resources, patient inability to assess HRQoL and clinicians’ 
views of the relevance and value of HRQoL measures in the care of patients. A 
systematic review of literature by Boyce, Browne and Greenhalgh (2014) revealed 
similar practical considerations in relation to assessment of HRQoL. Unquestionably, 
the issue of the various barriers to the use of such measures in routine clinical practice 
required consideration prior to the selection of a measure for this research. 
The clinical measurement of HRQoL has been opposed by what Higginson and Carr 
(2001) term ‘pressure groups’ who consider this to represent the ‘overmedicalisation’ 
of life and do not believe that clinical interference in all aspects of a patient’s life 
should be the clinicians’ concern (Higginson and Carr, 2001). In my practice, I did not 
consider that this would be an issue for most patients. Rather, I suspected that they 
would prefer to complete an assessment with the hope that appropriate interventions 
could meet their needs. 
Whilst the ability of patients with regards assessment of HRQoL is discussed below, 
other barriers are debated in more detail in section 3.12 when the features required for 
this research are considered. 
3.10.1 Patient Assessment of HRQoL 
Unfortunately, not all patients are able to articulate their own HRQoL through using a 
HRQoL measure, a potential barrier to this method of HRQoL assessment. Self-
reporting may be difficult for those with MS if they have difficulties with manual 
dexterity or cognitive problems which may impact the speed of information processing 
and memory (Matthews, 1998; Bruce, et al., 2010), influencing both the time to 
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complete a self-report outcome measure and the accuracy of the data. Cognitive 
impairment occurs at all stages of the disease trajectory; (Langdon, et al., 2012); it 
may occur early in MS in the absence of significant physical disability and is 
sometimes under-recognised (Rao, et al., 1991a; Amato, et al., 1995; Baumstarck, et 
al., 2012b). It is now realised 40-65% of patients with multiple sclerosis experience 
some form of cognitive changes with prominent involvement of memory, sustained 
attention and memory processing (Rao, et al., 1991a; Amato, Zipoli and Portaccio, 
2006). This figure rises to 72% in more disabled patients (Maor, Olmer and Mozes, 
2001). 
The extent to which MS patients with cognitive dysfunction can validly self-report 
their HRQoL is debated within the literature. Whilst Benedict, et al. (2004) argue that 
cognitively impaired individuals are unable to produce valid HRQoL measures, others 
have reported empirical evidence suggesting that individuals with a moderate degree 
of cognitive impairment can perform reliable HRQoL assessments (Gold, et al., 2003; 
Marrie, et al., 2003; Baumstarck, et al., 2012a, 2012b). Although proxy assessments 
may be used in cognitively impaired populations Riemsma, et al. (2001) described 
how there is little evidence to support the validity of such assessments suggesting that 
health status measures need to be validated for use by proxies in certain populations. 
However, they do suggest that the use of proxies (for example, partners, relatives or 
close friends) to assess HRQoL for a patient should be considered. The work of 
Howland, et al. (2017) studying older people with varying degrees of cognitive 
function demonstrated that patients and proxies generally agree in reporting on 
activities of daily living but that they differ in their respective evaluation of cognitive 
functioning and everyday executive function. Howland, et al. (2017) proposed that, 
due to the subjective nature of QoL assessment, proxies rated QoL lower than the 
patients. For any condition it is important that healthcare providers are aware of the 
differences between the patient and proxy perspective to create an accurate clinical 
picture and guide care. 
Communication deficits such as poor eye-sight will also affect the ability of a patient 
to complete a HRQoL instrument. Severe symptom distress (Sneeuw, Sprangers and 
Aaronson, 2002) and emotional factors such as severe mood disturbance (van der 
Linden, et al., 2005) may also interfere with self-assessment, potentially resulting in 
unreliable information. Additionally, a patient’s performance may fluctuate 
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throughout the day and from day to day, irrespective of any new disease activity. 
Others may find the HRQoL instrument too burdensome physically or emotionally 
(Addington-Hall and Kalra, 2001). It is likely that these are the patients where a 
HRQoL assessment is most needed to inform clinical decision-making. In this 
situation, it may be necessary for a ‘significant other’ to complete the assessment in 
the role of a proxy. 
Although there are potential barriers to using HRQoL assessments, some of which can 
be overcome, as a healthcare professional I would argue that there is a place for 
HRQoL assessment by clinicians in routine clinical practice and particularly by nurses 
who are often highly involved in the care of patients with MS. Detmar and Aaronson 
(1998) determined that introduction of individual QoL assessments in routine 
outpatient oncology practice was feasible and appears to stimulate physicians to 
inquire into specific aspects of the health and well-being of their patients. I would 
expect that this is also true for those healthcare professionals who care for patients 
with multiple sclerosis. 
3.11 SELECTION OF THE HRQOL MEASURE FOR PHASE 1 
The following two sections provide the background to the measure chosen for phase 1 
of this research. By reviewing the literature, acknowledging HRQoL measures used to 
assess health-related quality of life in MS and considering their psychometric 
properties and feasibility of use, an appropriate measure was selected. 
I required an evaluative measure as I wished to assess changes within individual 
patients over time, rather than between groups of patients. It had to be appropriate for 
use in the outpatient setting, short enough to be completed by patients or their carers 
whilst waiting for an appointment and demonstrate good psychometric properties. 
The first decision involved a choice of whether to use a generic, disease-specific, or 
hybrid measure. 
3.11.1 Generic, Disease-Specific and Hybrid Measures 
There are a number of measures which may be used to assess HRQoL or some of its 
dimensions. They may be broadly classified into generic, disease-specific or hybrid; 
the later includes elements of both generic and disease-specific scales. As I would be 
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assessing HRQoL in patients with MS I decided to explore the use of disease-specific 
measures as I felt they were likely to be most appropriate. 
Disease-specific instruments measure the patient’s subjective experiences of illness 
and health and the associated impact on quality of life. Such measures are primarily 
designed to ensure that any symptom impact item reflects all the symptoms relevant 
to the disease of interest and that any additional psychological or social items 
particularly relevant to the given disease are included (Rose and Weinman, 2007). 
Beiske, et al. (2012) concur, describing how using disease-specific measures enables 
accurate assessment of the issues that are important for a particular disease and that 
might be missed by using a generic measure (Rudick and Miller, 2008). Disease-
specific instruments are appropriate for assessing treatment effects and are more 
sensitive than generic measures to small, but clinically important changes in a patient’s 
health status (Ford, et al., 1997; Freeman, et al., 2001; Hobart, et al., 2001; Bowling, 
2014), a point of relevance to this study. Nortvedt and Riise (2003) also consider that 
an MS-specific questionnaire which addresses problems particularly relevant to MS 
patients might demonstrate greater sensitivity and better responsiveness, these being 
important features when measuring the effect of any interventions, which again is of 
particular relevance to this study. This point was demonstrated by Motl and Gosney 
(2008) who conducted a meta-analysis on the effect of exercise training on quality of 
life in MS, demonstrating that the effects of exercise on HRQoL were statistically 
significant when MS-specific HRQoL measures were used but there was a non-
significant effect when generic measures were used. They recommend that, where 
available, MS-specific outcome measures should be used. 
Although MS-specific measures offer advantages in assessing HRQoL in MS patients, 
they are perceived to have their limitations. For example, disease-specific measures 
may not capture health-problems not related to MS. 
Ultimately, I opted to use a disease-specific measure for phase 1 of my research as it 
enabled information to be captured which was specific to the group of patients being 
studied. 
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3.12 EVALUATION OF MS-SPECIFIC HRQOL MEASURES 
When evaluating the appropriateness of HRQoL measures for this research, the works 
of Ruta, et al. (1994), Fitzpatrick, et al. (1998) and Higginson and Carr (2001) were 
considered. These have been tabulated and are presented in Appendix A. Whilst Ruta, 
et al. (1994, p.1110) list the criteria of a truly valid measure of outcome that reflects 
the patients’ perceptions of their health, Fitzpatrick, et al. (1998) suggest that a 
measure should be chosen by evaluating evidence about the instrument in relation to 
the eight criteria listed in Appendix A. Similarly, Higginson and Carr (2001, p.1299) 
produced a set of questions for consideration when assessing a quality of life measure 
for use in clinical practice as listed in Appendix A. 
These three works, although presented from differing angles, demonstrate a degree of 
overlap; whilst the Ruta, et al. (1994) describe the need to assess areas important to 
patients, Higginson and Carr (2001) ask if relevant domains are covered. All state the 
need for a tool that has been psychometrically tested and measures change over time. 
Fitzpatrick, et al. (1998) and Higginson and Carr (2001) also describe various issues 
related to feasibility which require consideration. Many of the points in Appendix A 
are discussed and related to relevant literature in the following sections. 
Since the mid-1990s a number of MS-specific HRQoL instruments have been 
produced all of which are designed to capture clinically relevant issues with regards 
to MS. Only five measures involved patients, their involvement making them relevant 
to the population under study: Functional Assessment of Multiple Sclerosis (FAMS), 
Leeds MS Quality of Life scale (LMSQoL), Multiple Sclerosis Impact Scale (MSIS-
29), Multiple Sclerosis Quality of Life Inventory (MSQLI), and Multiple Sclerosis 
International Quality of Life Questionnaire (MusiQoL). The domains covered and 
psychometric properties of these five measures are tabulated below in Table 1. 
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Name of 
outcome 
measure 
Domains covered No. of 
items 
Validity Reliability Responsiveness and 
appropriateness 
Format 
Functional 
Assessment of 
MS (FAMS) 
Mobility, symptoms, 
emotional well-being, 
thinking/fatigue, and 
family/social well-
being 
59 Content derived in part from 
patient input 
Evidence provided for construct, 
content and concurrent validity 
In non-ambulatory subjects, 
correlations with MSIS-29 and 
SF-36 physical functioning 
lower than expected 
Alphas 0.82-/0.96, 
except mobility scale 
(alpha=/0.78 overall, 
except 0.39 in non-
ambulatory subjects) 
Test-retest reliability: 
r-/0.85-/0.91 
Small floor and ceiling 
effects, good 
responsiveness in both 
ambulatory and non-
ambulatory subjects 
Weighted toward 
assessment of 
psychosocial 
consequences of MS, 
assesses QoL impact of 
most domains 
Self-
completion 
Completion 
time 20 min 
(Benito-León, 
et al., 2003) 
Looks back 
over past 7 
days 
Multiple 
Sclerosis 
International 
Quality of 
Life 
(MusiQoL) 
Activity of living, 
psychological well-
being, relationships 
with friends, 
symptoms, 
relationships with 
family, relationship 
with the healthcare 
system, sentimental 
and sexual life, 
coping, and rejection. 
31 Content derived in part from 
patient input 
 
Alphas 0.60-/0.92 
Test-retest reliability: 
r-0.63-0.89 
No data given Self-
completion 
Completion 
time 10.6-22.9 
min (Simeoni 
et al., 2008) 
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Name of 
outcome 
measure 
Domains covered No. of 
items 
Validity Reliability Responsiveness and 
appropriateness 
Format 
Multiple 
Sclerosis 
Quality of 
Life 
Inventory 
(MSQLI) 
Physical functioning; 
social functioning; 
role limitations due to 
physical problems; 
role limitations due to 
emotional problems; 
mental health; energy 
& vitality; pain; 
general health 
perceptions; fatigue, 
pain effects, sexual 
satisfaction, bladder 
and bowel control, 
impact of visual 
impairment, 
perceived deficits, 
social support. 
138 
items, 
10 sub-
scales, 
shorter 
version 
of 81 
items 
Content derived in part from 
patient and caregiver input 
Evidence provided for construct 
validity of generic and 
symptom-specific scales 
included in MSQLI 
Construct validity demonstrated 
in older adults with MS 
Alphas 0.67-/0.97 
Test-retest reliability 
r- 0.75-0.94 except 
0.60 for SF-36 social 
functioning 
Responsiveness of full 
MSQLI unknown to our 
knowledge 
Based on generic SF-36 
that has marked floor 
effects in physical 
subscales 
Developed as a 
comprehensive outcomes 
assessment battery 
Tested for reliability and 
validity in subjects across 
a full range of 
neurological disability 
Comprised of established 
scales that can be 
administered 
independently 
Self-
completion, 
with 
assistance 
from 
interviewer if 
necessary 
Completion 
time 45 min 
(30 min for 
abbreviated 
version) 
Leeds 
Multiple 
Sclerosis 
Quality of 
Life 
(LMSQoL) 
QoL treated as a 
single dimension. 
Items selected based 
on impact on 
wellbeing, other 
domains of health 
excluded 
8 Content derived through focus 
groups with MS patients 
Closer correlation with GWBI 
than with SF-36 physical 
function 
Discriminates between patients 
with different types of MS 
Alpha 0.79 
Test-retest reliability: 
r- 0.85 at 2 weeks 
Minimal floor or ceiling 
effects 
Responsiveness unknown 
to our knowledge 
Assesses QoL impact of 
domains 
Self-
completion 
Completion 
time 5 min 
(Benito-León, 
et al., 2003) 
Considers past 
month 
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Name of 
outcome 
measure 
Domains covered No. of 
items 
Validity Reliability Responsiveness and 
appropriateness 
Format 
Multiple 
Sclerosis 
Impact Scale 
(MSIS-29) 
Physical health 
(symptoms, 
function), 
psychological health 
(mood, role 
limitations, 
autonomy) 
Other dimensions of 
health excluded based 
on psychometric 
analyses 
29 Content derived from interviews 
with people with MS 
Correlations with EQ-5D, SF-
36, FAMS, Barthel Index, GHQ-
12 consistent with predictions 
Alphas 0.89-/0.91 
In non-ambulatory 
subgroup, alpha 0.85-
/0.90 
Hospitalised pts: 
alpha>/0.80 
Test-retest reliability: 
r- 0.65-0.90 
Small floor and ceiling 
effects 
Good responsiveness 
Psychometric properties 
similar in community-
based and hospitalised 
patients 
In non-ambulatory 
subjects, psychological 
scale less responsive than 
FAMS, physical 
scale more responsive 
Assesses QoL impact of 
domains 
Self-
completion 
Completion 
time 15 min 
(Benito-León, 
et al., 2003) 
Completion 
time 5-10 
mins 
(McGuigan 
and 
Hutchinson, 
2004) 
Looks back 
over past 2 
weeks 
Table 1 Psychometric properties of measures for evaluating health-related quality of life 
(Based on the work of Gruenewald, et al., 2004 and Simeoni, et al., 2008 for MusiQoL) 
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3.12.1 Appropriateness 
As discussed in section 3.3.2 health-related quality of life cannot be equated with just 
one dimension of well-being. Rather, it is the subjective sum of multiple physical, 
emotional, social and objective dimensions of one’s life (Bowling, 2005). Whilst 
psychological well-being may be measured with indicators of anxiety and depression, 
coping, positive well-being and adjustment, sense of control and self-esteem, physical 
well-being is assessed with measures of physical health status such as mobility, 
dexterity, physical activity and also assessment of activities of daily living. Social 
well-being is assessed with indicators of social network structure and support, 
community integration and functioning in social roles. 
In 1997 there was little information about which aspects of health were considered 
important by patients with MS (Rothwell, et al., 1997). This issue has been addressed 
subsequently as the LMSQoL scale, the MSIS-29v2, MusiQoL, FAMS and MSQLI 
have been devised with patient input. When assessing health-related quality of life in 
patients with MS it is important that their experiences of the illness and their views on 
quality of life are assessed. What is important for maintaining a good quality of life, 
what impact the illness has had on both their life and their quality of life, and how they 
dealt with the changes brought about by their illness should be considered. Hence, I 
decided to use a measure designed with patient input. 
When assessing HRQoL a major challenge relates to how to decide which of these 
many factors should be measured (Aymerich, Guillamón and Jovell, 2009). Many 
disease-specific HRQoL assessment tools cover one or more of these domains, and 
group items into separate scales corresponding to different dimensions (Fayers and 
Machin, 2016). Consideration was given to which aspects of physical, functional, 
psychological and social health should be included in the chosen HRQoL measure for 
this research. As the measure was to be completed before and discussed during an 
outpatient appointment, the number of domains which could be assessed was limited. 
Also, I determined there was a requirement to assess domains which could potentially 
be influenced by clinical interventions offered during an outpatient appointment. The 
MSIS-29v2 assesses two dimensions of HRQoL: physical and psychological. The 
LMSQoL scale is a disease-specific quality of life self-report unidimensional scale 
that is targeted at the concept of well-being. It was developed by Ford, et al. (2001a) 
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with a community-based population of people with MS. It is concerned with 
adjustment to MS and thus it has considerable importance for long-term management. 
The LMSQoL is an eight-item scale which was addresses tiredness, loneliness, energy, 
worries about health, family relationships, appearance, attitudes of other people, and 
the future, in relation to the past month. However, it does not assess the physical 
impact of MS which, as a healthcare professional, I would argue is needed to inform 
an outpatient consultation. As the LMSQoL scale does not cover the physical impact 
of MS I decided it was not an appropriate measure for this study. 
3.12.2 Responsiveness 
The property of responsiveness, i.e., whether the instrument detects clinically 
important changes over time that matter to patients, was particularly important for this 
study as one of the purposes of the selected measure was to evaluate the effect of 
treatment on HRQoL. 
3.12.3 Acceptability 
It was essential that any measure chosen for this research was acceptable to both the 
patients and clinicians of this study. The lack of an instrument which has gained wide 
acceptability amongst clinicians may be a contributory factor to the lack of use of 
HRQoL measures in MS practice. Many busy clinicians do not see the clinical 
relevance of HRQoL measures when making clinical decisions (Mitchell, et al., 2005), 
are sceptical about the validity of HRQoL measures and are concerned about their 
inability to intervene should the questionnaire reveal any problems (Morris, Perez and 
McNoe, 1998). Also, some clinicians may be reluctant to use patient-based measures 
of health in routine clinical practice while there is a lack of evidence that their use 
actually improves patient care and outcomes (Greenhalgh and Meadows, 1999). 
However, the literature reviewed indicated that short and easy-to-use HRQoL 
instruments may encourage clinicians to measure HRQoL during a routine outpatient 
appointment. Baumstarck, et al. (2013) describe how it is commonly accepted that the 
average time of completion of a questionnaire should not exceed ten minutes to be 
fully compatible with clinical practice. Hence, I deemed FAMS, MSQLI and 
MusiQoL inappropriate as they take between twenty and forty-five minutes to 
complete. These measures also do not meet the recommendations of Skevington, Lofty 
and O’Connell (2004) and Solari (2005) who suggest that a measure should not be 
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burdensome for patients or clinicians. As previously discussed, many patients with 
MS fatigue quickly. Additionally, PwMS can experience reduced attention and 
concentration which could impair their ability to complete a longer form (Gold, et al., 
2001) accurately. Hence, the time taken to complete the measure and ease of scoring 
were of particular importance. The outcome measure selected needed to be convenient 
for the clinician as well as acceptable to the client. A short form was also required as 
the responses were to be discussed during a 20-minute outpatient appointment. 
3.12.4 Feasibility 
When deciding on an outcome measure for clinical purposes the practicalities of how 
it will be used is an important consideration. Many established HRQoL instruments 
have been designed for use in clinical trials and are not particularly user friendly with 
regards the constraints of a clinic appointment in a general outpatient setting; they may 
be too time-consuming to use or are difficult to score and interpret. 
A lack of resources for the administration, collection and storage of the data may be a 
barrier to the use of HRQoL instruments. Some clinicians may feel unable to score, 
interpret, and use HRQoL instruments to guide clinical care. The meaningful 
interpretation of changes in score from HRQoL measures can also be problematic 
(Greenhalgh and Meadows, 1999). 
3.13 A MEASURE FOR THIS RESEARCH 
Having examined the literature and considered the features required for a measure for 
this research, as well as the barriers to the use of HRQoL measures in daily clinical 
practice, I found only one disease-specific HRQoL measure which I considered 
suitable for this research, namely the Multiple Sclerosis Impact Scale (MSIS-29v2) 
which is presented in the following section. 
3.13.1 The Multiple Sclerosis Impact Scale- (MSIS-29) 
The Multiple Sclerosis Impact Scale is described by Hobart, et al. (2001) as a measure 
of the physical and psychological impact of MS from the patients’ perspective. As a 
self-administered questionnaire, it relies on the self-reporting of feelings, attitudes and 
behaviour. The items were developed through semi-structured interviews of people 
with MS, expert opinion and a literature review with the final items being developed 
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using the standard psychometric approach of reducing an item pool generated de novo 
from people with MS. There are two parts to the scale: part one (questions 1-20) 
measures 20 physical effects/impacts of MS, part two (questions 21-29) measures nine 
psychological effects/impacts of MS. These are: feeling unwell, sleep problems, 
fatigue, MS-related worries, anxiety, irritability, concentration problems, lowered 
self-confidence, and depression. 
The MSIS-29 was generated to be suitable for use as an MS outcome measure in 
appropriate clinical trials to assess therapeutic efficacy from the patient perspective, 
cross-sectional studies to assess the impact of MS, audit and routine clinical practice 
for continuing evaluation of individual patients (Hobart, et al., 2001; Hobart and Cano, 
2009). I would suggest that it may also be used to measure therapeutic effectiveness 
from the patient’s perspective in routine clinical practice. 
The MSIS-29 has been validated in a number of patient groups and in various clinical 
settings; studies demonstrate the validity, reliability, and psychometric properties of 
the MSIS-29 and its relationship to other measures (Hobart, et al., 2001; Riazi, et al., 
2002; Riazi, et al., 2003; Hobart, et al., 2004; Hoogervorst, et al., 2004; McGuigan 
and Hutchinson, 2004; Hobart, et al., 2005; Gray, McDonnell, and Hawkins, 2009; 
Hobart and Cano, 2009). The MSIS-29 was deemed a valuable outcome measure in 
intervention studies of patients with MS in a community and hospital setting by Riazi, 
et al. (2002) and McGuigan and Hutchinson (2004). They concurred with Hobart, et 
al. (2001) that the MSIS-29 is not only of use in cross-sectional studies to describe the 
impact of MS but may also be used longitudinally to monitor disease progression. 
They found the MSIS-29 responsive for change perceived by participants in their 
community sample and in the outpatient sample. Longitudinal stability and 
responsiveness have also been demonstrated in the studies of Hoogervorst, et al., 
(2004), Hobart, et al. (2005), Costelloe, et al. (2007) and Giordano, et al. (2009). 
Many authors including Gruenewald, et al. (2004) describe the MSIS-29 as a scale 
which can be used in the assessment of HRQoL of people with MS. Its author however, 
clearly states that the MSIS-29 is a measure of the physical and psychological impact 
of multiple sclerosis from the patients’ perspective (Hobart, et al., 2001, p.969) 
because the terms health-related quality of life and disablement, both of which could 
have been used to categorise the MSIS-29, have several definitions (Fitzpatrick, et al., 
1998). Motl, et al. (2013) describe the MSIS-29 as being consistent with accepted 
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definitions of HRQoL in the medical and rehabilitation literature as it consists of the 
physical and psychological domains of health status. 
Following Rasch analysis, the MSIS-29 was amended giving it better psychometric 
properties; it was renamed the MSIS-29v2. Since 2005 the use of this version has been 
recommended; consequently, it was this version which was considered and ultimately 
selected for this research. Hobart, et al. (2005) describes the MSIS-29v2 as having 
strong psychometric properties. It has been proven to be valid, reliable and responsive 
in PwMS (Hobart, et al., 2005; Hobart and Cano, 2009). Also, it enables legitimate 
analysis of study data at the individual person level. 
When the MSIS-29v2 is used, for each item (effect), participants rate their symptoms 
on a four-point Likert scale. 1=‘Not at all’, 2=‘A little’, 3=‘Moderately’, and 
4=Extremely’. Physical and psychological impact scores are generated. Questions 1-
20 are summed to generate the total score for the physical impact subscale; questions 
21-29 are summed to generate the total score for the psychological impact subscale. 
An overall impact score can be reported as the total scale satisfies criteria as a summed 
rating scale. Higher scores demonstrate a greater impact and greater compromise of 
either or both physical and psychological factors on patients with MS. Lower scores 
indicate greater independence. The physical scale score can range from 20 (best 
functioning) to 80 (worst functioning), and the psychological scale score can vary from 
9 (best) to 36 (worst). Hobart and Cano (2009) have provided instructions for 
administration and scoring the MSIS-29. I considered these to be readily transferable 
to the MSIS-29v2. 
The MSIS-29v2 looks back over the last two weeks and takes five to ten minutes to 
complete. McGuigan and Hutchinson (2004) found it to be acceptable to patients and 
no particular concerns were raised regarding the content or the phrasing of individual 
items. 
The MSIS-29 and MSIS-29v2 do not ask patients about sexual function despite the 
recognition that this is an area where people with MS do experience issues. As a 
potentially sensitive question, it is possible that the authors decided to not include this 
area to avoid compromising patient compliance over questionnaire completion; 
however, this decision is not described in the literature. 
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I concluded that the MSIS-29v2 met the requirements of my research as it addresses 
aspects of quality of life which are measurable and for which clinical interventions 
may be offered. I felt that the MSIS-29v2 would provide clinically useful information 
in the routine care of patients with MS. It is short enough for everyday use, both from 
a patient and healthcare professional perspective and, having been devised utilising 
patient input, represents those aspects of MS which are most important to them. An 
assessment using the MSIS-29v2 should enable quick screening to assess the physical 
and psychological aspects of HRQoL. Therapeutic effectiveness can also be assessed 
at subsequent appointments as the measure is appropriate for individual patient 
analysis. 
3.14 SUMMARY 
This literature review demonstrates that there are many benefits of HRQoL assessment 
for patients. Such assessments provide an opportunity to determine previously 
unrecognised needs potentially resulting in improvements in both physical and 
psychological wellbeing. Through consideration of the types of communication skills 
used during the outpatient appointment, and the types of models of consultation, a 
form of decision-making appropriate for each patient should be enabled. Patients' 
priorities for treatment are identified potentially leading to more appropriate care 
being offered. Realistic treatment goals can be facilitated resulting in enhanced 
concordance with therapy, theoretically resulting in improved or optimised health-
related quality of life, this being demonstrated through further assessments. This 
patient-centred approach requires a relationship, mutual understanding and respect to 
be developed between the healthcare provider and the patient. By practicing patient-
centred care, shared decision-making is promoted, which will potentially result in 
patients becoming more involved in the management of their condition. Any 
improvement in quality of life is likely to be due to management of patient 
expectations, the implementation of meaningful interventions, and patients adhering 
to treatment plans when they feel they have been treated individually and with respect. 
From a clinical perspective, I would suggest that the overall premise of care is that 
clinicians are able to help patients by managing or changing the impact of their 
condition following an outpatient consultation. Although I currently assess symptoms 
and issues associated with daily living, such as bathing during outpatient 
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consultations, there is insufficient time within an appointment to consider every aspect 
of life. I believe that a HRQoL assessment would enable the impact of the MS to be 
considered by the patient prior to the consultation, potentially highlighting areas they 
had not considered, and enable patient-perceived issues or concerns to be discussed 
and addressed as appropriate. 
Based on the review of the current literature I was keen to explore whether HRQoL 
could be regularly assessed and whether this would enable a comprehensive 
assessment of the impact of MS on a patient in all aspects of their life to be obtained. 
I would also suggest that as a nurse I should be striving to determine and address 
patient-perceived issues during an outpatient appointment as opposed to problems 
which I may see, and which are potentially easier to address. Thus, I perceived there 
to be a need for using an MS-specific HRQoL instrument with MS patients in the 
clinical setting and I wished to demonstrate this through research. A measure which 
enables systematic evaluation of some of the dimensions of HRQoL could minimise 
the likelihood of overlooking important information with regards to quality of life. As 
described by Fernández, et al. (2011), I would suggest that measurement of HRQoL 
is an important part of treatment evaluation and care-management and could be 
considered to be of particular value in the routine care of people with multiple sclerosis 
where treatments should have a positive impact on HRQoL. 
This review also demonstrates that, despite there being numerous generic and disease-
specific measures suitable for assessing HRQoL in various settings, there do not 
appear to be any published studies describing the routine assessment of HRQoL in 
patients with MS and its influence on their MS care management in the outpatient 
setting in everyday clinical practice. It is evident from the literature review that much 
research is concerned with testing the various psychometric properties of measures, 
thereby proving them to be of value. However, there appears to have been very little 
research published about participants’ thoughts and beliefs regarding HRQoL 
assessment in the routine clinical setting, which may provide an insight into whether 
they perceive assessment to be of benefit to them. There also appears to be very little 
published research concerning longitudinal assessment of HRQoL assessment in 
routine clinical practice. 
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This research aims to explore these gaps in the literature, by investigating the role 
routine assessment of HRQoL has in daily clinical practice and how it is experienced 
by patients and staff, through a mixed methods study. 
In this chapter I have explored the literature and looked at key issues in relation to 
HRQoL and its assessment during a consultation in an outpatient setting. The 
following chapter describes the research methodology and shows how the research 
design and methods have been influenced by this. 
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4.1 INTRODUCTION 
The methodology used for this doctoral research is presented in this chapter. When 
planning this research, one of the first decisions I had to make concerned choosing the 
methodological approach which would enable the exploration of the research 
questions. All researchers are influenced by their beliefs and ways of viewing and 
interacting with their surroundings, these beliefs being guided by principles or 
paradigms. This chapter, therefore, commences with a discussion about which 
paradigm best fits the focus of this study, demonstrating why this research was 
undertaken using a mixed methods approach underpinned by pragmatism, thereby 
enabling me to include elements of positivism and interpretivism. 
Following a discussion of the research paradigm the different research methodological 
approaches that may be used are considered before determining the most appropriate 
methods to answer the main research question: ‘Is there a role for the assessment of 
health-related quality of life in patients with multiple sclerosis in daily clinical 
practice? The research design and methods utilised in this study are presented and 
discussed within this chapter. Phases 1 and 2 are described separately in sections 4.5 
and 4.6, respectively. The ethical considerations addressed when carrying out the 
current research are discussed. 
4.2 RESEARCH IN HEALTH AND SOCIAL CARE 
This research is being undertaken as part of a Professional Doctorate (PrD) 
programme. The aim of such programmes is to find novel approaches for integrating 
professional and academic knowledge. According to the UK Economic & Social 
Research Council (ESRC, 2015) students undertaking a professional doctorate are 
expected to ‘…. make a contribution to both theory and practice in their field, and to 
develop professional practice by making a contribution to (professional) knowledge.’ 
I aim to demonstrate this through the work described in this thesis, which has resulted 
from a personal and professional interest in optimising the health-related quality of 
life of those with MS. 
Research may be either applied or theoretical in nature. In the latter, the main concern 
is with developing and extending an academic discipline. As a PrD research project 
this work is considered to follow an applied or ‘real-world’ stance; real-world research 
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focuses on problems and issues of direct relevance to people’s lives, to help find ways 
of dealing with the problem or of better understanding the issue (Robson, 2011). The 
question of whether there is a role for the assessment of health-related quality of life 
in patients with multiple sclerosis in daily clinical practice is evaluated through the 
examination of the secondary research aims, previously described in chapter 1. As a 
real-world research project, suggestions for addressing any issues raised by the 
research questions are provided and recommendations for change proposed, with 
changes in practice considered. Real-world research tends to take place in the field 
and often within the student’s own organisation- in this case two hospital outpatient 
departments of the Acute Hospital Trust where I work and am an insider-researcher. 
The tensions this brings to research are considered throughout this thesis. 
All research is underpinned by paradigms; an outline of the paradigm chosen for this 
research is presented in the following section. 
4.2.1 Paradigms and their Philosophical Assumptions 
A paradigm is a way of looking at the world, defined as a set of beliefs and 
philosophical assumptions that guide actions (Guba and Lincoln, 2005). This is 
supported by Morgan’s (2007) definition of a paradigm which reveals how research 
can be affected and guided by a certain paradigm; he describes a paradigm as a system 
of beliefs and practices that influence how researchers select both the questions they 
study and the methods that they use to study them. Paradigms provide a general 
philosophical orientation to research and can be used either individually or combined 
within a study. Whilst Guba and Lincoln (2005) identify four basic belief systems or 
philosophical questions that help define a paradigm, Monti and Tingen (1999, p.66) 
suggest that two of these, the ontological and epistemological assumptions of a 
paradigm, drive its methodologies. To clarify the structure of inquiry and 
methodological choices for this research an exploration of the paradigm adopted for 
this study is presented prior to any discussion about the specific methodologies utilised 
in this work. 
There are multiple paradigms or world views that may be considered when conducting 
research in health and social care; these broadly fall into three categories, positivism 
(often associated with quantitative research), interpretivism (usually associated with 
qualitative research) and pragmatism (typically associated with mixed methods 
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research). Tashakkori and Teddlie (2003), Burke Johnson, Onwuegbuzie, and Turner 
(2007), Creswell and Plano Clark (2011) and Denscombe (2014) all formally identify 
pragmatism as one of the paradigms that provides an underlying philosophical 
framework for mixed methods research. 
The pragmatic approach arose because of the need to use methods from more than one 
research approach to address the research questions being considered. Denscombe 
(2014, p.158) suggests that the core principles of pragmatism are that: ‘knowledge is 
based in practical outcomes and ‘what works’; research should test what works 
through empirical enquiry; there is no single, best scientific method that can lead the 
way to indisputable knowledge; knowledge is provisional and is a product of our times 
and; traditional dualisms in the field of science and philosophy are not helpful, there 
being scepticism about the distinction between quantitative and qualitative research’. 
Creswell and Plano Clark (2011) concur, describing how a pragmatic approach draws 
on many ideas, including employing ‘what works’, using diverse approaches, and 
valuing both objective and subjective knowledge. 
This approach resonates closely to my own perspective as a practitioner/researcher; I 
know from experience in practice that the health-related quality of life of those with 
MS is often compromised but may be optimised through the care offered. Thus, I made 
the decision to approach this study from a pragmatic viewpoint, thereby embracing 
the real-world stance described earlier in this chapter. Contemporary researchers 
working within the pragmatic paradigm view that the ethical goal of research is to gain 
knowledge in the pursuit of desired ends (Morgan, 2007). Burke Johnson and 
Onwuegbuzie (2004) and Robson (2011) reiterate this position suggesting that a 
pragmatist would advocate using the philosophical or methodological approach which 
works best for the particular research problem being explored. 
From a philosophical perspective, ontologically, a positivist approach recognises that 
there is a single ‘real-world’ and that all individuals have their own unique 
interpretations of that world (Morgan, 2007). The interpretivist approach conversely 
suggests that there are multiple realities; researchers may demonstrate these using 
quotes to illustrate different perspectives as in chapter 6. Pragmatists, however, accept 
philosophically that there are singular and multiple realities that are open to empirical 
inquiry and orientate research toward solving practical problems in the ‘real-world’. 
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Pragmatic epistemology is characterised by a broad emphasis on the importance of 
practical consequences, i.e. how theoretical ideas actually affect human life in general 
and the life of inquiry in particular. Epistemologically, pragmatists study in the 
different ways that they deem appropriate and utilise the results in ways that can bring 
about positive consequences within their value system (Tashakkori and Teddlie 1998). 
My aim as a nurse is to improve or at least maintain the HRQoL of those attending the 
clinics at my place of work. Within this research, theory generated from the literature 
review is combined with practical considerations in the workplace and information 
gained from two distinct phases combined into one study. As a researcher, it was 
necessary to move between the quantitative and qualitative approaches; the pragmatic 
emphasis on an intersubjective approach captures this duality (Morgan, 2007). 
Epistemologically, the interpretivist paradigm assumes that knowledge is maximised 
when the distance between the inquirer and the participants in the study is minimised. 
As the researcher I interviewed the participants; the findings were the result of this 
subjective interactive process. The opinions and interpretations of the participants 
were crucial to understanding the research questions; the semi-structured interviews 
of phase 2 were the primary way to access them. Distance and impartiality occur in a 
positivist paradigm. The use of a questionnaire in the first (quantitative) phase is 
commensurate with this philosophy, objectivity being demonstrated. 
Epistemologically, I was independent from the research participants and did not 
influence the findings as the participants completed the questionnaire without help or 
guidance from me or the other staff involved in the research. 
Within a pragmatic approach, the methods selected originate from different 
philosophical traditions, with paradigms which are conventionally regarded as 
incompatible (Robson, 2011). Ardent supporters or ‘purists’ of either the positivist or 
interpretivist paradigm, have engaged in disputes over the superiority of one over the 
other (Burke Johnson and Onwuegbuzie 2004). This continuing divide has been called 
the ‘paradigm war’ (Feilzer, 2010). Bryman (2008) describes how there is now a 
recognition that although the epistemological and ontological assumptions related to 
quantitative and qualitative research are distinctive they are not viewed as fixed or 
ineluctable within the pragmatic approach. Although some researchers question the 
appropriateness of mixing qualitative and quantitative methods in the same study, 
others acknowledge that combining methods permits a fuller perspective on a 
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phenomenon of interest and addresses the limitations of either approach exclusively 
(Brewer and Hunter, 1989, Creswell, 2013). 
One of the main differences between a positivist and interpretivist approach to 
research is the researcher’s starting point. Methodologically, positivist researchers 
start with a specific hypothesis which is tested through data collection, resulting in the 
theory being supported, or shown to need revision. In this research a positivist 
approach enabled the HRQoL of patients to be assessed and the effects of clinical 
interventions to be determined. The role of the interpretivist researcher is to understand 
the multiple constructions of meaning and knowledge. Such an approach aims to 
provide a greater understanding of people’s experiences from their own perspective. 
An interpretivist approach facilitated an exploration of the participants’ feelings about 
the collection of the data, their experience of using the MSIS-29v2 during an 
outpatient appointment, and what it meant to them. The interpretivist research method 
of interviewing allowed for the acquisition of multiple perspectives which would not 
have been possible using the positivist approach of a questionnaires alone. Values of 
the researcher are assumed to exist within interpretivism and subjectivity is an integral 
part of the research. Hence, it is not always possible to ask a very specific question 
prior to commencing research. Whilst the use of deductive reasoning at the beginning 
of this research indicates a positivist orientation to this mixed methods study, the 
discovery of emerging constructs through the qualitative interviews points towards an 
interpretivist perspective. However, the integration of the findings once merged in the 
discussion demonstrates a pragmatic stance. The combined features of both 
interpretivist and positivist approaches enabled research which would allow for the 
understanding of the role that assessment of HRQoL plays in the care of a patient with 
MS. The pragmatist paradigm permitted a satisfactory approach combining all the 
required methodological aspects. 
Within this section I have provided justification for combining a pragmatic worldview 
with my choice of diverging methodologies. A research method should enable the 
overall problem and research questions to be answered. The next section describes 
mixed methods research, relating the principles of this approach to the research 
undertaken, thereby validating the approach. 
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4.3 MIXED METHODS RESEARCH 
Mixed methods research is defined as a methodology where: 
‘a researcher or team of researchers combines elements of qualitative 
and quantitative research approaches (e.g. use of qualitative and 
quantitative viewpoints, data collection, analysis, inference 
techniques) for the broad purposes of breadth and depth of 
understanding and corroboration’. 
(Burke Johnson, Onwuegbuzie and Turner, 2007; p.123) 
Mixed methods research has been dubbed the third major research paradigm (Burke 
Johnson and Onwuegbuzie, 2004). This approach incorporates a distinct set of ideas 
and practices that separate it from other main paradigms (Denscombe, 2008). Creswell 
and Plano Clark, (2011, p.5) describe mixed methods research as ‘a research design 
with philosophical assumptions as well as methods of inquiry.’ The philosophical 
assumptions were discussed in section 4.2.1. 
As an approach mixed methods research involves the collection, analysis and 
integration of quantitative and qualitative data (Creswell and Plano Clark, 2011). 
Guetterman, et al. (2017) elaborate further suggesting that the distinguishing feature 
of mixed methods is the integration (i.e. mixing) of quantitative and qualitative data 
to generate meta-inferences beyond what either approach could alone. Thus, a more 
complete understanding is achieved through incorporating the depth of participants’ 
lived experiences with broader, generalised quantitative results. Denscombe (2014) 
suggests that a mixed methods approach is ‘problem-driven’ rather than theory-driven 
as the research question and its answers are the main concern. For these reasons, I 
considered this method appropriate for this practice-based research. 
When using a mixed methods design, several principles should be followed during the 
design development. Table 2 illustrates the steps required to implement the design for 
this research. The decisions regarding level of integration, priority, timing and mixing 
of the quantitative and qualitative strands for this research should result in a strong 
mixed methods design. Within this explanatory mixed methods design both the 
quantitative and qualitative methods have equal priority, the qualitative (phase1) study 
following the quantitative (phase 2) study. 
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Step 1 Design and Implement the Quantitative Strand: 
State quantitative research questions and determine the quantitative 
approach. 
Obtain ethical approval. 
Identify the quantitative sample. 
Collect the data using structured questionnaires. 
Analyse the quantitative data using descriptive statistics, inferential 
statistics, and effect sizes to analyse the quantitative questions and 
facilitate the selection of participants for the second phase. 
Step 2 Use Strategies to Follow from the Quantitative Results: 
Determine which results will be explained such as: significant results, 
non-significant results, individual differences, and group differences. 
Use these quantitative results to: 
• refine the qualitative and mixed methods questions, 
• design qualitative data collection protocols. 
Step 3 Design and Implement the Qualitative Strand: 
State qualitative research questions that follow from the quantitative 
results and determine the qualitative approach. 
Obtain ethical approval. 
Theoretically select the qualitative sample that can help to explain the 
quantitative results and answer the secondary questions. 
Collect data using semi-structured interviews, the schedule being 
informed by the quantitative results. 
Analyse the qualitative data using thematic analysis to answer the 
qualitative and mixed methods questions. 
Step 4 Interpret the Connected Results: 
Summarise and interpret the quantitative results. 
Summarise and interpret the qualitative results. 
Discuss to what extent and in what ways the qualitative results help to 
explain the quantitative results, and mixed methods questions. 
Table 2 Pathway of the research explanatory sequential mixed methods design 
(adapted from Creswell and Plano Clark, 2011, p.84) 
A key principle of mixed methods design is to identify and provide justification for 
the reasons for mixing quantitative and qualitative methods within a study. Sieber 
(1973) describes several reasons for combining qualitative and quantitative research, 
suggesting that at the data collection stage, the quantitative data can play a role in 
providing base-line information and that, during the data analysis stage, qualitative 
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data can play an important role by interpreting, clarifying, describing, and validating 
quantitative results. Monti and Tingen (1999) also suggest that in mixed methods 
research different perspectives of qualitative and quantitative research can emphasise 
different dimensions of the same phenomenon and are often complementary. This 
view is supported by Greene, Caracelli and Graham (1989, p.259) who describe 
complementarity as ‘seeking elaboration, enhancement, illustration and clarification 
of the results from one method with the results from the other method’. In this study 
the quantitative results guided the interview questions which in turn provided 
information clarifying how the patients felt about HRQoL assessment. 
A sense of completeness may also be achieved by using a mixed methods approach; a 
more comprehensive answer can be achieved to a set of research questions by utilising 
both qualitative and quantitative methods (Bryman, 2008). This principle is echoed by 
Burke Johnson, Onwuegbuzie, and Turner (2007) and Creswell and Plano Clark 
(2011) who describe how mixed methods research enables a greater breadth and depth 
of understanding and corroboration and provide a better understanding of research 
problems than either approach alone. These reasons for using a mixed methods 
approach are demonstrated when the results of the two phases are combined. 
Creswell and Plano Clark (2011) suggest that some research problems are more suited 
to a mixed method inquiry. These include those where one data source may be 
insufficient, results need to be explained, exploratory findings need to be generalised, 
a second method is needed to enhance a primary source, a theoretical stance needs to 
be employed, or an overall research question can be best addressed with multiple 
phases or projects. Robson (2011) concurs suggesting that this choice of method 
allows different but complementary questions to be addressed within a study. For this 
study neither a quantitative nor a qualitative approach alone would have been adequate 
to develop multiple perspectives and provide a complete understanding of the different 
research questions. For the first phase, a quantitative approach was utilised to collect 
data to assess the physical and psychological impact of MS on patients with MS. This 
enabled three of the research questions to be addressed: (1) ‘Is assessment of HRQoL 
in patients with MS feasible in daily clinical practice?’, (2) ‘Can the results of HRQoL 
assessment be used to inform therapeutic interventions?’ and (3) ‘Can a HRQoL 
measure detect change in HRQoL after the implementation of interventions?’ 
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To further understand the quantitative data, a qualitative approach was used. 
Denscombe (2014) describes how qualitative research is used to see things ‘in context’ 
and for stressing how things are related and interdependent. Semi-structured 
interviews were conducted to address the use of the questionnaire. For example, it was 
not evident from the quantitative phase whether the patient-participants found using 
the questionnaire to be beneficial and if so why. The results from an initial analysis of 
the data from the quantitative strand were used to aid the selection of patient-
participants for the qualitative strand during which information was gathered about 
the merits and issues of using the questionnaire. Thus, the benefits of using the MSIS-
29v2 were investigated from a patient perspective; the quantitative data being 
enhanced by qualitative data. The qualitative approach was also used to determine an 
in-depth view of healthcare professionals’ perceptions of the feasibility and benefits 
of using the MSIS-29v2 in daily practice. Utilising a qualitative methodology enabled 
the views of the study participants to be gathered in a way which quantitative methods 
are unable to achieve. This strand of the research allowed the research question, ‘Does 
assessment of HRQoL with an appropriate measure make a meaningful difference to 
patients?’ to be addressed. 
Through utilising a mixed method approach I was able to draw on the strengths of both 
the quantitative and qualitative approaches and minimise the weaknesses as suggested 
by Burke Johnson and Onwuegbuzie (2004) and Bryman (2008). For example, a 
quantitative-only methodology may focus on numerical data and lack the ability to 
gather data related to understanding the context of participants’ behaviour, whilst a 
qualitative-only methodology may be seen as being subjective and lacking reliability 
and validity (Creswell and Plano Clark, 2011). Using only quantitative methods would 
also risk missing a wealth of rich data available if the participants’ viewpoints were 
not examined qualitatively. The credibility of this research was also enhanced as 
employing both qualitative and quantitative methods improves the integrity of the 
findings as suggested by Bryman (2006). 
When conducting mixed methods research challenges may be encountered. The 
process is time consuming; for this research conducting and writing up two studies 
within the time frame of the PrD was extremely challenging. Also, the work must be 
clearly presented and the rationale for all steps fully explained; this proved to be a 
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steep learning curve for myself. I have endeavoured to provide a full account of the 
methodology and methods for the readers of this work. 
In summary, a mixed methods approach was deemed appropriate for this project as it 
enabled all the research questions to be addressed. This study follows an emergent 
mixed methods design as described by Creswell and Plano Clark (2011). An 
explanatory sequential design allowed for different research questions to be addressed; 
the secondary research questions required data to be collected in different ways to 
enable the primary research question to be answered. 
4.4 STUDY DESIGN AND METHODS 
The aims of phase 1 and the associated study design and methods are described in 
section 4.5, expanding on the information presented earlier in this chapter. The aims 
of phase 2 and a description of how the pragmatic and grounded theory-informed 
approaches affected sample selection, data collection and analysis for phase 2 is given 
in section 4.6. 
The ethical issues relating to this study in general are discussed in the following 
sections. 
4.4.1 Ethical Considerations 
A variety of ethical issues must be considered before commencing social research 
(Kimmel, 1988) as ethical concerns permeate every aspect of the design and execution 
of a study. Polit and Beck (2004) suggest that the type of ethical issues encountered in 
quantitative and qualitative research differ slightly due to the more intimate nature of 
the relationship that typically develops between researchers and study participants 
within a qualitative study. Ethical issues relevant to protecting research participants 
throughout this study included informed consent, voluntary participation, risks and 
benefits, anonymity and confidentiality, and data storage. These topics are briefly 
discussed in the following sections and related to the two designs throughout sections 
4.5 and 4.6. 
4.4.1.1 Informed Consent 
Informed consent means that participants have adequate information regarding the 
research, are capable of comprehending the information, and have the power of free 
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choice enabling them to consent to, or decline, participation voluntarily (Polit and 
Beck, 2004). Thus, to provide potential participants with information about the 
studies, two information sheets were developed, one for phase 1 and one for phase 2 
(Appendix D, Appendix O). All written information, including the consent forms, 
followed the guidelines of Anglia Ruskin University and the NHS Health Research 
Authority. 
4.4.1.2 Voluntary Participation 
Parahoo (1997) discusses how as a researcher, a nurse must not use their position to 
recruit participants unfairly. The potential participants could be considered to be a 
captive audience (Denscombe, 2014). As there is a power differential between myself 
and the patients, care was taken when writing the patient information leaflet to stress 
that participation was voluntary. 
4.4.1.3 Risks and Benefits 
The RCN (2011, p9) states that ‘participants should be informed of the possible risks 
or burdens of taking part in a research project’. A risk is considered to be something 
that may pose as a potential harm to participants and can include injury, emotional 
distress, loss of self-esteem or embarrassment. This principle is reiterated by Parahoo 
(2014) who describes one of the most important aspects of research as protecting 
participants from harm and ensuring that the rights of these humans are protected. 
I considered there to be a potential risk to participants of emotional distress as a 
consequence of completing the HRQoL questionnaire or taking part in a semi-
structured interview. Issues surrounding the illness and its symptoms, which the 
participant might not normally choose to discuss or had learnt to live with and so not 
considered an issue, had the potential to be highlighted by the questionnaire and thus 
cause distress or upset. Additionally, completing the MSIS-29v2 could give 
participants an unwelcome insight into their own level of health and functioning, 
possibly causing them to reflect on their condition. Cartwright (1987) suggests that it 
is reasonable to ask people about things that they might find painful or embarrassing, 
providing they are discussed in an appropriate context. A referral would be made for 
counselling if required. 
The RCN (2011) also suggests several perceived benefits of taking part in a research 
study. As a chronic disease MS affects many aspects of a patient’s life. Assessments 
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of healthcare needs and treatment decisions can be informed by a HRQoL assessment 
(Higginson and Carr, 2001). Thus, interventions could be offered which may not have 
been considered if the MSIS-29v2 had not been used. Additionally, interventions 
could potentially be offered at an earlier stage than without the use of the 
questionnaire, possibly resulting in an improved quality of life. The principles of 
beneficence, ‘the requirement to benefit the patient and an underlying principle in all 
medicine, health care and research’ (Faden and Beauchamp, 1986) were thus adhered 
to. 
4.4.1.4 Data Storage 
To protect participants data must be stored in compliance with the current 
requirements of the Data Protection Act (1998) (Gooch and Williams, 2015). All 
documentation pertaining to the research, including consent forms, sociodemographic 
forms, completed questionnaires and interview transcripts were stored in my office. 
The digital interview recordings were stored electronically on the main hospital server 
and will be destroyed three years after completion of the study thereby allowing time 
for publication. 
4.4.1.5 Insider-Researcher 
Ethical issues may arise with regards relations between researchers and participants 
during the course of research. For this research my position as an MS nurse with prior 
professional contact to both patient and staff participants would indicate that I was an 
insider-researcher. As such there was already a relationship with the participants, a 
level of trust and rapport having previously been developed. As suggested by Polit and 
Beck (2004) I was acutely aware that special care was required to avoid exploiting this 
bond. As previously stated care was taken to ensure voluntary participation. 
My relationship with the staff at my place of work meant that throughout the research 
period I drew on the shared understandings and trust of my colleagues with whom I 
have developed the normal social interactions of a working community and in 
particular the two members of staff who were most involved in this work. Again, I 
was acutely aware of the need to not exploit this bond. Respecting their views and 
ways of working and demonstrating care for others was key to the success of this 
research. 
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4.4.2 Ethical Approval 
Prior to commencement of phase 1 ethical approval was sought from the National 
Research Ethics Service Committee, London - City & East in May 2014. Following 
an initial review of the application by the panel, my supervisor and I were asked to 
present and defend the research at meeting in London. Subsequently, further questions 
were submitted in writing by the panel. Once satisfactorily answered ethical approval 
was granted in August 2014. The REC reference for this research is 14/LO/1178 
(Appendix B). The research proposal was approved by Anglia Ruskin University 
Faculty of Health, Social Care and Education Research Degrees Sub Committee in 
July 2014. Research and development approval was obtained from Mid Essex 
Hospitals NHS Trust in August 2014 (Appendix B). 
During the meeting for phase 1 concern was raised about whether the data from phase 
1 would enable the research questions to be fully addressed. In response to some of 
the queries, and in consultation with my supervisor, I decided that the study would be 
much stronger if I included a second phase. Thus, a substantial amendment was 
submitted for ethical approval. Following clarification of several points, as detailed in 
Appendix M, ethical approval for this phase was granted by the National Research 
Ethics Service Committee, London - City & East in August 2015 (Appendix M). 
Research and development approval for this second study was obtained from Mid 
Essex Hospitals NHS Trust in September 2015 (Appendix M). 
4.5 PHASE 1: A QUANTITATIVE STUDY 
4.5.1 Introduction 
This section details the rationale for phase 1. Baumstarck, et al. (2013, p.4) state that, 
‘to our knowledge there are no studies that have explored the effect of assessing QoL 
in MS care management’. This phase of the research explores the effect of an 
assessment of HRQoL in the outpatient setting of a district hospital. 
Chapter 4 Research Design and Methodology 
93 
 
4.5.2 Aims 
The purpose of this phase of the study was to address the research questions: 
• Is assessment of HRQoL in patients with MS feasible in daily clinical practice? 
• Can the results of HRQoL assessment be used to inform therapeutic 
interventions? 
• Can a HRQoL measure detect change in HRQoL after the implementation of 
therapeutic interventions? 
4.5.3 Study Design 
Phase 1 was the first part of the explanatory sequential design of this research project. 
A quantitative deductive approach was used for this phase, a longitudinal prospective 
panel design being followed (de Vaus, 2001). Whilst a longitudinal design allowed the 
measurement of change over time, a panel design involved repeated surveys of the 
same participants. The panel design enabled change at the individual level to be 
examined. As data was collected on several occasions the study was prospective in 
nature. A key strength of a longitudinal study is the ability to measure change in 
outcomes at the individual and group level. 
A prospective longitudinal panel study design lacks a randomised control group, a 
consideration raised by the National Ethics Research Service. This meant that 
potentially it would not be possible to know whether any change was due to an 
intervention initiated at the outpatient appointment, the lapse of time since last 
appointment, stability of the MS, shift response or some other influence (de Vaus, 
2001). The analysis of longitudinal data will however typically create statistical 
control groups (de Vaus, 2001). In the case of this research the sample sizes were too 
small to allow propensity matching and thus a control group could not be formed. 
In the design and execution stages of a longitudinal study de Vaus (2001) suggests 
that there are a number of methodological, practical and ethical issues to resolve. 
Whilst some of these are concerned with maximising internal and external validity, 
others are concerned with completing the study. de Vaus (2001, p.145) states that 
‘voluntary participation must remain the basis on which people continue to 
participate’, participants being aware that they can withdraw from the study at any 
time (Bowling, 2014). It was therefore imperative to check for voluntary participation 
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immediately prior to the time a questionnaire was offered for completion, as described 
in section 4.5.2. 
During phase 1 the physical and psychological impact of MS from the participants’ 
perspective was assessed using the MSIS-29v2 at each outpatient appointment 
attended over a twelve-month period. The results of the assessment were used to 
identify problems and guide interventions. The influence of these interventions on the 
physical and psychological impact of MS was assessed through further assessments. 
During data analysis the pre-intervention impact scores were compared with the post-
intervention impact scores, changes in the scores potentially reflecting the influence 
of those interventions taken up on the physical and/or psychological impact of MS for 
the participant. A health transition question was used to determine patient-perceived 
changes in health-related quality of life since previous review. Qualitative data was 
also collected via a comments box located at the end of the questionnaire. 
4.5.4 Methods 
Within a longitudinal study de Vaus (2001) suggests that a number of decisions must 
be made about the structure of the study. These include the setting, the number of 
times the participants are followed up, the overall duration of the study, the use of 
interventions, and the way attrition is dealt with. These issues are considered in the 
following sections. 
4.5.4.1 Site Selection 
This research was undertaken in the outpatient departments of an acute hospital and a 
community hospital, both of which form part of an NHS Trust in the Eastern Region 
of the UK. Myself and the other two healthcare professionals involved in the research 
are employees of this NHS Trust. 
4.5.4.2 Sample Size 
Before the onset of the study advice was sought from a statistician at Anglia Ruskin 
University concerning the number of participants required to achieve the necessary 
statistical power. The primary outcome measure in this study was the change in the 
overall physical and psychological subscale scores of the Multiple Sclerosis Impact 
Scale version 2 (MSIS-29v2). Following Hobart and Cano (2009), when scaled to 
standardised units, the overall physical impact subscale has a standard deviation of 
1.312 and the overall psychological impact subscale has a standard deviation of 1.211 
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units. A quarter of the larger standard deviation (0.328) is regarded as the minimum 
clinically important difference that it is required to detect. For a t-test at the 5% 
significance test to have a power of 80% to detect this change the minimum number 
of evaluable volunteers is 253. However, it was expected that the combined non-
response rate and discontinuation rate could be about 50% and so a precautionary 600 
patients needed to be approached to take part in the study. 
4.5.4.3 Participants 
To be eligible to take part in the research patients had to have a diagnosis of clinically 
definite MS as determined by a neurologist. They also had to be fluent English 
speakers as they needed to be capable of understanding the questions of the two data 
collection tools. Patients with cognitive impairment were not immediately excluded 
as this is a common symptom in MS (see section 3.10.1). If a patient was physically 
unable to complete the questionnaire but were deemed by the healthcare professionals 
involved in the research to have the cognitive ability to do so they were included in 
the study providing a partner or friend was available to record their responses. 
The sample of patients was drawn from the population of MS patients who had been 
reviewed at the two hospital sites between 1st August 2013 and 31st July 2014. Patients 
were identified using the patient administration system of the NHS Trust. Deceased 
patient names were removed using the tracer system, thereby preventing information 
being sent out inappropriately. A local database was also checked to ensure 
information was not sent to patients who had moved away from the area and thus were 
no longer under the care of the NHS Trust where this research was carried out. 
Five hundred and ninety-eight unique patients were identified from the hospital 
administration system as having been reviewed at least once within the above stated 
twelve-month period. All were diagnosed with clinically definite MS and were fluent 
English speakers and therefore eligible for inclusion in phase 1. Of these, six had 
moved away from the area prior to the commencement of the research. Thus, 592 
patients were invited to participate in phase 1 (Chapter 5, Figure 9). It is acknowledged 
that this method of sampling can threaten the external validity of the study as certain 
types of people are more likely than others to decline to take part, e.g. older people (de 
Vaus, 2001). By using a large number of participants, I hoped to achieve a 
representative sample, thereby enabling external validity to be demonstrated. 
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4.5.4.4 Recruitment 
Potential participants were approached by post and invited to take part in this research. 
An introductory covering letter (Appendix C), patient information sheet (Appendix D) 
describing the nature of the research, its rationale, and introducing the assessment tool, 
consent form (Appendix E), an example of the data collection tool (MSIS-29v2) 
(Appendix G) and freepost envelope were sent out to potential participants. 
Denscombe (2014) suggests that presenting an example prior to commencing the 
research can set the potential participant’s mind at rest and indicate exactly what is 
expected of them. Patients thus had the option to review the research, decide if they 
wished to participate and then sign their consent form in their own home. The aim of 
this process was to try and ensure voluntary participation. Many potential participants 
have known me for a long time and a strong relationship exists. I anticipated that by 
consenting at home they were less likely to feel obliged to take part in the study than 
if consent was sought in clinic. I suspected that some might have believed that they 
would cause upset by not agreeing to take part if they had to inform the nurses directly 
in clinic. Also, I did not consider taking consent during a clinic appointment to be 
feasible. Appointments are of twenty minutes duration and so the consultation time 
would have been reduced and almost undoubtedly the quality compromised. 
Potentially, the clinic appointment would overrun causing delays for patients, both 
those taking part in the research and those not involved. No coercion or persuasion 
was used to recruit the participants for this study, a potential issue highlighted by 
Denscombe (2014). If a patient stated that they did not wish to take part in the research, 
they were reassured that their decision was respected and would not affect their care. 
No pressure was placed on that patient to change their mind and take part. 
Potential participants were given two weeks to consider whether to take part during 
which time queries and concerns could be addressed. Details of how to contact the 
myself and academic supervisor were provided; several queries were received and 
addressed accordingly. A closing date of 31st October 2014 was given for receipt of 
consent forms but, forms received up to and including 14th November 2014 were 
accepted. A pre-paid envelope was included enabling those patients who wished to 
take part to return their signed consent form without incurring a cost. Participants were 
given a copy of their signed consent form during their first outpatient appointment 
following commencement of the research. 
Chapter 4 Research Design and Methodology 
97 
 
It was important to maximise the response rate as a large number of participants were 
required for statistical significance to be achieved (see 4.5.4.2). It is recognised that 
the willingness of people to take part in research is affected by certain factors including 
the nature of the respondents and the subject of the research (Denscombe, 2014). Time 
pressures, sight problems, cognitive issues, and severe fatigue can also potentially 
affect the response rate. Fatigue is reported in 53-90% of patients with MS (Fisk, et 
al., 1994; Bakshi, et al., 2000). The enquiring nature of the research and the 
relationship to the researchers might also have influenced the response rate. Research 
participants may be motivated to complete a questionnaire through interest, altruism, 
because they feel pressurised to do so, or for an unconscious ulterior motive such as 
pleasing the researcher (Boynton, 2004), all of which introduce potential bias into the 
recruitment and data collection process. 
The participants’ GPs were also informed of their participation in the research 
(Appendix F). 
4.5.4.5 Identification Numbers 
In this phase, two main types of data were collected: sociodemographic and clinical 
data and, responses from the MSIS-29v2. To maintain confidentiality each participant 
was assigned an identification number. The participants were numbered sequentially 
in the order they had attended clinic in the previous twelve-month period. The 
identification numbers enabled me to link an individual to a questionnaire, this being 
essential for the longitudinal aspect of the study. Participant numbers rather than 
names were recorded on all forms. 
4.5.4.6 Integration into Practice 
As this research is clinically based, integration into the routine of the two clinical nurse 
specialists for MS and the consultant neurologist was essential for the duration of the 
study. Implementing HRQoL assessment in routine clinical practice to aid individual 
patient management involves a number of methodological and practical decisions 
(Snyder, et al., 2012). From a theoretical perspective, the implementation of the MSIS-
29v2 into the consultation process of an outpatient appointment represented a 
significant change and challenge to the clinical practice of the individual clinicians 
involved in the research. 
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To facilitate the integration process, prior to the initiation of data collection, a copy of 
the paperwork sent to the potential participants was given to the other two health 
professionals involved in the study with a covering letter. All questions were 
addressed. An information sheet about the research was also given to the outpatient 
sisters of the two departments where the research was occurring. I provided the other 
CNS involved in data collection with training in the use of the MSIS-29v2 and 
sociodemographic data collection tool prior to commencement of the study; all 
questions were answered, and reassurance given concerning her practice and role in 
the research process. 
The feasibility of assessment of HRQoL was considered throughout phase 1. The 
practical issue of giving participants questionnaires was studied, and the patients’ 
ability to complete the questionnaire observed. Staff were encouraged to discuss 
difficulties as they arose. Feasibility was further examined through the phase 2 
interviews. 
4.5.4.7 Data Collection 
Self-completion questionnaires were chosen for this phase as I wanted to test a method 
of data collection which could potentially be used in everyday clinical practice. Also, 
information was required from a large number of patients to demonstrate external 
validity. As a research tool, questionnaires do not set out to change people’s attitudes, 
rather their purpose is to discover things (Denscombe, 2014); in this research, the 
impact of MS on two domains of HRQoL. The MSIS-29v2 can be considered to be a 
survey and as such it provides a snapshot of how things are at the time at which the 
data is collected (Denscombe, 2014); in the specific case of this survey participants 
were asked to reflect back over the previous two weeks. 
There are advantages and disadvantages of using questionnaires such as the MSIS-
29v2. Data is easily collected using a questionnaire and may be readily analysed. The 
main reasons for selecting the MSIS-29v2 were that it is quick for participants to 
complete, relatively simple to score and can be analysed quickly in the presence of a 
patient. 
Denscombe (2014) suggests that questionnaires are relatively easy for respondents to 
answer as they do not need to think how to express their idea, rather they only need to 
select one of the answers listed. However, using a structured questionnaire can be 
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frustrating and restricting if the supplied answers do not represent the respondents 
view (Bowling, 2014) or describe their condition (Fayers and Machin, 2016). Boynton 
and Greenhalgh (2004) also describe how closed ended questions can cause 
frustration, particularly if a participant does not feel that the questionnaire covers all 
responses. Ringing an answer may make respondents want to explain their answer. 
Thus, a free text comments box was added at the end of the questionnaire allowing 
respondents to explain their answers and provide additional information as they 
wished. Boynton and Greenhalgh (2004) suggest that free text annotations may add 
richly to the quantitative data. 
Several potential problems of self-administration required consideration when 
designing the research. There is often missing data (Hays, et al., 2009). This was 
addressed during the appointment if detected by the nurse. Self-administration is 
potentially a problem for patients with MS who often have poor cognitive function 
and potentially cannot recall how their MS has affected them the last two weeks. 
Bowling (2014) suggests that recall will depend on the saliency of the topic to the 
patients. Also, completion is only possible for those who have sufficient reading and 
comprehension skills (Hays, et al., 2009). Poor manual dexterity may also cause 
problems when completing questionnaires. Friends or relatives were often observed 
helping complete the questionnaire in this situation. A question was added to the 
MSIS-29v2 asking whether help was required to complete the questionnaire. 
Unfortunately, there was no way of determining if the participant had actually been 
involved in completion of the questionnaire. 
Font size may also require consideration. One participant has extremely poor vison 
and struggled to complete the questionnaire. The questionnaire was therefore 
reproduced in larger font for subsequent appointments; unfortunately, the participant 
did not attend his next appointment within research period. 
It is generally considered that the data obtained through self-administration is less 
reliable than face-to-face interviews because there is no interviewer present to clarify 
questions as at the time of completion (Bowling, 2014). For this research this was not 
considered to be an issue as the healthcare professionals in clinic were able to explain 
questions as required. 
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4.5.4.8 Data Collection Tools 
Both measures were piloted for one week prior to the start of the data collection period. 
No issues were detected during this time. 
a. Sociodemographic Data 
Sociodemographic data was collected using a structured questionnaire (Appendix H) 
designed specifically for this study to help describe the sample and demonstrate its 
representativeness. Gender, date of diagnosis, age, type of MS, marital status, number 
of children, and employment status were recorded. 
Bowling (2014) suggests that there is generally a high level of reported concordance 
between medical record data and patient’s report of their conditions. In relation to 
medical conditions, recall will depend on the amount of information given by health 
professionals and whether it is understood and remembered at the time. Recall was 
found to be an issue, particularly with regards patients knowing when they were 
diagnosed and their type of MS. Thus, clinical characteristics, including age at 
diagnosis and type of MS, were validated using the medical notes. 
b. MSIS-29v2 
For the reasons presented in section 3.13.1, the MSIS-29v2 was selected for this phase. 
Three additions were made; participants were asked if they required help to complete 
the MSIS-29v2, a free text box enabling comments to be collected was added and a 
health transition question included. 
Central to the importance of measuring patient-reported outcomes are methods that 
evaluate changes in health-related status over time. Health transition questions (HTQ) 
do this by directly asking respondents to assess whether they consider their health or 
functioning to have stayed the same, improved, or worsened compared with a previous 
time point, often a pre-intervention time point. Cella, Hahn and Dineen (2002) 
describe a health transition question as a measure of subjectively meaningful change 
from the patient’s perspective which is useful in clinical decision-making. The 
following HTQ was added at the end of the MSIS-29v2: 
‘Since you last completed a questionnaire do you think that your 
quality of life has significantly improved, slightly improved, no change, 
slightly deteriorated, significantly deteriorated? 
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This brief retrospective question added value as it provided another perspective from 
the patient concerning changes in their quality of life. However, reliability and validity 
could not be achieved as inter-item consistency, the usual test of reliability for multi-
item scales is not possible for single items (Norman, Stratford and Regehr, 1997). 
They also describe the issue of ‘present state bias’, where subjects are inclined to judge 
their change in health status in relation to their present health status; respondents with 
good health at follow-up are more likely to assume their health has recently improved, 
and respondents with poor health at follow-up are more likely to assume it has 
worsened. 
4.5.4.9 Distribution of Data Collection Tools 
At the Acute Trust of this research, a nurse from the outpatient department is allocated 
to each multi-professional clinic. Once in the waiting room the outpatient nurse 
verified whether participants were still willing to participate in the research. Affirming 
participants were then given the MSIS-29v2 to complete prior to their appointment. 
The CNS running nurse-led clinics followed the same procedure. 
At the outlying Community Hospital, the outpatient receptionists gave out the data 
collection forms. The patients’ medical notes are kept at the check-in desk. The 
clipboard with the questionnaire was slotted into the patients’ notes. The receptionist 
agreed to ask the participants if they were willing to continue participating and if an 
affirmative was given, then the clipboard was given to the participant. Participants 
were allowed time to complete the questionnaires prior to entering the consulting 
room. 
All participants also gave written consent via the ‘yes/no’ option on the MSIS-29v2. 
If a participant withdrew from the research their wishes were respected and no 
coercion was applied to encourage them to continue. Socio-demographic forms were 
also given out at the first appointment during the research period. 
Participants could have potentially completed the MSIS-29v2 at home before their 
outpatient appointment. However, there are additional resource implications for this 
option; time would have had be made available to send out the questionnaire and the 
cost of postage would need to be considered. Also, this approach relies both on patients 
completing the measure at home and bringing it with them to their clinic appointment. 
For these reasons this method was not considered feasible for this research study. 
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4.5.4.10 Duration of Phase 1 
Data was collected using the MSIS-29v2 over a twelve-month time-period, from 24th 
November 2014 to 22nd November 2015. 
4.5.4.11 Use of the MSIS-29v2 during the Consultation 
Snyder, et al. (2012) describe how processes are required to manage data, to ensure 
timely review of the data, and to respond to patients’ identified needs. Each completed 
MSIS-29v2 was reviewed and interpreted with the participant during their clinic 
appointment. Questions were elucidated by the nurse running the clinic when 
participants asked for clarification. The responses given to the 29 questions of the 
questionnaire were used to guide the consultation. The answer for each question was 
considered and discussed as appropriate, enabling potential interventions to be 
discussed with the participant. This discussion informed any changes in care in a 
shared decision-making process. All treatments and interventions, both 
pharmacological and non-pharmacological, commenced, altered, stopped or declined 
were recorded on the intervention recording sheet (Appendix I). After each 
appointment, the MSIS-29v2 was scored for both the physical and psychological 
dimensions. 
When the MSIS-29v2 was used at a subsequent appointment previous questionnaire/s 
and intervention recording sheets were available for comparison. Impact scores were 
available for earlier questionnaires. The responses were reviewed with the participant, 
and changes in both individual question and impact scores examined and discussed, 
enabling a comparison between the response at appointment T2 and the response at 
T1, or T3 and T2 etc. The effect of the intervention/treatment on the physical and/or 
psychological impact score was assessed and discussed with the participant during the 
consultation. A change in scores could indicate that an intervention had made a 
difference to one or both of the dimensions of HRQoL being assessed. 
The response to the health transition question was also discussed. The participant’s 
perception of any change in their condition was compared with the impact scores and 
the results discussed. The participant was asked how they felt about any changes in 
their scores and what it actually meant to them. This aspect is further explored in phase 
2 (section 6.3.4.2e). Table 3 (section 4.5.4.12) illustrates the use of the MSIS-29. 
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Panel conditioning may occur in longitudinal studies when participants respond to 
questions in ways that are influenced by their previous exposure to the same questions 
(de Vaus, 2001). When a second or third questionnaire was given to participants to 
complete they also had access to previous ones. Hence, they could compare and 
contrast before, during or after completing the current survey. I would suggest that this 
could potentially have influenced their responses which threatens the external validity 
of this research. I am therefore aware of the need to be cautious about any claims made 
from this work. This issue could be avoided in future studies by only giving 
participants the questionnaire they were required to complete that day. Participants 
may also have attributed changes in their HRQoL to an intervention when really the 
effect was due to them taking part in the study, thus threatening internal validity. If 
the use of the MSIS-29v2 becomes embedded in routine clinical practice access to 
previous questionnaires would not be an issue as they would be filed in the case notes 
after each appointment. 
de Vaus (2001) also details how, if participation in a longitudinal study produces 
change because it alerts participants to matters that they would not otherwise think 
about, it is difficult to say that any changes observed in the study will take place in the 
wider world. Several participants described how using the MSIS-29v2 highlighted 
symptoms to them that they were not aware of, whilst others described how as a 
consequence of completing the questionnaire they had made changes in their life such 
as initiating adaptations at home. 
4.5.4.12 Frequency of Assessment 
Within a longitudinal study frequency of assessment must be considered. In this 
research, assessments were linked to outpatient appointments (Table 3, below). de 
Vaus (2001) suggests that the gap between introducing an intervention and the post-
test, i.e. re-administering the questionnaire, is influenced by previous experience of 
how long it would take for an effect to be detectable. One of the aims of this research 
was to detect changes in HRQoL after the implementation of various therapeutic 
interventions. Thus, a review was booked at an interval deemed appropriate for an 
intervention to have taken effect; this was usually after three, four or six months. For 
example, if a patient was offered a course of intravenous steroids they were reviewed 
after three months as this is when the optimum benefit derived from the medication 
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will be evident. This interval should demonstrate the effect of any intervention 
initiated through a change in the MSIS-29v2 scores. 
Appointment Assessment Discussion Plan 
First outpatient 
appointment in 
research period 
(T1) 
 
Initial 
HRQoL 
assessment 
during 
outpatient 
appointment 
Treatments and 
interventions suggested 
and discussed as 
appropriate 
Next outpatient 
appointment agreed 
with patient, 
considering any 
changes in care 
Second 
appointment 
during research 
period (T2) 
Further 
HRQoL 
assessment 
during 
outpatient 
appointment 
Effect of treatments and 
interventions on 
HRQoL discussed with 
participant 
Changes in HRQoL 
discussed with patient 
HTQ response discussed 
Further treatments and 
interventions suggested 
and discussed as 
appropriate 
Next outpatient 
appointment agreed 
with patient, 
considering any 
changes in care 
Third and 
subsequent 
appointments 
during research 
period (T3, T4, 
T5) 
As above 
Table 3 Summary of the assessment process using the MSIS-29v2 
If no intervention was necessary then the participant was reviewed at an interval 
agreed mutually between the clinic nurse and the participant, taking into consideration 
the stability of the patient’s MS and/or any disease modifying therapy they were 
receiving. More frequent assessment can provide a more complete picture for patients 
who are very symptomatic and/or in active treatment (Snyder, et al., 2012). Less 
frequent assessment is less burdensome and may be appropriate for generally healthy 
patients (Greenhalgh, Long and Flynn, 2005). These timings of assessment fit well 
with the recommendations of CG186 (2014) which suggests that frequency of review 
is based on the needs of a patient and those of their family and carers, and the 
frequency of review required for disease-modifying therapies. CG186 (2014) also 
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recommends that all people with MS have a comprehensive review of all aspects of 
their care at least once a year. 
Those participants who were reviewed more than once within the time frame of the 
study completed the MSIS-29v2 at their first and all subsequent appointments within 
the research period. 
4.5.4.13 Statistical Analysis 
Computer software packages are often used to facilitate data analysis. After outpatient 
appointments, the data from the MSIS-29v2 and socio-demographic forms was 
entered into Microsoft Excel. The data was then checked for accuracy of inputting. 
Subsequently, the data was transferred to Statistical Package for Social Scientists 
(SPSS) (Version 24), (SPSSv24) where it was cleansed; frequencies were then 
checked to ensure data had been accurately entered. Once clean, personal identifiable 
information was removed. 
When examining the questionnaires, it was evident that not all questions had been 
answered. Hobart and Cano (2009) describe how when some questions have not been 
endorsed by an individual, a total score can still be computed providing that at least 
50% of the questions have been answered (i.e. ten or more physical impact questions; 
five or more psychological impact questions). Under these circumstances each missing 
question score can be replaced with the person-specific question mean score, i.e. the 
mean score of the items completed by that individual. This process is known as 
imputing and is considered psychometrically sound (Ware, et al., 1993). Hobart and 
Cano (2009) suggest that replacing missing data with the person-specific mean score 
raises concern as an assumption is made about how a person would have responded to 
an item. Another approach is to use only the answered questions to generate a score. 
In either case, Hobart and Cano (2009) suggest that it is questionable whether an 
accurate score can be determined if not all the questions have been answered. For this 
research I chose the option of imputing. 
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The MSIS-29v2 comprises 29 questions, each of which was scored from 1-4 as 
described in section 3.13.1. The physical and psychological impact scores were 
calculated as follows: 
Physical impact score (%) = (
∑ 𝑥𝑖−20
20
𝑖=1
60
) × 100, 
where 𝑥𝑖 is the score in Question 𝑖 
Psychological impact score (%) = (
∑ 𝑥𝑖−9
29
𝑖=21
27
) × 100. 
a. Sociodemographic data 
Descriptive statistics were used to describe the sociodemographic data and clinical 
characteristics of the population. Frequencies, proportions, means and standard 
deviations, medians and inter-quartile ranges were calculated using the computer 
package SPSSv24. 
b. MSIS-29v2 
Data analysis aimed to demonstrate whether the MSIS-29v2 showed responsiveness 
thereby enabling the question: ‘Can a HRQoL measure detect change in HRQoL after 
the implementation of therapeutic interventions?’ to be addressed. In this study change 
occurred at two levels, group and individual. Statistical analysis was performed using 
SSPSv24. 
Responsiveness to change is an important aspect of scale performance. The most 
common method of determining responsiveness is to examine the change scores 
following an intervention of known efficacy. Responsiveness can be assessed using a 
paired-samples t-test; here group mean scores over time were compared. Analysis of 
the data compared the individual post-intervention physical and psychological impact 
scores from the MSIS-29v2 with the pre-intervention physical and psychological 
impact scores. Results are reported as an effect size, a standardised change score. 
These are calculated by taking the mean change score and dividing by the standard 
deviation of the score. In general, an effect size of 0.2 has been interpreted as small, 
one of 0.5 moderate and one of 0.8 or greater as large (Cohen, 1988). 
I was also interested to know if a minimally important change could have been 
determined. The concept of minimally important change in the MSIS-29v2 is 
important in both clinical and research studies as it is necessary to know whether a 
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change in the MSIS-29v2 score reported by the patient is clinically relevant and 
identifies a meaningful change to that patient. There is little discussion concerning this 
aspect for the MSIS-29v2 in the published literature. Phillips, et al. (2014) describe 
how understanding which patients achieve a change in score that represents an 
important and non-trivial improvement or decline from their perspective is essential. 
The term minimally important difference (MID) describes the threshold that identifies 
an important level of individual change over time. The minimum clinically important 
difference can be calculated by dividing the mean change score for minimally 
improved/deteriorated patients by the mean change score for unchanged patients. 
Regrettably, due to the small sample sizes of this research it was not possible to 
consider this aspect. 
Another way to statistically interpret the meaning of the scores on an instrument is to 
use the smallest detectable change (SDC). The SDC is the smallest change that can be 
estimated as a real difference whereby smaller SDC values may be better for detecting 
an intervention effect. A score above the SDC value may be estimated as a meaningful 
change in HRQoL (Beckerman, et al., 2001). Again, due to small sample sizes this 
could not be considered. 
At the individual level, changes in the physical and psychological domains of HRQoL 
were assessed once two or more questionnaires had been completed. The impact scores 
of the second questionnaire were compared with the first, the third with the second 
and so on. Possible reasons for the changes were analysed with the relevant participant. 
Differences may reflect the influence of an intervention on HRQoL. 
Another method of estimating the ability of instruments to detect change is by 
comparing change scores on a health status instrument with an external criterion of 
change such as a health transition question. An important consideration for this 
research concerned the relationship between change in the two impact scores and 
patient reported change, as indicated by the HTQ. In this study participants assessed 
the amount of change in their HRQoL retrospectively using the HTQ located at the 
bottom of the MSIS-29v2. Responsiveness could then be determined by correlating 
change scores with the transition question. The responses to the HTQ were analysed 
as a categorical variable and are rated from 2 (significantly improved) to -2 
(significantly deteriorated). These scores were statistically and manually compared 
with the MSIS-29v2 physical and psychological impact scores. The comments from 
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participants in the free text box were analysed, predominantly providing context for 
certain quantitative responses or changes in HRQoL.  
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4.6 PHASE 2: A QUALITATIVE STUDY 
4.6.1 Introduction 
This section describes the rationale for phase 2. The literature reviewed in chapter 3 
revealed a dearth of knowledge about assessment of HRQoL in patients with MS 
during a routine outpatient appointment from either the patient or healthcare 
professional perspective. This study was designed to gather the views and opinions of 
study participants concerning HRQoL assessment using qualitative methods. 
Establishing the views and opinions of those taking part in this research was important 
to help ensure the relevance and quality of the research. 
4.6.2 Aims 
The purpose of this study was: to explore the views and perceptions of patients with 
MS about whether they felt that using a questionnaire, namely the MSIS-29v2, to 
assess two dimensions of HRQoL had made a difference to them, to their consultation 
and to the care they received. Also, to explore the views of healthcare professionals 
concerning the use of the MSIS-29v2 during outpatient appointments. 
By investigating from the insider’s perspective, I hoped that the findings, in 
combination with those from phase 1, would provide a rich and insightful 
understanding of the impact of assessing two dimensions of HRQoL. 
Phase 2 aimed to answer the following questions: 
• Is assessment of HRQoL feasible in daily clinical practice? 
• Can the results of HRQoL assessment be used to inform therapeutic 
interventions? 
• Does assessment of HRQoL with an appropriate measure make a meaningful 
difference to patients? 
thereby contributing to answering the main research question: 
• Is there a role for the assessment of health-related quality of life in patients 
with multiple sclerosis in daily clinical practice? 
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4.6.3 Study Design 
There are a number of approaches to qualitative research; two of the best known are 
phenomenology and grounded theory. In this study, I have conducted an in-depth 
analysis of qualitative data drawing on the broad principles of grounded theory (GT) 
but acknowledge that I have not taken a purist approach. This phase is informed by, 
but does not adhere strictly to, all of the principles of GT. Grounded theory seeks to 
describe and understand key social, psychological and structural processes that occur 
in a social setting, i.e. the lived experience. In this phase of the research, the 
participants experience of completing the MSIS-29v2 was examined and the impact 
this had on them explored. 
As an approach, grounded theory is dedicated to generating theories and emphasises 
the importance of empirical field work and the need to link any explanations very 
closely to what has happened in practical situations in ‘the real-world’ 
(Denscombe, 2014). It is regarded as a rigorous qualitative approach that incorporates 
a set of procedures or fundamental operations to inductively develop a theory or 
explanation of a social or social-psychological process or phenomenon. 
Grounded theory can be used in nursing to explore complex social phenomena or that 
for which there is little or no theory (Glaser and Strauss, 1967; Field and Morse, 1994). 
Elliott and Lazenbatt (2005) suggest that grounded theory is being used increasingly 
in nursing research, providing a means of generating theory grounded in the realities 
of everyday clinical practice. Hence, Engward (2013) suggests that grounded theory 
aims to provide an understanding of human behaviour to deliver optimum care by 
exploring patients’ perspectives or experiences of living with a particular condition. 
As described in chapters 1 and 3, there is little written in the literature about the 
phenomenon of the impact of measuring HRQoL and whether it makes a meaningful 
difference to people with MS although benefits have been observed in other groups 
with long-term conditions. I considered a grounded theory-based approach appropriate 
for the qualitative phase of this study. This would enable me to investigate the 
participants’ points of view with regards the use of the MSIS-29v2 and subsequently 
develop a theory concerning the impact of assessment of HRQoL on patients with MS 
during a routine clinic appointment. The overall aim would be to provide a unique 
contribution to the literature. The resulting analysis would potentially guide the future 
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use of health-related quality of life measures in daily clinical practice at my place of 
work and, through the sharing of best practice, within other services. 
The grounded theory approach to qualitative research originated with the work of 
Glaser and Strauss (1967). Both Glaser’s and Strauss’ versions of GT use coding, 
constant comparison of data, simultaneous data collection and analysis, theoretical 
sampling, and memo writing in the process of generating theory. However, when 
reviewing the literature, it became evident that there is no clear-cut way to proceed 
with a grounded theory study, as each researcher brings their own personal stance, 
disciplinary perspective and own way of conducting it (Charmaz, 2006; Bowers and 
Schatzman, 2009; Wasserman, Clair and Wilson, 2009). This, in itself, could be 
construed as indicative of a pragmatic approach to its methodology. Indeed, 
Denscombe (2014, p108) states that ‘the grounded theory approach has its roots in 
pragmatism’. 
The grounded theory-based approach I used was influenced by the stance of Charmaz 
(1990; 2000). She offers a social constructivist approach to grounded theory. 
Ontologically she advocates that ‘social reality does not exist independently of human 
action’ (Charmaz, 2000, p.521) whilst epistemologically she recognises that ‘the 
categories, concepts and theoretical level of an analysis emerge from the researcher’s 
interaction with the field and questions about the data’ (Charmaz, 2000, p.522). 
Charmaz (1990, p.1161) states that the term social constructionist means: ‘(1) Ill 
people’s creation of taken-for-granted interactions, emotions, definitions, ideas, and 
knowledge about illness and self and (2) Researchers’ sociological constructions 
which they develop, in turn, by studying chronically ill people’s constructions’. 
Charmaz (1990) describes how ‘ill people’s’ constructions reflect their understandings 
of their experiences. Also, that grounded theory analysis can provide physicians with 
alternative understandings of patients’ beliefs and actions than those readily available 
in the clinical setting. These two points fit very well with data arising from the 
interviews and also my knowledge, both prior and subsequent to the interviews. 
Grounded theory methods specify data analytical strategies but not data collection 
methods (Denzin and Lincoln, 2000). As a methodology, the grounded theory 
approach is adaptable and as such data may be collected in a way that best addresses 
the research problem. Semi-structured interviews using open-ended questions were 
used for data collection as they allow for the collection of information which is not 
Chapter 4 Research Design and Methodology 
112 
 
unduly shaped by prior concepts or theories. The participants were selected using 
theoretical sampling as described in section 4.6.4.1. 
In the grounded theory approach the raw data is analysed, coded and categorised; 
subsequently theories are generated from the data (Denscombe, 2014). Data analysis 
and data collection occur at the same time with data collection and analysis constantly 
influencing each other. An iterative approach is used. The emerging codes and 
categories are constantly compared with the data and concepts and theories generated 
that help to explain the phenomenon: the constant comparative method. Ryan and 
Bernard (2000) locate thematic coding as a process performed within major analytic 
traditions such a grounded theory. The emerging concepts are grounded in the data 
and have relevance to the practical world from which they were derived. Indeed 
Bryman (2006) describes how the search for themes is an activity that can be discerned 
in most approaches to qualitative data analysis including grounded theory and, 
suggests that GT probably represents the most influential general strategy for 
conducting qualitative data analysis. 
Purists advocate constant comparative analysis in the grounded theory approach. 
Although I did not follow the strict process of data analysis followed by participant 
selection, my method was broadly iterative and reflective. Through listening to the 
interview tapes collected during phase 2, themes appeared which informed those 
selected. Thematic analysis is a method of for exploring the participant’s experience 
of the world and consequently provides a detailed account from an insider’s 
perspective (Braun and Clarke, 2006). This approach identifies, analyses and reports 
themes within the data. Following discussions with my supervisors, thematic analysis 
was deemed the most appropriate form of analysis for this study. 
In accordance with the explanatory sequential design of this research, data collection 
commenced after the quantitative phase finished. Fifteen patients from phase 1 
participated in semi-structured interviews led by myself. The interviews explored the 
participant views of the assessment of the physical and psychological impact of MS 
during outpatient appointments. Two staff-participants were also interviewed to 
examine their views regarding using the MSIS-29v2 in daily practice. The recorded 
interviews were transcribed and then analysed using a thematic approach. Emergent 
themes were refined to establish key themes. The specifics of the design are discussed 
in the following methods section. 
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4.6.4 Methods 
4.6.4.1 Sampling in Grounded Theory 
Theoretical sampling is a central tenet of the grounded theory method (Cutliffe, 2000). 
Glaser and Strauss (1967, p.45) indicate that theoretical sampling, occurs ‘when the 
analyst jointly collects, codes and analyses his data and decides what data to collect 
and where to find them, in order to develop his theory as it emerges. The process of 
data collection is controlled by the emerging theory’. This definition conveys a crucial 
characteristic of theoretical sampling: namely that it is an ongoing process rather than 
a distinct and single stage. Charmaz (2000, p519) also describes how theoretical 
sampling is a ‘defining property of grounded theory’, her paper suggesting that it is 
concerned with the refinement of ideas, rather than boosting sample size. An iterative 
sampling approach is followed whereby the researcher moves back and forth between 
sampling and analysing data such that preliminary analytical findings shapes 
subsequent sampling choices. 
In grounded theory data is collected until theoretical saturation is achieved. Strauss 
and Corbin (1998, p.212) suggest that this occurs ‘when no new or relevant data is 
emerging regarding a category, the category is well developed in terms of its properties 
and dimensions demonstrating variation, and the relationships between the categories 
are well established and validated’. Cutliffe (2000) similarly suggests that in order for 
concepts and categories to emerge during the data analysis, the need for sampling of 
specific data sources continues until each category is saturated. Therefore, at the 
beginning of the study, no limits are set on the number of participants, interviews, or 
data sources. The researcher continues selecting participants until they are saying 
nothing new about the concept being explored. Further interviewees are sought to add 
to the fullness of the understanding of the concept. 
a. Patient-participants 
For this phase of the research, potential participants were selected using theoretical 
sampling. de Vaus (2001) suggests that this approach to sampling may be justified if 
one considers that the research process is one of discovery rather than the testing of 
hypotheses. Before I began to collect and analyse data, I considered my research 
questions and the preliminary results from phase 1. I then determined the issues that I 
wanted to investigate. Thus, the selection of participants was an iterative process based 
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on reflection. The sample size was a function of theoretical completeness as described 
by Baker, Wuest and Stern, (1992) and Cutliffe (2000). 
In the initial phases of a study Glaser (1978) acknowledges that researchers will 
approach those individuals who will maximise the possibilities of obtaining data and 
leads for more data on their question. Also, that they will talk to the most 
knowledgeable people, thereby determining leads for more data. Thus, theoretical 
sampling involves the purposeful selection of a sample in the initial stages 
(Glaser, 1978). The sample of participants for this study emerged from a sequence of 
decisions based on the outcomes of phase 1. Firstly, potential participants had to have 
completed at least two questionnaires to be eligible for inclusion in phase 2 (n=248), 
to enable the responses to the question concerning a change in quality of life to be 
considered. Participants were selected to represent as much diversity of illness as 
possible in terms of disability, duration of illness and age of onset. The responses given 
to the MSIS-29v2 and HTQ were also considered. Five participants, male and female, 
who represented the differing types of MS and had been diagnosed for different 
lengths of time were initially selected for interview thereby following the suggestions 
of Schatzman and Strauss (1973) and Baker, Wuest and Stern (1992) who describe 
how the researcher using grounded theory initiates the sampling process by 
interviewing significant individuals. Morse (1991) describes a good interviewee as 
someone who is articulate, reflective and willing to share with the interviewer. I hoped 
that the individuals selected would represent these points and describe a variety of 
views. Those known to suffer with severe fatigue, communication problems or 
cognitive impairment were excluded as these symptoms are likely to have made 
interviewing problematic. Although I was aware that excluding these patients may 
have limited the interview sample, representativeness was not a key aim of my sample; 
rather I wished to develop an understanding of how patients’ experiences of using the 
measure shaped their consultations. 
One of the aims of the sampling strategy for this research was to achieve maximum 
variation in narratives around assessment of HRQoL. Lincoln and Guba (1985) argue 
that maximum variation within theoretical sampling is best achieved by selecting each 
unit of the sample only after the previous unit has been taped and analysed. This first 
set of data and subsequent analysis acts as a ‘gatekeeper’ and sets the ‘tone’ or 
highlights the direction of further theoretical sampling. As I was unaware of how many 
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patients would agree to be interviewed five participants were initially sent invitations. 
Subsequently, as per the process of theoretical sampling, following a provisional 
analysis of the interview data and the developing themes, further patients were chosen 
to enable me to elaborate on and develop the emerging themes and their relationships 
regarding the experience of using the MSIS-29v2. For example, one of the first 
patients interviewed had concerns about the MSIS-29v2 being used with newly 
diagnosed patients; consequently, a newly diagnosed patient was invited for interview. 
Thus, the process of data collection was controlled by the emerging themes. 
The work of Coyne (1997) argues that researchers should be adaptable and creative in 
designing sampling strategies that are responsive in real-world conditions and meet 
the information requirements of the study, the ultimate aim being to address the 
problem of the discipline thereby informing the knowledge of healthcare professionals 
in order to provide high quality nursing care based on research. I have striven to follow 
the principles of theoretical sampling in this work but acknowledge that inviting more 
than one patient at a time for interview, and not fully analysing one interview before 
commencing the next, i.e. concurrent data collection/analysis, demonstrates a 
compromise. 
For this phase, as potential participants were selected from phase 1, representativeness 
of the population of MS patients cannot be assumed (Bowling, 2014), and thus internal 
validity was compromised. 
b. Staff-participants 
Only two other healthcare professionals were involved in this research both of whom 
were invited for interview. 
Both patient-participants and staff-participants are referred to jointly as participants in 
the following sections. 
4.6.4.2 Recruitment 
a. Patient-participants 
Invitations to take part were sent out in four phases, each phase being informed by the 
characteristics and interview data of participants who had previously been 
interviewed, thereby ensuring that new categories could be explored. Recruitment took 
place between mid-November 2015 and late February 2016. A patient-participant 
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introduction letter (Appendix N), information sheet outlining the aims of the study and 
proposed interview (Appendix O), and consent form (Appendix P) were posted to 
potential participants. These patients were asked to consider the research, and then 
complete the consent form if they wished to take part, returning it by post in the 
supplied pre-paid envelope. 
Qualitative research tends to be based on relatively small sample sizes (Robson, 2011). 
It was anticipated that 10-15 participants would potentially provide sufficient data on 
the participants’ view of assessment of HRQoL. After 15 interviews, I consulted my 
supervisors and it was agreed that theoretical saturation had been achieved. The 
characteristics of the sample of patients are given in Table 10 and Table 11, section 
6.2.1. 
The response rate of potential patient-participants for this phase could have been 
affected by several factors. A time commitment of 45-60 minutes for the interview 
plus travelling time and the ability to get to the chosen place of interview was required. 
Thus, those in full-time employment could have perceived the time commitment too 
great. A face-to-face interview may be daunting for some. Also, the relationship to the 
principal researcher could influence the decision as to whether to take part, 
Denscombe (2014) suggesting that participants need to feel comfortable with the 
researcher. 
b. Staff-participants 
The two healthcare professionals involved in phase 1 were both invited for interview. 
A staff introduction letter (Appendix R), information sheet detailing the rationale for 
this part of the research (Appendix S), and consent form, (Appendix T) were written. 
I personally delivered these to the two staff members. The staff were asked to return 
the consent form to me if they agreed to be interviewed. Both members of staff agreed 
to participate and were provided with a copy of their consent form. For staff, the issue 
of honesty about the research could have caused a problem with agreeing to take part. 
4.6.4.3 Time and Place for the Interviews 
The interviews were arranged by telephone or email. Patient-participants were given 
the option of when and at which hospital site their interview took place. Most patients 
chose to be interviewed during the morning at the hospital closest to where they lived. 
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The staff were interviewed in a quiet room at their permanent place of work at a time 
convenient for them. 
Only one hospital site had an interview room which was appropriate for patient use. 
At the other site a room was set up as an interview room; a central table was used for 
a small digital audio-recorder. Consideration was given to the positioning and type of 
chairs, ensuring equal power between the researcher and the participant. Arranging the 
chairs of the same height at a 90-degree angle enabled eye contact without the 
confrontational feeling which can arise from sitting opposite each other. One 
participant attended in a wheelchair; in this case I found a chair of more equal height 
for myself. 
The face-to-face interviews were conducted by the author between December 2015 
and May 2016. 
4.6.4.4 Data Collection 
When considering data collection methods for this phase of the research, one-to-one 
semi-structured interviews were chosen as they encourage open, reflective and 
informative responses from participants, thereby allowing the researcher to investigate 
peoples’ views in greater depth (Kvale, 1996), a key requirement for this part of the 
research. A questionnaire or structured interview would have limited the depth of 
explanation in the participants’ answer and within focus groups some participants may 
not have felt able to contribute extensively. Interview responses may be treated as 
giving direct access to an ‘experience’ and associated feelings (Silverman, 2013) such 
as using the MSIS-29v2 during a consultation. 
Qualitative research can play a key role in highlighting the existence and extent of 
problems which can stimulate interventions and actions that lead to change 
(de Vaus, 2001). Through interviewing, data based on the participants’ priorities, 
opinions and ideas would be realised, as described by Denscombe (2014), since the 
participants have the opportunity to expand their ideas and explain their views. If the 
interviews demonstrated that the use of the MSIS-29v2 made a difference to 
participants during the research period, its use in daily clinical practice would require 
consideration. 
The element of trust already established through my work with the participants, and 
particularly the patients, over the time before commencing the research could have 
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contributed to a rapid development of rapport and trust during the interview. Bryman 
(2008) suggests that this is positive as it encourages interviewees to persist with the 
interview. However, he does indicate the importance of not becoming overfriendly as 
this may result in the respondent answering questions in a way designed to please the 
interviewer. The interviewee may say what they think the interviewer wishes them to 
say, rather than what they feel. As a health professional, I envisaged a potential issue 
of honesty from both the patients and the members of staff; hence all participants were 
asked to be honest with their answers prior to the start of the interview, the relationship 
between the researcher and the participant being acknowledged. 
Denscombe (2014) suggests that there are several disadvantages of interviews: they 
are time consuming as the analysis of data takes a considerable amount of time, 
validity is difficult to achieve and, the interviewer effect must be considered. It was 
likely that my role, as an insider-researcher could have had an effect on the participants 
and possibly have impacted adversely on the interviews and resulting data 
(Denscombe 2014). There was also the potential for interviewer bias; I endeavoured 
to reduce this by using good interview technique. Interviews can be tiring which is of 
particular relevance to people with MS for whom fatigue may be an issue. Data was 
not collected concerning which of the participants in this research suffer with fatigue. 
However, myself and the other MS nurse are aware of those who experience severe 
fatigue; they were not invited for interview. 
4.6.4.5 Process of Interviewing 
a. Interview Guides 
Prior to the interviews, patient-participant and staff-participant interview guides were 
devised to inform the interviews. The questions were designed to explore the 
worldview of those being interviewed in relation to assessment of HRQoL. They were 
deliberately broad to be consistent with the grounded theory informed approach being 
followed. A list of issues to be addressed, themes to be explored and open-ended 
questions to be asked was compiled into two interview guides 
(Appendix Q, Appendix U). Space was included for recording date and place of 
interview, and information gathered during the interview. Following Rubin and Rubin 
(2011) the interviews started with a main question to begin and guide the conversation; 
probes were used to clarify answers and request further information. Finally, follow-
up questions explored the implications of the replies to the main questions. There was, 
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however, flexibility to vary the sequence of questions, and latitude to ask further 
questions in response to what were considered significant replies as suggested by 
Bryman (2008). 
b. Patient-participant Guide 
The open-ended questions developed for the patient interview schedule (Appendix Q) 
reflected the experiences of the researcher during the first phase of the study, and the 
literature review; they were externally reviewed by my supervisors. Five key areas 
were covered. The patients were asked to discuss their experience of living with 
multiple sclerosis, their experience of attending outpatient appointments with and 
without the MSIS-29v2, their experience of completing the questionnaire, whether the 
questionnaire made a difference to their consultation, and finally whether completing 
questionnaire had any impact on them or the care that they received. Participants were 
encouraged to discuss issues they considered to be personally important. Open-ended 
questions ensured that the participants could elaborate on their answers as options for 
responding were not restricted (Creswell and Plano Clark, 2011). 
Data collection and analysis was iterative, the interview data and technique being 
considered after each interview. The interview guide was amended following the data 
analysis of several interviews as interviewees were relating their story of diagnosis 
rather than their experience of living with MS when asked the question: ‘Can you tell 
me about your experience of living with MS’? The amended questions included: What 
is it like living with MS? Has having MS changed the way you think about yourself as 
a person? and, Do you think that MS has changed the way people see you? 
(Appendix Q, questions in italics). These changes reflect the work of Strauss and 
Corbin (1990) who describe how some interview questions will seem less salient or 
require supplementation. Following two further interviews the schedule was further 
amended to ask about the style of consultation (Appendix Q, questions in bold font). 
As previously discussed, the MSIS-29v2 only assesses the impact of two domains, but 
for the purposes of clarity the term HRQoL was used throughout the interviews. 
c. Staff-participant Guide 
The views of the HCPs were also explored through a face-to-face interview 
(Appendix U) with myself to determine whether they believe there is a role for the 
assessment of HRQoL in patients with MS in the daily clinical practice of the MS team 
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at the NHS Trust of this research. The staff interview schedule focused on the style of 
outpatient appointments prior to the use of the MSIS-29v2, the experience of 
conducting outpatient appointments using the questionnaire, whether using the 
questionnaire made a difference to the style of consultation and finally, the impact of 
the MSIS-29v2 on appointments and the care offered. Staff were encouraged to 
describe their experience of and views regarding the use of the MSIS-29v2. Attitudinal 
barriers in relation to the use of the MSIS-29v2 by the HCPs were also explored. 
d. Conducting the Interview 
All interviews were recorded as this allowed me to be as attentive as possible and 
communicate that the respondent was being listened to (Bowling, 2014). The recorder 
was switched on immediately prior to the start of the interview and switched off as 
soon as the interviewee had been thanked for attending. A separate audio recording 
was made of each participant interview. Each interview was initially allocated the 
participant number from phase 1, thus affording confidentiality but not anonymity. 
Anonymity could not be guaranteed as the data from phases 1 and 2 required linking. 
When presenting the results, the interviews were allocated numbers reflecting the 
order of the interviews, the first interview conducted being number 1, the second 
number 2 and so on. 
At the beginning of each interview participants were welcomed and the aims of the 
research and my interest in the topic reiterated. Confirmation was given that the 
research had ethical approval. Reassurance was provided that confidentiality of the 
interview data would be maintained and that although the conversation would be 
audio-recorded to facilitate verbatim analysis, no identifiable reference to individuals 
would be made in the transcripts, in the final thesis or in any published works. 
Participants were informed that they could stop the interview at any time. 
I endeavoured to put the participants at ease during their interview thereby enabling 
them to feel confident at expressing their opinions honestly, as suggested by Polit and 
Beck (2004). To allow the patient-interviewees a chance to relax and feel at ease, I 
initially asked them to describe their experience of living with MS, something with 
which they are all familiar. Throughout the interview I encouraged all participants to 
talk freely and spontaneously about their feelings and experiences of using the 
questionnaire. Prompts and probes were utilised when required. An inductive 
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approach was adopted, the interview guide acting as an aide memoir rather than a rigid 
schedule. Additional unplanned questions were asked to follow up what the 
interviewee described, and the order of the questions modified based on the flow of 
the interview. During the interviews, I adopted a process of reflecting and probing; I 
often asked for additional details to elicit a more insightful account of how the 
participant felt about the assessment of HRQoL. Information was checked and 
clarified as necessary; thus, validity was confirmed. 
Once all areas for discussion had been covered, I gave the participant the opportunity 
to raise any additional points that they wished to discuss. At the end of an interview 
participants were thanked for taking part and reassurance was again given regarding 
confidentiality of the data. The interview was then brought to a close. 
e. Reflection on the Interview Process 
During the early interviews, I struggled not to ask leading questions as I was mindful 
of the importance of not leading an interview and thereby shutting down the possibility 
of a participant providing valuable information. Aware that I also had a tendency to 
rush the participants in the early interviews, struggled to get some participants to talk, 
and did not tolerate silence well, I sought advice from my supervisors. As the 
interviews progressed, I became aware of my thoughts and if I felt I was about to lead 
the participant I paused and rephrased the question prior to asking it. I sought to ask 
additional questions of a non-leading nature, using phrases such as ‘tell me more’, 
‘could you elaborate on that?’, ‘what do you mean?’, ‘could you clarify?’, thereby 
leading to a greater richness of data. Thus, I became more adept at probing, thereby 
enabling participants to talk about their experiences, in relation to the questions of the 
interview schedule. Throughout the interview process it I recognised that as the 
interviewer my perspective is only one way of looking at the world. 
4.6.4.6 Qualitative Data Analysis 
For this study the qualitative data was analysed using thematic analysis as described 
in section 4.6.3. The codes arose from interaction with the data, allowing the 
experiences of the participants which were captured during interview to be reported. 
The data were, therefore, coded without trying to fit them into pre-determined 
categories or a priori assumptions. Consequently, the form of analysis adopted was 
data driven. 
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The analysis of the data was guided by four principles following Denscombe (2014). 
The analysis of the data and conclusions drawn from the research were rooted in the 
data. Linking into this, my interpretation and explanation of the data developed 
through careful reading of the data. I had no preconceptions about the data as no 
literature was found describing the benefits of using HRQoL measures from a patient 
perspective. However, as a clinician-researcher, it is likely that my social background, 
values, identity and beliefs had a significant influence on the nature of the data 
collected and the interpretation of that data. Finally, an iterative process was required, 
the data being analysed and subsequently interpreted (Polit and Beck, 2004). 
Data analysis involved moving between collection of data, coding and analysis, with 
each part of the process informing the others. Data collection and data analysis 
occurred together in this explanatory sequential design. Informal data analysis and 
interpretation began at completion of the first interview, as I considered the content of 
the interview and reflected upon potential themes. Formal analysis began after four 
interviews had taken place. When analysing the data, patterns were sought, and 
consistency of responses considered. 
There are generally considered to be five stages associated with qualitative data 
analysis: 
a. Preparation of the Data for Analysis 
The interviews were recorded using a digital dictation machine and backed up 
electronically prior to transcription. They were subsequently transcribed verbatim by 
an outside source. I listened to the interviews and checked the transcripts for accuracy 
prior to data analysis. During and following transcription, it was necessary to ensure 
that the transcript remained loyal to the process and reflected the discussion that had 
taken place and that anonymity was maintained, a process described by Charmaz 
(2002). Accuracy of transcription was essential for confirmability of the research. The 
layout of the transcripts allowed space for notes and a margin at the side of the page 
for coding and classifying the data. 
b. Familiarity with the Data 
Familiarity of the data was obtained by reading and re-reading the interview transcripts 
whilst listening to the recordings on several occasions, thereby developing an 
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understanding of the data and thus providing a platform from which to develop codes 
and categories in the next stage of the analysis. 
c. Interpreting the Data 
The coding framework was developed in conjunction with my supervisors who have 
extensive experience of qualitative analysis; key themes and sub-themes were 
discussed, and agreement reached. Firstly, I scrutinised the transcripts for ‘key’ themes 
using thematic analysis; these were reviewed and examined for thematic elements and 
topics, the codes determined from the reading of the transcripts. Initial descriptive 
codes were generated by identifying key words and phrases across the entire data set. 
These were clustered into groups to identify the emerging themes. The data was then 
grouped into thematic categories in order to identify key themes. The list of categories 
continued to change and expand as issues emerged as important or their relevance was 
questioned. Very similar categories were merged, and redundant categories removed. 
Themes and sub-themes were identified with representative quotes. The transcripts 
were then re-scrutinised and phrases recoded as necessary. Patterns within and 
between themes were identified. The qualitative computer package NVivo 10 (QSR 
Int. Ltd.) was used to aid analysis. Nodes were created without consideration of 
structure. The nodes were then sorted into groups using the modeller function of 
NVivo 10 and arranged into a tree-structured system. 
d. Verifying the Data 
Qualitative researchers should strive to achieve reliable and valid results (Cavanagh, 
1997), demonstrating that their findings are the result of a rigorously conducted 
process (Morse, 1999). However, in qualitative research it is often difficult to 
demonstrate validity and reliability of the findings. Therefore, four criteria (credibility, 
transferability, dependability and confirmability) for assessing the quality of 
qualitative research were used as suggested by Lincoln and Guba (1985). 
The establishment of credibility of findings entails ensuring that research is carried 
out according to the canons of good practice. Credibility may be achieved by 
submitting research findings to those who were studied for confirmation that the 
researcher has correctly understood the arising data-respondent validation (Bryman, 
2008) i.e. by giving participants a copy of their interview transcript. However, as most 
of the participants had known me for a long time, my supervisors and I decided that 
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there could be a reluctance on their part to be honest and critical, as suggested by Bloor 
(1997). Instead, information was clarified and checked during the interview process. 
Lincoln and Guba (1985) also recommend triangulation which involves using more 
than one method or source of data. In the case of this research, observations from the 
quantitative phase were checked with the interview data to clarify and further 
understand these observations; e.g. when there was a discrepancy between the findings 
of the MSIS-29v2 impact scores and a change in HRQoL as perceived by the 
participant, this was explored during the interview. 
By providing information about the sample of participants and also a ‘thick 
description’ (Geertz, 1973), i.e. a rich account of the interview data, transferability 
was addressed. Lincoln and Guba (1985) argue that a thick description provides others 
with a ‘database’ for making judgements about the possible transferability of findings 
to their workplace. 
Dependability may be addressed by demonstrating that complete records are kept of 
all phases of the research process (Lincoln and Guba, 1985). Detailed records were 
made of research participants, interview transcripts, and data analysis decisions. 
Objectivity or confirmability concerns the extent to which qualitative research 
produces findings that are free from the influence of the researcher who conducted the 
enquiry. As the data produced from this research was interpreted by myself there was 
inevitably consequences for objectivity. I was very aware of the need to keep an open 
mind and be willing to consider alternative and competing explanations for the data. 
Robson (2011) suggests that both the personal commitment and reflexivity of the 
researcher is valued in qualitative research. This research has been influenced by my 
personal experience of looking after people with MS. The accuracy of the recording 
the interviews and transcription are also important considerations when considering 
confirmability, a process to which I strictly adhered. 
e. Representing the Data 
The final stage of data analysis involves producing an explanatory account 
encompassing the data obtained. This is presented in chapter 6. 
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4.7 SUMMARY 
The aim of this chapter was to present and discuss the methodology used in the current 
doctorate research. The chapter began with a description of the research paradigm 
which guided the methodological approach selected for this study. Following the 
discussion about the reasons for choosing a pragmatic paradigm and mixed methods 
approach, the ethical issues taken into consideration when designing the research are 
presented. 
A detailed description of the study designs and methods used for both phases was 
subsequently presented demonstrating the rationale behind the choices made 
concerning sampling, data collection and analysis. The results of phase 1 are presented 
in chapter 5. The findings of phase 2 which are grounded in the data and gleaned from 
both patient and healthcare professionals’ perspectives are described within chapter 6. 
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5.1 INTRODUCTION 
The aim of phase 1 was to address the research questions: 
• Is assessment of HRQoL in patients with MS feasible in daily clinical practice? 
• Can the results of HRQoL assessment be used to inform therapeutic 
interventions? 
• Can a HRQoL measure detect change in HRQoL after the implementation of 
therapeutic interventions? 
Within this chapter the results of phase 1 are presented. The characteristics of the 
sample are examined, and the representativeness of the population considered. Uptake 
of interventions and data quality is examined. Subsequently the results of the 
MSIS-29v2 data analysis is presented. Patient reported issues when completing the 
MSIS-29v2 are also considered. The qualitative comments of both patient and staff 
participants are related to the results throughout this chapter. The results are discussed 
briefly within each section when the findings are related to the literature. Some of the 
results are explored further in Chapter 6 when the results of the interviews are given; 
they discussed more fully in Chapter 7 when the findings of phases 1 and 2 are drawn 
together. Methodological limitations relating to this phase are discussed. 
5.2 RESPONSE TO THE INVITATION TO PARTICIPATE 
A total of 592 patients were invited to take part in the research. Of these 162 were 
male and 430 were female (1:2.65 m:f). Three hundred and forty-one completed 
consent forms were returned by 14/11/14, with an overall response rate of 57%, 
indicating a favourable attitude to the research. The study of Cartwright (1987) 
reported a response rate of 50% after the initial mailing. The high response rate could 
be considered an indicator of the amount of interest shown in the subject under study. 
I did not investigate why patients chose not to take part. As this research took part 
within the constraints of a normal outpatient appointment it is unlikely that time 
constraints would have been cited by potential participants. It is possible that those 
with sight problems, cognitive issues, or severe fatigue might have felt less inclined 
to participate. The staff involved in the research are known to all the participants which 
may have influenced people’s choice as to whether they wished to participate. 
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5.3 SAMPLE SIZE 
As the research was conducted over time it was inevitable that there would be a loss 
of participants. Although 341 of the 592 invited to take part returned valid consent 
forms the actual number potentially participating in the research reduced further to 
323 for the following reasons: 
• One participant moved away during the research period and was not reviewed 
before she moved. 
• Eleven participants were not reviewed during the study period; they either did 
not attend appointments without reason, were ill and so were not able to attend 
their appointments within the research period or, had deteriorated such that 
they were no longer able to attend hospital-based outpatient appointments. 
• Two participants died never having been reviewed as part of the study. 
• One participant withdrew their consent during the first appointment as they 
found MSIS-29v2 too onerous. 
• One participant declined to take part as they were reviewed close to the end of 
the research period and could not see the point of participating. 
• One participant was excluded from the study by the consultant at an outpatient 
appointment due to severe cognitive impairment; he considered that the patient 
did not have the ability to understand or provide true answers to the questions 
despite having given consent. The mother had initialed the boxes on the 
consent form as the patient not capable of this, although the patient had made 
a mark which was interpreted as giving consent. 
• Another participant was excluded by a nurse because of poor cognition; they 
demonstrated a lack of understanding of the questions precluding reliable 
completion of the questionnaire, could not complete the form themselves and 
attended the appointment alone. 
• One participant was reviewed once but died before her next scheduled review 
within the research period. 
• Another decided not to continue with the research at her second appointment 
as she couldn’t see the benefit of it to her.  
Figure 9 provides a flowchart of the participants included in phase 1. 
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Figure 9 Patient recruitment and participation flowchart 
Three hundred and twenty-three participants attended between one and five 
appointments between 24th November 2014 and 22 November 2015. Nine potential 
participants who only had one scheduled appointment within the study period were 
excluded as they were not given forms at their consultation. An additional two 
potential participants were excluded as although they attended two appointments 
forms were not given at either of their reviews. A further potential participant was 
excluded as despite attending four appointments no forms were given, due to an 
administrative error. Thus 12 patients were excluded from the research because of 
human error; the nurse running the clinic omitted to give the MIS-29v2 to the 
participants, time pressures due to the clinic running behind time or being overbooked 
contributing to the omission. 
Patients invited to 
take part 
n=592 
Patients 
moved away 
n=6 
Participants not 
given forms 
n=12 
Final number of 
participants 
n=311 
Reasons for not taking 
part 
Contacted service not 
wanting to participate, n=5 
Unidentifiable participants, 
n=3 
Consent form returned too 
late, n=4 
Telephone consultation 
refused 
Total =13 
 
Patients excluded from 
phase 1 
Moved away, n=1 
Did not attend an appointment 
in research period, n=11 
Death, n=2 
Poor cognition, n=2 
Withdrew consent, n=2 
Total=18 
 
Withdrawal of consent, n=2 
Participants 
included in phase 1 
n=323 
Patients eligible for 
phase 1 
n=598 
Patients consented 
to take part 
n=341 
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The final sample size comprised 311 participants at appointment one (T1). Many of 
these participants attended two, three, four or even five appointments within the 
research period. 
5.4 PARTICIPANT CHARACTERISTICS 
Data is presented for the sample of 311 participants. Participant characteristics are 
presented in Table 4. The sample comprised 90 (29%) males and 221 (71%) females, 
ratio 1:2.46, with a mean (±SD, range) age of 55.91 (±10.816, 28-82 years). The mean 
age at diagnosis of MS was 42.12 (±11.42, 17-69 years). The median time since 
diagnosis was 12 years (IQR 6-20.25). Clinically, participants typically had a 
diagnosis of RRMS (n=163, 52.3%) or SPMS (n=120, 38.7%). Of the remaining 
participants, 16 (5.2%) had PPMS, and 12 (3.9%) progressive MS. 
One hundred and ninety-eight (63.7%) participants were married, 30 (9.7) separated 
or divorced, 40 (12.9%) had a partner, 33 (10.6%) were single, and 9 (2.9%) were 
widowed. 
Of the 311 participants, 63 (20.3 %) were in full-time employment and 46 (14.8%) in 
part-time employment. An additional six (1.6%) stated that they were self-employed. 
Seventy-four participants (23.8 %) had retired due to ill-health. Another 81 
participants (26 %) were retired (reasons not known); of these 18 were aged 64 or less 
at the beginning of the research and of these seven were aged 59 or less. Twenty-eight 
participants (9%) stated that they were a housewife/househusband. Eight (2.6%) 
unemployed due to MS or ill health. Six participants also stated that as well as being 
retired they were a housewife. One indicated that she was part-time employed and a 
housewife. 
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 Patients n=311 
Sex (female) 211 (71%) 
Age at time of research (years): mean ± SD 
(range) 
55.91 ± 10.82 (28-82) 
Age at diagnosis (years): mean ± SD (range) 42.12 ± 11.42 (17-69) 
Time since diagnosis (years): median 
(interquartile range, IQR) 
12 (IQR 6-20.25) 
Marital status 
Married 
Not stated 
Partner 
Separated or Divorced 
Single 
Widowed 
198 (63.7%) 
1 (0.3%) 
40 (12.9%) 
30 (9.6%) 
33 (10.6%) 
9 (2.9%) 
Employment status 
Full-time employment 
Full-time mother 
Housewife/Househusband 
Not stated 
Part-time employment 
Retired due to ill health 
Retired 
Self-employed 
Student 
Unemployed due to MS/ill health 
63 (20.3%) 
1 (0.3%) 
28 (9.0%) 
3 (1.0%) 
46 (14.8%) 
74 (23.8%) 
81 (26.0%) 
6 (1.9%) 
1 (0.3%) 
8 (2.6%) 
Type of MS 
Primary progressive 
Progressive MS 
Relapsing-remitting MS 
Secondary progressive MS 
16 (5.2%) 
12 (3.9%) 
163 (52.3%) 
120 (38.7%) 
Table 4 Sociodemographic and clinical characteristics of the study population 
The percentage of married patients is comparable to the study of Hobart, et al. (2005), 
as shown in Table 5 below. However, the figure of 26.4% participants unemployed or 
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retired due to MS is rather lower than the figure of 65.8% quoted by Morales-
Gonzáles, et al. (2004). Other statistics are considered in the following sections. 
5.4.1 Gender 
The population of 592 patients invited to take part showed a division of male to female 
1:2.65. The study sample of 311 demonstrated a ratio of male to female 1:2.46. These 
two ratios closely echo the study of Mackenzie, et al. (2014) which estimated how 
many people in the UK have MS and found the male to female ratio to be 1:2.4. My 
figures also reflect those of the MS Trust's 'Generating Evidence in MS Services' 
(GEMSS) programme (Mynors, Suppiah and Bowen, 2015) where the ratio of 
male:female was 1:2.57. The GEMSS programme supported fifteen MS specialist 
teams which represented UK services and had a combined caseload of over 15,000 
people with MS to evaluate their services over 2014-15. The sample characteristics 
for this research are also similar to those of the study sample used by Hobart and Cano 
(2009) (Table 5) when the psychometric properties of the MSIS-29 were re-evaluated 
following the lessons of Rasch analysis. Thus, it may be concluded that the sample of 
patients for this research was representative of the general UK population of people 
with MS when considering gender. The figures are also comparable with the wider 
world population echoing figures of Compston and Coles (2002), Confavreux and 
Compston (2005), Orton, et al. (2006), and Wallin, et al. (2012) who present figures 
of 1:2.3-3.5 male:female. 
 This research Hobart and Cano. (2009) 
Sex (% female) 71% 68.2% 
Age [mean (SD); range] 55.91 (10.82); 28-82 50.5 (12.2); 18-87 
Duration of MS [mean 
(SD)] since diagnosis 
14.2 (11.06) 11.3 (7.5) 
 
Married 63.7% 65.8% 
Table 5 Comparison of research study figures 
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5.4.2 Age of Participants at the Start of the Research 
 
Figure 10 Age of participants at the start of the research 
The distribution of ages in 5-year groups at the beginning of the research period is 
shown in Figure 10. The mean (± SD, range) age of the participants at the beginning 
of the research (December 2014) was 55.91 (± 10.816, 28-82 years). These figures are 
comparable to the mean age of 54 years for patients in the MS Trust GEMSS project 
(Mynors, Suppiah and Bowen, 2015). Whilst MS is a disease generally diagnosed in 
young adults, a growing proportion of any caseload is older people (Mackenzie, at al., 
2014). The percentage of patients aged over 65 in this project was 22.5%. The GEMSS 
project (Mynors, Suppiah and Bowen, 2015) which also included patients who were 
unable to access hospital due to their level of disability showed a proportion of 20%. 
As home visits are not offered at the place of this research it is possible that more 
patients with a higher level of disability and who are generally older accessed services 
at the hospitals of this research. Although the figures are not directly comparable, both 
demonstrate a high proportion of older patients with MS. This suggests that I can have 
confidence on the representativeness of my data. 
Figure 11 demonstrates the most common age for women at the start of the research 
to be 56-60. A peak prevalence rate for women at 57 and for men at 66 was 
demonstrated in this research. Mackenzie, et al. (2014) demonstrated peak prevalence 
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rates occurring at the ages of 56 years for women and 59 years for men, this being 
demonstrated graphically when age in 2010 was plotted against prevalence per 
100,000 patients. The population of patients for this research closely mimics these and 
can thus be considered representative of a larger population. 
 
Figure 11 Age at the start of the research by gender 
5.4.3 Age at Diagnosis 
The age at diagnosis with MS for each participant was determined from the medical 
notes as not all participants could remember their date of diagnosis. The age 
distribution of the research participants at diagnosis is shown in Figure 12. The mean 
(± SD, range) age at diagnosis of MS as per the case notes was 42.12 (± 11.42, range, 
17-69 years). 
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Figure 12 Age at diagnosis 
Figure 13 demonstrates that the peak age of diagnosis for women occurred between 
age 40-45 and for men between 41-45 reflecting the work of Mackenzie, et al. (2014) 
who showed the peak incidence of MS occurred at the age of 40 in women and 45 in 
men. 
 
Figure 13 Age at diagnosis by gender 
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5.4.4 Time since Diagnosis 
 
Figure 14 Time since diagnosis 
The median time since diagnosis of MS as per the case notes was 12 (IQR 6-20.25), 
(range, 1-50 years). The duration of MS disease was 1 year or less in 13 participants 
(4%), 2-5 years in 62 participants (20%), 6-10 years in 67 participants (22%), 11-15 
years in 55 participants (18%) and 16 years or longer in 114 participants (37%). 
5.4.5 Type of Multiple Sclerosis 
When analysing the data it became evident that not all participants were aware of their 
type of MS. The definitive diagnosis for each participant at the time of the research 
was determined from the medical notes. 
Figure 15 shows the composition of the 311 patients in the sample by type of MS. At 
the start of the research 163 participants (52.4%) had RRMS and 120 participants 
(38.6%) secondary progressive MS, this resonating closely with the GEMSS 
combined caseload of 51% for RRMS and 35% for secondary progressive MS. Also, 
the work of Gray, McDonnell and Hawkins (2009) whose study of 248 patients 
included 58% RRMS, 34.7% SPMS and 7.3% PPMS. My figure of 16 participants 
(5.14%) with PPMS is somewhat lower than the GEMSS figure of 11%. A diagnosis 
of progressive MS was recorded in the case notes for 12 participants (3.86%) in this 
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research, rather than specifically PPMS or SPMS groups. These twelve cases, 
however, amount to less than 0.5% of the total and thus would have little impact on 
the overall figures. This figure may reflect the current caseload at my place of work. 
 
Figure 15 MS types in the research sample 
The number of females and males with each type of MS is shown in Figure 16. 
Noseworthy, et al. (2000) reported that PPMS has a similar incidence amongst men 
and women however my sample did not reflect this as demonstrated in Figure 16. This 
may be due to the nature of current caseload at my place of work or the makeup of the 
research sample. For example, only certain patients might have felt inclined to take 
part in this research project, reflecting the work of de Vaus (2001). 
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Figure 16 Type of MS by gender 
When analysing the figures for type of MS and age at time of research my figures 
(Figure 17) show that the proportion of people with RRMS declines with age and the 
number with progressive forms increases. This is unsurprising as after a period of time 
patients with RRMS develop SPMS as discussed in section 2.7.2. 
 
Figure 17 Type of MS by age 
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The reasons why some participants were unclear about what type of MS they had was 
not explored. However, I would suggest that it is possible that some were not aware 
that they had secondary progressive MS as they had never been told or had never asked 
if they had transitioned to this stage. The study of Davies, et al. (2016) reveals that 
healthcare professionals find it challenging to determine when a person with MS has 
entered the transition phase to SPMS or has definite SPMS, this resulting in diagnostic 
uncertainty (Sand, et al., 2014). Despite recognising the importance of discussing 
SPMS in a timely manner thereby allowing patients to prepare for the future, clinicians 
found initiating the conversation challenging. Also, professionals reported that 
patients rarely raised the subject of transition themselves, so professionals struggled 
to know when they should tackle the subject (Davies, et al., 2016). From experience, 
patients can find being given a diagnosis of SPMS devastating, particularly as 
currently there is no treatment. This reflects the work of Sand, et al. (2014) who 
describe how due to the subtle nature of early progressive disease, caution is often 
used when applying a progressive label, in light of the lack of evidence-based 
treatments. My view is further reflected in the work of Kessels (2003) who suggests 
that the information given by a doctor often has profound implications for a patient 
with the stress caused by the diagnosis potentially being enhanced by the information 
about the prognosis and treatment. 
5.4.6 Summary 
I would consider the sample of patients taking part in this research to be representative 
of the wider MS population when figures from other research projects and the 
literature are considered. The population is comparable when characteristics such as 
gender, age at the start of the research, age at diagnosis, time since diagnosis and type 
of MS are considered. Whilst external validity has been demonstrated I would suggest 
that as the sample of patients for this study was drawn from the local population of 
patients with MS who are able to attend outpatient appointments the results should 
only be generalised to this type of group. 
5.5 INTERVENTIONS 
All interventions taken up or declined were recorded on the intervention recording 
sheet, Appendix I. The frequency of each intervention offered is shown in Appendix 
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J and examples of why various interventions were offered following discussion of the 
MSIS-29v2 are presented in Appendix K. 
A total of 812 interventions were taken up and 25 declined. Reassurance was the 
intervention most frequently given; many participants sought reassurance that they are 
doing well and managing their MS in an appropriate manner. This reflects the findings 
of Donaldson (2007) who suggests that simply listening to patients’ concerns, even 
when no remedies are available, may result in improved HRQoL. 
The second most frequent intervention offered was medication for both disease 
modification and symptom control. During the research period many more patients 
changed the type of disease modifying therapy they were taking than would do so 
normally within a twelve-month period. In January 2015 an oral medication, 
Tecfidera, became available for the first time for people with relapsing remitting MS. 
Some participants had been injecting themselves for up to fifteen years at this point 
and so welcomed the option to change to an oral medication. This accounted for thirty-
three medication changes and also many of the MRI requests during the research 
period as an MRI is required within three months of commencing Tecfidera. 
Medications for symptom control were commenced, stopped, or doses altered. 
Following discussion about side effect profiles some medications were declined. For 
example, some participants declined neuropathic pain relief as this may cause weight 
gain. 
A number of MRIs were requested during the research period. Regular MRI scans are 
part of the monitoring requirements for participants receiving Tysabri. Also, MRI 
scans were ordered if a participant’s condition had deteriorated, potentially requiring 
an escalation in therapy. 
Participants were referred to the continence service for both bladder and bowel 
problems. Bladder problems included: accidents (incontinence), frequency, hesitancy, 
leaking, nocturia, urgency, not fully emptying bladder (residual urine), and inability 
to initiate passing urine. Many participants described more than one issue. The 
predominant reason for a referral for bowel issues was constipation. 
The most commonly declined intervention was a referral or re-referral to the 
continence service, with a total of eight potential referrals being refused. Other 
interventions declined included: counselling, dietician, physiotherapy, disease 
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modifying therapy, medication for stiffness/spasms and, referral to the wheelchair 
services. 
Although it was evident that the MSIS-29v2 informed the interventions offered I am 
aware that other factors such as the nature of the consultation may also have had an 
influence. It is likely that some, if not all, of these interventions would have been 
offered during a consultation without such a questionnaire. 
5.6 DATA QUALITY 
Two types of missing data, item non-response and unit non-response, are a particular 
problem in longitudinal panel analysis. Both are discussed in the following two 
sections and in section 5.12.8. 
5.6.1 Unit Non-response 
Unit non-response is a problem that is peculiar to panel designs. Panel attrition, a form 
of unit non-response, arises when participants drop out of a study; this threatens 
internal and external validity. In this study attrition was low, with only three 
participants withdrawing consent and three dying. Unit-non-response also occurs 
when people are missed from some waves of data collection but are not permanently 
lost to the panel, for example when questionnaires were not given out. 
A major feasibility issue for this research project was determining ways to ensure that 
participants received the MSIS-29v2 before their clinic appointment. The issue of 
identifying and then providing research participants with a questionnaire had to be 
overcome as not all patients attending clinics were research participants. Fortunately 
for the consultant-led multi-professional clinic and at the outlying Community 
Hospital nurse-led clinics this problem was easily resolved (section 4.5.2). However, 
it was problematic for nurse-led clinics at the main hospital as the nurse running the 
clinic had to identify participants in the waiting room prior to their appointment and 
provide them with their forms. For reasons already discussed (section 5.3) this did not 
always occur. 
Only 583 of the 636 MSIS-29v2 forms which should have been distributed were given 
out (92%). The MSIS-29v2 was not given to all attending participants at 33 of the 141 
clinics run during the research period. They were not given out at twenty nurse-led 
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clinics and thirteen consultant-led multi-professional clinics. The number of forms not 
distributed per clinic varied from one to four. Additionally, forms were not given when 
two appointments occurred in very quick succession; two participants required an 
urgent consultant review following a nurse-led appointment. Both participants were 
seen by the consultant within two weeks and thus it was deemed clinically 
inappropriate to give the questionnaire again so soon. The number of participants 
eligible for longitudinal analysis reduced when the MSIS-29v2 was not given to 
participants at the second or subsequent appointments. 
5.6.2 Item Non-response 
Item non-response occurs when individuals do not answer a particular question. Not 
all patients answered all questions resulting in missing data item. Table 6 shows the 
total number of participants attending appointments at T1, T2, T3, T4 and T5, and the 
percentage of participants who did not answer all questions at each appointment. Note 
that patients attending two appointments attended an appointment at T1 and T2; 
patients who attended three appointments attended an appointment at T1, T2 and T3, 
and so on. 
No of appointments 
attended 
1 2 3 4 5 
No of participants 
attending 
311 248 78 20 3 
% Participants with 
missing item data 
8 7.3 2.6 5 0 
Table 6 Missing data 
The nurse running the clinic checked if any missing data was deliberate. No participant 
stated that they had deliberately not answered a question, rather that they had missed 
it. One person who had missed more questions than most was interviewed in phase 2. 
They stated that they had just missed answering the questions rather than choosing to 
not answer them. This is described by Hand (2008) who suggests that participants may 
just miss answering a question for no particular reason or may omit to answer the 
question erroneously. 
Three participants omitted to turn the MSIS-29v2 over and thus did not complete 
questions 13-29 on the back. One participant who did not turn the form over was 
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helped to complete the questions on the second side by the nurse in clinic but at 
question 20 (not answered) were too overwhelmed to continue. All questions were 
answered at subsequent appointments by these participants. 
Five hundred and eighty-three questionnaires were given out and 105 (0.62%) 
questions were not answered giving a response of 99.38%. This reflects the findings 
of Fayers and Machin (2016) who suggest that for any one item there will always be 
a few (1-2%) patients with missing data. It is also comparable to the real-world data 
of Gray, McDonnell and Hawkins (2009) who described their data quality as excellent 
with 99.98% of questions completed. 
Questions were most frequently missed at appointment one (T1) and in the 
psychological impact section (question 21-29), possibly because participants were 
unfamiliar with the form. Which questions were not answered at which appointments 
is tabulated in Appendix L. When participants omitted to answer questions, they 
missed between one and four per questionnaire. Hand (2008) describes how a missing 
data item can be informative. The work of Solari, Ferrari and Radice, (2003) 
demonstrated that Italian patients had routinely not answered questions about sexual 
function, and satisfaction with sexual function, an area not covered by the MSIS-29v2. 
When the data was analysed no question was missed particularly frequently indicating 
that the nature of the questions was acceptable to all participants, reflecting that 
patients were involved in the design of the MSIS-29 (Hobart, et al., 2001). 
As described in section 4.5.4.13 each missing question score can be replaced with the 
person-specific question mean score. When this was done the number of 
questionnaires which could be analysed for longitudinal change increased. All 
questionnaires from appointments 2, 3 and 5 could potentially be analysed. 
Questionnaires from 18 out of 19 participants were examined for 4 appointment 
follow-ups. 
The number of participants where longitudinal follow-up is potentially possible is 
shown in the Table 7, below. However not all participants who attended two or more 
appointments were given a full complement of forms or took up interventions and thus 
the numbers eligible for longitudinal analysis reduced further. 
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No of 
appoint-
ments 
attended 
No of 
participants 
attending 
appointment 
Participants excluded Number eligible for 
analysis 
2 172 No of participants only 
given one form=15 
No of participants given no 
forms=2 * 
One participant withdrew 
consent when attending for 
second appointment 
Therefore analysed as one 
appointment participant ** 
Therefore, number for 
comparison at follow 
up appointment 
T2=155 
 
3 58 Nine participants only 
given forms twice 
One only given forms once 
Number available for 
three form comparison 
(T3) =48 
4 18 One participant completely 
missed for whole study *** 
Two participants only given 
3 out of four forms 
One participant only given 
two out of four forms 
Number available for 
four form 
comparison(T4) =14 
5 3 One participant only given 
4 out of 5 forms 
Number available for 
five form comparison 
(T5) =2 
 Total=323   
Table 7 Participant numbers for longitudinal analysis 
* Forms were not given as the nurse running the clinic omitted to give the forms to 
these potential participants. 
** Participant withdrew consent as they could not see the relevance of the research to 
them. 
*** This participant was not given forms due to a transcription error by myself when 
compiling the list of participants from the returned consent forms. 
5.6.3 Floor and Ceiling Effect 
A floor effect which occurs when a participant scores minimum on a scale was noted 
on 22 occasions (3.4%) for the physical impact score and on 30 occasions (4.7%) for 
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the psychological impact score. These figures are similar to those of Costelloe, et al. 
(2007) who noted a floor effect in the physical impact score in 6% of patients with 
lower disability levels. Although EDSS scores were not recorded as part of this 
research those who scored floor effects were generally less affected by MS and have 
lower EDSS scores recorded in their notes. The results for this work are also 
comparable to those of Gray, McDonnell and Hawkins (2009) in whose research a 
floor effect was observed in 2.0% of cases for the physical impact score and 7.3% of 
participants for the psychological impact score. 
A ceiling effect which occurs when a participant scores the maximum on a scale was 
noted on four occasions (0.6%) patients for the physical impact score and on eight 
occasions (1.3%) for the psychological impact score. These figures are somewhat 
lower than the ceiling effects noted by Gray, McDonnell and Hawkins (2009) in 3.6% 
of patients for the physical impact score and 2.4% of patients for the psychological 
impact score. They are considerably less than the recommended maximum of 15% 
stated by Gray, McDonnell and Hawkins (2009). 
5.7 PARTICIPANT AND STAFF COMMENTS 
Many comments were recorded by both participants and staff at the end of the 
MSIS-29v2. The other CNS MS and I found the participants comments particularly 
useful as they helped to clarify issues such as why a patient stated that they had 
deteriorated. Comments revealed that an increased impact of MS could be related to 
life events such as personal health issues which were unrelated to MS, or health issues 
of significant others; e.g. looking after a wife with dementia. Participants also 
described how issues related to work contributed to an increased impact of MS. 
Staff comments clarified why, despite being offered intervention, some participants 
were not reporting an improvement in HRQoL. For example: 
• Several interventions had been suggested and referrals accepted at previous 
appointment. At T2 some referrals were still pending, and the participant was 
not compliant with advice. At T2 the impact scores demonstrated a greater 
impact of MS 
• The patient had had a fall and so had reduced confidence 
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• Had deteriorated due to pain related to a fracture. Was very limited at home so 
deteriorated psychologically between appointments 
• Increased isolation as increased difficulty to use stairs: stays upstairs most of 
the time. Most 4's- all related to restriction of stairs 
• Functional electrical stimulation device (FES) broken so mobility reduced1 
• Not liking injecting 
• Worse due to stress related to trying to retire due to ill health: significantly 
deteriorated 
• Infected injection sites. 
The comments of staff also indicated why participants had improved following 
interventions; for example, now attending the day hospital. 
The reasons why some tests or interventions were requested were noted by staff in the 
comments section. For example, the patient was positive for the JC Virus and so 
needed an MRI scan; the patient was in relapse so required steroids. The comments 
also provided information about referrals/treatments not related to MS. For example, 
a referral to the pain clinic, brain tumour. It was also recorded, when known, if the 
MSIS-29v2 was completed without help from the participant. Some of the comments, 
both patient and staff are referred to in section 5.10 where they are analysed to help 
explain the impact scores in relation to the responses to the HTQ. 
  
                                                 
1
Functional electrical stimulation (FES) is a treatment that applies small electrical charges to a muscle 
that has become paralysed or weakened, due to damage in the brain or spinal cord. The electrical charge 
stimulates the muscle to make its usual movement. In MS it is mostly used as a treatment for foot drop, 
where disruptions in the nerve pathways between the legs and brain mean the front of the foot cannot be 
lifted to the correct angle when walking. 
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5.8 LONGITUDINAL FOLLOW-UP 
Longitudinal analysis was used to determine if, after the implementation of 
intervention/s, a change in the physical and/or psychological impact of MS was 
detected when using the MSIS-29v2. The time gaps between appointments were not 
even. Rather they reflected the time required to assess the effect of the interventions 
as described in section 4.5.4.12 or the stability of a participant’s MS. Participants with 
more stable MS were reviewed less frequently. The frequency of attendance and 
therefore the time between completion of questionnaires varied from 3-12 months. 
Longitudinal analysis occurred between the time points of the appointments. The 
number of participants eligible for longitudinal analysis was affected by both unit and 
item non-response as discussed in sections 5.6.1 and 5.6.2. 
5.9 DISTRIBUTION-BASED RESPONSIVENESS 
The distribution of the differences of the physical impact scores and the psychological 
impact scores of the MSIS-29v2 were individually assessed using histograms. These 
showed the data to be approximately normally distributed thus meeting the criteria for 
parametric analysis. The paired-samples t-test was selected to analyse differences 
between the impact scores (physical and psychological, respectively) for early 
appointments when compared with later appointments under the null hypothesis of no 
treatment effect. p<0.05 was considered statistically significant. 
Of the 155 participants who only attended two appointments and completed two forms 
only 121 took up any intervention. When the physical impact scores pre- and post-
intervention for these participants were compared using the paired-samples t-test the 
samples were not found to be significantly different. This was also true for the 
psychological impact scores. Likewise, no statistically significant differences were 
found when the physical impact and psychological impact scores were compared 
within the groups of participants who had attended three, four or five appointments. 
These results are surprising in respect of the potential benefit that interventions can 
provide and the responses to the HTQ as reported in section 5.10. 
As stated earlier in this work (section 4.5.4.2) for a t-test at the 5% significance test to 
have a power of 80% to detect any change the minimum number of evaluable 
volunteers is 253. One of the challenges for research in specific conditions is that 
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sample sizes can be small. In the year prior to commencing the research 598 patients 
had attended clinic appointments, so it seemed likely that there would be enough 
participants for statistical significance to be achieved. A good response rate was 
achieved (n=323), the sample still potentially being large enough. However, the 
number of patients who attended two, three or four appointments was lower than the 
statistical cut-off required. Thus, although a large sample was recruited for the 
quantitative phase of the project the final numbers of participants was not great enough 
to be able to demonstrate statistical significance. As no statistical differences were 
found, results could not be reported as effect sizes for participants who attended two, 
three or four appointments. I would suggest that the variety of interventions offered 
and differing times between reviews and response shift could also have contributed to 
this result. 
Thus, I inferred that there was no discernible statistically significant benefit from 
interventions in this research as assessed by MSIS-29v2. 
5.10 ANCHOR-BASED RESPONSIVENESS 
There is little published in the literature as to what score changes represent a 
meaningful change in the HRQoL of a patient following assessment with the MSIS-
29v2 or even if the changes reported by patients are clinically relevant. A positive 
change in the physical and/or psychological impact of MS is demonstrated by a 
decrease in one or both of the two sub-scores. 
The data for those participants who had attended more than one appointment was 
examined for correlation between changes in physical and psychological impact scores 
and the participants responses to the health transition question (section 4.5.4.8). The 
HTQ was used as a reference measure for external responsiveness in this study. It 
represented a measure of self-perceived change in health. To enable statistical analysis 
responses were coded as follows: significantly improved=2, slightly improved=1, No 
change=0, slightly deteriorated=-1 and Significantly deteriorated=-2. 
Anchor based responsiveness is determined using receiver operating characteristic 
(ROC) curves. Due to the small sample sizes in this research ROC curves were not 
plotted. 
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5.10.1 Participants who attended two appointments 
Of the 155 participants who attended two appointments only 121 participants took up 
at least one intervention. Seventy-eight participants (65%) received reassurance as 
their only intervention. This possibly reflects the more stable nature of their MS as 
they only required two reviews in twelve months. 
Figure 18 demonstrates that, following at least one intervention, 49 participants (42%), 
when answering the HTQ, described their HRQoL as remaining the same. Whilst 18 
participants (15%) described a slight or significant improvement, 51 participants 
(43%) experienced a slight or significant deterioration. 
When asked if their quality of life had improved, remained the same or deteriorated 
from T1 to T2, the answers from 41 of the participants correlated with changes in the 
physical and psychological impact scores. In these cases, the scores for both domains 
had either increased, decreased or one had remained the same and the other had 
increased or decreased; the response to the HTQ reflected these changes. For example, 
the impact scores reduced for one participant who was prescribed pregabalin for 
neuropathic pain, paresthesia, restless legs and difficulty sleeping; they commented 
that ‘the tablets are great’. They stated that they had ‘significantly improved’, 
demonstrating a very positive effect of this particular intervention. At T2, they only 
required reassurance. Another participant who was only offered reassurance at T1, had 
reduced impact scores and had ‘slightly improved’ according to the HTQ; they stated 
‘Better because I have moved to a bungalow! No stairs :)’. One participant who had 
‘improved significantly’ according to the HTQ and had lower impact scores wrote: 
‘Although my wife is still in hospital I am coping well. We are now financially secure. 
I have retired but have taken on a six-month part time contract’. These two examples 
reveal that the actions of patients can have a big impact on their life and that they do 
not need to be initiated by the multi-disciplinary team to make a difference to HRQoL. 
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Figure 18 Change in HRQoL between two appointments 
For two participants the impact scores remained the same from T1 to T2 and they 
reported no change in their HRQoL. For one participant at T2 the two impact scores 
indicated a deterioration and the HTQ response was ‘slightly deteriorated’. This 
participant had been referred to the continence service at T1 for frequency, urgency 
and nocturia. On review at T2 they had described several bad days with spasms and 
neuropathic pain; they were offered and accepted an increase in the medication they 
were receiving. Thus, although the previous intervention may have improved their 
HRQoL, the effect of new symptoms had increased the impact of MS and reduced 
their overall HRQoL. I would suggest that for this patient the MSIS-29v2 did not 
detect a change in the impact of MS following an intervention as at their subsequent 
review they were experiencing new symptoms. Another participant whose impact 
scores had increased and who responded to the HTQ ‘slightly worse’ stated, ‘Balance 
is worse so confidence in walking outside decreased’. However, they told the clinic 
nurse that the physiotherapy referral from T1 was helping. Again, this is evidence that 
although interventions often do help, the variability of MS means that this may not 
always demonstrated when the MSIS-29v2 is completed at a subsequent appointment. 
Thirteen participants’ answers did not correlate with the direction in which the impact 
scores changed. The impact scores for 17 participants indicated a reduction in the 
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impact of MS but they stated there was no change in their HRQoL. Eighteen 
participants impact scores demonstrated an increased impact of MS, yet they answered 
no change to the transition question. For the remaining 28, one of the physical impact 
or psychological impact scores increased whilst the other decreased, and so it was not 
possible to determine if the participants answer to the quality of life question correlated 
with the change. Three participants did not answer the health transition question 
concerning a change in their QoL. 
On analysis of the data a statistically significant relationship (Spearman’s correlation 
coefficient, r= -0.28, p=0.002) was demonstrated between the change in physical 
impact scores from T1 to T2 and the change in the HTQ scores from T1 to T2. 
 
Figure 19 Scatterplot and line of best fit showing the relationship of the change 
in physical impact of MS and response to the HTQ 
The scatterplot (Figure 19) demonstrates an approximately linear relationship with the 
expected negative gradient. Patients located in the upper left quadrant experienced an 
increased physical impact of their MS between T1 and T2 and described a 
deterioration in their HRQoL when responding to the HTQ. Conversely those patients 
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who experienced a reduction in the impact of their MS and responded to the HTQ 
indicating an improved HRQoL are located in the lower right quadrant. 
The correlation coefficient of -0.28 is significant at the p=0.01 level and according to 
Cohen’s rule of thumb for effect size (1988) indicates a medium effect size. Effect 
sizes should be used as rough guides. Figure 19 shows that R square (coefficient of 
determination) = 0.098, which indicates that only about 10% variation in y (Diff_T2-
T1_Physic) can be explained by x (change in HRQoL between T1 and T2). 
Figure 20 shows that a statistically significant relationship (Spearman’s correlation 
coefficient r= -0.41, p=0.000) was also demonstrated between the change in 
psychological impact scores from T1 to T2 and the change in the HTQ scores from T1 
to T2. 
 
Figure 20 Scatterplot and line of best fit showing the relationship of the change 
in psychological impact of MS and response to the HTQ 
The scatterplot (Figure 20) again demonstrates an approximately linear relationship 
with the expected negative gradient. Patients located in the upper left quadrant 
experienced an increased psychological impact of their MS between T1 and T2 and 
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described a deterioration in their HRQoL when responding to the HTQ. Conversely 
those patients who experienced a reduction in the impact of their MS and responded 
to the HTQ indicating an improved HRQoL are located in the lower right quadrant. 
The correlation coefficient of -0.41 is significant at the 0.01 level and according to 
Cohen’s rule of thumb for effect size (1988) indicates a medium effect size. Figure 20 
shows that R square (coefficient of determination) = 0.180, which indicates that only 
about 18% variation in y (Diff_T2-T1_Psych) can be explained by x (change in 
HRQoL between T1 and T2). 
Because of the small sample sizes scatterplots were only produced for those 
participants who attended just two appointments during the research period. 
5.10.2 Participants who attended three appointments 
Of the 58 participants who attended only three appointments, 48 took up interventions 
at T1; three participants did not answer the health transition question. Forty-four 
participants took up interventions at T2; all answered the HTQ. 
Figure 21 demonstrates that between T1 and T2 and following at least one intervention 
17 participants (38%) described their HRQoL as remaining the same whilst seven 
participants (16%) described a slight or significant improvement. Twenty-one 
participants (47%) experienced a slight or significant deterioration. 
Between T2 and T3 17 participants (39%) described their HRQoL as remaining the 
same whilst 10 participants (23%) described a slight or significant improvement. 
Seventeen participants (39%) experienced a slight or significant deterioration (Figure 
21). 
An equal number of participants reported no change in HRQoL between appointments, 
i.e. T1 to T2 and T2 to T3, although these are not necessarily the same patients. 
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Figure 21 Changes in HRQoL for three appointments 
5.10.2.1 T1 to T2 
When asked if their quality of life had improved, remained the same or deteriorated 
from T1 to T2, the answers to the HTQ of 18 of the 45 participants eligible for data 
analysis correlated with the changes in the physical and psychological impact scores. 
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One participant for whom the impact scores had reduced, and who had stated that her 
HRQoL had ‘slightly improved’ attributed this to a referral to the continence service 
and pads being provided; in this case the MSIS-29v2 revealed a positive impact of an 
intervention which correlated with the patients view. This is also demonstrated by 
another participant whose impact scores had reduced and who had said they were 
‘significantly better’. They stated ‘My quality of life continues to improve following a 
lifestyle change 18 months ago. Apart from a slight relapse (last week) which I think 
is due to going back to work I feel better than I have in years.’ At T1 it was suggested 
that they try decaffeinated drinks to see if this helped reduce bladder frequency and 
urgency. The impact of self-management is also evident here in the form of lifestyle 
changes. One participant for whom the MSIS-29v2 at T2 indicated a lower impact of 
MS responded to the HTQ as ‘no change’; they commented ‘feeling frustrated at 
slowing down and not being able to do things i.e. DIY’, which could have potentially 
accounted for their response to the HTQ. 
For eight participants, one of the physical impact or psychological impact scores 
increased whilst the other decreased, and so it was not possible to determine if the 
participants answer to the health transition  
question correlated. This is illustrated in the following two examples. One participant 
whose physical impact score had increased but psychological score had decreased 
stated ‘no change’ in her HRQoL yet added in the comments: ‘Pregabalin has made 
such a difference because I sleep through the night. Such an improvement in my life. 
No longer tired and so able to do so much more’. This demonstrates that the benefit 
of interventions may occur in only one domain of HRQoL and may not be evident to 
the patient. Another participant whose physical impact score reduced, but 
psychological score increased, responded to the HTQ as ‘slightly improved’, 
attributing this to change of DMT from an injectable to an oral medication stating that 
‘new meds do seem to be helping reduce day-to-day MS symptoms’. They were unclear 
why the psychological impact of MS had increased. 
5.10.2.2 T2 to T3 
When asked if their quality of life had improved, remained the same or deteriorated 
from T2 to T3, the answers from 18 of the 48 participants correlated with changes in 
the physical and psychological impact scores. Twelve participants described no 
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change when the impact scores indicated an improvement; two had impact scores 
indicating a deterioration. 
Two participants’ answers did not correlate with the direction in which the impact 
scores changed, i.e. their impact scores indicated an improvement, but the participants 
stated their quality of life deteriorated. For one participant who was prescribed 
medication at T1 for pain, stiffness, and spasms the impact scores were lower, yet the 
patient’s response to the HTQ was ‘slightly deteriorated’ and the patient complained 
of feeling more fatigued. The nurse comments, ‘recently had dental work that had 
gone wrong, no appetite and increased spasms’ could explain why they said they had 
deteriorated. 
For the remaining 10, one of the physical impact or psychological impact scores 
increased whilst the other decreased, and so it was not possible to determine if the 
participants answer to the quality of life question correlated. 
Interestingly, one participant who attended three appointments and took up no 
interventions described no change in their HRQoL when answering the HTQ. This 
could indicate that their MS was very stable or that they were adjusting to changes and 
required no interventions. 
5.10.3 Participants who attended four appointments 
Of the 18 patients who had attended four appointments, 10 took up interventions at 
T1, 16 at T2 and 12 at T3. 
Figure 22 demonstrates that between T1 and T2 and following at least one intervention 
40% of participants described their HRQoL as remaining the same whilst 10% of 
participants described a slight or significant improvement; 50% experienced a slight 
or significant deterioration. 
Between T2 and T3 56% of participants described their HRQoL as remaining the same 
whilst 13% of participants described a significant improvement; 31% experienced a 
slight or significant deterioration. 
Between T3 and T4 42% of participants described their HRQoL as remaining the 
same. No one reported an improvement; 58% experienced a slight or significant 
deterioration. 
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Figure 22 Changes in HRQoL for four appointments 
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Although the numbers of participants attending four appointments only is small it 
would appear that for these patients taking up intervention appears to help maintain 
HRQoL or minimise deterioration rather than improve it, when assessed using the 
HTQ. As these participants were seen more frequently than others during the research 
period it is possible that they were experiencing issues with their MS such as relapses 
or deteriorating symptoms. Thus, I would suggest that maintenance of HRQoL rather 
than improvement would be a realistic expectation. 
5.10.3.1 T1 to T2 
When asked if their quality of life had improved, remained the same or deteriorated 
from T1 to T2, the answers to the HTQ from three of the ten participants correlated 
with changes in the physical and psychological impact scores. For one of these 
participants the dose of amitriptyline was increased at T1 for head pain; at T2 they 
stated: ‘had gastroenteritis and felt very unwell as couldn’t keep meds down- felt really 
depressed’. These events occurred shortly before the review and therefore I would 
suggest that it was not possible at this time to detect whether the medication had made 
a difference to HRQoL as measured by the MSIS-29v2. 
Two participants’ answers did not correlate with the direction in which the impact 
scores changed; the scores for one indicated the impact of MS was less yet they said 
no change and vice versa for the other participant. For the remaining five, one of the 
physical impact or psychological impact scores increased whilst the other decreased, 
and so it was not possible to determine if the participants answer to the quality of life 
question correlated. 
5.10.3.2 T2 to T3 
When asked if their quality of life had improved, remained the same or deteriorated 
from T2 to T3, the answers to the HTQ for four of the sixteen participants correlated 
with changes in the physical and psychological impact scores. Nine participants’ 
answers did not correlate with the direction in which the impact scores changed. For 
the remaining three, one of the physical impact or psychological impact scores 
increased whilst the other decreased, and so it was not possible to determine if the 
participants answer to the quality of life question correlated. 
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5.10.3.3 T3 to T4 
When asked if their quality of life had improved, remained the same or deteriorated 
from T3 to T4, the answers for three of the twelve participants correlated with changes 
in the physical and psychological impact scores. Five participants’ answers did not 
correlate with the direction in which the impact scores changed. Four described no 
change in their HRQoL yet the impact scores indicated a worsening. One of these 
participants was given reassurance at T3 and stated at T4 that she was now 
permanently in a wheelchair. Her response to the HTQ may indicate a change in 
standards or values, and conceptualisation of QoL (Schwartz and Sprangers, 1999). 
For the other participant the scores indicated a reduced impact of MS, yet the 
participant indicated no change. For the remaining three, one of the physical impact 
or psychological impact scores increased whilst the other decreased, and so it was not 
possible to determine if the participants answer to the quality of life question 
correlated. 
One of the participants impact scores fluctuated slightly over the time of the research, 
sometimes the physical impact score reduced, and the psychological score increased 
or vice versa; or both slightly increased despite counselling, a referral to the continence 
service and changes in medication doses. At each appointment the participant 
answered the HTQ question indicating deterioration, sometimes significant, yet 
always attributed this to their son being diagnosed with cancer. Even although they 
described positive benefits from counselling when interviewed this was not reflected 
in the MSIS-29v2 scores. 
5.10.4 Participants who attended five appointments only 
Of the two participants whose MSIS-29v2 who attended five appointments, and who 
completed the MSIS-29v2 five times, the changes in the physical and psychological 
scores correlated with the answers to the HTQ for three of the four times intervals for 
one participant and for two of the time intervals for the other participant. 
One of the participant’s response to the HTQ correlated with lower impact scores in 
both domains, which they attributed to, ‘since stopping the Avonex I feel so much 
better. The fatigue has lifted’, demonstrating that stopping interventions can also give 
positive benefits to people with MS. 
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From the above analysis it was evident that there was not always correlation between 
the participants perception of changes in their HRQoL and the MSIS-29v2 scores. I 
would suggest that the patient’s perception of the impact of MS is of more value than 
impact score changes when considering whether assessment makes a difference to 
patients or the assessment is of value to them. 
5.11 ISSUES WITH THE MSIS-29V2 
Throughout phase 1 two issues became evident for those completing the MSIS-29v2. 
5.11.1 Help to Complete the MSIS-29v2 
Help was required to complete the MSIS-29v2 on 92 (17%) occasions. Reasons for 
requiring help are discussed in section Error! Reference source not found.. From o
bservation, it was evident that whilst some relatives discussed the MSIS-29v2 with the 
participant, others completed the questionnaire without participant involvement. As 
this was not systematically recorded it was impossible to measure any impact this may 
have had on responses. However, the fact that some patients will have completed the 
instrument with help arguably reflects the reality of using self-assessed measures. This 
point is also discussed further in section 7.2. Being able to complete the MSIS-29v2 
either alone or with the help of a significant other is key to the feasibility of assessment 
of HRQoL. Unfortunately, there were no resources available for those who attended 
appointments alone and who were not able to complete the MSIS-29v2 unaided. From 
experience, I would suggest that a number of these patients would benefit as they are 
not always the most articulate people. 
5.11.2 Limitations of the MSIS-29v2 
Several limitations relating to completion of the MSIS-29v2 were determined during 
phase 1. These are presented below and discussed further in chapter 6, section 6.4. 
The results demonstrated that some participants found the lack of an option to clarify 
their answers to questions frustrating. They described the need to clarify and give more 
specific answers than the predetermined answers allowed, reflecting the work of 
Bowling (2014). The examples in Table 8 highlight areas where a lack of clarity in 
relation to responses for some of the questions was evident. 
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Participants thought it was important for the healthcare professional to know what was 
affected, for example, right leg, left hand. The answers to the questions stimulated 
discussion, resulting in possible interventions being suggested, discussed and 
potentially taken up.
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Question 
number 
Question Example responses 
Question 1 How much has your MS limited your 
ability to do physically demanding 
tasks? 
One participant answered, ‘a little’, clarifying that she has a cleaner. 
Question 2 How much has your MS limited your 
ability to grip things tightly? 
One participant clarified answering ‘extremely’ for their left hand and 
‘moderately’ for their right hand. 
Question 3 How much has your MS affected 
your ability to carry things? 
One participant commented, ‘it depends how heavy- over 50kg presents a 
problem’. 
Another stated that ‘when holding on, I can carry with one hand’. 
Question 5 How much have you been bothered 
by difficulties moving about 
indoors? 
One participant answered that they had been bothered ‘a little’ by 
difficulties moving about indoors, clarifying that they use a wheelchair 
indoors. 
Another answered ‘not at all’ stating that she uses a wheelchair indoors. 
Question 6 How much have you been bothered 
by being clumsy? 
One participant stated that he is clumsy as he blind. 
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Question 
number 
Question Example responses 
Question 8 How much you have been bothered 
by heavy arms and/or legs? 
One participant indicated that they were ‘not bothered at all by heavy 
arms’ but were ‘extremely bothered by heavy legs’. 
Another answered they were ‘extremely bothered by heavy arms and/or 
legs’ but clarified that only one leg was affected. 
Another stated that it was their feet that were affected. 
Three participants underlined or ringed legs when answering this 
question. Another ticked legs. 
One participant crossed out ‘or’, indicating that she was bothered by 
heavy arms and legs. 
Question 9 How much have you been bothered 
tremor of your arms or legs/ 
One underlined ‘arms’ when responding to this question. 
Question 10 How much have you been bothered 
by spasms in your limbs? 
One underlined ‘arms’ when responding to this question. 
One participant answered ‘extremely’ but wrote that the spasms in his 
limbs only occurred ‘periodically’. 
Question 11 How much have you been bothered 
by your body not doing what you 
want it to do? 
One participant wrote that for some parts there were no problems and that 
others were extremely affected. 
Question 17 How much have you been bothered 
by problems using transport (e.g. car, 
bus, train, etc.)? 
One participant clarified stating ‘car’. 
Another wrote ‘bus’. 
Table 8 Examples of responses to questions of the MSIS-29v2 
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When discussing the responses given it became evident that some participants felt the 
answers of ‘not at all’ (scored as 1), ‘a little’ (2), ‘moderately’ (3) and, ‘extremely’ (4) 
to be too restrictive, mimicking the work of Boynton and Greenhalgh (2004). Some 
participants answered questions indicating that they would like to reply between two 
answers; for example, their answer lay between ‘a little’ and ‘moderately’. ‘A little’ 
was not a strong enough description but ‘moderately’ indicated a greater impact than 
they felt appropriate. These findings reflect those of (Fayers and Machin, 2016) who 
describe how a structured questionnaire can be frustrating and restricting for a patient 
if the supplied answers do not describe their condition. Where patients had indicated 
an answer between two values, the higher value was recorded for the purpose of data 
analysis. 
Some examples of how participants answered questions are given below in Table 9. 
Question 
number 
Example responses 
Question 1 One participant wrote that her reply was between ‘a little’ and 
‘moderately’. 
Question 4 One participant at their first review ringed between ‘moderately’ 
and ‘extremely’. 
Question 6 One participant circled 2 and 3 in one large circle. 
Question 11 One participant placed a tick midway between the response ‘a 
little’ and ‘moderately’. This participant responded in the same 
manner for questions 13 and 14. 
Question 20 One participant wrote 3.5. 
Question 22 One participant gave up a stressful job one week before the initial 
review. Over the two-week period in which they were required to 
consider the impact of their MS they stated that they ‘had gone 
from being extremely bothered by problems sleeping and also 
feeling anxious or tense to not at all bothered by these issues’. 
Question 26 One participant ringed both ‘moderately’ (3) and ‘extremely’ (4), 
but drew an arrow going from 3 to 4. 
Question 27 One participant ringed ‘moderately’ and ‘extremely’ and wrote 
‘to’ in between. 
Question 29 One participant wrote 3.5. 
Table 9 Examples of responses to scoring of the MSIS-29v2 
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5.12 METHODOLOGICAL LIMITATIONS 
Despite finding support for assessment of HRQoL, there were a number of 
methodological limitations that have emerged through the course of this phase of the 
research which must be considered. 
5.12.1 Sample Size 
Although the required patient-participant sample size to determine statistical power 
was calculated prior to commencement of the research the number of patients who 
attended more two or more appointments during the data collection period was less 
than this, meaning that statistical analysis was limited. Even if all the patients who had 
attended two appointments had been considered in one group less than 253 took up an 
intervention at T1, this being below the number required for statistical significance. 
5.12.2 Lack of a Control Group 
The lack of a randomised control group, a consideration raised by the National Ethics 
Research Service, meant that potentially it was not possible to know whether any 
change was due to an intervention initiated at the outpatient appointment, the lapse of 
time since last appointment, stability of the MS, shift response or some other influence 
(de Vaus, 2001). There was also a possibility that improvements occurred due to 
participant participation in the research (Arnoldus, et al., 2000) when the consultation 
took a different format and participants were asked more about those areas where they 
revealed that MS was impacting on them. 
5.12.3 Cognitive Impairment 
The cognitive function of patients was not tested before administering the 
questionnaire. Nor were patients asked to disclose cognitive impairment. This is an 
important consideration given the requirement to self-administer the MSIS-29v2. 
Studies by Gold, et al. (2003) Marrie, et al. (2003) and Baumstarck, et al. (2012a, 
2012b) showed that a moderate degree of cognitive impairment in multiple sclerosis 
does not affect reliability and validity of self-report measures. The work of Benedict, 
et al. (2004) refutes this. However, the MSIS-29 was tested by van der Linden, et al. 
(2005) and found to be reliable for those with cognitive impairment. Future studies 
should examine the possible impact of cognitive impairment on the ability of patients 
to complete the MSIS-29v2. 
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5.12.4 Assisted Completion 
As noted in section 3.10.1 it could be perceived as a limitation that some patients 
required help to complete the MSIS-29v2; however equally this could be seen as a 
pragmatic reflection that many patients manage and discuss their health with 
significant others. 
5.12.5 History and Longitudinal Assessment 
This research demonstrates that analysing longitudinal data with varied intervals of 
data collection and differing interventions for a diverse group of individuals is 
extremely problematic. Participants completed the MSIS-29v2 at their first 
appointment (T1) following commencement of the research and then at subsequent 
appointments (T2, T3, T4, T5). The length of time between appointments varied from 
participant to participant from three months to a year. The problem of extraneous 
events potentially becomes greater as the time between questionnaires increases. This 
was potentially a problem for those patients only reviewed yearly and may have 
contributed towards a skewing of the results. MS is a highly variable condition and 
thus it is conceivable that participants could have had a relapse, infection or 
experienced a general deterioration in their condition between completing 
questionnaires. Health-related quality of life could be reduced in the short or long term 
depending on the severity of the event. As data was not collected about these factors I 
had to consider that it was not possible to fully attribute any changes in the impact 
scores to interventions commenced, potentially compromising the internal validity of 
the research. 
When assessing longitudinal effects of interventions on HRQoL longitudinal 
correlations of change scores may be weak (Costelloe, et al., 2007). They suggest that 
this may in part be due to the relative short periods of follow-up or differing 
perceptions between the patient and the neurologist as to whether change has taken 
place (Hoogervorst, et al., 2003). This was an issue as patients could only be followed 
up for 12 months during the data collection phase. The time between follow-up periods 
was relatively short for those patients who had attended three or more appointments 
during this data collection period. The lack of ability to detect change could also be 
accounted for by the response shift phenomenon which is recognised in QoL studies. 
Costelloe, et al. (2007) describe response shift as an intrinsic, unavoidable and 
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undesirable aspect of self-report measures which may limit the validity of such 
measures over time. Response shift is discussed further in chapters 6 and 7. 
5.12.6 Maturation 
Campbell and Stanley (1963) suggest that when change is being studied some of the 
change may be due to the passing of time rather than the interventions. As MS is a 
chronic progressive condition it was likely that some participants would deteriorate 
over time. Although the questionnaire asks the participants to reflect back over the last 
two weeks, if deterioration had occurred and the time between assessments was great 
it is likely that some of the changes in scores were due to the deterioration, rather than 
the interventions offered to potentially reduce the impact of the physical or 
psychological symptoms. Some participants may also have adapted to their change in 
condition and consequently described an improvement in their HRQoL. 
5.12.7 Testing 
Testing participants on several occasions can contaminate results and thus affect 
internal validity (Campbell and Stanley, 1963). In this research many participants were 
assessed at several outpatient appointments. Thus, they could have become familiar 
with the questionnaire which may have affected the way they responded. When given 
the MSIS-29v2 to complete, the clipboard also held previous questionnaires from that 
participant. Thus, participants were able to look back at previous questionnaires which 
could also have potentially influenced how they completed the current one. During 
outpatient appointments, several participants did state that they had looked at previous 
questionnaires to compare their results. Score changes might then be attributable to 
participants reviewing their previous questionnaire responses and thus measuring their 
condition in relation to these answers. Although a problem during the research period 
the ability to compare with previous ones would not be an issue if the MSIS-29v2 was 
embedded into everyday practice as patients would not have access to previously 
completed forms. 
Additionally, (Campbell and Stanley, 1963) suggest that completing questionnaires 
can sensitise people to issues which they had previously given little thought and this, 
rather than therapeutic interventions, could produce changes which would potentially 
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be reflected in the questionnaire scoring. This became apparent when interviewing 
participants in phase 2 of the research and is discussed in section 6.3.4.2b. 
5.12.8 Missing Data 
Telephone and email support play a huge part in the care offered to the patients where 
this research occurred, thereby providing a proactive service to patients who would 
possibly have to wait many weeks to be reviewed face-to-face. When research 
participants contacted the service by telephone or email because they were 
experiencing problems any interventions which were commenced, altered or stopped 
were not captured on the intervention sheet and thus potentially were not evaluated at 
the next appointment. Additionally, any changes in HRQoL noted on a questionnaire 
could not be related back to such interventions. 
Similarly following an outpatient clinic appointment when a treatment was offered 
such as steroids, or pain management was altered, participants would be subsequently 
reviewed in the telephone clinic. Thus, the effect of these interventions on HRQoL 
would not necessarily be captured. 
5.13 SUMMARY 
This phase of the research demonstrated that assessment of HRQoL is feasible, 
although not without difficulties. Feasibility issues determined included both 
distributing the MSIS-29v2 to participants immediately prior to appointments and 
patients being able to complete it alone. Two types of limitations of the MSIS-29v2 
were found; participants highlighted the inability to give clear and precise answers to 
some questions. The four responses were found to be too restrictive for others. 
This phase also showed that the results of an assessment of HRQoL can be used to 
inform therapeutic interventions, although it is probable that some interventions may 
have been suggested without such an assessment. 
When considering the question ‘Can a HRQoL measure detect change in HRQoL after 
the implementation of therapeutic interventions?’ no statistical significance was found 
between the implementation of interventions and the physical and psychological 
domains of HRQoL using the paired-samples t-test. However, it would appear from 
the patient perspective that interventions helped to maintain HRQoL or to least 
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minimise deterioration, as evidenced by the HTQ responses. The health transition 
question and the interviews of phase 2 indicated positive benefits of the interventions 
at times and an improvement in HRQoL. However, these results could also be 
accounted for by the variable nature of the condition and the response shift. 
Additionally, patients could have felt better for taking actions even if they were not 
statistically significant. The length of time of the study and the fact that patients could 
review their previous questionnaire/s may also have influenced the results. 
When the transition question responses were analysed it was apparent that some of 
those patients who had attended two or three appointments within the year of the 
research period did report an improvement in HRQoL following interventions. I would 
suggest that this reflects the fact they are frequent attenders who require and are getting 
more interventions. However as already discussed (5.10.3) for those attending four 
appointments no such improvement was noticed. The graphs of Figure 22 show that 
over the twelve-month research period following the uptake of various interventions 
the HRQoL of the majority of patients was maintained or only deteriorated slightly. 
This is a positive finding and reinforces the findings of the literature review which 
suggest that maintaining or optimising HRQoL is key to the care of patients with MS. 
The findings of this study are unique in that the MSIS-29v2 impact scores were 
compared with an HTQ when considering whether the implementation of an 
intervention makes a difference to HRQoL. 
The question of whether a HRQoL measure can detect changes in HRQoL following 
interventions is considered more fully in chapter 7, section 7.4. In conclusion, the 
exploratory character, sample size and time frame of the research is likely to have 
prevented me from drawing more pragmatic conclusions. 
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6.1 INTRODUCTION 
The aim of this phase was to address the following research questions: 
• Is assessment of HRQoL feasible in daily clinical practice? 
• Can the results of HRQoL assessment be used to inform therapeutic 
interventions? 
• Does assessment of HRQoL with an appropriate measure make a meaningful 
difference to patients? 
The presentation of results from phase 2 includes descriptive information about the 
sample of participants selected from phase 1 who consented to take part in phase 2. 
Contextual information includes the reasons participants were selected. Following this 
the qualitative findings from the interviews are presented and discussed, illustrating 
the main themes that have emerged from data analysis. Methodological limitations 
relating to this phase are considered. Some results are discussed more fully in Chapter 
7 when the findings of phases 1 and 2 are drawn together. 
6.2 SAMPLE AND SETTING 
6.2.1 Patient-Participant Characteristics 
Eighteen participants from phase 1 were invited to take part in phase 2 as described in 
section 4.6.4.1. Of these fifteen returned a signed consent form (response rate=84%). 
Participants selected for this phase had to have attended at least two outpatient 
appointments. Initially participants were chosen to represent the different types of MS, 
differing ages of onset and differing lengths of time since diagnosis. A mix of those 
receiving and those not on disease-modifying therapy were selected; four participants 
were receiving no DMT when selected for interview. The type of clinic appointment 
attended, the types of intervention offered, the changes in the impact scores between 
appointments, the response to the HTQ and correlation between changes in the 
physical and psychological impact scores and response to the HTQ were all 
considered. Five participants either experienced a relapse during the research period 
or a deterioration in their MS. How the MSIS-29v2 was completed also influenced 
who was initially invited for interview. Two participants were selected because they 
had missed questions or ringed two answers, thereby enabling me to discuss the 
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reasons and consider the appropriateness of the MSIS-29v2 for future use. Subsequent 
participants were selected based on the interview responses, thereby ensuring a wide 
range of views were collected. The reasons for selecting particular patient-participants 
are presented in Appendix V. 
The background and patient-participant characteristics are tabulated below in Table 
10 and Table 11. The final sample comprised of eight (53.3%) males and seven 
(46.7%) females. The age of participants ranged from 30 to 70 years old, with a mean 
age of 52.6 years (median=53). The time since participants had received their 
diagnosis varied between 2 years and 26 years and the mean time since they had 
received their diagnosis was 10.93 years (median=9) years. Eight participants (53.3%) 
were diagnosed with relapsing-remitting MS and seven (46.7%) with secondary 
progressive MS. No participants with primary progressive multiple sclerosis were 
interviewed. Of the sixteen participants with PPMS who took part in phase 1, nine had 
only one completed one form, and one died during the study. Of the remaining six, I 
considered that only two would be appropriate for interview; the remaining four either 
suffered with extreme fatigue (1), cognitive issues (2) or a lack of confidence (1). 
 Patients n=15 
Sex (female) 7 (46.7%) 
Marital status 
Married 
Partner 
Single 
10 (66.7%) 
3 (20%) 
2 (13.3%) 
Employment status 
Full-time employment 
Housewife/Househusband 
Part-time employment 
Retired due to ill health 
Retired 
5 (33.3%) 
1 (6.7%) 
2 (13.3%) 
6 (40%) 
1 (6.7%) 
Type of MS 
Relapsing-remitting MS 
Secondary progressive MS 
8 (53.3%) 
7 (46.7%) 
Table 10 Sociodemographic and clinical characteristics of the study population 
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Except for sex ratio, the participants interviewed are representative of the 311 
participants of phase 1 from which the interviewees were drawn (mean age of 55.91, 
range 28-82 years; median time since diagnosis 12 years; 52.3% RRMS, and 38.7% 
SPMS). Further characteristics of the sample are presented in Table 11. 
Interview 
and 
Participant 
No 
Gender 
Age at 
time of 
research 
in years 
Time since 
diagnosis in 
years 
MS Type 
1 Male 30 8 RRMS 
2 Male 48 4 SPMS 
3 Female 45 10 SPMS 
4 Female 54 26 RRMS 
5 Female 46 14 SPMS 
6 Female 59 22 RRMS 
7 Female 41 12 RRMS 
8 Male 49 2 RRMS 
9 Male 53 3 RRMS 
10 Male 66 3 SPMS 
11 Female 66 9 RRMS 
12 Male 70 24 SPMS 
13 Male 57 14 SPMS 
14 Female 49 9 SPMS 
15 Male 56 4 RRMS 
Table 11 Characteristics of the patient-participants in Phase 2 
6.2.2 Staff-Participant Characteristics 
Only three healthcare professionals were involved in this research, myself and two 
others, one is a consultant neurologist and one a CNS MS. The staff-participants are 
referred to as HCP1, HCP2 and myself throughout the text. My views are presented 
throughout the following chapter and related to the responses of the two staff 
interviews. 
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6.2.3 Patient-Participant Interviews 
Eleven participants were interviewed at the Acute Hospital, three at the outlying 
Hospital and one at their place of work as this participant had transport and mobility 
issues. Interviews lasted between fifteen and thirty-two minutes. I wanted to keep the 
interviews relatively short so as not to tire participants unduly. 
Initially as the researcher-interviewer I wore uniform for the interviews. However, 
after four interviews, role confusion, as described by Holloway and Wheeler (1995) 
was evident; participants brought their experience and memory of the patient-clinician 
relationship to the research setting (Gardner, 1996), participants viewing me as a nurse 
rather than a researcher and raising issues about their current symptoms or problems. 
As their CNS, I found this duality of roles very difficult to manage reflecting the views 
of Holloway and Wheeler (1995) as I have always endeavoured to answer patients 
queries in a timely manner. During the interviewees I recognised the need to divorce 
myself from my clinical role and thus took the decision to inform participants that their 
concerns would be addressed after the interview. As a clinician, I was disconcerted 
that these patients had not felt able to call the MS Service to discuss their concerns; as 
a researcher, however, I know from the body of literature, that many MS patients do 
not appear to fully understand their condition. This dilemma of duality of roles, 
clinician versus researcher has also been highlighted by Carolan (2003) and is a 
common dilemma faced by clinicians who undertake research within their clinical 
area. Civilian clothes were worn for the remaining interviews; participants no longer 
mentioned their own symptoms but focused fully on the questions, many providing 
insightful information. 
After fifteen interviews I decided in consultation with my supervisors that data had 
been collected from a diverse sample and analysis had reached a point where no new 
themes were occurring (i.e. data saturation) as described by Strauss and Corbin (1998). 
Thus, recruitment ceased. 
6.2.4 Staff-Participant Interviews 
The two members of staff were interviewed at the Acute Trust Hospital. The 
interviews lasted between thirteen and seventeen minutes. They were relatively brief 
as we already knew each other and so focused on the interview schedule. Uniform was 
worn for these interviews. 
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6.3 PRESENTATION OF DATA 
The purpose of this section is to present the major findings of the qualitative phase of 
the study which emerged through the inductive thematic data analysis process. The 
analysis was built up from the data, rather than originating from a pre-existing 
theoretical framework or my expectations. Key themes are presented. The verbatim 
extracts selected have been chosen because they provide powerful or insightful 
accounts of any given theme, thereby substantiating them. Whilst some extracts 
represent the view of the majority of respondents, others illuminate the views of only 
a few. Denscombe (2014) suggests that interview extracts can be used to good effect 
in social research; they let the reader ‘hear’ the points as stated by the interviewee, act 
as an illustration of a point, and they may be used as evidence supporting an argument 
that is being constructed in the report by the researcher. Where interview extracts are 
used, names have been removed to ensure anonymity; interview number and gender 
is given, enabling cross referencing to Appendix V. 
6.3.1 Themes 
Three major themes together with sub-themes and their associate-themes were 
identified which captured key aspects of the data: these are listed below in Table 12. 
The data from patient-participants and healthcare professionals are presented together 
revealing how the assessment of two dimensions of HRQoL is perceived by both 
groups. The commentary of the HCPs is prominent when I discuss the theme of 
‘process’ which looks at outpatient appointments and the use of the HRQoL measure 
in relation to assessment of HRQoL. 
The term interviewee, participant and patient are used interchangeably throughout the 
analysis. 
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Theme Sub-theme 
Condition History of MS 
Reaction to the diagnosis of MS and burden of the diagnosis 
The uncertainty and lack of predictability due to MS 
Identity 
Self Reflection of the impact of MS on self 
Reflection of the impact of MS on daily life 
Reflection of the impact of MS on significant others 
Assessment of HRQoL 
Quality of life 
Theme Sub-theme Associate-theme 
Process Outpatient 
appointments 
Role of HCPs 
Style of consultation 
Experience of attending outpatient appointments  
Benefits of attending outpatient appointments 
Issues of concern addressed 
MSIS-29v2 Properties of the MSIS-29v2 
Informing the consultation 
Impact of completing the MSIS-29v2 on self 
Impact of completing the MSIS-29v2 on care 
offered 
Assessment of changes in HRQoL 
Practical considerations 
Table 12 Themes, sub-themes and associate-themes 
The themes of condition and self were identified when the transcripts were analysed 
and the relevance of the impact of a diagnosis of MS to assessment of HRQoL realised. 
6.3.2 Condition 
This category explores how the participants viewed the condition of multiple sclerosis. 
As an introductory question I invited participants to talk about their experience of 
living with MS. Participants talked about the way they regarded themselves and the 
way others viewed them following their diagnosis. It was evident that their identity 
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was affected. Identity is discussed in section 6.3.2.4 and related to self in section 6.3.3. 
As discussed in chapter 2, MS is an incurable unpredictable condition which affects 
people in many ways; people will inevitably react to such a diagnosis differently. It 
was striking how important this part of the interview was to the participants and how 
rich the resulting data was. Ultimately, this information contributed to understanding 
the participants use of the MSIS-29v2 and whether there is a role for such an 
assessment in daily clinical practice. 
From the transcripts the sub-themes of: history of MS, reaction to diagnosis of MS and 
the burden of the diagnosis, uncertainty and lack of predictability due to MS, and 
identity were identified (Figure 23). 
 
Figure 23 Relationship of the sub-themes to the theme ‘Condition’ 
6.3.2.1 History of MS 
Although participants were asked to recount their experience of living with MS, it was 
evident that some participants were keener to describe their experience of being 
diagnosed with MS. Some participants were diagnosed quickly: 
‘I felt like that I did not have a build-up really for me, it just happened 
over night.’ (P3:F) 
Condition
History of MS
Reaction to 
diagnosis and 
the burden of 
diagnosis
Uncertainty 
and lack of 
predictability 
due to MS
Identity
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However, as discussed in section 2.6.1, diagnosing MS can be difficult and often takes 
time. This was illustrated by four interviewees (P4, P8, P10, P11) who described how 
they had been living with symptoms, sometimes of an intermittent nature, for several 
years prior to diagnosis. Some developed further symptoms before a diagnosis was 
finally given: 
‘It just seemed to slow. (Life). It started off as just an ache in the back 
of the leg. And then no one could identify what it was. So, I had been 
living with it for a lot longer than I realised I’d had it.’ (P10:M) 
This comment reflects the work of Koopman and Schweitzer (1999) who suggest that 
if symptoms are mild or vague in nature the time to diagnosis may be lengthy. The 
above quote also resonates with the work of Courts, Buchanan and Werstlein (2004) 
who discuss how patients described the period before diagnosis as a time of trying to 
make sense of symptoms, seeking medical help and feeling powerless. 
The experience of Participant 1 also illustrates how complex it can be to diagnose 
someone with MS: 
‘They first thought it was a brain tumour and then they thought I had a 
stroke. And then after a week of being in hospital they then diagnosed 
me.’ (P1:M) 
It is very likely that the journey a person has been on prior to receiving their diagnosis 
will ultimately affect the relationship with their healthcare practitioners, how they 
cope with the diagnosis (Johnson, 2003) and ultimately their HRQoL. 
6.3.2.2 Reaction to Diagnosis of MS and the Burden of the Diagnosis. 
Receiving a diagnosis of MS is a challenge for patients and their families. When a 
person is diagnosed with a life-long incurable chronic condition, such as MS, it is 
inevitable that they will experience a variety of different emotions, including distress, 
anxiety, anger, depression and even relief, both in relation to acceptance of, and 
adaptation to the diagnosis. Lysandropoulos and Havrdova (2015) suggest that MS 
can be described as a journey of feelings which change over time. These reactions are 
likely to impact on and ultimately affect their HRQoL. Thus, I suggest that assessing 
HRQoL, thereby determining issues of importance to the patient, could contribute to 
an improvement in HRQoL for these patients. 
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Realising that there is variability within the condition and that different people with 
MS develop different symptoms, that one person won’t develop all the symptoms, and 
that no two people develop the same symptoms is all part of understanding MS. P8 
suggested that: 
‘Developing an understanding MS allows you to deal with it, get 
around the problems and thus life becomes a little easier’ (P8:M) 
whilst Participant 3 suggested ‘it made the condition less frightening’. Participant 14 
described how they had grown to understand MS over time. 
One participant was relieved to be given a diagnosis as they could understand why 
they felt the way they did, echoing Burgess (2010b) who discusses how some people 
feel relief at finding out what is wrong with them. Two (P10, P13) described the shock 
of being diagnosed with an incurable illness and the subsequent gambit of emotions 
experienced, illustrating the findings of Johnson (2003) in which many people 
reported being devastated and shocked at their diagnosis. Lysandropoulos and 
Havrdova (2015) also describe how at the time of diagnosis patients can feel afraid, 
angry and wonder ‘why me?’ 
Generally, it appears that it takes people time to recognise and accept that they have 
MS: 
‘You have to acknowledge MS before you can then move on and accept 
the condition.’ (P1:M) 
This quote reflects the views of Moss-Morris (2013) who suggests that adaptation to 
chronic illness is an on-going process and will potentially re-occur at different stages 
in the disease trajectory. The realisation that one has been diagnosed with a long-term 
condition was described by Interviewee 8 as a big challenge and by Participant 1 as 
shocking and frightening; P1 stated that ‘diagnosis just has to be dealt with’, 
suggesting a pragmatic approach. This view contrasts with others who struggle to 
come to terms with the diagnosis, possibly for many years. For example, Participant 6 
suggested: 
‘I would be much better if I actually settled on well this is where I am, 
and this is how I ought to be dealing with it instead of pretending it's 
not there.’ (P6:F) 
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She (P6) concluded that after more than 20 years she is still struggling to accept her 
diagnosis and the impact on her, attributing this to the fact that she has declined slowly. 
P6 acknowledged that she may need help to accept her diagnosis. Moreover, there was 
recognition by Participant 6 that she ignored symptoms which were making life 
difficult and that MS was impacting on her life more than she acknowledged to herself. 
It is possible that this view coloured the way she completed the MSIS-29v2 and HTQ, 
particularly in relation to longitudinal comparisons. Although Participant 4 also 
struggled to accept their diagnosis for a very long period they stated that: 
‘It took me a while to actually get used to having the label but knowing 
what's going on with you is better than not knowing,’ (P4:F) 
thereby demonstrating that with time acceptance and understanding can occur. 
For Participant 14, compromising has enabled her to cope with the diagnosis, live with 
MS and, achieve certain goals. Both P14 and P15 suggested that their outlook on life 
had changed as a consequence of diagnosis: 
‘I have to compromise and in one way that’s how I cope with it I think.’ 
(P14:F) 
‘Thinking about my outlook on life, yeah I think it is very unfair but 
there you go. It’s like any disease innit? Nobody wants it.’ (P15:M) 
A range of emotions were described by participants when they talked about the burden 
of living with MS including anger, irritation, frustration and fear. Whilst P15 stated 
that he was angry, Interviewee 10 considered MS an irritating condition, interfering 
with activities of daily life. This view was supported by Interviewee 11 who suggested 
that the condition is also frustrating, and there is a gradual loss of independence, but 
it was necessary to keep going; Participant 14 agreed: 
‘I knew people that had it before I was diagnosed, and then when I was 
diagnosed I realised I have just got to get on, you can’t sit down and 
so that’s the reason I think I am more motivated. I think my quality of 
living is, and how I coped with it, is that I now think of MS as not 
something you can fight, but I think of it as my partner, so it’s like my 
second partner. Even (partner) says things, and I go we’ve got to talk 
to the, let me think about the MS, and you have to think about that and 
the MS does come first in your life because it’s always there, and again 
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you can’t fight it, but you have got to work with it and compromise.’ 
(P14:F) 
This participant has adapted to her limitations and uncertain disease progression by 
altering her life and self in socially and personally acceptable ways (Barker, et al., 
2014). Charmaz (1995) describes how this process of adapting shades into acceptance 
as demonstrated by this participant. It is likely that some of this participant’s MS 
symptoms were not visible to her partner, reflecting the view of Cella, et al. (1996) 
who describe how the disease, although limiting, may not be readily apparent to others. 
6.3.2.3 The Uncertainty and Lack of Predictability due to MS 
The uncertainty and a lack of predictability of MS were frequently mentioned during 
the interviews reflecting the work of Koopman and Schweitzer (1999) who describe a 
diagnosis of MS as opening the door to uncertainty, variability and unpredictability. 
Both day-to-day variation and the possibility of deterioration over time were 
described. Participant 7 described the impact of the daily fluctuations of her MS: 
‘It can differentiate between being really good and erm being so care 
free and then just having problems with walking. It differentiates every 
single day.’ (P7:F) 
Another (P3) reflected on how the daily variation in her symptoms affected everyday 
choices such as the type of shoes to wear that day; she described how one just learnt 
to adapt. She (P3) was also experiencing some deterioration in her symptoms at the 
time of the interview and recognised the impending need for treatment to settle these 
symptoms and thus reduce the impact of MS on her daily routine. These two examples 
illustrate the findings of Benito-León, et al. (2003) who describe how the 
unpredictability or uncertainty of MS relates to symptoms, treatments, relationships, 
disease progression and future planning, and potentially contributes to emotional 
distress and the practical challenges associated with living with the disease, all of 
which adversely affect HRQoL. 
The narrative of P3 reveals how she could be considered to be an expert patient; she 
has become highly skilled at living with a chronic condition as described in section 
3.4.6, demonstrating some of the various strategies which may be utilised when coping 
with the uncertainty of living with MS such as learning to manage symptoms on a 
daily basis and understanding the variability of the disease. Positive thinking was also 
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felt to be an important part of coping with the fluctuation of symptoms, as every day 
is different which can be frightening (P3). Although Finlayson and van Denend (2003) 
describe how, because of the unpredictability, many people find it difficult to adapt to 
and cope with their diagnosis and its consequences, this patient had gained many of 
the necessary skills over time. 
Patients are often concerned about their short and long-term disease activity, how they 
will progress and what type and level of disability they will acquire, whether they will 
have severe relapses and become severely disabled quite quickly, or whether their MS 
will follow a benign course. Although people with MS live with uncertainty regarding 
their prognosis as MS often follows a variable and uncertain trajectory (Lublin and 
Reingold, 1996), for some the disease can follow a relatively benign path as illustrated 
by Interviewee 6. When considering the impact of her MS she described herself as 
lucky; she had had MS for a long time and had seen others who were diagnosed after 
her deteriorate more rapidly. This suggests a long period of relative stability in her 
condition and reveals that although all patients face an uncertain trajectory, MS does 
not affect everyone in this manner. 
The unpredictability for the future was described by several interviewees. Participant 
3 touched on the realisation that she may get ‘really bad’, with symptoms becoming 
worse and worse. The unpredictability of the condition was stated by Participant 2 as 
their ‘biggest concern’. They acknowledged that they wanted to know when they 
would achieve a level of stability, stating that then they would be able to ‘deal with 
it’. Both Participants 2 and 9 acknowledged that no-one can tell a person with MS 
when the progression will stop. For Participant 9 the uncertainty of the progression of 
the disease had been of extreme concern, however, he was able to rationalise this 
following counselling, subsequently demonstrating stoicism: 
‘Well the biggest thing I had was the fear of nobody knows how the MS 
is going to progress. There is no one who can tell ya. And I had that 
fear. And now I've got that fear of what will be will be. There's no point 
worrying about it, coz if it's going to happen it's going to happen. And 
that's what he (counsellor) taught me to do.’ (P9:M) 
The qualitative research of Somerset, Sharp and Campbell (2002) and Finlayson, van 
Denend and Dalmonte (2005) highlights how day-to-day and longer-term uncertainty 
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are central to the experience of living with MS and are often difficult to come to terms 
with. Understanding the potential impact of MS in the future enabled Participant 1 to 
make the most of life as they felt that they were ‘pretty’ good at the time of the 
interview. It is evident from the data presented that patients understood MS to be a 
variable disease with inherent uncertainty as described by Dennison, et al. (2016). 
6.3.2.4 Identity 
Identity is largely concerned with the question: Who are you? Charmaz (1995) 
describes how identity refers to the way an individual defines, locates and 
differentiates themselves from others. This reflects the view of Oyserman, Elmore and 
Smith (2014, p69) who define identities as ‘the traits and characteristics, social 
relations, roles, and social group memberships that define one’. Identities can be 
focused on the past,- what used to be true of one; the present,- what is true of one now, 
or; the future,- the person one expects or wishes to become, the person one feels 
obligated to try to become, or the person one fears one may become (Oyserman, 
Elmore and Smith, 2014). Chronic illness makes it increasingly important to attain, 
maintain, or recreate a valued identity, this being influenced by: the type and degree 
of illness, meanings of illness experiences, timing and sequencing of illness, and 
expectations of and for the self (Charmaz, 1987). In addition, Charmaz (1987) 
describes how identity levels may change, particularly in response to the evaluation, 
recognition, confirmation or disconfirmation, and treatment by others in the social 
context. Charmaz, (1987) study demonstrated that chronically ill persons aged 20-91 
revealed a strong rejection of identities founded in invalidism. Identity in illness also 
must be considered in the context of factors such as ethnicity, gender and culture. 
Whilst the variability of MS means that living with MS can be physically, emotionally, 
psychologically and financially challenging (Aronson, 1997, Riether, 1999), the 
challenge of living with MS may be increased further as people who are diagnosed 
with MS have generally established their identity as a person without MS (Finlayson, 
Van Denend and Dalmonte, 2005). Wilkinson and das Nair (2013) describe how 
continual changes in functional ability also threaten an individual’s identity. 
Analysis of the transcripts revealed that a diagnosis of MS did not appear to influence 
the way some participants, e.g. P11, P12, P13, P15 viewed themselves as a person. 
However, Participants 2 and 9 viewed their identity very differently to that before 
diagnosis, both having been bread-winners. This reflects the findings of Barker, et al 
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(2014) who found that some people with MS reported a loss of identity. Participant 2 
pronounced of his diagnosis and the severity of his decline: 
‘The whole thing has changed lives irreparably.’ (P2:M) 
Participant 9 described how: 
‘I've gone from a person who's supported his family to someone who's 
now on benefits.’ (P9:M) 
These two patients’ words reflect the work of Charmaz (1987) and Haslam, et al. 
(2008) who describe how the changes to a person’s identity following a diagnosis of 
MS can a have negative psychological effect on the individual. Self-efficacy, self-
esteem and perceived control over life also appear to have been affected as described 
by Bowling (2014). Contrastingly, Participant 13 described a positive impact of his 
diagnosis; he changed his career several years after diagnosis and is now working in a 
field where he feels his diagnosis has enabled him to employ an empathetic approach. 
These examples echo the work of Finlayson, Van Denend and Dalmonte (2005) who 
describe how when people are diagnosed with MS they may have to rethink who they 
are, their strengths and limitations as a person and their plans for the future. Barker, et 
al. (2014) suggests that forming new identities reduces the negative effects of the loss 
of identity, a point demonstrated well by Participant 13 above. 
There were also some perhaps surprisingly positive aspects to being diagnosed with 
MS. For example, Participant 14 suggested that she had become a more positive person 
following diagnosis. Her identity however had changed as she was no longer able to 
do what she wanted as she had to consider the impact of MS. Participant 13 stated: 
‘I would say that multiple sclerosis visiting me in my life has been a 
very positive factor, and it has allowed me to become the person that I 
have always wanted to become.’ (P13:M) 
It was also acknowledged that having a diagnosis of MS can change the way others 
perceive those with MS. Family and friends were frequently regarded as viewing the 
participants as individuals who required help; e.g., as someone who needed help to 
walk when out and about or needed help with activities of daily living: 
‘I find that people are kind of checking that I can get up some stairs, or 
something, which they didn't used to do.’ (P11:F) 
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Whilst some reactions to a diagnosis of MS by family and friends were understood by 
the participants, other reactions appeared misplaced. Participant 3 described how 
others have reacted to her diagnosis, suggesting that she is lucky as she has a mobility 
car. She refutes this, suggesting that the car and her blue badge are the tools that allow 
her to keep going and enable her to work. It is possible that her viewpoints could have 
implications regarding how she perceives her HRQoL and how she completed the 
MSIS-29v2. Another participant (P14) felt that colleagues and friends viewed her 
differently to how they did prior to her diagnosis although did not clarify how. She 
described: 
‘The guy I am with now, it’s really weird being back with him, because 
he knew me before the MS, and he does not see my disability at all. But, 
when I don’t feel well or anything he’s all like ok, ok, and he’ll 
understand.’ (P14:F) 
One participant (P15) reported that whilst he didn’t feel different in the way he saw 
himself, others treated him differently: 
‘They look at you like they feel sorry for you, don’t they?’ (P15:M) 
The theme of condition demonstrates many aspects related to the complexity of living 
with a diagnosis of MS, some of which may adversely affect HRQoL. I would suggest 
that using a HRQoL measure in daily clinical practice could aid detection of such 
aspects. 
6.3.3 Self 
Self is considered a difficult construct to define (Leary and Tangney, 2014). It may be 
considered to be an individual’s character or behaviour, i.e. the set of someone's 
characteristics, such as personality and ability, that are not physical and make that 
person different from other people. Leary and Tangney (2014) suggest that the self is 
involved in (1) peoples experiences of themselves, (2) their perceptions, thoughts, and 
feelings about themselves; and (3) their deliberate efforts to regulate their own 
behaviour. Thus, they suggest that self has there very different meanings. The work of 
Leary and Tangney (2014) suggests that self and identity are linked. 
Chronic illness with impairment intrudes upon a person’s daily life and undermines 
self and identity, forcing identity changes (Charmaz, 1983; Charmaz, 1995). Charmaz 
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(1995) describes how chronically ill people grow more resolute in self as they adapt 
to their impairments, gaining a deeper awareness of self, situation and of their place 
with others. Goffman (1959) describes how, when an individual comes in contact with 
other people, that individual will attempt to control or guide the impression that others 
might make of him by changing or fixing his or her setting, appearance and manner. 
At the same time, the person the individual is interacting with is trying to form and 
obtain information about the individual. MS can have a devastating impact on a 
person’s sense of self (Boeije, et al., 2002). 
This category explores how the interviewees viewed living with multiple sclerosis, 
which will inevitably affect the way they view their HRQoL. Within this theme five 
sub-themes (Figure 24) are presented. Three emerged from the analysis of the 
interview transcripts when patients were asked about their experience of living with 
MS and two from direct questions. The impact of living with MS on self, daily life 
and significant others is considered in the first three sections. Finally, the sub-themes 
of ‘assessment of HRQoL’ and ‘judgement of QoL’ are described. 
 
Figure 24 Relationship of the sub-themes to the theme 'Self' 
Self
Judgement of 
QoL
Assessment 
of HRQoL
Reflection of 
impact of MS 
on self
Reflection of 
impact of MS 
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6.3.3.1 Reflection of the Impact of MS on Self 
The impact of MS on those interviewed was evident in a wide range of areas, including 
the physical and psychological domains of HRQoL, one participant describing how 
the psychological symptoms were harder to deal with than the physical. The degree of 
impact is affected by individual differences in patients understanding of their 
condition, degree of optimism, coping skills, emotional adaptation or reprioritisation 
of values (the latter are both examples of response shift) (Rose and Weinman, 2007) 
many of which are apparent in the following narrative. Words such as demoralising, 
reduced confidence, restricting, and frightening were used to describe the impact of 
MS. This type of terminology underscored the significant psychological impact that 
MS can have on people with the condition. 
MS is a progressive condition and thus it was inevitable that some participants would 
have noticed a deterioration in symptoms and increasing disability with associated 
decline in function over time: 
‘I do feel that this last eighteen months things have got a bit worse.’ 
(P6:F) 
‘I suppose I have got a bit worse over the years.’ (P3:F) 
Keeping track of progression, whether it is in the form of daily fluctuation or a gradual 
increase in disability level can be difficult, particularly for those with cognitive issues. 
Some describe how it is only by reflecting back to what they could do at key events 
such as birthdays that they are able to recognise changes in their abilities. These key 
events act as markers of changes to social and physical self. An assessment of HRQoL 
would be another way of monitoring change. Patients are encouraged to keep of diary 
of changes and bring a list of questions or concerns about their MS to appointments; 
new symptoms, changes in symptoms and the effect on that person are often presented. 
The assessment of HRQoL would potentially be informed by these records. Participant 
1 illustrates the use of a diary: 
‘I generally keep a log of how I am anyway. So, then you can actually 
see if it’s getting worse. Sometimes you can’t look back three months, 
you’ve got to have documented it, otherwise you forget. Yeah with MS 
yeah it (memory) can be a bit of a challenge.’ (P1:M) 
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Participant 5 reflected on how she was experiencing more symptoms in relation to her 
MS. She described a decline in physical function as she was falling more frequently; 
she also reported a decline in cognitive function, relating how she has become more 
forgetful, muddled and confused, forgetting significant events such as birthdays: 
‘I say since about November they (cognitive abilities) have definitely 
deteriorated, and I feel muddled every day now. Whereas I used to be 
able to go right this is a problem that needs dealing with, this is how I 
deal with it. Now I kind of go erm what am I doing? You know, and I 
will get half way through doing something and I will completely forget 
what I am doing and it's just driving me crazy’ (P5:F) 
These points reflect the work of Hoogs, et al. (2011) who describes how mental speed 
processing may influence a wide range of daily activities, including recreational 
activity, social interaction and task completion and also Hankomäki, et al. (2014) who 
state that the cognitive issues of processing speed and handling of complex 
information deteriorate in MS. 
Several participants reflected on the impact of their MS on themselves and daily life 
when considering how their MS had progressed since diagnosis, contemplating what 
they used to be able to do as opposed to what they can do now. These reflections are 
congruent with the work of Devins and Seland (1987) who describe how chronic 
illness can disrupt lifestyles by interfering with continued involvements, valued 
activities and interests. Whilst some participants focused on the daily variations of the 
impact of MS and the ‘roller-coaster ride’ (P3, P7) with the associated uncertainty and 
fear created by this, others described how the impact of MS had changed over time 
(P11). The impact of a deterioration in symptoms meant that handrails were required 
on stairs, energy levels were lower, walking stamina was reduced and, the type of 
footwear that could be worn had changed. A reduction in independence was discussed 
by some participants; limitations in ability to function alone were described, an arm 
was required to hold onto when walking, help was needed do up shoe laces. 
Limitations and the inability to no longer be able to do things such as mow the lawn 
were frequently described as irritating and frustrating. Many of these limitations are 
due to illness-induced stressors such as physical disability and incapacitation and 
decreased strength and stamina as described by Devins, et al. (1993). 
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Some participants were determined not to let MS affect them, adapting to their 
changed level of function. The impact scores of one participant, who lives in a nursing 
home, is wheelchair dependent and requires all physical care indicated that her MS 
had no impact on her; she described a full social life. This patient demonstrates the 
work of Lysandropoulos and Havrdova (2015) who describe how MS patients with a 
high degree of physical disability may continue to participate fully in life and 
consequently view their QoL more positively. The patient admits to fully accepting 
her limitations; reflecting the findings of McCabe, Stokes and McDonald (2009) who 
describe how the way in which a person with MS copes with the condition impacts on 
their HRQoL. 
Participants 5 and 6 reflected that the impact of MS on them was not as bad as for 
other people with MS but considered that they should be looking after themselves 
more. Participant 5 felt that she was ‘good’, and life was good in view of that fact that 
friends who were diagnosed at about the same time as she were in a much worse state 
than she was. This theme seems to pervade the data collected with those who perceive 
themselves as better than others with MS feeling lucky. 
Only one participant described mourning for what she had lost as her life had changed 
so much. She reflected upon the impact: 
‘It does affect me, yeah, I know, I think I have mourned for what I have 
lost because my life has changed big time, umm, it affects me from 
being able to do the things I want to do; I would love to do more 
travelling, I would love to do more things, but I know about my limits.’ 
(P14:F) 
This participant suggested that MS had changed her lifestyle but not her, as MS has 
interfered with her social activities. This is an example of ‘illness intrusiveness’ which 
is defined as ‘illness-induced lifestyle disruptions that interfere with continued 
involvements in valued activities and interests’ (Devins and Seland, 1987). 
6.3.3.2 Reflection of the Impact of MS on Daily Life 
Analysis of the transcripts also revealed both physical and psychological impacts of 
MS on daily life. Morales-Gonzáles, et al. (2004) suggest that the core symptoms of 
MS impact considerably upon the activities of daily living of people with MS. More 
broadly, Moss-Morris (2013) describes how chronic illnesses are diseases that endure 
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over time and have the potential to profoundly impact on people’s day-to-day lives. It 
was apparent from the narratives how the effect of MS on daily life was closely 
interlinked with how MS impacts on oneself. 
Some participants (P5, P8, P11) reflected on tasks that they had been able to do in the 
past but were now no longer capable of doing. Others described limitations in their 
ability to work and a poorer QoL because of their MS symptoms. This echoes the 
findings of Carr, Gibson and Robinson (2001) who suggest that HRQoL is concerned 
with whether a disease or impairment limits a person’s ability to fulfil a normal role 
(for example, whether the inability to climb stairs limits a person at work). 
Lysandropoulos and Havrdova (2015) also describe how patients may have a poorer 
QoL due to patient-centred factors such as depression, inability to work, fatigue and 
cognitive decline. Participant 9 described how, prior to diagnosis, they had worked 
full-time and cared for their family; they now required much support from the family, 
this change occurring over a matter of months. This affected their identity also as they 
were no longer the ‘breadwinner’. Some participants had retired due to ill health whilst 
others had reduced their hours. These figures reflect many studies which reveal that 
as many as two-thirds of MS patients are unable to maintain employment (Honarmand, 
et al., 2010). 
Walking ability and stamina were reflected on frequently. Participant 10 described 
catching a bus rather than walking. Going out alone, perhaps to the shops, and social 
lives were restricted, the lack of independence (P11) being cited as a reason for not 
participating in activities. Hence it becomes harder for people to maintain their sense 
of self as evident in aspects of performance of daily life. Many interviewees required 
an arm to hold when walking so could not go out alone thus appearing to the world as 
someone who requires care rather than someone who is independent. These finds are 
commensurate with the findings of Hakim, et al. (2000) who describe how withdrawal 
from social activities and a shrinking circle of friends was common among patients 
with MS, especially those with severe disability. 
Conversely, Participant 5 described the impact of her MS: 
‘It doesn't have too much of an effect on my daily life. I don’t, I refuse 
to let it affect me too much.’ (P5:F) 
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I would suggest that this reaction implies that this patient is coping well and has 
adapted to the diagnosis of MS. Alternatively, this could be seen as countering the 
victimhood narrative associated with MS and other long-term chronic conditions, 
demonstrating a resistance to the condition rather than being defined by it. This may 
potentially have affected how the participant completed the MSIS-29v2. Either the 
participant could be seen as minimising the impact she was experiencing, or this could 
be interpreted as a positive reframing of her illness experience which could be 
enhancing her HRQoL. 
Only one participant mentioned the future when talking about her experience of living 
with MS. Completing the questionnaire enabled this participant to consider future 
planning; for the short-term she made adaptations to her house and in the longer term 
she planned for end of life. These findings are in accordance with the views of Devy, 
et al. (2013) who suggested that assessing HRQoL might help to predict future 
difficulties for patients. In this case, it was the participant who identified areas for 
concern and addressed them accordingly. 
6.3.3.3 Reflection of the Impact of MS on Significant Others 
Participants recognised that the impact of a diagnosis of MS and the resulting 
limitations reached beyond themselves, impinging on their family and friends. Disease 
progression may impact significantly and detrimentally on relationships and family 
planning. Potentially the impact of MS can be far reaching. In my sample those 
predominantly affected were partners and children. 
Whilst Participant 6 described how her husband worried about her because of her MS, 
Participant 2 acknowledged that there had been many changes for the both him and 
his family. Poor memory was described by one participant as having an impact on 
others; she had forgotten her child’s birthday. These examples are consistent with the 
findings of Lysandropoulos and Havrdova (2015) who describe how a diagnosis of 
MS is traumatic not only for the patient but also for the patient’s family. Life plans 
such as relationships and family planning may be adversely affected by such a 
diagnosis. Participant 7 described how, because of the impact of MS, she did not feel 
able to have another a baby. 
There was overwhelming evidence from the interviews that those with MS required 
help from others, either friends or family. Participants described how people would 
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watch them when walking to check they wouldn’t fall, help them with personal 
hygiene requirements or be required to cook for them. Dependency tensions were 
evident as family members did not know whether they should assist the person with 
MS. P3 suggested that as a consequence of the impact of MS on her she had developed 
a strong supporting network of friends and family. 
Participants also described how their families had adapted to their condition. Whilst 
Participant 12 suggested that his family were used to the MS and so did not treat him 
differently, Participants 4 and 5 described how their partners and children had adjusted 
to the impact of MS and learnt to live with the symptoms. Explaining to a child that a 
parent has MS was touched on by one participant. 
I suggest that depending upon how much a patient recognised the impact of MS on 
themselves, daily life and others prior to completing their first MSIS-29v2, and how 
their view changed subsequently, could have affected the way that they completed 
further forms. Potentially more appropriate interventions could be offered, ultimately 
contributing to an optimised HRQoL. 
6.3.3.4 Judgement of Quality of Life 
When asked: ‘Who do you judge your quality of life against?’ most participants stated 
their former or past self, the majority believing that their old quality of life was better: 
‘I don't even what to compare them. (old and current self). Well it's... I 
know I use the word feel like a nothing but that's quite a short way of 
putting it.’ (P9:M) 
When considering this statement, the concept of illness intrusiveness comes to mind. 
This participant’s loss of the ability to participate in many valued activities can be 
assumed to be contributing to their reduced HRQoL as described by Shawaryn, et al. 
(2002). This view contrasts dramatically with the opinion of Participant 7 who, when 
considering her current QoL, compared it to her old quality of life which she described 
as ‘disgusting’; pregnancy had made her re-evaluate her life. One participant 
compared her QoL to others describing how, compared with them she was lucky, that 
she was doing alright, and life was good. 
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Participant 8 stated that: 
‘My wife has a hell of a lot to do with my quality of life. She helps 
massively.’ (P8:M) 
This comment potentially reflects this patient’s acceptance of, and adaptation to living 
with MS. Similarly, Participant 11 also demonstrates acceptance and adaptation when 
she described how she compares her QoL with her old self, describing how she is more 
limited in what she can do now. 
6.3.3.5 Assessment of HRQoL 
To explore the research question; ‘Does assessment of HRQoL with an appropriate 
measure make a meaningful difference to patients?’ interviewees were asked: ‘Do you 
think that the assessment of your HRQoL with the questionnaire has made a difference 
to you? If the assessment of HRQoL was not found to make a positive difference to 
participants I would need to question whether assessment should continue in the 
future. 
Various views concerning assessment were determined from the narratives. Some 
participants felt that assessment of HRQoL had not made a difference to them yet 
described several benefits. 
Participants described increased self-awareness following assessment: 
‘I think, as I have said before, it has made me more focused and more 
aware of what I am going through and things that, you know, that are 
happening to me every day. It's made me think hang on a minute I need 
to deal with that you know so it's it’s a lot better. It's made me more 
serious about the whole thing.’ (P5:F) 
‘I understand myself more………. I think it (the assessment) makes me 
more aware of myself.’ (P14:F) 
I found that using the questionnaire resulted in a different type of consultation; the 
patient responses prompting a very different kind of discussion, particularly in the 
earlier part of the research period. 
Although Participant 8 stated that the assessment made him more able to understand 
his MS and deal with it he described how he was not bothered about assessing HRQoL 
but recognised that his QoL had improved. Interviewee 2 suggested that the 
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questionnaire made one think about what had changed. I would suggest these are 
positive findings, particularly if participants later made changes to their lifestyle or 
accepted interventions which could be of positive benefit to them. This is illustrated 
by Interviewee 10; once he realised the impact of his MS he decided that he needed to 
address the situation: 
‘It was more the fact of seeing that I was on the extremely column. That, 
er, it was necessary to try and just ease back and relax, so that I came 
down to the lower end.’ (P10:M) 
Participant 12 stated that his quality of life had deteriorated at each assessment, but 
this did not concern him as: 
‘I am one of those, I think you've just got to get on with it you know. 
Whatever it is. It's no good just sitting back and thinking oh you know 
I'm deteriorating. You just push yourself as much as you can, to get as 
much as you can out of life really.’ (P12:M) 
These sentiments are reflected in the views of participant 13: 
‘It didn’t make me think oh my god I’m getting worse, it’s just reality. 
It’s just reality, and life is an ebb and flow.’ (P13:M) 
The role of HCPs in the assessment of HRQoL was mentioned by Participant 12; they 
described how assessment was important because if a deterioration was noticed or they 
had a problem, the HCP could refer the patient on to the appropriate department who 
could deal with it. The work of Miller and Allen (2010) describes how incorporating 
HRQoL measures on an individual level can enrich the clinical encounter by informing 
the clinician of the patient’s current HRQoL status, a point with which many of the 
patients and all HCPs interviewed reinforced. Two participants described how the 
questionnaire benefitted both patients and HCPs; a point with which I would agree. 
From the nurse perspective, the more information we have the more productive the 
appointment potentially is for the patient. HCP1 suggested that the MSIS-29v2 should 
be incorporated into practice as measuring QoL is important. 
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Also, participants suggested that by comparing their questionnaires they could assess 
and monitor changes in their HRQoL; some described how being able to see changes 
was a good thing: 
‘Sometimes people ask you how you are feeling, and you say well I 
haven't changed much. But, by looking through the forms you can see 
slight changes, either in the bad way or the good way, which I think 
was a good thing to do.’ (P12:M) 
Following cessation of data collection, many patients when attending outpatient 
appointments asked where their questionnaire was, stating that they missed it. One 
described how it made her think about her MS which she didn’t do every day. Hence, 
it may be assumed that these participants found the assessment of benefit to them. 
In summary, the process of assessment of HRQoL enabled some participants to 
become more aware of the impact of their condition and subsequently more active in 
the management of their MS and care. From the above comments, I would conclude 
that assessment of HRQoL did make a difference to patients and its inclusion in 
everyday practice should be considered. 
6.3.4 Process 
Within the theme of process, two sub-themes are described: outpatient appointments 
and the questionnaire, i.e., MSIS-29v2; there is considerable overlap between some of 
the associate themes described within the two sub-themes. For example, there is 
common ground between the experience of attending outpatient appointments when 
the MSIS-29v2 was utilised, the impact of the questionnaire on the consultation, and 
properties of the MSIS-29v2 with regards focusing thoughts and concerns and 
informing the consultation. 
The sub-theme of outpatient appointments is presented first. The five associate-
themes, shown in Figure 25, which emerged from analysis of the interview narratives 
all relate directly to the experience of attending outpatient appointments. Two of the 
themes emerged from interview questions. 
6.3.4.1 Outpatient Appointments 
When attending neurology clinics at the Trust where this research took place, MS 
patients are reviewed at one of two hospitals, in a consultant-led multi-professional 
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clinic, or in a nurse-led clinic. Some participants are only ever reviewed in nurse-led 
clinics, others only at multi-professional appointments whilst some are reviewed in 
both. The types of appointment attended by each participant in phase 2 and place of 
review are given in Appendix V. As the MSIS-29v2 will potentially be used in the 
outpatient department I considered it important to develop an understanding of how 
consultations worked before and after the introduction of the MSIS-29v2, thereby 
allowing a considered opinion to be made regarding the impact of assessment of 
HRQoL in the outpatient setting. 
Figure 25 Relationship of the associate-themes to the sub-theme 'Outpatient 
Appointments’ 
Process-
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a. Role of HCPs 
Participants’ accounts of their experience of attending outpatient appointments often 
digressed into the role of the nurse versus the consultant. Participant 3 perceives the 
role of the consultant: 
‘I think the neurologist is more if you've had an attack and things are 
deteriorating. I think sometimes the way I when I am stable I would be 
happy just to see an MS nurse, but obviously, there is times where you 
know that it is more evolved and perhaps you want to speak to your 
neurologist.’ (P3:F) 
This was a common theme and illustrates the view of Dennison, et al. (2016) who 
describes how neurologists tended to be viewed as a ‘diagnoser’ with little time and 
interest in patients’ ongoing struggles. This is refuted by the neurologist of this 
research in the following section when he talks positively of the benefits of using the 
MSIS-29v2 to help guide the consultation and learn about the impact of MS for 
individual patients. Contrastingly, the MS nurses tended to be perceived as ideally 
suited for discussing emotional and practical issues relating to MS, again reflecting 
the findings of Dennison, et al. (2016). It was felt that the CNSs understood patient 
problems and reviewed patients holistically. 
A supportive role by the HCPs was acknowledged throughout the data in relation to 
the time of diagnosis, a life-changing event, and also subsequently: 
‘I think in my personal opinion that MS nurses are so important. When 
I first was diagnosed if it hadn't been for the MS nurse then I don't know 
what I would do.’ (P3:F) 
‘Since I was diagnosed I have had so much support, like from you 
guys.’ (P14:F) 
This demonstrates both expert knowledge of the specialty area and an in-depth 
knowledge of the consultation process which Hodges, Poteet, and Edlund (1985) 
suggest are essential for the role of a consultant; I would consider this applies the CNS 
role also. It also reflects the work of Koopman and Schweitzer (1999) and Burgess 
(2010b) who describe how the need for support is crucial both at diagnosis and 
subsequently. Participant 6 and P12 described how they found the MS nurses listened 
and gave them the time and space to talk, describing professionalism throughout their 
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appointments. In contrast, it was acknowledged that the supportive role of the 
consultant was limited by the length of clinic appointments. The nurse-led 
appointments are of twenty minutes duration, whilst the consultant-led appointments 
tend to be shorter due to the demands on the service, generally lasting between five 
and fifteen minutes. The work of Dennison, et al. (2016) found that the patients were 
conscious that the valued support nurses could provide was limited by their workload. 
At the place of this research the consultant is very aware of the inadequacies of the 
length of clinic appointments and hence his abilities to be more supportive; regrettably 
this cannot be resolved due to recruitment issues: 
‘Neurologists haven't really got time to sit there and go through 
everything with you. So, then I think the MS nurse is great coz you can 
talk to them about it.’ (P3:F) 
The value of the support of an MS nurse at the end of the telephone or email was also 
described by several participants. Patients felt able to contact the service when they 
were having a bad day, or new symptoms appeared, recognising that the nurses would 
return their call if not available to answer the call immediately, or reply to an email. 
One participant (P3) described how she derived reassurance from knowing that she 
could ring the MS service if needed between appointments, suggesting that without 
this alternative means of contact life would be very hard. The value of the long-term 
relationship with the nurses was also described; for several a level of trust had been 
developed over many years. 
b. Style of Consultation 
Patient-centred care with shared decision-making was described throughout the 
interview transcripts, which reflects the requirements of NICE Guidelines 138 (2012) 
and 186 (2014). Whilst the Calgary-Cambridge model provides a basis for 
consultations (section 3.4.2) it does not provide a framework of questions. All HCPs 
described how the outpatient appointments felt more structured using the MSIS-29v2, 
this being deemed a positive addition. HCP1 described how the style of consultation 
felt more complete using the questionnaire as it facilitated an understanding of the 
patients’ social background and the wider issues they face, reflecting the view of 
Miller and Dishon (2006) who describe how directly assessing HRQoL can increase 
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physicians’ understanding of the impact of the disease on patient perception of well-
being and functioning. 
Both HCPs interviewed described unease at asking certain types of question: 
‘I would be a little bit at unease to ask patients about their umm 
worries, about whether they are feeling depressed or not. It’s probably 
a better way of eliciting this information through a questionnaire…’ 
(HCP1) 
‘Maybe it encouraged me to perhaps ask questions that are a little bit 
more tricky to ask, like the, especially around the irritability and 
concentration, confidence, depression side of things. So, I think it was 
easier to ask the patient because you’re, because you’re asking them 
through the questionnaire, especially if they’d like pointed it out there 
was a problem.’ (HCP2) 
These views support those of Detmar, et al. (2000) who noted that some oncology 
physicians believe that their patients, rather than themselves, should be the ones to 
raise question about psychosocial (emotional) problems; the HRQoL measure, thus 
contributed to a more productive consultation. The patient-centred approach of using 
a HRQoL measure also helps the patient to ‘live with the illness’ rather than just 
‘receiving treatment for the disease’ (Lohr and Zebrack, 2009) as the impact of MS is 
considered. 
All HCPs believed the appointment to be of a better quality for both patients and staff 
when the MSIS-29v2 was used, as patient-perceived problems were addressed, with 
more interventions possibly being considered. The fact that options for care were 
suggested which the participant then pursued was commented on (P14), indicating that 
a partnership of care was occurring. Additionally, HCP1 suggested that using the 
MSIS-29v2 enabled the significance of therapeutic treatments to be considered. 
HCP2 acknowledged that, as problems were illuminated by patients and information 
and ideas to address the problems discussed jointly, shared decision-making was 
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occurring. Interviewee 12 suggested that the appointment was equally balanced, with 
regards involvement of the nurse and themselves: 
‘It's normally 50/50 really which is very good. There is always a 
discussion prior to sort of giving me anything, whether you like it or 
not....’ (P12:M) 
This was evidenced when he explained why he did not wish to take up offer of a 
referral to the wheelchair services. This participant felt that the care was centred 
around them, the patient, and that they were driving the appointment as they were the 
one with questions which needed answers. They described how they discussed the 
physical side of MS and also home-life problems, referrals being made as appropriate. 
A multi-disciplinary approach was being followed here; HCP1 described how the 
questionnaire promoted such an approach. Newsome, et al. (2016) suggest that such 
an approach to care is required for long-term conditions. 
Participant 14 described being involved in care decisions. Whilst Participant 4 felt that 
she was informed about treatments that could help her, Participant 13 described how 
he felt both informed and involved in his care: 
‘I think it’s an interactive service that you offer me, and you give me 
choice.’ (P13:M) 
It was evident, however, that not all patients wanted the same level of involvement in 
their care. One participant did not wish to be involved in decision-making during the 
consultation as described in section 3.4.4. He suggested that he didn’t know what 
medication would be appropriate for him, stating that ‘that was the nurses’ 
department’. He described how when he had described troublesome symptoms, 
medications had been suggested which he had tried, and which had provided benefit. 
He stated that he did not feel pressurised into taking anything yet did feel involved in 
his care. Participant 8 stated that as long as his questions were answered and any 
doubts in his mind discussed, he was happy with the style of appointment. 
Appointments were perceived as ‘relaxed’ by one patient; another (P6) described how 
she felt that she was given the time she needed to discuss her concerns but realised 
that there was not an infinite amount of time; she was happy with the length of the 
consultations. 
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c. Experiences of Attending Outpatient Appointments 
When considering the future use of the MSIS-29v2 in routine clinical practice, gaining 
an understanding of patients’ experience of attending appointments: before the 
research began; with the questionnaire, and; after data collection had ceased was 
essential if a considered and informed decision was to be made. 
The experience of attending outpatient appointments from the patient perspective was 
addressed with the question: ‘Can you tell me about your experience of attending 
outpatient appointments?’. Many described broadly positive experiences; 
appointments were described as ‘fine’ (P6, 9, P11) ‘excellent’ (P2, P12), ‘really 
positive’ (P13), or ‘brilliant’ (P8). Participants felt well received when attending 
(P13), describing good treatment with written information from the MS Society or MS 
Trust, and supporting letters being provided as appropriate or requested: 
‘It is quite nice to come and to know you feel that somebody is taking 
an interest, Yeah, or somebody's monitoring what is happening.’ 
(P11:F) 
‘Because the staff obviously understand your problems, and you can 
discuss it quite easily with them. And they are always willing to sort of 
spend more time if they have to, to try and go through your problems.’ 
(P12:M) 
Conversely, P2 and P13 did not feel that they got much out of attending appointments 
as they contacted the service by telephone whenever they had problems, and so 
generally had little to discuss at appointments. Interestingly, P13 had previously 
described appointments as ‘really positive’. Two patients (P1 and P5) suggested that 
attending appointments was rather a waste of time when they felt well and there had 
been no changes in their condition; but acknowledged the importance of attending as 
the HCPs needed to monitor their condition. 
Participants were not directly asked about their experience of attending appointments 
before the introduction of the questionnaire. Participant 1, who describes themselves 
as very articulate and self-managing felt that the attending outpatient appointments 
before the introduction of the questionnaire was fine possibly suggesting they did not 
gain much from using the questionnaire. 
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It was important to determine participants’ views concerning the use of the 
questionnaire at an outpatient appointment because, without positive feedback, the use 
of a HRQoL questionnaire in appointments would have to be questioned. Opinions 
were explored with the question: ‘Did the questionnaire make a difference to your 
consultation?’. There was considerable overlap in the transcripts concerning the 
experience of attending outpatient appointments when the MSIS-29v2 was utilised, 
and the properties of the MSIS-29v2 (section 6.3.4.2a). 
The questionnaire was found to highlight areas where there was a physical or 
psychological impact due to MS. Those issues which were of concern to the patient 
could then be addressed. It was deemed that the appointment was more directed (P6), 
more productive and of a better quality when the questionnaire was used. Participant 
13 suggested: 
‘I think it was different is because all of a sudden, you are physically 
presented with more information about me, that I haven’t actually got 
to articulate to you, or remember to say or, whatever, so I think this is 
a good tool’ (P13:M) 
This is concurred with by P12 who described how the HCP were given an insight into 
his current problems. It was also suggested that the MSIS-29v2 helps HCPs focus in 
on issues that have been circled when patients ‘waffle on’ (P7). Consideration of issues 
for discussion, prior to entering the consultation room, was considered important by 
P4, the use of the MSIS-29v2 facilitating this. The questionnaire was also found to 
remind participants of issues that they needed to discuss and illuminate areas that they 
hadn’t necessarily thought of or realised were due to MS (P8). It was suggested that 
the questionnaire made the patient more aware of what they needed to say and also 
how to explain symptoms: 
‘I was quite reassured by it really, coz you could explain, as I say you 
can explain the symptoms quite easily on the form. Rather than sort of 
trying to get there and forget things.’ (P12:M) 
Participant 6 suggested that the questionnaire was about raising awareness, making 
them think about how ‘it has been’ rather than giving a less considered answer which 
they felt was not helpful to them. 
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One participant described how they felt the questionnaire could be beneficial for those 
who are less articulate as symptoms or concerns would be highlighted, it then being 
the responsibility of the HCP to discuss these, thereby giving the patient the 
opportunity to verbalise their concerns. The questionnaire was also found to 
enable/empower participants to discuss their issues with HCPs. Participant 5 described 
how the questionnaire had highlighted issues, which they then felt able to discuss, the 
questionnaire giving them the necessary confidence. Consequently, the appointment 
was more productive, the consultant offering various options for care which were 
discussed. 
Further benefits of using the questionnaire were highlighted by P13 who described 
how, through comparison of responses between questionnaires, the HCPs were able to 
identify an improvement or deterioration in condition and then discuss how the 
participant was coping with the changes. This was considered reassuring, the 
participant describing how they then didn’t feel on their own. It was also considered 
important that the HCPs could see how participants were coping (P4). These points 
are in accordance with the work of Miller (2002) who describes how the routine use 
of HRQoL measures allows physicians to review, quickly and systematically, patient 
functioning and concerns and to help patients to become active participants in their 
care. 
When asked, ‘Did the consultation feel different when using the questionnaire?’ views 
were divided. Six participants did not perceive the consultation to be any different 
when using the questionnaire. Length of appointment, lack of integration of the 
measure into the appointment, and the ability to vocalise issues without prompting 
were all described. Participant 7 who only attended multi-professional appointments, 
felt the questionnaire had not made any difference to her appointment as it was so 
short. Two participants described how they did not feel that the MSIS-29v2 had been 
fully integrated into the consultation; P11 suggested that the MSIS-29v2 was an ‘add-
on’ and didn’t feel that the appointment felt different using it. Despite saying this they 
stated that the appointment felt more productive as areas were highlighted for 
discussion. Participant 2 also did not perceive that the questionnaire has been 
integrated into the consultation; he described how talking to the healthcare 
professionals was a totally separate thing from the questionnaire in his mind. He stated 
that the questionnaire did not make a difference to his outpatient appointment but was 
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unable to clarify why. These two comments could indicate the need for further training 
when using the MSIS-29v2 in clinic. Participant 3 felt that the questionnaire did not 
make a difference to her as she was a very ‘open’ person who would discuss her 
worries. Another, (P15) stated that the appointment did not feel different and that the 
information provided was for the nurses. Although this participant is vocal in 
informing the HCPs with regards issues, he is less assured in terms of decision-
making, as discussed in section 3.4.4. This participant indicated strongly throughout 
their interview that they had trust in the healthcare professionals and would follow 
advice: 
‘Well, I felt involved, even though I didn’t know really what was going 
on. I mean I don’t know what medication is gonna be good for me. 
That’s your (HCPs) department.’ (P15:M) 
Several participants did consider that appointments felt different when the MSIS-29v2 
was used because the HCPs were presented with information about them which 
provided a starting point for the consultation: 
‘Yes, a lot different. Yep with this (questionnaire). Yeah yeah. Because 
of the prompting? (HCP) Yeah. Yeah. Because I'd answered it and then 
I went through and then you or whoever had it in front of ya and you 
knew what the answers were on there.’ (P9:M) 
‘If only because it gives insight obviously to the nurse or neurologist 
when you go to see them.’ (P12:M) 
P14 suggested that because of how depressed she felt, she did not want to talk; 
however, the HCPs were able to use the questionnaire to guide the consultation, 
determine the root of the issue and jointly determine a plan of care; hence she felt that 
the questionnaire had helped, and that the consultation did feel different. 
When interpreting participants accounts of their outpatient experiences it was 
necessary to consider that the participants and healthcare professionals are well known 
to each other, often with relationships that have developed over many years. Patients 
might have found it difficult to disclose any difficulties or tensions they had 
experienced in appointments. Nonetheless, I would suggest that discussion of the 
questionnaire responses by the HCP is imperative if the questionnaire is to be 
meaningfully incorporated into daily clinical practice. P9 and P12 both described how 
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their answers were discussed and care offered accordingly. The data revealed that the 
nurses discussed the responses to the questions on the forms with most patients. This 
is in accordance with Donaldson (2007) who describes how the information from 
HRQoL assessments should be viewed by patients as a valuable part of their care and 
must be used during consultations. Regrettably, Participant 1 who only attended 
consultant-led appointments did not believe that the questionnaires were reviewed. 
They were of the opinion that if the questionnaires were reviewed then there would 
potentially be benefits of using the questionnaire, a view with which I agree. 
Additional training or longer appointments could facilitate more effective use of the 
measure in this instance. I believe I was more adept at discussing responses during 
later appointments in the research period, potentially due to increasing confidence in 
using the MSIS-29v2. Jensen, et al. (2013) describe how, in qualitative interviews 
exploring patients’ attitudes, the patients clearly state that if they see their patient 
reported outcome data being used by clinicians and influencing their care, this will 
encourage continued participation. It was therefore disappointing that some 
participants did not consider that the data had been discussed with them, especially as 
Baars, et al. (2004) suggest that nurses are seen as the most appropriate clinicians to 
undertake formal HRQoL assessments. 
Participant 10 said that he missed completing the questionnaire when he attended 
appointments in the period after data collection had ceased. He suggested that he did 
not tend to consider issues that he wanted to talk about and so the questionnaire gave 
some structure to the consultation. 
Participant 14 described how: 
‘You (nurses) always and Dr (consultant) always ask of my wellbeing, 
so I think that’s there, but for the forms it makes me a bit more aware. 
(P14:F) 
Thus, it may be deduced that whilst there was high satisfaction with the appointments 
prior to the assessment of HRQoL, the measure was deemed to raise awareness. 
Several participants suggested that they did not prepare themselves for appointments. 
Thus, before the introduction of the questionnaire, I would suggest that issues or 
concerns may not have always been covered. 
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The HCPs all described their perceptions that using the questionnaire resulted in a 
better-quality appointment: 
‘I think for the patient, if they enjoyed doing the questionnaire, I think 
for them it was maybe a better experience because they perhaps felt 
that they got more out of the outpatient appointment by doing that. 
Because I know when they, and also quite a few people after it was 
finished would ask me “Where is their questionnaire?”’ (HCP2) 
HCP2 also stated that because the participant had a better experience it: 
‘made me feel maybe better in some cases because erm, you know you’d 
pick something up that you wouldn’t have picked up before.’ (HCP2) 
These comments reflect the findings of Boyce, Browne and Greenhalgh (2014) who 
describe how professionals also appreciated PROMs which complemented their own 
clinical judgement. Boyce, Browne and Greenhalgh (2014) also found that the use of 
a PROM had the negative potential to narrow the focus of a consultation, an effect 
which was not found in this work. As an HCP I found appointments to be more 
productive as issues were more readily raised by research participants than by those 
not involved. 
d. Benefits of Attending Outpatient Appointments 
Various benefits were described when participants were asked: ‘What do you feel that 
you get out of attending outpatient appointments?’. Keeping in touch and the provision 
of reassurance and support are themes that pervaded the interview data. Phase 1 
revealed that the most frequently offered interventions was reassurance. One 
participant suggested: 
‘A lot of relief actually, believe it or not. Relief that there is somebody 
there for you that's looking after your well-being as well, trying to help 
your well-being as well’ (P8:M) 
Some patients (e.g. P4) described how their GP does not know much about MS and so 
found appointments extremely beneficial; continuity of treatment occurred, potential 
treatments were discussed and questions about MS answered honestly. Additionally, 
information was provided about which symptoms were due to MS rather than a blanket 
statement ‘that’s due to your MS’ being given. Patients also described appointments 
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as beneficial because they could discuss any problems or issues they had (P1, P5, P11, 
P12, P15) and ask questions (P3). Appointments were described as helpful by two 
participants (P3, P10). Appointments were also used to review the impact of 
treatments or interventions (P5). However, it is important to acknowledge that patients 
may simply have wanted to be polite about their experience in view of their 
relationship with the HCPs; nevertheless the details they gave of their appointments 
do suggest positive benefits. 
e. Issues of Concern Addressed 
Although using a HRQoL measure could help issues of concern to be detected, it was 
interesting to know if patients considered what they wished to discuss prior to 
attending an appointment, or whether they discussed issues of importance to them. 
One prompt used during the interviews was: ‘At the hospital do you feel that issues 
which are important to you are covered?’ When analysing the transcripts, it soon 
became evident that few patients (P10) consider what they wish to discuss prior to 
attending appointments. Using the MSIS-29v2 could help to address this issue. 
Participant 11 acknowledged that if issues were not covered: 
‘I mean I think if they're not it's partly down to me because I don't 
prepare myself enough.’ (P11:F) 
Conversely, Participant 12 stated: 
‘If I do have a problem at home I always sort of ask the nurse, and 
always get the good answers.’ (P12: M) 
Most participants felt that any issues they raised were addressed during the outpatient 
appointments. This is demonstrated by two interviewees. Participant 6 suggested that 
her concerns were addressed as she had space to talk about them during appointments. 
Similarly, Participant 14 asked questions as she was keen to hear whether there were 
any new treatments that could help to slow of stabilise her condition. 
6.3.4.2 MSIS-29v2  
The views of patients with MS and HCPs were sought concerning many aspects of the 
MSIS-29v2 and its use in the outpatient setting. It was essential to determine if the 
MSIS-29v2 was acceptable to patients and HCPs when used in the outpatient setting. 
Although the MSIS-29v2 has been demonstrated to be appropriate for use in many 
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situations including hospital settings this research differs in that it explored the 
opinions of users in the outpatient setting. 
When analysing the interview transcripts six associate-themes emerged which are 
presented below in Figure 26. These all relate to the use of the MSIS-29v2 during 
routine outpatient appointments and are of relevance when considering the future use 
of the MSIS-29v2. The views of HCPs are included in this section and related to the 
patients’ views as several of their interview questions focused on the MSIS-29v2. 
 
Figure 26 Relationship of the associate-themes to the sub-theme ‘Questionnaire' 
a. Properties of the MSIS-29v2 
Several properties of the MSIS-29v2 were described when patient and staff 
participants were asked what it was they liked about the MSIS-29v2. The 
questionnaire was pronounced clear (P1), simple (P2, P15) and straightforward (P2, 
P4, P5). Whilst some questionnaires are long-winded and repeat themselves (P1, P5) 
Participant 5 felt it was not too long. It was described as well set out and therefore 
easy to read, follow/understand (P2, P12, HCP2) and easy to complete (P5); P5 stated: 
Process-
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‘you just ring the answer nearest to how you feel’. Some patients indicated that they 
struggled with which answer to ring; this point is discussed later in this section. No 
concerns were raised regarding the content or the phrasing of individual items 
reflecting the work of McGuigan and Hutchinson (2004). 
The MSIS-29v2 was described as broad-based and comprehensive (P12) covering 
most aspects of life (P13, HCP2) and every aspect of MS (P1, HCP2): 
‘I mean it covered most things. It obviously covered balance and things 
like that and things that you are capable of doing, which I thought was 
very good.’ (P12:M) 
Later HCP2 realised that sexual function was not covered. The questions were 
considered relevant by Participants 6 and 10, with Participant 14 describing the tool 
as good because all the questions related to MS, which she suggested was something 
that generally does not happen in the real-world. I would surmise that this reflects the 
use of a disease-specific measure rather than a generic one. Over half of the patient-
participants stated that there was nothing they didn’t like about the MSIS-29v2. The 
words of Participant 6 suggest that the questionnaire is well designed, this potentially 
reflecting that people with MS were involved in its design, as described by Hobart, et 
al. (2001): 
‘I've not read it and sort of thought oh I wonder why you didn't ask that. 
So, I think there’s pretty well everything on there. And I've never sort 
of thought oh I well wonder why you're asking that because it all makes 
absolute sense actually. It might not be affecting me particularly now, 
but I can think that well yeah it has done at sometimes. So, I can sort 
of see why the questions are what they are.’ (P6:F) 
For a measure to be effective at assessing the impact of MS it should cover the full 
range of symptoms potentially experienced as a consequence of having MS. Thus, 
when interviewed participants were asked: ‘Are there areas which aren’t covered that 
perhaps there should be questions about?’. Only three patient-participants described 
any such areas; Interviewee 1 suggested that memory, brain fog and word finding were 
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missing. One patient and all three HCPs commented that sexual function was not 
covered. The HCPs felt this was an important area that should be covered: 
‘That would be a good one to put in, because that’s something that we 
don’t ask patients, erm, naturally and at the end of the day.’ (HCP2) 
The literature reviewed suggests that structured questionnaires are formulaic as only 
certain areas of life and symptoms are considered. When interviewed during phase 2 
most participants could not describe areas/symptoms that they felt were missing from 
the MSIS-29v2 (section 6.3.4.2a). Some described how not all questions were 
necessarily relevant to them, however acknowledged that the MSIS-29v2 allows for 
this with the response ‘Not at all’. I would suggest that these findings reflect the 
rigorous design process of the MSIS-29v2 which included patient involvement 
(Hobart, et al., 2001). 
The literature widely recognises that whilst sexual function may be adversely affected 
in MS it is not asked about as much as it should be, the MSIS-29v2 reflecting this 
omission. Some 40-80% of people with MS experience sexual dysfunction which 
contributes to reduced HRQoL (Nortvedt, et al., 2001). P15 suggested that the mental 
health side was not covered; I would suggest that because of the time between the use 
of the questionnaire and the interview they had possibly forgotten the questions of the 
psychological section which cover this area. Participants 12 and 14 could not think of 
anything to improve the MSIS-29v2, reflecting the view of Interviewee 6: 
‘I can’t think that that I've ever come away from filling it in thinking I 
wonder why they didn't ask about that.’ (P6:F) 
Only one participant 1 felt that the questionnaire was too general, and that adaptations 
were required to make it more specific as all patients are different. Drop in questions 
specifically for individuals were suggested. 
Participants 2, 7, 12, 13 and 14 described the questionnaire as a very good tool. Two 
others elaborated suggesting that the questionnaire would be very helpful to many 
people including less vocal patients (P3) and newly diagnosed patients (P1, P3). 
Although this could be seen as an example of participants valuing an intervention on 
behalf of ‘others’ less capable than themselves, the fact that newly diagnosed patients 
were very appreciative of the instruments suggests it has a genuine role in practice. 
Participant 8 who was diagnosed just before the research commenced was interviewed. 
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He found the questionnaire to be informative, illuminating symptoms that he didn’t 
necessarily know were due to MS. It enabled him to consider the impact of his MS 
before appointments and reminded him of symptoms he wished to discuss. It also 
made him aware that he was not the only person suffering with these symptoms. 
Several other participants echoed these sentiments. Participant 1 later contradicted 
himself suggesting that the MSIS-29v2 would scare newly diagnosed patients as it 
indicates symptoms or impacts which potentially could occur in the future. 
Several participants, including P1, P11 and P14 described how the MSIS-29v2 raised 
their awareness of the impact of MS: 
‘It’s a nice reflection to see where you have come from and where you 
are on that day’ (P1:M) 
‘I like the questions in the questionnaire because they do make me 
think; definitely make me think.’ (P14:F) 
These points are discussed further in the following sections. 
One patient (P14) described how the MSIS-29v2 could help HCPs to monitor patients: 
‘I think it’s good for you, saying oh she’s a bit down at the moment, 
we’ll keep an eye on that.’ (P14:F) 
We currently arrange additional clinic or telephone reviews for patients who are 
struggling because of their MS. However, if the MSIS-29v2 highlighted additional 
patients who required closer monitoring this must be considered a positive aspect of 
using such a tool. 
Several issues were described concerning the number of response categories or their 
wording. Participant 9 liked the four choices, rather than ‘yes’ and ‘no’, stating that 
this was what was good about the questionnaire. Conversely, Participant 1 felt that 
five response categories would be better, describing the current four responses of: ‘not 
at all’, ‘a little’, ‘moderately’, and ‘extremely’ as too broad. Ironically, the original 
MSIS-29 had five response categories which were reduced to four following Rasch 
testing. 
Difficulties experienced when selecting a response are illustrated by Participant 11 
who suggested that she would probably under-estimate the impact of symptoms as she 
felt that it was difficult to go from ‘moderately’ to ‘extremely’, describing this as a big 
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gap; she suggested that she would answer ‘moderately’. Participant 5 suggested that 
she fitted between two answers for the question concerning mobility. These views 
reflect the concerns of Boynton and Greenhalgh (2004) and Bowling (2014) who 
describe how fixed answers can cause frustration, particularly if a participant does not 
feel that the questionnaire covers all responses. The inability to provide an answer 
which accurately represented the impact of MS could have had implications when 
considering what to discuss because, as nurses, we tended to discuss the areas of higher 
impact; thus, we may have missed cues from patients concerning areas that might 
benefit from further exploration. The rating of the impact of MS was liked by two of 
the HCPs, one describing how this aspect allowed them to gain an understanding of 
how adjusted the patient was within themselves to their level of disability and 
associated limitations. They described how the scoring indicated whether 
interventions should be discussed and considered. 
When the frequency of questions missed was analysed in section 5.6.2, no pattern was 
established; no particular question was regularly not answered. Participant 15 was 
selected for interview because he had not answered all of the questions at the four 
outpatient appointments he attended during the research period. When asked about 
this no specific reason was given. He speculated that it could be due to problems with 
concentration. Cognitive function is affected in approximately 40-65% of people with 
MS (Rao, et al., 1991a; Amato, Zipoli and Portaccio, 2006), so could account for such 
omissions. 
The questionnaire asks patients for their views on the impact of their MS on their day-
to-day life during the past two weeks. Both Participants 6 and 10 both questioned the 
period of two weeks to look back at symptoms, especially as they are reviewed six-
monthly. Participant 6 did suggest, however, that if the period was longer than two 
weeks she might have forgotten the true impact of the physical and psychological 
components of her MS; two weeks was felt to focus the mind. 
In summary, the questionnaire was well received by the majority of the patient 
interviewees and by both staff interviewees. It was suggested by Participant 2 that: 
‘It achieves what it set out to achieve’. (P2:M) 
I would suggest that the MSIS-29v2 is appropriate for use in the outpatient setting. 
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b. Informing the Consultation 
From the patient perspective, there was a pervading view that the MSIS-29v2 informed 
the consultation, particularly as it was considered very easy to forget what one wants 
or needs to say when attending an outpatient appointment. It was considered that the 
questionnaire makes one consider the whole condition and areas it is affecting (P1, 
P11). The impact of MS was thus considered. Interviewees 6 and 11 considered that 
the questionnaire helped them to focus their thoughts, describing how they did not 
generally consider what they wanted to discuss prior to attending an appointment. One 
participant described how symptoms were highlighted that he was not aware of (P10). 
HCP1 suggested that: 
‘I felt that it was highlighting aspects of the problems of the patients 
which could be of overlooked basically.’ (HCP1) 
Participant 5 also suggested that using the MSIS-29v2 made them aware of what did 
not need to be discussed at that time, thereby contributing to a more productive 
appointment. It was also considered that during the time patients were waiting to go 
into an appointment there was time for reflection which the MSIS-29v2 could guide. 
Participant 10 says, of using the MSIS-29v2: 
‘It's the only time that I think about some of those things as to whether 
they are causing a problem or not.’ (P10:M) 
These examples demonstrate conclusively that symptoms and areas of concern were 
highlighted, time for reflection permitted, and areas for discussion determined as 
suggested by Lohr and Zebrack (2009). The examples also echo the realist synthesis 
of Greenhalgh, et al. (2017) which showed that PROMs completion prompts patients 
to engage in self-reflection about their health. 
Some participants described an educational component to the MSIS-29v2; Participant 
11 did not realise that some of her symptoms were due to MS. The MSIS-29v2 also 
revealed that she was experiencing ‘hidden’ symptoms of MS such as bladder or bowel 
dysfunction which many patients do not disclose as they are embarrassing, or they 
have learnt to live and are not aware that they are a problem, echoing the work of 
Giovannoni, Foley and Brandes (2012). Also, the questionnaire enabled some patients 
to talk about issues they had not mentioned before. It became apparent during analysis 
that four patients had lived with MS for a long time and accepted their symptoms as 
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‘normal’. Thus they described how they did not realise something was a problem for 
them until they read about it on paper (P2 and concentration). This then gave them the 
impetus to address the issue and deal with it. P5 also suggested that the questionnaire 
made her realise that she did not have to manage symptoms alone or just accept them; 
rather she should discuss them and seek help to address them: 
‘I think because, again going back to the pains in my feet, which I am 
still getting every day. I just, I have got them, and they are an issue but 
like everything else I just thought oh well it's just part of the MS, so, 
I've just got to deal with it. Whereas that made me realise that maybe 
it's not just something I need to deal with. It's something that, you know 
that we need to take some action. And so, I was able to, it made me kind 
of go no stop ignoring that. And actually, do something about it. So, 
that was good.’ (P5:F) 
One participant (P4) suggested that the questionnaire highlighted how well she was 
coping with some issues and illuminated areas where she needed help. The HCPs 
explained, of the MSIS-29v2: 
‘Yes, so it did make a difference because I think you could go through 
it properly once you had it and you could have a look and you erm, you 
could then pick up what was, erm what was worrying the patient or was 
a bigger problem for the patient and then you could do it in a more 
structured fashion, OK, although it took a lot longer.’ (HCP2) 
Not only did the questionnaire help participants remember what they wished to 
discuss, participants recognised that the MSIS-29v2 informed the HCP in clinic of 
problems for discussion: 
‘I found them very good, Aha, erm because, well it's easier for the 
consultant to flick through and understand what your problems are, 
Mhmm, because sometimes you can go in there and it goes completely 
out your head what you want to ask them all or what you feel like, Right, 
and it's very handy having filled the form in before, Yep. that if you 
become sort of like forgetful then obviously, you know, the neurologist 
or the nurse has got the answers there, Ok, or a guide to the answers.’ 
(P12:M) 
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The consultation could then be directed around issues the participant had determined 
when completing the form, rather than the points they raised or ‘chatted’ about once 
in the appointment. Participant 3 also suggested that the questionnaire would enable 
HCPs to discuss the answers given by patients who would not necessarily have raised 
the concerns themselves. HCP2 agrees suggesting: 
‘it was good because then you could focus on the problems that they’d 
put, say like as a four erm and, then you could specifically ask them 
about those problems and it might be they’d already been dealt with 
but they, on a few occasions, erm specifically the questionnaire tipped 
up a problem that had occurred that we probably wouldn’t have picked 
up in clinic otherwise, if we hadn’t have had the questionnaire.’ 
(HCP2) 
HCP2 described how when the MSIS-29v2 was not used problems were not always 
detected during an appointment: 
‘They’d ring back and say, ‘I’ve forgotten to ask something’ or maybe 
they’d call you back in a month and like you know, they’d have a 
problem that you hadn’t perhaps picked up at that appointment and 
you’d have to deal with it like on the telephone a little while later.’ 
(HCP2) 
The above points are in agreement with the findings of Fayers and Machin (2016) who 
suggest that a reason for assessing HRQoL is to establish information about the range 
of problems that affect patients. 
All HCPs and two participants (P3, P4) described how the MSIS-29v2 made a 
difference to appointments as it revealed how patients with differing levels of 
disability viewed the impact of MS on themselves and everyday life. Patients felt that 
HCPs would then able to develop more of an understanding of the impact of MS on 
patients: 
‘It was quite useful because it was expanding our understanding of the 
wider issues that patients with MS do face.’ (HCP1) 
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‘I think it did make a difference because it was structured, and because, 
it was, it was tricky because some of the patients, you, you look at their 
disability, erm and it depended on how the person was within 
themselves depends on where they tick the boxes. So like, you might 
have someone with limited, very limited erm, mobility and very 
disabled who would tick the minimal boxes because their life wasn’t 
affected but you might have somebody who had minimal disability who, 
who was extremely affected, in their you know, that’s the way they 
thought about their disease but it wouldn’t necessarily, you’d need to 
do something about it if you know what I mean.’ (HCP2) 
HCP1 suggested that because of an increased awareness of the impact of MS they 
would be asking more questions concerning daily activities: 
‘I became more aware through this questionnaire of how important it 
is to address these kind of issues, plus the psychological impact of the 
disease. The two major issues basically, because the other physical side 
we tend to ask them, routinely basically.’ (HCP1) 
These points are in accordance with the work of Donaldson (2007) who discusses the 
effects of inclusion of HRQoL measures in routine care and its role in patient-centred 
care. She suggested that the use of HRQoL measures allowed the patient and the 
clinician to share information, helped both to be more knowledgeable about the effects 
of the disease and its treatment and, promoted the involvement of patients in the 
decision-making process. 
It was also suggested that by both patients (P3, P4) and staff that completed forms 
provided information, thereby enabling HCPs to develop more of an understanding of 
the impact of MS on patients: 
Highlight issues, yeah, in a more formal way rather you try to be more 
interrogating somehow in some difficult areas.’ (HCP1) 
Thus, it is apparent that using the questionnaire helped both participants and HCPs to 
focus on symptoms and areas of concern and discuss these during the appointment. It 
was also evident that completing a HRQoL measure made patients and health 
professionals much more aware of the impact of their MS. Also, that areas which as 
healthcare professionals we do not routinely ask about are more comprehensively 
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covered when a structure is given to a consultation. It may be concluded that the MSIS-
29v2 is of benefit to both patients and healthcare professionals. 
c. Impact of Completing Questionnaire 
It was considered possible that there would be some impact for those completing the 
MSIS-29v2. The nature of this impact required consideration in relation to future use 
of this measure. If a number of patients had become unduly distressed when 
completing the questionnaire and required formal counselling, it is unlikely that the 
measure could be incorporated into routine clinical practice. It was apparent from the 
transcripts that the questionnaire made patients consider their condition and its impact. 
It was suggested of the questionnaire: 
‘It does make you think about the whole condition and the areas which 
it could affect’ (P1:M) 
‘It was highlighting things I wasn't aware of, so it was to an extent a 
little concerning.’ (P10:M) 
‘It makes you think of the symptoms, more than what you would 
normally do without having sort of a form like that’ (P12:M) 
Five participants (P3, P10, P11, P12 and P15) suggested that completing the MSIS-
29v2 did not make them feel differently about their MS; Participants 12, 13, and 15 
did not go home and think about the questionnaire. However, four participants (P5, 
P10, P13, P14) reflected that they only realised the true impact of MS on themselves 
when completing the questionnaire, describing how they do not usually think about 
their MS, associated symptoms, or themselves. Participants described an increased 
awareness of themselves as a consequence of using the forms: 
‘That's the trouble I don't want to think about it. Certainly, in the first 
ones I filled in I was surprised to find that let’s say the irritability, I 
wasn't aware of it to any great extent. I have always had a temper or 
whatever. So yes, it was bringing out things that I wasn't aware of.’ 
(P10:M) 
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When asked how: How did completing the questionnaire make you feel? one 
participant replied: 
‘Reflective I think. It didn’t make me feel sad. It umm you know, just 
reflective in actually thinking about my condition really and how it was 
affecting me at the time.’ (P13:M) 
However, he did not consider this to be an unpleasant experience, the questionnaire 
did not have a negative experience on him and he didn’t consider it painful to 
complete. 
Another suggested: 
‘I think it makes, when you, when you, fill in any form for medical 
reasons it it does dawn on you what what you've actually got wrong 
with you, but I sort of put it to one side. I mean I can't change that I've 
just got to make the most of my situation.’ (P3:F) 
Several participants described a reduction in mood after completing the MSIS-29v2. 
Participant 5 suggested that completing the questionnaire was good for her as it forced 
her to think about things. However, she did also acknowledge that it made her feel 
down for a short time. Similarly, Participant 9 described how completing the 
questionnaire made him feel down when he went home although not for long; he 
attributes the feelings to the stark reality of the questions stated in black and white. In 
contrast Participant 4 stated: 
‘I won't say it made me feel good or anything but it's just the fact was, 
it is addressing the situation of when my MS is really bad, how bad it 
can be……I think it shows how good I am in actually coping most 
probably.’ (P4:F) 
Participant 6 also described how the questionnaire made her realise that she had 
symptoms and that she should be facing them and not pretending they were not there. 
Some participants described how the new insight into the impact of MS prompted 
them to address issues of concern. This is illustrated by Participant 7 who described 
how the questionnaire had impacted on her as it had aided communication, suggesting 
that the MSIS-29v2 made her more open as she does not normally talk about her MS. 
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She described how, because of reading the questionnaire, she became aware of 
symptoms which she then addressed and then felt better in herself: 
‘It's made me realise that the fact that it's a condition, it's not an 
illness.’ (P7:F) 
P14 concurs, suggesting that she had not realised how low in mood she was prior to 
completing the MSIS-29v2; once at home she considered her mood and took 
appropriate action. Similarly, P4 described how, because of completing the 
questionnaire, she has sorted out various aspects of her life which the MS was 
impacting on and consequently felt better in herself. 
The questionnaire was also found to help family members understand the impact of 
MS on patients. This is illustrated by two participants. P4 described how significant 
others had a better understanding of how the MS affects her. Participant 14 suggested 
that everyone could relate to the questions, describing how her mother had developed 
more of an understanding of how she felt as a result of watching the patient complete 
the MSIS-29v2. 
Other impacts of completing the questionnaire were the realisation that others felt that 
same way; Participant 11 described how the questionnaire made her realise that she 
was not the only one who feels as she does. 
As a consequence of completing the MSIS-29v2 at least two participants (P4, P5) 
realised the symptoms they experience were not normal, but they have lived with them 
for so long that they know no difference; prior to the form P4 had accepted herself for 
what she was. She now realised that she needed to address her problems. 
Also, an understanding was developed of the condition; Participant 8 focused on the 
education side of the questionnaire, describing how the questions of the MSIS-29v2 
answered unresolved questions in his head and explained things, this being a positive 
point. 
The impact of completing the questionnaire was spontaneously raised by HCP2 when 
interviewed. They were very aware of the potential stress that could result for some 
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participants and indicated that this would need addressing on an individual patient 
basis: 
‘Only that maybe with the quality of life questionnaires for some 
patients, erm is that they’ve got to think about what they can’t do, and 
I think that can be upsetting for some group of patients but that’s not 
for all of them. I think there would be people that enjoyed doing it. 
And there would be people that would, erm, that it would be upsetting 
for them because they, they’re, it’s like when they fill out a PIP 
(Personal Independence Payment) form, they’ve got to concentrate on 
actually what is, erm, you know, their bad points. Whereas maybe this 
would encourage some of them to think about their bad points if you 
know what I mean, but that, but that’s, that’s like with different 
patients, some patients their glass is half empty, some is half full.’ 
(HCP2). 
When asked: ‘Is there anything about the form in particular that you didn’t like?’ 
several themes became apparent. The realisation that participants were experiencing 
issues in relation to their MS which they were not necessarily acknowledging meant 
that some people felt challenged by the MSIS-29v2: 
‘I suppose it was because it was bringing to my attention what I was 
having problems with. Erm at the time when I was filling this in I really 
wasn't thinking that er I was being stuck at home should we say. And 
there are questions on here that I really don't like answering.’ (P10:M) 
Participant 7 did not like the fact that the form made her feel down and she was then 
unable to pick herself back up. Despite this she stated that she liked completing the 
questionnaires, describing how they made her re-evaluate the impact of MS; 
consequentially she realised that despite being ‘bad’ at one point she had got through 
it. Participant 14 described how she liked being able to rate how she felt; she then 
realised that she was ‘not too bad’. 
Thus, it may be concluded that completing the questionnaire had a powerful effect on 
the both those who completed it and significant others, enabling them to consider their 
condition, focus on how they feel and address some of the issues. The revelations of 
the patients have given me a much greater insight into how people live with MS. 
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d. Impact of Completing the Questionnaire on Care Offered 
This theme emerged from analysis of the transcripts and the question: ‘Do you think 
that completing the questionnaire has had any impact on you or the care that you have 
received?’ 
It was evident from the analysis of the transcripts that, in many cases, discussion of 
the questionnaire did inform the care offered or received, although at interview not all 
interviewees could remember this; potentially this may have been related to the time 
interval between completing the forms and the interview date. Interventions in many 
forms were initiated following assessment. Interviewee 10 was prescribed a course of 
steroids from which he derived benefit. Participant 14 described how the questionnaire 
informed the care she was offered; counselling was discussed although declined. 
Another (P12) found the form very helpful although he could not cite any instances 
when his care had changed; with prompting he remembered that he (P12) had been 
referred to falls prevention which he had attended and found to be beneficial: 
‘Not really no. It's still the same (Care). But no. It's nice to talk to 
someone that understands your problems. I think so yeah. It does help 
a lot. Not that I can think of directly. I know it’s very helpful when HCP 
has got the form she will go through it and discuss points that you are 
obviously sort of concerned about.’ (P12:M) 
Participant 15 described how the discussion of the questionnaire had resulted in 
changes to his pain medication regime, and also his disease-modifying therapy. 
Changes to disease modifying therapy were discussed with Participant 11 but 
subsequently declined, demonstrating shared decision-making. Although 
physiotherapy and a referral to the continence clinic were made for this interviewee, 
she admits that she did not obtain the full benefit as she did not practice the exercises 
given. She (P11) stated that the physiotherapist had told her: 
I don't think it's worth you coming, but if things get worse then let me 
know and that's fine. (P11:F) 
Hence, although care can be arranged, it is evident that the outcome can be dependent 
on patient engagement. 
Chapter 6 Results and Discussion of Phase 2 
222 
 
Another (P5) described how, when care requirements were detected a discussion with 
the consultant ensued, options being discussed, and a mutually acceptable plan agreed; 
the participant described how this style of consultation felt good as she knew what the 
consultant was thinking and what to expect. Participant 9 described how, as a 
consequence of completing the questionnaire, he was offered more than prior to its 
use, the MSIS-29v2 highlighting issues for which he could be offered help. HCP2 
stated that issues for which interventions could be offered were detected using the 
MSIS-29v2 which would not have been picked up without using it. Care options were 
subsequently discussed; referrals were made for physiotherapy and counselling. The 
counselling was extremely beneficial for this participant: 
‘I will say since the questionnaire come out it, mhmm, it has made it 
better. And why do you say that? I have been given more. One of them 
was the counselling I was given, Right, which I was never offered 
before. Ok. And it only came up because of the erm (coughs) excuse me 
questionnaire. Right. And that helped me enormously. Good. I've never 
actually spoken about MS to anyone apart from family. Right ok. But 
this counsellor, it was here that I had it and it was amazing. Mhmm. 
Really helped.’ (P9:M) 
Three participants were unsure that the questionnaire had had any impact on the care 
they had received. Participant 1 stated he did not know if the questionnaire had had 
any impact on the care he received but clarified saying that he did not feel that he 
needed much care at that time. Whilst Participants 3 or 13 were unsure that the 
questionnaire had impacted on the care they were offered, they elaborated describing 
themselves as either vocal (P3) or a good communicator (P13) and expressing how if 
they needed anything they would telephone for advice; both stated that their care was 
very good. 
The capacity of the MSIS-29v2 to focus thoughts was cited by some participants who 
felt that as a consequence of this, the requirement for interventions was discussed. 
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Participant 2 described how using the questionnaire possibly had an impact on his care 
because: 
‘going through it made you... one of the questions may ignite a little 
box in the back of your mind and make you think oh I had better 
mention that.’ (P2:M) 
Potentially issues were then detected, and interventions suggested that would not have 
occurred without the use of the MSIS-29v2. Participants 5 agreed suggesting that the 
questionnaire made her actually think about what she was going through on a daily 
basis, enabling her to explain things more easily and, because she was more focused 
after doing the questionnaires, she was able to give people a bit more information. 
Participant 6 suggested that as the HCP focused on the answers to the MSIS-29v2 
during the consultation, the ensuing discussion may result in the need for 
interventions. Participant 8 goes further suggesting that: 
‘answering the questions, answered a few questions and also put a few 
more questions in your head so you can ask the questions in the 
consultation’. (P8:M) 
From an HCP perspective, the focusing of thoughts enabled a discussion around the 
responses given which at times revealed the requirement for interventions. 
HCP1 describes the consultation process as more complete using the MSIS-29v2. 
They describe it as better for the patient and better for them in understanding the social 
background of the patient and the wider issues, and problems that they can face. This 
concurs the work of Detmar and Aaronson (1998) who describe a significant increase 
over time in the physicians’ perceived awareness of their patients’ problems in daily 
living, relating the effect in part to the fact that the clinician has known the participant 
for a period of time and, partly due to the QoL summary. 
HCP1 suggested that an understanding of the wider issues patients face: 
‘Could improve our therapeutic interventions, both pharmaceutical or 
otherwise in terms of counselling, in terms of involving them in 
activities organised by local bodies or whatever, umm with the use of 
physical activity, social activity, things like that.’ (HCP1) 
Chapter 6 Results and Discussion of Phase 2 
224 
 
Thus: 
‘It makes you understand how significant or not significant is the 
therapeutic offers you give them basically. So, you tend to treat these 
patients according to protocols, when probably treatment per se 
doesn’t improve their quality of life, because it doesn’t really, you don’t 
handle the variety of issues they face which can be addressed in a 
different way probably, so it expands the management field basically.’ 
(HCP1) 
Specific quality improvements might arise from considering HRQoL assessment 
feedback; they include ordering additional tests, referring the patient to a new 
specialist, amending prescribed medicines or treatments, using personalised advice 
and education on symptom management, and altering the goals of treatment plans to 
better reflect patient concerns (Greenhalgh, Long and Flynn, 2005; Santana and Feeny, 
2014). 
If a measure is to be useful in clinical practice it should be able to promote detection 
of patient issues and identify needs for supportive intervention (Greenhalgh and 
Meadows, 1999; Lohr and Zebrack, 2009; Solari, 2005; Santana and Feeny, 2009). I 
would suggest that the MSIS-29v2 can do this when used in routine outpatient 
appointments, care being tailored to patient requirements, resulting in a patient-
perceived improvement of HRQoL. These findings also reflect the work of Boyce, 
Browne and Greenhalgh (2014) who concluded that professionals value PROMs when 
they are useful for the clinical decision-making process. 
Although it is evident that the requirement for interventions was detected though the 
discussion of the responses to the questionnaire, it is likely that some, although maybe 
not all of these interventions would have been suggested and discussed during an 
outpatient appointment without the use of the MSIS-29v2. During the research period 
three participants (P4, P5, P15) changed to a second-line oral DMT, this treatment 
change reflecting the course of their MS. For participant 5 the benefit of changing to 
a more efficacious DMT was demonstrated by the change in her quality of life; she 
was able to take part in her hobbies more fully as her tiredness reduced. These changes 
in treatment would have occurred without the use of the MSIS-29v2. 
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Thus, it is evident that the responses to the questionnaire informed the consultation 
and raised issues for which care, and interventions could be offered. 
e. Assessment of Changes in HRQoL 
Part of this research was concerned with the detection of change in HRQoL after the 
implementation of interventions. As described in section 4.5.4.7 a question concerning 
change in QoL and a comments box were added to the MSIS-29v2 for this research. 
Both CNS MS described these additions as beneficial, enabling clarification around 
changes in HRQoL to be discussed and any comments elucidated upon. 
The results of phase 1 demonstrated no significant differences during longitudinal 
analyses of the questionnaires. However, when participant’s individual questionnaires 
were analysed from both the point of view of individual questions and impact scores, 
changes in the form of improvements and deterioration were apparent. Following an 
intervention an improvement in or at least maintenance of HRQoL scores would be 
expected. However, this was not always apparent possibly due to the complex array 
of factors affecting the stability of MS and the subjective nature of HRQoL 
assessment. It was evident from one interview that the impact scores of the MSIS-
29v2 did not always demonstrate a reduced impact of MS; Participant 12 commented 
that his pain was better, but this was not reflected in the impact scores or HTQ. Bueno, 
et al. (2015) suggest that the impact of a high degree of clinical heterogeneity, as 
evident in MS, on HRQoL is poorly understood. By exploring the views of participants 
about the impact of MS it is possible that this body of knowledge could be added to in 
the future. 
Many patients suggested that the HCPs did discuss the MSIS-29v2 responses. HCP1 
described discussing changes of scores in the two domains covered by the MSIS-29v2: 
‘I do recall you questioning them why some of their scoring changed 
over a period of time regarding the domains here, of things we don’t 
usually ask people in clinic because we would usually ask them about 
some physical disabilities which we don’t cover other things which are 
depression, social interaction, housing, all these kinds of things.’ 
(HCP1) 
Changes in a patient’s care regime should affect HRQoL, ideally for the better. This 
would be demonstrated when the scores from one questionnaire to the next are 
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compared. Three participants stated that their HRQoL had improved following starting 
new treatments. Participant 5 suggested that her quality of life had significantly 
improved following the commencement of a new drug; her energy levels had 
improved, she had less bad days, and she was better than she had been for a long while. 
This was reflected in the scoring of her MSIS-29v2 forms. Another Participant (P15) 
described an improvement following the initiation of pain relief. 
Not every interviewee experienced a change in the HRQoL during the research period. 
Participant 3 described how there had been no dramatic changes in her MS recently; 
however, she experienced daily fluctuations. Again, this was reflected in her scores 
and comments. 
f. Practical Considerations 
Although the data analysed clearly demonstrated that patient-participants wish to 
continue using the MSIS-29v2, this can only occur if deemed feasible by the 
healthcare professionals running the clinics. The main barrier identified in this 
research was a lack of resources. For this research project, the staff involved 
endeavoured to ensure that the questionnaires were given to participants immediately 
prior to their appointment, as discussed in section 4.5.2. However, this was not without 
issues, predominantly related to time. This was illustrated by HCP2 who, when asked 
what they didn’t like about using the MSIS-29v2, stated: 
‘Giving it out before I did clinic, because it was too stressful because 
it took too much, it took too much time up of the clinic and if you had a 
busy clinic…and the fact that I kept forgetting to give it out.’ (HCP2) 
HCP2 also described how outpatient appointment delays could occur if participants 
did not arrive early for their appointment as the MSIS-29v2 had to be completed prior 
to them being reviewed. This was deemed frustrating but could potentially be resolved 
by giving out questionnaires at the end of an appointment for use next time. These 
findings echo the work of Boyce, Browne and Greenhalgh (2014) who describe how 
the workload associated with data collection was identified as a significant barrier to 
the routine use of PROMs in nine studies reviewed. 
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Several suggestions were made by participants concerning giving out the 
questionnaires after the research period. Participant 11 suggested: 
‘I mean it would almost be worthwhile having one of these about a 
week before an appointment, so that you could come with it. Kind of as 
a, oh yeah, I must bring that up. Otherwise life goes on and you forget 
to bring things up, quite honestly. When I have an appointment, you 
can give me one of these, but I can fill it in before I come to the next 
one or something like that. Might be quite useful.’ (P11:F) 
This idea has positive implications as it would enable those who required assistance 
to complete the questionnaire to seek help. However, the MSIS-29v2 would have to 
be distributed either electronically or by post and so has several cost implications 
which make this recommendation unfeasible. HCP2 suggested giving out the MSIS-
29v2 at the end of a clinic appointment for completion immediately prior to the next 
appointment. I would suggest that they could be placed in the MS leaflet rack in the 
outpatient department with an explanatory letter. I would deem both options feasible, 
although favour the first as a brief explanation can be given to the patient if required. 
Initially, as clinicians, it was challenging to effectively incorporate the MSIS-29v2 
into the flow of the consultation. This reflects the work of Greenhalgh, et al. (2017). 
The MSIS-29v2 was disruptive of our normal pattern of communication with patients 
when first used. I would suggest that this issue would potentially reduce with increased 
experience of using the MSIS-29v2 both from a patient and HCP perspective. 
However, the perceived benefits meant that with continued use the measure became a 
valuable part of the appointment. 
For a measure to be successfully used acceptability is essential; approval is required 
from those using it, both patients and staff. The MSIS-29v2 was extremely well 
received by the majority of participants, with thirteen patient-participants and all HCPs 
wanting its use to continue; indeed, several patients including Participant 10 were 
disappointed that its use may cease. 
HCP2 raised the issue of appropriateness suggesting that giving the questionnaire to 
those with severe cognitive issues was not appropriate. They also recognised that not 
all patients would want to complete the form; respecting patient choice is imperative. 
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Frequency of useage was also discussed. Comments varied from every appointment 
to yearly. 
Thus, although several issues were raised concerning feasibility, it was evident that 
continued use of the MSIS-29v2 was felt to be possible. 
6.4 METHODOLOGICAL LIMITATIONS 
Several methodological limitations relate to phase 2. The first concerns sampling. 
Initially, I purposively sampled participants with varied clinical and sociodemographic 
characteristics to build up a picture of patients’ views regarding HRQoL assessment. 
However, in accordance with the qualitative methodology I did not seek to sample 
representatively. The sample of participants was not representative of the wider MS 
population as no participants experiencing primary progressive MS were interviewed. 
Therefore, the findings of the present study are not strictly representative of the MS 
population attending outpatient clinics at the place of this research. 
A further limitation is that only participants able to travel to a hospital for interview 
could be interviewed. An exception was made for the participant who was interviewed 
at her place of work as I felt that she would contribute a wealth of data. Also, those 
who were more disabled, suffered with fatigue or were full-time workers may have 
not felt able to attend an interview. Hence, the opinions of these types of patient 
concerning the use of the MSIS-29v2 may not have been fully explored. 
The healthcare professional sample size was very small, this being limited by the size 
of the neurology department at the site of the research. Thus, the results must be 
interpreted with caution. It would be valuable to establish the views of a larger number 
of healthcare professionals regarding the assessment of HRQoL in the outpatient 
setting. 
6.5 SUMMARY 
This qualitative phase enabled me to realise the participants viewpoints regarding 
assessment of HRQoL. The data gathered from the interviews showed that participants 
were willing to share their experiences about using the MSIS-29v2 to assess two 
dimensions of HRQoL. The data revealed that the MSIS-29v2 was generally liked; 
both staff and patients wished for its use to continue, varying reasons being given. 
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Patient-participants described the opportunity to consider and reflect on the impact of 
MS on themselves prior to entering the consultation room and so felt more prepared 
for their appointment. Patients described how the use of the HRQoL measure made a 
difference to them during consultations with regards to the information discussed and 
the care offered; the question responses gave a structure to the consultation, which was 
then more focused, with important issues being considered. HCPs found the MSIS-
29v2 helpful in guiding the consultation. Outpatient appointments were generally 
deemed more productive by patients. Some patients described feeling more 
empowered, suggesting that attending an appointment can be intimidating. The MSIS-
29v2 was described as informative, educating one about MS, and making one realise 
that others experienced similar symptoms, and therefore it was felt to be an invaluable 
resource. 
Patients did not appear unduly concerned about changes in HRQoL scores, rather the 
individual answers to the questions were more important to them, revealing the actual 
impact of MS on themselves. These findings contribute to the knowledge and 
understanding about the use of HRQoL measures in outpatient consultations, the value 
of such a measure being realised. All HCPs and many participants wished to continue 
using the MSIS-29v2. 
In the following chapter the data produced from both studies of the research is drawn 
together, the results being discussed in relation to the research questions. 
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7.1 INTRODUCTION 
The aim of this study was to determine whether there is a role for the assessment of 
health-related quality of life in patients with multiple sclerosis in daily clinical 
practice. The literature review revealed no published studies regarding assessment of 
HRQoL in patients with MS and whether it made a difference to them. This study 
builds on the findings of previous works, both in the field of MS and other areas, and 
looks at the feasibility of assessing HRQoL using the MSIS-29v2 in daily clinical 
practice in a UK neurology outpatient department. It explores whether HRQoL 
assessments can be used to guide therapeutic interventions and subsequently detect 
changes in HRQoL and, in addition, whether patients consider such an assessment to 
be beneficial. Many previous studies have focused on the psychometric properties of 
HRQoL measurement; no published studies have considered assessment from the 
perspective of the patient with MS. During the research period it became evident that 
evaluating the role and impact of the MSIS-29v2 was more complex than initially 
considered. 
The key findings of both phases of this doctoral research are drawn together within 
this chapter and related to the literature review of Chapter 3. This chapter addresses 
each of the proposed research questions presented in Chapter 1 (section 1.5) before 
answering the main question: Is there a role for the assessment of health-related quality 
of life in patients with multiple sclerosis in daily clinical practice? 
7.2 IS ASSESSMENT OF HRQOL IN PATIENTS WITH MS 
FEASIBLE IN DAILY CLINICAL PRACTICE? 
Within this section the feasibility of assessment of HRQoL using the MSIS-29v2 in 
daily clinical practice is examined. Practical limitations are considered in respect of 
use in the outpatient setting. The effect of the inability of patients to self-assess is 
discussed and the potential role of proxies considered. The views of patient and staff-
participants are recognised throughout. 
My study has demonstrated that using the MSIS-29v2 in routine clinical practice is 
feasible although not without issues, particularly during the initial phase of its use. 
Detmar and Aaronson (1998) determined that introduction of individual QoL 
assessments in routine outpatient oncology practice was feasible, and whilst my 
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findings are commensurate with this, I would dispute the claim of Schäffler, et al. 
(2013) that PROMs can easily be implemented in MS daily clinical practice. Several 
difficulties were encountered during the research period which are considered in the 
following text. 
With regards to assessing HRQoL during the research period, there was no additional 
funding to enable the research participants to be identified on arrival in clinic and 
forms issued. Nor was there any help available to participants who attended alone and 
had cognitive or manual dexterity issues. Arguably these issues mean that the results 
of this work are more readily transferable to the everyday setting as the level of support 
will not change from the research to the everyday setting. They all affected the 
feasibility of assessment of HRQoL during the research period, as indicated in the 
work of Solari (2005) and Boyce, Browne and Greenhalgh (2014) who argue that a 
lack of resources for the administration, collection and storage of the data may be a 
barrier to HRQoL assessment. However, once the assessment of HRQoL is integrated 
into daily practice all patients will have the opportunity to complete the MSIS-29v2 
and thus identifying participants will no longer be an issue. 
Santana, et al. (2015) suggest that a lack of knowledge in how to effectively utilise the 
data in a clinical encounter limits successful implementation. Healthcare professional 
support for performing assessment of HRQoL was key to the success of this research. 
Thus, prior to starting data collection, a meeting was held with the clinicians involved 
in this research to introduce the MSIS-29v2; implications of its use were debated, and 
interpretation and scoring of data discussed. One of the major concerns of the 
healthcare professionals was that the introduction of the MSIS-29v2 might potentially 
increase the time required per patient consultation which would then affect waiting 
times of the outpatient clinic, supporting the views of Detmar and Aaronson (1998). 
In reality, using the MSIS-29v2 during appointments did take time to adjust to; both 
clinical nurse specialists initially found that appointments took longer due to the new 
format of consultation required. This increased burden on time when using the 
measure mimics the systematic review report of Porter, et al. (2017) who looked at the 
perspectives of patients and professionals on the use of patient-reported outcomes in 
primary care. Although the two disciplines are different, I would suggest the 
appointment process is similar in both. In my research setting both clinical nurse 
specialists are keen to continue using the MSIS-29v2 because of the resulting benefits 
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for both patients and themselves. Job satisfaction has improved as the consultation is 
more effective and both patients and staff have a better understanding of the impact of 
MS on a patient’s life. 
When considering using a health-related quality of life measure, not only do patients 
have to be able to access it, the output should be discussed accordingly. When 
interviewed some participants did not always believe their completed MSIS-29v2 had 
been reviewed effectively with them during their outpatient appointment. Some of 
these participants reported only a minimal physical and/or psychological impact of 
MS which may have contributed to the belief that the MSIS-29v2 responses had not 
been evaluated. If there was no, or minimal impact reported, then there is little to 
discuss in relation to the measure. I would suggest that in the multi-disciplinary clinics 
a lack of time rather than knowledge may have contributed to the MSIS-29v2 not 
always being discussed exhaustively. Conversely, the MSIS-29v2 was found to be 
particularly beneficial to both the HCPs in the multi-professional appointments as 
these are often very short; the MSIS-29v2 highlighted areas of greatest MS impact 
which could then be discussed, enabling a more productive appointment, both from 
the patient and HCP perspective. If a large number of patients had raised concerns 
about the MSIS-29v2 not being discussed, then I would have to question the feasibility 
of use. 
It was important to me that the measure selected for this research would be appropriate 
for use in the daily routine clinical practice setting. Most patient-participants found 
the MSIS-29v2 quick and easy to complete; many were able to complete it in the 
waiting room prior to their appointment without assistance. The interviewees data 
revealed the questions to be relevant, and the ensuing discussion of the responses was 
found to be beneficial. High levels of data completeness also indicate that the MSIS-
29v2 was acceptable to patients. One participant was interviewed as they had missed 
several questions on all the forms they completed. They attributed this to reduced 
concentration which reflects the work of Gold, et al. (2001); they suggest that reduced 
attention and concentration could impair a patient’s ability to complete long HRQoL 
measures, or in this case a short measure. Although this could potentially affect overall 
results in a research study, this would not be a major issue in everyday practice as 
HCPs can pick up these questions when analysing the measure with the patient. All 
participants were willing to complete the MSIS-29v2 at every visit to the outpatient 
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clinic during the research period, indicating that questionnaire fatigue was not 
experienced. 
These favourable findings reveal that HRQoL assessment can occur in daily practice 
with a short, easy to use measure, namely the MSIS-29v2; they support the comments 
of Freeman, Hobart and Thompson (2001) who propose that without such a short, easy 
to use measure HRQoL assessment is unlikely to occur in clinical practice. The 
MSIS-29v2 was also found to be acceptable to the three healthcare professionals 
involved in my research. It was deemed user friendly, practical to administer, and easy 
to score and interpret. These findings reflect the comments of Sharrack, et al. (1999) 
who describe how any measure must be acceptable to healthcare professionals whilst 
Hobart, Lamping and Thompson (1996) and Amato and Portaccio (2007) state this 
should be true for patients. 
Although the MSIS-29v2 was found to be suitable for the majority of patients a few 
exceptions were noted. It became evident that not all participants were able to self-
complete the MSIS-29v2, the research demonstrating that 17% of patients required 
help. Observationally, reasons for inability to complete the form unaided included: the 
physical burden of completing the questionnaire; communication deficits such as poor 
sight; physical limitations including poor manual dexterity and; cognitive impairment. 
These problems all increase with the severity and progression of MS and make it 
particularly difficult to acquire health-related quality of life data for those patients for 
whom it may be most needed to inform clinical decision making, as suggested by 
Addington-Hall and Kalra (2001) and Tripoliti, et al. (2007). 
Sloan, et al. (2002) and Skevington, Lotfy and O’Connell (2004) propose that 
questionnaires for use in clinical populations should be as brief as possible in order to 
minimise respondent burden. Although the MSIS-29v2 is described as short in the 
literature, respondent burden was demonstrated by one participant who, with the help 
of her husband, took 45 minutes to complete the MSIS-29v2, describing the form as 
daunting; she declined to complete further questionnaires. She also demonstrates the 
findings of Addington-Hall and Kalra (2001) who state that some might find 
completing a HRQoL measure too burdensome. I would suggest that as per Matthews 
(1998) her speed of information processing affected her ability to assess HRQoL. For 
this participant, the ethical appropriateness of measuring HRQoL required 
consideration; I would consider that this patient was one for which information derived 
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from the MSIS-29v2 is most needed in order to inform clinical decision-making, in 
line with the work of Addington-Hall and Kalra (2001). 
In a few cases I observed that the person who attended the appointment with a 
participant completed the form without that participants involvement. In this case the 
person who completed the form could be considered a proxy. Van der Linden, et al. 
(2005) psychometrically evaluated the MSIS-29 for proxy use, concluding that it is a 
reliable and valid instrument when used by proxies. As the MSIS-29v2 was used in 
this research; I would hope that these results would also apply to this version and that 
reliable information resulted. I would consider proxy rating preferable to no 
information, as the resulting information about the impact of MS, although potentially 
not a complete and accurate representation of the patient, can then be used to guide 
treatment options for a patient who potentially has little ‘voice’ of their own. 
Discussing the responses would also help validate the answers given. The review of 
Sneeuw, Sprangers and Aaronson (2002) found in general that moderate to high levels 
of patient-proxy agreement were reported. 
Although patients with minor cognitive impairment were able to complete the 
MSIS-29v2 some did state that they were glad that the measure only looked back over 
the previous two weeks as they would not be able to remember further back in time. 
These comments resonate with the findings of Marrie, et al. (2003); they describe how 
cognitive impairment may potentially have an important impact on the reporting of 
HRQoL as knowledge and recall of one’s current and past experiences are needed to 
assess the impact of disease on HRQoL. Benedict, et al. (2004) suggest that cognitive 
decline could result in invalid self-reporting of HRQoL. Severe cognitive impairment 
was found to be a barrier to assessment of HRQoL due to the time taken to complete 
and discuss the measure. Addington-Hall and Kalra (2001) propose that in cases of 
severe cognitive impairment the information could be gained from proxies. For this 
research a decision was made to exclude those with severe cognitive impairment 
because of the limited length of clinic appointments. Thus, other methods of 
assessment such as proxy evaluation need consideration if the HRQoL of these 
patients is to be evaluated. 
Regarding feasibility and continued use of the MSIS-29v2 after the research period, 
several issues became evident. Although the MSIS-29v2 gained approval of the staff 
for the research period, the practicality of introducing the concept of HRQoL 
Chapter 7 Discussion of Findings of Phases 1 and 2 
236 
 
assessment to all patients, and the feasibility of ensuring that patients can access the 
questionnaire prior to their appointment are proving stumbling blocks in establishing 
the successful implementation of the questionnaire as part of the standard clinical 
routine. This reflects the views of Gutteling, et al. (2008a) and Boyce, Browne and 
Greenhalgh (2014) who describe how, if the use of a HRQoL measure is considered 
disruptive to normal work routines, this can be a barrier to its use. I believe that the 
benefits of using a HRQoL measure outweigh the disadvantages and so ways of giving 
out the MSIS-29v2 are being considered. This is discussed further in section 8.6. 
In summary, this research has shown that during the research period, assessment of 
HRQoL using the MSIS-29v2 was feasible in daily clinical practice for those who 
were able to complete the forms unaided or who attended with a significant other, 
providing they were not significantly cognitively impaired. I would propose that these 
results should transfer to the non-research setting. Staff education, distribution of 
questionnaires and the ability of patients to self-complete an appropriate measure are 
all key to successful integration in daily clinical practice. 
7.3 CAN THE RESULTS OF HRQOL ASSESSMENT BE USED 
TO INFORM THERAPEUTIC INTERVENTIONS? 
Within this section the effect of the using the MSIS-29v2 on the consultation style is 
considered, the impact of using the questionnaire during an outpatient consultation is 
presented and whether or not question responses may be used to inform therapeutic 
interventions examined. 
My findings indicate that the responses to the questions of the MSIS-29v2 provided a 
framework for the outpatient consultation. This was not something which I had 
expected to find; it was not discussed in the literature I read concerning HRQoL in MS 
patients. This may have been because most of the literature discusses use in the 
research rather than the outpatient setting. The results would not have been as apparent 
without the qualitative phase, but they greatly add to the findings. The interview data 
revealed that the responses to the questions guided the consultation as they enabled 
patients to express their concerns and discuss these during their appointment. The 
healthcare professionals all described the MSIS-29v2 as excellent at enabling patients 
to express their concerns. HRQoL issues were detected and discussed and the HCPs 
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made more aware of patients’ problems; this reflects the work of Detmar, et al. (2002) 
who reported similar findings in daily oncology practice. 
A key finding of this research relates to the detection of symptoms as, without realising 
patient-perceived issues, interventions cannot be considered. The MSIS-29v2 records 
information about a range of problems. From analysis of the interview data it became 
apparent that the systematic approach of the MSIS-29v2 served as a prompt to patients, 
causing them to consider their symptoms and the way that MS was impacting on them. 
This finding is in concurrence with those of Aymerich, Guillamón and Jovell (2009) 
who describe how HRQoL instruments can also reveal aspects of illness that are not 
reflected by standard clinical instruments, and they can measure results that are of 
major concern to the patient. Patient-participants described how problems were 
detected which had not been highlighted in appointments prior to using the form and 
intimated that the measure covered areas which were not always raised in the 
consultation prior to its use. The focusing aspect of the measure was described as very 
useful by the majority of those interviewed. Symptoms that patients had been 
struggling with, had overlooked due to possible memory problems or did not realise 
were due to MS, were illuminated by the MSIS-29v2 and discussed. These findings 
reflect the work of Rothwell, et al. (1997) who describes how the assessment of 
HRQoL reveals aspects of the disease that are not generally obvious during an 
outpatient appointment but can markedly affect individual’s lives. They also echo the 
work of Higginson and Carr (2001) who suggest that some patients’ problems can be 
overlooked unless specifically enquired about, especially psychological and social 
ones. It was evident that the questionnaire was found to highlight issues from the 
patient perspective which they would not otherwise have raised, as discussed by 
Lysandropoulos and Havrdova (2015). Furthermore, the MS nurses were prompted to 
assess areas that they might otherwise have missed or find harder to address, or that 
patients feel embarrassed to mention. The interview with one of the HCPs provides 
evidence for this, describing how sensitive issues, such as depression, are not always 
discussed. Thus, I would conclude that the MSIS-29v2 is a valuable addition to the 
consultation process, contributing to a more productive appointment. 
Additionally, several participants described how their understanding of the impact of 
MS had improved, as symptoms that they did not normally consider or discuss were 
raised. Whilst these participants were comfortable with discussing their issues it 
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should be remembered that just because a symptom has been illuminated by a HRQoL 
assessment it does not mean that a patient wishes to discuss it. They may have been 
aware of the issue prior to the HRQoL assessment and chosen not to discuss it at 
previous appointments, reflecting the work of Greenhalgh, Long and Flynn (2005) 
who noted that patients or clinicians may not wish to discuss certain topics in the 
consultation. As an HCP I would ask about all issues raised on a completed form but, 
respect the patient’s wishes should they not wish to discuss one at that particular time. 
It could be that the issues are upsetting for the patient and should only be considered 
when that patient deems the time to be right. Although this aspect of the MSIS-29v2 
may not have contributed to therapeutic interventions being offered, it certainly 
contributed to the patients’ understanding of the impact of their MS, and thus again I 
would conclude that the MSIS-29v2 played a valuable role in the consultation. 
Outpatient appointments are of a fixed length, so it can be difficult to cover all the 
issues a patient wishes to discuss. Alternatively, some patients do not vocalise issues. 
Thus, as an HCP, one can be left with the feeling that the appointment has not been as 
useful as it could have been. The fact that the issue and associated level of impact was 
also determined when using the MSIS-29v2 was of benefit to both staff and 
participants. It was then possible for the patient and HCP to assess which problems 
were having most impact and needed discussing in depth. These could either be 
addressed or referred on to other members of the multi-professional team as 
appropriate. For some, the fear of deterioration in their condition was evident and for 
these patients discussing the importance of treatment compliance would be of benefit. 
Devy, et al. (2013) suggest that discussing HRQoL with a patient may increase their 
confidence in the therapist and indirectly improve treatment compliance. Also, in 
accordance with Devy, et al. (2013), areas such as an increase in disability, which 
would potentially impact on the HRQoL of patients in the future, were detected and 
addressed. 
The MSIS-29v2 promoted more discussion about the impact of MS and how patients 
cope with everyday life. Appropriate therapeutic interventions could then be 
introduced and discussed; this demonstrates that the MSIS-29v2 covers domains for 
which interventions can be readily provided. The later point reflects the guidance of 
Freeman, et al. (2000) who describe the importance of selecting a measure bearing in 
mind the purpose of the study. In this study the aim was to optimise HRQoL of those 
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with MS. It is possible that training clinicians to ask the ‘right’ questions could be 
equally effective as using a HRQoL measure. However, I would suggest that the 
guiding influence of a HRQoL measure on a consultation is beneficial as it enabled 
the patients to highlight issues of concern to them and staff to discuss accordingly. 
An interesting finding of this research relates to the influence using the MSIS-29v2 
had on the appointments of those not taking part in the research. Initially during the 
research period for those not taking part in the research, the style of appointment 
tended to be symptom led; for example, how is your bladder, bowels, walking, and 
then if time allowed the consultation focused on how the patient was coping with life, 
asking for example if they were becoming socially isolated. However, as time 
progressed it became evident that using the MSIS-29v2 influenced my style of 
appointment. There was a carry-over effect of the research into daily practice as I 
found myself asking more about the impact of MS on patient life. These findings echo 
the work of Hobart (1997) who describes how assessing HRQoL enables the extent of 
the impact of the health problem and its treatment to be determined, and the effect on 
a person’s ability to perform activities and roles that she/he values to be determined 
from that individual’s perspective. This finding further confirms my earlier finding 
that the impact of using a HRQoL measure in daily clinical practice extends beyond 
just assessment of HRQoL. The influence on communication is discussed below. 
The three clinicians of this research recognised that communication was improved 
when a HRQoL measure was used, reflecting the work of Detmar, et al. (2002). The 
information obtained from the MSIS-29v2 enhanced communication and facilitated 
management of patients. These findings are consistent with the results of previous 
studies. Detmar and Aaronson (1998) determined that individual QoL assessments in 
routine outpatient oncology practice appeared to stimulate physicians to inquire into 
specific aspects of the health and well-being of their patients. The two phases of this 
research both demonstrated that such an inquiry leads to areas where interventions 
might be of benefit. Again, in oncology care, Donaldson (2007) suggested that the use 
of HRQoL measures allowed the patient and the clinician to share information, helped 
both to be more knowledgeable about the effects of the disease and its treatment and, 
promoted the involvement of patients in the decision-making process. Similarly, 
Santana and Feeny’s (2009) work with heart and lung transplant patients concluded 
that the results of their HRQoL assessment were clinically relevant and enhanced 
Chapter 7 Discussion of Findings of Phases 1 and 2 
240 
 
communication. Also, the information provided facilitated management of their 
patients. My research found that the use of the MSIS-29v2 facilitated changes in care 
management as often therapeutic interventions were discussed and subsequently taken 
up, contrasting with the view of Greenhalgh, Long and Flynn (2005) whose paper 
found that the use of HRQoL measures in clinical practice has little influence on 
clinical decision-making, and Boyce and Browne (2013) who found little evidence 
that the feedback from PROMs changes care management. Although the MSIS-29v2 
highlighted issues which were discussed and interventions offered, it is likely that 
some of these may have been considered without the use of such a measure as many 
patients do raise concerns during outpatient appointments. Rather, I would suggest 
that a greater understanding of the impact of MS from a patient perspective is realised 
by both the patient and HCP, potentially enabling more timely interventions to be 
considered. 
In summary, the MSIS-29v2 provides a framework for consultations and has 
contributed to a change in consultation style to one where patients feel more 
empowered to discuss their concerns, patient-centred care is practised, and informed 
decisions made. Communication has been facilitated. The results of the assessment of 
the physical and psychological impact of MS enables patient-perceived symptoms to 
be determined and their significance to be realised by both patients and health care 
professionals. The results of this research demonstrate that the results of an assessment 
with the MSIS-29v2 can be used to inform therapeutic interventions once patient 
determined issues have been realised and an understanding of the impact of these 
issues gained. 
7.4 CAN A HRQOL MEASURE DETECT CHANGE IN HRQOL 
AFTER THE IMPLEMENTATION OF INTERVENTIONS? 
The MSIS-29v2 has been proven in various studies to detect changes in HRQoL. Of 
particular relevance to this study is the work of Hobart, et al. (2004) who describe how 
the MSIS-29v2 may be used in longitudinal studies to monitor the natural history of 
the disorder and in evidence-based practice to monitor the progress of people with MS 
from their perspective. This research was conducted in the outpatient setting where 
the purpose was to assess changes in individual patients HRQoL over the course of 
twelve months, a purpose for which Hobart, et al. (2004) stated that the MSIS-29 can 
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be used. Whether the MSIS-29v2 can detect changes when used within the everyday 
outpatient setting, with patients across the disease trajectory attending appointments 
at various time intervals and receiving differing interventions, is now discussed. This 
is considered both at the group level and individual level. 
The literature reviewed indicates that HRQoL is an outcome of considerable interest 
in relation to the therapeutic success of healthcare interventions in chronic illness, 
conditions with significant disease burden and, conditions in which curative 
interventions are either limited or uncertain. Multiple sclerosis is one such condition. 
Wilson and Cleary (1995) suggest that the principal goal of clinical care is 
improvement of patient outcomes which can be determined through changes in 
HRQoL assessment scores. 
When considering whether HRQoL has improved, Yorkston, Johnson, and Klasner 
(2005) suggest that one should consider the intervention commenced and what 
difference this has made to life as a whole. The following scenario (Yorkston, Johnson, 
and Klasner, 2005) demonstrates the complexity of determining whether an 
intervention has made a difference. For a patient who stumbles and falls at her place 
of work, the physician may consider the scenario from the perspective of symptom 
management and seek information about leg strength and coordination, whilst the 
physiotherapist may view this situation from the perspective of functional status and 
whether mobility aids are required to maintain independence. The individual, 
however, may view this scenario from a more global and personal perspective and ask 
questions such as: ‘what do my co-workers think of me?, ‘should I really be working?, 
how can I manage financially if I no longer work. 
In this longitudinal study, no statistically significant differences were noted within the 
physical or psychological impact scores of the MSIS-29v2 for groups of patients 
between baseline and follow-up appointments (i.e. distribution-based responsiveness) 
following the initiation of interventions. Thus, I have to conclude that the MSIS-29v2 
did not detect a change in HRQoL after the implementation of interventions. This lack 
of statistical significance could be attributed to group size as this was below that 
required to enable significance to be demonstrated. However, there are many other 
reasons why a statistical change in HRQoL may not have been detected and also, why 
at times there was a lack of correlation between the changes in impact scores and 
patients’ perception of any change in their HRQoL. These are now considered. 
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When assessing treatment effects, a change in HRQoL may reflect adjustment to 
disease, a response shift, a treatment effect, disease progression or, a combination of 
these. The lack of detection of change may also be due to the numerous different 
interventions that were offered and the varying time gaps between reviews. 
Additionally, I would suggest that the variable responses to interventions and the wide 
range of score changes may account for small to moderate effects and indicate that all 
participants do not respond equally. 
As a measure of subjectivity, quality of life may reflect adjustment to disease (Ford, 
et al., 2001b). Beiske, et al. (2012) suggest patients with more advanced disease may 
develop psychological coping strategies. Thus, the longer the duration, and the older 
the individual, the more likely they are to perceive a relatively good quality of life. 
Conversely, younger people with relatively recent onset, who are experiencing 
difficulties in mobilising but are not yet wheelchair users, may perceive their quality 
of life as poor (Ford, et al., 2001b). This mismatch between disease severity and 
HRQoL may also be due to the response shift theory which proposes that, over time, 
individuals with chronic conditions change the internal criteria which they use to 
assess their own HRQoL and that this involves not only a recalibration of internal 
standards, but also a reconceptualisation of the meaning of items and a reprioritisation 
of values (Rapkin and Schwartz, 2004). Thus, when the impact of interventions on 
quality of life is considered, adjustment (both emotional and physical) to the disease, 
recalibration, coping skills, changes in identity and response shift should be borne in 
mind. The results may also be related to the participants altered perception of HRQoL 
over time, or that they had simply learnt to cope with the limitations of the disease 
(Hadgkiss, et al., 2012). Expectations may have changed to match experience (Carr, 
Gibson and Robinson, 2001). Osborne, et al. (2012) also describe how, although 
HRQoL can be assessed using an appropriate measure, the ability to detect 
improvement after an intervention is complicated by maturational and adaptational 
changes. Maturational changes occur as a result of ageing whilst adaptational changes 
are related to time since diagnosis. Dealing with hidden symptoms as suggested by 
Ford, et al. (2001b) and Lysandropoulos and Havrdova (2015) also interacts with an 
individual’s health status to determine the overall impact of the disease on HRQoL. 
As these factors are likely to vary over time the impact of MS will vary. Thus, 
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detection of changes in HRQoL due to the implementation of clinical interventions 
may not be detected at the time the MSIS-29v2 was completed. 
When assessing HRQoL in either the trial or outpatient setting consideration must be 
also given to the fact that changes in scores may reflect life events rather than disease 
changes. Also, the results may be heavily influenced by the subject’s personality and 
mood disorders (Amato and Portaccio, 2007) as well as physical and cognitive 
attributes. King-Kallimanis, et al. (2011) and Boucekine, et al. (2013) describe how 
self-reported data in longitudinal studies is often difficult to interpret due to response 
shift. The differing stages of disability of those involved and the variable nature of MS 
could also have affected the results. Additionally, symptoms may be transitory and 
thus potentially were not always detected when the tool was used (Ford, et al., 2001a). 
It is possible that during the time between assessments symptoms came and went. 
Thus, I would propose that the length of time between appointments may have affected 
results. If an intervention had been offered and the patient not reviewed for many 
months subsequently, the impact of that intervention may have been superseded by 
other life events such as an infection, hot weather or a relapse, all of which affect MS 
symptoms and thus the way that the patient would have responded to the questionnaire. 
When comparing the MSIS-29v2 responses between two questionnaires it was 
apparent that whilst the answers to some questions demonstrated an improvement in 
HRQoL, others demonstrated a deterioration; hence the overall score remained the 
same or only changed slightly, this amount being imperceptible to the patient. These 
findings are important as the may represent why statistical changes were not apparent 
in HRQoL despite interventions. They reflect the work of Osborne, et al. (2012) who 
describe how HRQoL scores may remain unaltered, but individual elements 
contributing to the overall score may alter with time. I was unable to conduct an 
analysis of this type in my study as it would have required a substantially larger sample 
to produce statistically significant results. 
Hobart, et al. (2005) describe how, if the changes in impact scores were small it is 
possible that the ability of the scale to detect change can be perceived to be limited. 
Whilst statistically this is true, from observation I found that the MSIS-29v2 did 
demonstrate change for many patients at an individual level but often only very small 
changes. It is probable that for some patients the very small changes in scores between 
appointments potentially accounted for the lack of correlation between the MSIS-29v2 
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impact scores and the HTQ. Where impact scores had increased or decreased very 
slightly and the response to the HTQ was ‘no change’, it is likely that the difference 
was not enough for the patient to detect and so could be considered to be below the 
smallest detectable change score or minimally important difference for one or both 
scales. 
The focus of use of a HRQoL measure in the outpatient setting with regards detecting 
meaningful change differs from in the trials setting where the focus is frequently on 
comparing groups of patients and monitoring changes and responses to treatment. I 
believe that in daily clinical practice concern should be centred around individuals and 
monitoring changes and responses to treatments. This view echoes the work of 
Freeman, et al. (2001) who describe how measuring the outcomes of therapeutic 
interventions from the patient’s perspective is important. 
Although not detected at a group level, this research revealed that changes in patient 
physical and/or psychological impact scores between appointments was demonstrated 
at the individual level. The relationship between changes in impact scores and patient 
reported change was considered using a health transition question, the relationship 
between the two scores being examined. Changes in HRQoL were noted by patients 
using the HTQ which at times correlated with the changes in impact scores. I perceive 
that these patient-perceived changes are more important than changes in composite 
scores as they relate to how the patient actually feels. Although the changes noted in 
HRQoL as determined by the impact scores from one appointment to another did not 
always correlate with the patient-perceived change, I would propose that the most 
important aspect to consider is how the patient feels and the value of the assessment 
to them. Indeed, McGuigan and Hutchinson (2004) describe how the assessment by 
patients of their own state of well-being, and of the limitations imposed by a condition, 
is increasingly recognised as a valid part of the assessment of therapeutic 
interventions. 
During an appointment subsequent to the one at which an intervention had been 
offered, some patients stated that their symptoms had improved. However, these 
comments did not always correspond to an improvement in HRQoL or improvement 
in summed impact scores. If only the response to the question that had triggered an 
intervention was considered, there was often an improvement in that score. These 
findings are in accordance with the work of Kuspinar, Rodriguez and Mayo (2012) 
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who conducted a meta-analysis of the effects of clinical interventions on HRQoL in 
MS. They concluded that the extent to which interventions were able to improve 
outcomes depends on delivering a potent intervention to those persons who have the 
ability to benefit. Therefore, interventions targeting specific outcomes will be more 
effective for those people with the targeted problem e.g. pain, spasticity, incontinence, 
or memory and attention deficits. 
The majority of participants did not appear concerned about the statistical analysis as 
they felt that they were aware of how any changes in their condition were affecting 
them. Many patients were more interested in the changes in their responses to 
questions from T1 to T2, etc. and why that might be, rather than in the fact that their 
physical and/or psychological impact scores had changed. Some authors maintain that 
as HRQoL is a multidimensional construct it is meaningless to try and sum the 
individual items to form a domain score (Fayers and Machin, 2016); the above points 
illustrate this. 
In summary, although there was no evidence for statistically-detected improvement in 
HRQoL following the implication of interventions at the group level, there was 
evidence from patients regarding detection of change in HRQoL when comparing 
questionnaires and response to individual questions as part of the longitudinal aspect 
of this study, particularly when the HTQ responses were evaluated. The health 
transition question was considered to be a valuable addition to the MSIS-29v2 by all 
involved in the project. I would, however, propose that the real significance of this 
research is that it reveals that patients value the use of the MSIS-29v2 in their 
appointments to demonstrate the impact of their MS more than whether interventions 
make a statistically significant difference to their HRQoL. Thus, outpatient 
appointments are potentially more productive and the care for patients improved 
which will hopefully contribute to healthcare professionals considering the use of the 
MSIS-29v2 in daily clinical practice. 
7.5 DOES ASSESSMENT OF HRQOL WITH AN APPROPRIATE 
MEASURE MAKE A MEANINGFUL DIFFERENCE TO 
PATIENTS? 
This research question is subjective in nature and as such relies on the comments of 
both patient and staff participants to be answered. Unless assessment of HRQoL is 
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considered to be of a tangible benefit to patients I would not consider it to have a role 
in the neurology outpatient setting. The discussion that follows demonstrates the 
benefit of assessment to patients as described by the participants of this research and 
is related to literature where possible. No published research was found demonstrating 
the benefits of assessing the physical and psychological impact of MS for patients 
during a routine clinic appointment at a hospital. 
My results demonstrate that the staff-participants found using the MSIS-29v2 during 
a clinic appointment beneficial. The work of Hay-Smith, et al. (2016) describes this 
as an instance of ‘dual-role’ as I, the researcher and clinician, am recognising that 
information obtained during the therapeutic relationship is useful as study data. The 
results also reveal that patients found assessment with the MSIS-29v2 beneficial. 
Indeed, since data collection ceased, several participants have asked if they had an 
MSIS-29v2 to complete. One stated that they missed completing the questionnaire. 
Several other patients attending outpatient appointments entered the consulting room 
and stated that they had not been given a form to complete. I would suggest that these 
comments could be interpreted as indicating that the patients found the HRQoL 
assessment beneficial. 
The results from this research revealed that patients felt more confident to articulate 
issues that had been illuminated by the MSIS-29v2. These were then discussed with 
the HCPs. These findings are in accordance with the works of Greenhalgh and 
Meadows (1999), Higginson and Carr (2001), Solari (2005), Santana and Feeny 
(2009) and Bandari, et al. (2010) who describe how assessing HRQoL using an 
appropriate instrument can facilitate and enhance patient-physician communication 
allowing the main concerns of the patient to be focused on (section 3.8.1). 
Higginson and Carr (2001) suggest that because measures present clear information 
on a range of problems it can help patients to communicate their problems. In this 
current study, many of those interviewed described how completing the MSIS-29v2 
had helped them to actually realise the impact of their MS. Considering the questions 
of the MSIS-29v2 helped patients to reflect on their health and raise issues with 
clinicians echoing the conclusions of Greenhalgh, et al. (2017). The majority of those 
interviewed appeared to find this process extremely beneficial. Problems were then 
discussed as the questions had focused their mind on their condition and its impact, 
thereby confirming work of Higginson and Carr (2001). Participants stated that 
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completing the questionnaire was beneficial to them as care was offered in response 
to the answers given. Consultations were also described as more valuable and 
productive by patients. Additionally, the use of the MSIS-29v2 made a difference to 
both the CNS MS; they felt better informed about the range of physical, functional and 
psychological problems the patients were experiencing. Staff indicated that the 
measure was useful for monitoring and contributed towards a better understanding of 
the lives of patients. This information could then be utilised to plan future care for 
patients. 
Many benefits of using the MSIS-29v2 were demonstrated in the findings. It soon 
became apparent that the MSIS-29v2 provided a very different and extremely valuable 
insight to the participants’ world and the physical and psychological impact of MS; 
this is supported both anecdotally, by patients in clinic and the healthcare 
professionals, and also by the interview data. With growing confidence in the use of 
the measure, issues that required further discussion with patients could be focused on 
quickly. Discussing subsequent questionnaires was quicker and, comparisons could be 
made with earlier ones, thereby enabling the effect of any interventions to be 
considered. Detmar and Aaronson (1998) describe how some physicians found that 
their efficiency increased when using the HRQoL summary provided to them. I would 
suggest that rather than HCPs being more efficient, appointments were more effective. 
My findings demonstrate that if the questionnaire was discussed each time it was 
utilised it provides worthwhile benefits in the form of interventions offered. 
Participants indicated how the MSIS-29v2 provided the health professionals with 
areas for addressing. Both CNS MS described how completed questionnaires were 
helpful as they guided the consultation. These findings echo the work of Higginson 
and Carr (2001) who propose that the potential benefit to patients of using quality of 
life measures in clinical practice is that their problems are identified and dealt with 
and that treatment decisions are based on their priorities and preferences. However, 
they also suggest that evidence for these benefits is lacking because these measures 
are rarely used in clinical practice. I would propose that this study provides evidence 
of these benefits. 
The findings of my research contradict the work of Santana, et al., (2015) who describe 
how the data from PROMs was originally used to support treatment recommendations 
or inform health policy, but there was no direct benefit for the participants providing 
Chapter 7 Discussion of Findings of Phases 1 and 2 
248 
 
the data. Boyce, Browne and Greenhalgh (2014) describe how, as the experience of 
those using measures increases, the clinical value of using individual patient PROMs 
in daily practice to identify/monitor symptoms, evaluate treatment outcomes and 
support shared decision-making has become obvious. My work suggests that these 
benefits may also apply to those using HRQoL measures. The findings of my research 
have established a direct value to patients with MS as described by them in the form 
of an increased awareness and understanding of the impact of their MS following 
assessment using the MSIS-29v2. 
The unique findings of this study indicate that most of those interviewed found an 
assessment of HRQoL using the MSIS-29v2 beneficial as it helped both patients and 
healthcare professionals to realise the significance of the impact of MS on the lives of 
those living with the condition. The results also demonstrated that patients gained an 
increased awareness of their symptoms and an enhanced ability to discuss issues of 
importance to them. Communication during consultations between staff and patients 
was improved and possible interventions were discussed. The assessment was 
described as helping to guide the consultation. Subsequent assessments provided an 
overview of any changes in the patient’s condition. Additionally, many patients 
became more active with regards to participating in their care planning. The impact of 
using the MSIS-29v2 during the consultation was more far-reaching than I had initially 
expected; the nature of the consultation was changed, and it quickly became evident 
that in many cases the patient’s own perception of the impact of MS was not 
immediately visible without qualitative interviews. This is what the research added.  
In summary, I would conclude that assessment of HRQoL with an appropriate 
measure, namely the MSIS-29v2, does make a meaningful difference to the majority 
of patients. 
7.6 SUMMARY 
‘Is there a role for assessment of health-related quality of life in 
patients with multiple sclerosis in daily clinical practice? 
When considering whether there is a role for HRQoL I would have to ask who this 
question is relevant to, people with MS or healthcare professionals. Despite the 
inconclusive quantitative findings, I conclude that because of the benefits described 
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by both patients and healthcare professionals there is a role for assessment of HRQoL 
in routine clinical practice when using an appropriate measure such as the MSIS-29v2. 
I hope that these beneficial findings encourage others to use the MSIS-29v2 to assess 
the physical and psychological impact of MS in their daily clinical practice. 
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8.1 INTRODUCTION 
The words of Cella, et al. (1996) and Baumstarck, et al. (2013) both helped guide my 
choice of subject for this PrD. Cella, et al. (1996, p.130) noted that ‘the assessment of 
quality of life in longitudinal research will increase our knowledge of the impact of 
symptoms and the disease process on patient perception of well-being and function.’ 
In 2013, when considering areas for my research I found the paper of Baumstarck, et 
al. (2013, p.4) which stated that, ‘to our knowledge there are no studies that have 
explored the effect of assessing QoL in MS care management’. The aim of this thesis 
is to contribute to this gap in knowledge by investigating whether there is a role for 
the assessment of health-related quality of life in patients with MS in daily clinical 
practice. Although there is now considerable evidence relating to the impact of MS on 
HRQoL, there remain unanswered questions concerning whether patients perceive 
assessment of HRQoL beneficial. The two phases of this work were designed to 
address some of these unanswered questions with the following specific aims: 
• To establish the feasibility of assessment of HRQoL during a routine outpatient 
appointment 
• To determine whether the results of the assessment can inform therapeutic 
interventions 
• To establish whether a change of HRQoL could be detected after the 
implementation of interventions using the MSIS-29v2 
• To establish the views and opinions of patients who had completed the MSIS-
29v2 about such assessments and what it means to them. 
The following sections conclude the study. The unique contributions to knowledge 
and practice of the research are discussed. Strengths and limitations of the research are 
considered. Implications for embedding the research into everyday practice are 
described and recommendations for further studies given. A reflexive account of 
conducting research as a practicing clinician is presented. Finally, an overall 
conclusion is provided. 
8.2 CONTRIBUTION TO KNOWLEDGE AND PRACTICE 
To my knowledge this is the first study to consider the value to patients of 
incorporating assessment of health-related quality of life in patients with multiple 
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sclerosis in routine clinical practice using the MSIS-29v2. In undertaking this research 
additional knowledge has been added to the growing body of literature surrounding 
assessment of quality of life in patients with MS. The effect of interventions, suggested 
at an outpatient appointment, on the physical and psychological impact of MS was 
established using quantitative analysis. This study provides valuable new information 
concerning the relationship between changes in the physical and psychological impact 
of MS and a health transition question when the MSIS-29v2 is used in routine clinical 
practice. Currently there is no published information with which to compare this 
aspect. The views and opinions on the assessment of those taking part in the research 
concerning assessment were established. These are important areas for the healthcare 
management of people with MS and offer insight into the appropriateness of 
assessment in routine clinical practice. 
The findings of my two-phase study have a number of important implications for both 
people with MS and healthcare professionals working with MS patients. The results 
indicate that the introduction of individual HRQoL assessments using the MSIS-29v2 
into an outpatient neurology setting is feasible. Patients were able to complete the form 
quickly and easily. The interviews revealed that patients valued the structure of the 
MSIS-29v2 which many considered to focus their thoughts, thereby enabling them to 
provide detailed relevant information on their health and the impact of MS to 
healthcare professionals. The three healthcare professionals involved determined that 
the information provided was invaluable for: identifying important issues that might 
otherwise have been overlooked, for suggesting therapeutic interventions, monitoring 
the status of the patients over time, and improving patient-clinician communication. 
Whilst it is important not to overstate findings based on a small sample, these points 
demonstrate validity of the MSIS-29v2 in the outpatient setting. 
This study is original as qualitative methods were used to determine whether the 
patients believed there to be a benefit to them of using a HRQoL measure in clinic. 
Although the literature reviewed indicates that HRQoL should be measured by 
clinicians over time as in phase 1 of this study, I was curious to know whether patients 
believed there to be a tangible benefit to them. The findings of phase 2 are unique in 
that they conclusively demonstrated such a benefit. The key finding of this study is 
that assessment of HRQoL does make a difference to patients who live with the 
incurable condition of MS and is of value when used in the outpatient setting. This 
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research demonstrates that the effect of assessing HRQoL in MS care management is 
profound; patients describe how such an assessment makes them consider the impact 
of their MS and in many cases empowers them to become more involved in, and take 
control over, their health care. In this study, healthcare professionals described 
appointments as more structured and productive. 
The in-depth investigation into the patient experience of assessment of HRQoL was 
key when determining whether such an assessment is of value and whether there is a 
role for assessment in daily clinical practice. The findings suggest that care has 
improved as patients have been able to identify issues of concern to them, and then 
discuss these issues and make decisions using a shared decision-making approach. 
The questionnaire appears to have altered the style of consultation for some patients 
from one where the participant was asked questions to one where the participant feels 
empowered to discuss the impact of their MS. Participants described how they found 
that the questionnaire guided the consultation and provided prompts for discussion. 
Issues which participants were not aware were related to MS were highlighted by the 
questionnaire and discussed, which was felt to be a good thing. The requirement for 
interventions for symptoms which had not been previously identified but were 
highlighted by the questionnaire became evident in several cases. Both patients and 
staff described the consultation as more productive using the questionnaire. The 
MSIS-29v2 was found to incorporate the patients view of their disability in a 
structured manner within a consultation. It may be concluded that the process of 
assessment of HRQoL enabled some participants to become more aware of the impact 
of their condition and subsequently more active in the management of their MS and 
care. I would conclude that I came to rely on the HRQoL information from the research 
participants and found its use beneficial. 
MS is a highly variable condition, with many factors affecting HRQoL. Any method 
of determining these factors can only be considered beneficial to the patient. At times 
interventions determined from the appointment using the questionnaire were found to 
maintain or improve HRQoL when impact scores were considered. This study 
demonstrates the value of the health transition question as a measure of change during 
outpatient appointments; patients took time to consider the impact of their MS prior 
to the appointment. Reasons for any change could be considered and related to the 
responses to the MSIS-29v2. Whether overall HRQoL changed did not appear to be 
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of major concern to patients. Rather they were more focused on resolving their issues 
and reducing the impact of MS. 
The data resulting from the patients’ interviews concerning the assessment of two 
dimensions of HRQoL leads me to propose the following recommendation for future 
use of the MSIS-29v2 in routine practice. Rather than using the MSIS-29v2 to measure 
changes in the physical and psychological impact of HRQoL, I would suggest that, 
when used in the outpatient setting of an Acute Trust, the value of the MSIS-29v2 rests 
in its ability to empower patients to consider the impact of their MS in a structured 
manner. The measure is then a really useful tool which can be used on an individual 
basis as frequently as that person wishes. The responses to the twenty-nine questions 
may be considered and used to guide any requirements for therapeutic interventions, 
both pharmacological and non-pharmacological, using the multi-disciplinary team to 
offer holistic patient-centred care through shared decision-making. The interview 
narratives indicated that the majority of those interviewed were not unduly concerned 
about summary impact scores and changes in them between appointments. Instead, 
they appeared more interested in how the response to individual questions changed 
from one appointment to the next. Summary impact scores could still be calculated for 
those who were interested in how their HRQoL was changing. 
My research has explored the effect of assessing QoL in MS care management as 
suggested by Baumstarck, et al. (2013), the findings indicating that such an assessment 
should become embedded in everyday clinical practice. The views of patients and staff 
regarding the MSIS-29v2 point towards the importance of assessment of HRQoL in 
routine clinical practice. The overall feeling from the participants was that the 
questionnaire should become part of routine practice. Although there is a pervasive 
view that there are many barriers to assessing health-related quality of life or 
dimensions of it during routine outpatient appointments, the findings of this study 
show that assessment using the MSIS-29v2 is possible, although not entirely without 
logistical problems. I would suggest that overcoming the barriers to assessment of 
HRQoL in daily clinical practice is worthwhile as the appointment becomes more 
productive for both patients and staff; HRQoL is optimised and job satisfaction is 
increased. 
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8.3 LIMITATIONS OF THE STUDY 
Despite finding support for the primary research question there are some limitations 
to this work which need to be acknowledged when interpreting the results. Limitations 
relating to each phase were presented at the end of chapters 5 and 6. They are 
summarised in this chapter. 
Phase 1 was a longitudinal study designed to investigate whether a HRQoL measure 
can detect change in HRQoL after the implementation of interventions. I expected that 
the time frame of twelve months would be a long enough time period in which to 
detect changes. However, the results indicated that there was no statistical difference 
in HRQoL between time 1 and follow up appointments. One explanation for this may 
be that the time between appointments, even at 12 months, was not long notice for any 
change following interventions in such a chronic long-term illness to be detected. 
Alternatively, response shift and adjustment may have influenced the results. These 
points highlight the need for research to investigate these relationships further over a 
longer time period. The size and heterogeneity of the sample also limited my ability 
to draw conclusions about whether the MSIS-29v2 could detect changes after the 
implementation of interventions; also, the fact that the interventions were varied and 
the time gaps between appointments of differing lengths. This highlights the need to 
undertake research both using a larger sample of patients and over a longer time 
period. 
As the principal researcher, I recruited participants for phase 2 and as such it is 
possible that a selection bias is present. Those with fatigue or cognitive issues were 
not invited for interview yet may have provided valuable data. The final limitation is 
the size of the sample of HCPs for phase 2, as discussed in section 6.4. At the hospital 
of this research only three healthcare professionals review patients with MS in 
outpatient clinics. All took part in the research. Replicating this research at a hospital 
with more HCPs is required to validate the results provided by the healthcare 
professionals. 
8.4 STRENGTHS OF THE STUDY 
The major strengths of this study are the mixed methods approach and the longitudinal 
design. The quantitative strand allowed data about two domains of HRQoL to be 
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gathered enabling the effect of interventions to be considered, thereby providing 
baseline information as suggested by Sieber (1973). The quantitative findings 
informed the choice of participants and interview schedule design for the qualitative 
study. The qualitative approach supported a more in-depth understanding of the use of 
a HRQoL measure in routine care than would have been possible using a quantitative 
method alone; the quantitative results were interpreted, clarified, described, enhanced 
and validated through the interviews as described by Greene, Caracelli and Graham 
(1989). This adds to the research making it more than just a validation study of the 
MSIS-29v2. 
Research findings within the current body of literature relating to the how patients 
perceive assessment of HRQoL with an appropriate HRQoL measure is limited. As 
such, there is currently a gap within research which this study has now sought to fill. 
To my knowledge this is the first study investigating MS patient perceptions of the 
benefit of HRQoL assessment to themselves. Although important to know if the 
measure was acceptable to both patients and staff, and whether it could be used to 
inform therapeutic interventions, the views and opinions of the patient interviewees 
make a unique contribution to knowledge regarding the benefits of using the 
MSIS-29v2 during outpatient appointments in a hospital setting. 
The sample of patients taking part in phase 1, and setting of the research, may also be 
considered to be strengths of this work. The sample is representative of the wider MS 
population when figures from other research projects and the literature are considered. 
The research took place in the ‘real-world’ at two outpatient departments of an Acute 
Trust hospital and was conducted by staff who normally care for the MS patients at 
that Trust. No research staff were involved. Thus, I consider that any recommendations 
for future practice should be readily transferable to other hospital outpatient settings. 
Another strength lies in the impact that using the MSIS-29v2 has had on the 
consultation style of myself and the other MS nurse involved. Since ceasing to use the 
MSIS-29v2 I believe that I am considering the impact of symptoms raised by patients 
during the outpatient appointment and ways that these can be addressed on a more 
regular basis, thereby taking a more person-centred approach. 
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8.5 ADOPTION OF THE MSIS-29V2 INTO ROUTINE PRACTICE 
Adoption of the MSIS-29v2 into routine practice is essential if people with MS who 
attend hospital outpatient appointments are to benefit from this research. I am keen for 
this not just to be a piece of stand-alone research. Ideally, I would like it to contribute 
to a change in practice and become widely used. Clearly there are many challenges 
associated with embedding the MSIS-29v2 into everyday practice. Addressing these 
issues are key to ensuring that this work is not just viewed as a research project. 
I would suggest that there are several levels within the health system that will need to 
be influenced if the use of the MSIS-29v2 is to be routinely used across the NHS in 
neurology practice. These include NHS England and NICE at policy agenda level 
where key stakeholders could be approached. The current NICE Guideline for MS 
(CG186) (2014) states that ‘it aims to improve the quality of life for adults with 
multiple sclerosis by promoting symptom management, comprehensive reviews and 
effective relapse treatment’. Although the guideline states that people with MS should 
have a yearly review it does not mention assessment of quality of life. No date is given 
for the review of this guideline, but I would hope that a recommendation for formalised 
assessment of HRQoL using the MSIS-29v2 could be included at this time. 
Organisations such as the MS Society and MS Trust could be contacted for help and 
guidance with regards facilitating MS nurses at the various Trusts to adopt the 
MSIS-29v2. As described previously in this work there are also challenges at the 
hospital level including the understanding of practitioners about the benefits of 
including such a measure in their daily practice. MS neurologists, clinical nurse 
specialists and all those involved in the care of patients at the various NHS Trusts 
around the country will need to be convinced of the value of using the MSIS-29v2 in 
their daily clinical practice. These benefits will be portrayed through the presentation 
of posters at conferences, and published papers and articles in the MS press. 
Investigating whether and how other Trusts assess patient health-related quality of life 
would provide a basis for an implementation strategy for the widespread adoption of 
the MSIS-29v2 into routine clinical practice at the NHS level. A survey could be 
conducted using MS clinical nurse specialists identified from the MS Trust database. 
Data could be collected concerning the number of patients reviewed at each Trust, 
how often they are reviewed, the number of MS nurses and whether or not HRQoL is 
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currently assessed. The benefits of using the MSIS-29v2 could then be shared. 
Examining the outpatient appointment system, ways of distributing the MSIS-29v2 
and, discussing and scoring the measure in an appointment could all be discussed by 
telephone. This could lead to the consolidation of a proposal for managers of 
neurological departments for making recommendations for the implementation of the 
MSIS-29v2 thereby potentially improving patient care with minimal additional costs. 
Also, a poster presentation at the annual MS Trust Conference should potentially lead 
to interest in assessing the health-related quality of life of patients. Those staff showing 
interest could be asked to trial using the MSIS-29v2 at their place of work with a view 
to long term usage. 
The various barriers to adoption of HRQoL measures described in this work will also 
need to be overcome if the MSIS-29v2 is to be used routinely. As indicated in the 
literature review (Chapter 3) realising the benefits of using the MSIS-29v2 is not 
sufficient to ensure adoption. Ways of overcoming the many challenges of 
incorporating such a measure need to be considered and presented to staff. The main 
barriers I found are related to: ways of introducing patients to the concept of HRQoL 
assessment and the time this takes; distribution of questionnaires; the additional time 
required when the MSIS-29v2 is first used in clinic. My research shows that the 
benefits of using the questionnaire outweigh these barriers. Once confident in the use 
of the questionnaire patient issues can be focused on quickly. 
I would suggest that staff education is essential for successful adoption of the 
MSIS-29v2 and can contribute to overcoming potential barriers. Education should 
include informing staff about how to use the measure and score it. Information about 
the impact of using the measure within in a clinic appointment both in terms of the 
time aspect and also its effect on the consultation style are also key to the adoption of 
the MSIS-29v2. 
Understanding the benefits of such an assessment should also help to encourage 
adoption. The practical benefits for people with MS and healthcare professionals of 
adopting the MSIS-29v2 have been described throughout this work. Prior to using the 
MSIS-29v2 I did not reflect upon HRQoL during clinic appointments. I suspect that 
many patients did not either. However, using the MSIS-29v2 during appointments has 
changed the nature of the consultation. HRQoL is recognised, the consultation is more 
structured, clinic appointments are more effective and the consultation more holistic. 
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There is better recognition of issues important to patients and, better job satisfaction 
for staff as they perceive that they are giving a better service. Other benefits include 
the realisation and awareness of the overall impact of MS on the everyday life of 
patients, thereby aiding in the selection of effective treatment regimes that satisfy the 
treatment goals of the patient. Moreover, many patients become more involved in their 
care. 
How practical using a paper-based HRQoL assessment such as the MSIS-29v2 is 
within routine clinical practice also requires consideration. At my place of work, 
patient records are predominately paper-based and thus using a paper questionnaire 
works well. In areas where paper records are used the paper copy may be filed in the 
patient notes. It then forms part of the documentation and can be easily reviewed from 
one appointment to the next. Various methods for distributing the MSIS-29v2 have 
been discussed, the most feasible for the place where I work being to post the MSIS-
29v2 out with the patient’s clinic letter. Each place adopting this measure would need 
to consider their own systems to determine the most appropriate method for 
themselves. 
At Trusts where patient records are electronically-based using an electronic version 
which could be attached to notes would potentially be preferable for those patients 
with the necessary computer-based skills and access to a computer, laptop, tablet or 
phone. The MSIS-29v2 could be put on the hospital internet or emailed to patients for 
electronic or printed completion prior to appointments. Completed forms could be 
attached to the patient record. However, it must be recognised that a proportion of 
patients do not have computers or smart phones so for them a paper-based system 
would be essential. 
The benefits of assessing HRQoL may be demonstrated to patients through discussion 
during their appointments. Using the health transition question, patient perceived 
changes in HRQoL following interventions can be recorded. These results may be 
communicated to patients during their outpatient appointments. Individual question 
score changes may also be considered and reasons for them debated. The MSIS-29v2 
can also be scored and comparisons made from one appointment to another, thereby 
potentially demonstrating the effectiveness of various treatments. Using the MSIS-
29v2 also provides opportunities for auditing one’s service; for example, the health-
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related quality of life of those with MS and how it changes over time could be 
examined. 
8.6 CHALLENGES FOR FUTURE PRACTICE 
An argument for assessment of the impact of two dimensions of HRQoL has been 
developed throughout this thesis. Assimilation into daily clinical practice is a 
fundamental requirement if the patients of the NHS Trust of this research are to benefit 
from the study findings. Ways of integrating such an assessment into routine clinical 
practice are now considered. 
Difficulties with distribution of questionnaires were encountered as previously 
described (section 5.3) during the research period. A major challenge centres around 
how to ensure patients receive the MSIS-29v2 for completion prior to their 
appointment. An acceptable method for distributing the MSIS-29v2 needs to be 
determined. If the MSIS-29v2 is given for completion during a clinic appointment 
valuable consultation time will be used up. Questionnaires and an information sheet 
could be offered to patients at the end of their appointment for completion prior to 
their next appointment. Following discussion with the other HCPs of this research it 
was decided that the most feasible way was to post out an information sheet describing 
the MSIS-29v2 and the MSIS-29v2 with the clinic letter that is sent to each patient 
after their appointment. The information sheet would provide patients with 
information allowing them to choose whether to complete a questionnaire or not. This 
latter option appears the most practical in terms of efficient use of time, the patient 
completing the questionnaire immediately prior to their subsequent appointment. This 
decision aligns with the work of Lysandropoulos and Havrdova (2015) who suggest 
that the concept of patients completing forms between clinic visits seems practical in 
terms of efficient use of time and, can facilitate patient recall if clinical visits are 
infrequent thus improving the quality of the information. Having the MSIS-29v2 
available for patients to complete either immediately before their appointment or to 
take home for completion, possibly with the help of a significant other, will improve 
accessibility for all. Unfortunately, assessment will still not be an option for those who 
are more physically disabled, or who suffer moderate to severe cognitive impairment 
and who attend alone. Questionnaires could also be placed in the MS information rack 
in the outpatient waiting area for patients to pick up. It may be possible in the future 
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to put the MSIS-29v2 on the hospital internet so that patients can access and complete 
it from home if they so desire. 
Another challenge is the additional time required when using the measure with patients 
for the first time as part of their clinic appointment. I hope that in the near future 
assessment of HRQoL using the MSIS-29v2 will become embedded in the clinical 
practice of the team at the Acute Trust where this research is taking place, becoming 
an integral and valuable part of the consultation for those patients with MS who wish 
to use it. 
8.7 RECOMMENDATIONS FOR FUTURE RESEARCH 
Although the assessment of two dimensions of HRQoL was found to be feasible in the 
routine outpatient setting, the findings of the current research only provide limited 
support for the MSIS-29v2 as a useful measure for predicting changes in HRQoL 
following interventions, either pharmacological or non-pharmacological. What is now 
required is the replication of the present research over a longer time period, with a 
larger sample size and ideally patients and staff from multiple hospital sites. This 
would help to determine whether the issues identified in the current study are a result 
of a limitation in the sample size and/or the time frame of the research design. Also, 
any further study should include more HCPs using the questionnaire with patients and 
interviews of these staff to assess acceptability and feasibility of assessment of 
HRQoL. 
Another area which requires further research relates to the use of the MSIS-29v2 by 
proxies and the validity of such measurements. 
8.8 DISSEMINATION OF FINDINGS 
Having gained such positive results regarding the assessment of HRQoL for both 
patients and staff from this research I am keen to disseminate them widely. The 
audience of relevance is wide, comprising service users, i.e. people with MS; 
healthcare professionals including neurologists and clinical nurse specialists; charities 
such as the MS Society and MS Trust who are involved in the care of those with MS; 
and researchers. This group of people have differing priorities, needs and 
requirements, and therefore information needs to be conveyed accordingly. 
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I plan to publish in academic journals, patient publications and liaise with the MS 
Society and MS Trust to increase access to the findings. Publishing in several journals 
with differing target audiences will potentially result in a wider adoption of the MSIS-
29v2. Thus, I am currently considering journals such as: British Journal of 
Neuroscience Nursing; International Journal of MS Care; Multiple Sclerosis Journal - 
Experimental, Translational and Clinical; Applied Research in Quality of Life; Journal 
of Mixed Methods Research, and; AMRC Open Research. 
A final report of the research will be submitted to the MS Society. I shall also be 
writing an article for the two local MS Society Group newsletters. During the consent 
process participants were asked if they wished to receive a copy of the results of the 
study. A summary document will be produced for these participants. Following 
discussion with the MS Trust I have been asked to produce an article for their 
publication for health professionals, MS in Practice. I also plan to investigate whether 
an article can be submitted to the NHS Quality Improvement website: 
https://improvement.nhs.uk/improvement-hub/quality-improvement/ 
Subject to acceptance I will produce a poster for ECTRIMS (European Committee for 
Treatment and Research in Multiple Sclerosis) conference in September 2019 and also 
the MS Trust conference in November 2019. These will enable networking at a UK 
and global level. The results will be further disseminated as my name will be 
recognised in the online and printed programme of ECTRIMS as well as in the 
congress mobile App and Online Library. Having a poster accepted for ECTRIMS 
also provides an opportunity for publication as all accepted abstracts are published in 
the Multiple Sclerosis Journal Online. Attending both ECTRIMS and the MS Trust 
conference would allow me to share my research thereby contributing to more 
healthcare professionals being aware of the benefits of using the MSIS-29v2 in the 
routine clinical setting which could potentially contribute to improved care for 
individuals with MS all around the globe. 
8.9 REFLEXIVITY 
Reflexivity is an issue which must be taken into consideration in the present research. 
Finlay (2002) defined reflexivity as thoughtful conscious self-awareness. Within the 
context of research, reflexivity seeks to understand the possible effects of the 
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researcher’s behaviour or knowledge on the process of conducting research. As 
discussed earlier I am a clinical nurse specialist for MS service, the principal 
researcher and the sole interviewer for Phase 2. Thus, I would consider myself to be 
an insider-researcher and also a clinician-researcher which is defined as an individual 
who conducts research and provides direct patient care (Yanos and Ziedonis, 2006). 
My clinical background has enabled me to get to the heart of the issues raised; indeed, 
it was this clinical knowledge that inspired the undertaking of this PrD study. The level 
of knowledge I have about MS and the access to patients all facilitated this work. Also, 
I could understand the tensions described in the literature in relation to assessment of 
HRQoL and relate them to this work. The symbolic interactionist perspective of the 
research design ensured that the participants and I had a shared understanding of the 
language spoken, in that we were both ‘on the same page’. This may have been 
problematic for a researcher who had no prior knowledge of how life is affected by 
living with multiple sclerosis. However, there are also tensions arising from my 
professional expertise; it may have led me to make assumptions about participants 
experiences or have inhibited participants discussing negative aspects of care. 
The dilemma of performing dual roles– that of researcher and clinician came to the 
fore during both phases of the research. In the first phase during clinics I had to switch 
from being a researcher for those patients who were participating in the research to 
clinical nurse specialist for those who were not. I soon found that the style of 
consultation for both client groups altered, one being directly influenced by the use of 
the MSIS-29v2 and the other by the ‘carry-over’ effect of the beneficial aspects of the 
MSIS-29v2 such as probing more deeply into the lives of the patients and how MS 
was impacting on them. It is my opinion that my clinical knowledge had a positive 
influence on the data collection process in this case, rather than adversely affecting it. 
Undoubtedly the presence of the myself would have impacted upon the discussions of 
the MSIS-29v2 in phase 1 and the interviews of phase 2. Breuer, et al. (2002) argues 
any ‘close range’ technique for gathering data or information is likely to be subject to 
possible influences. The relationship myself and the other healthcare professionals 
have developed with patients over time would also have undoubtably affected how 
some of the patients responded when discussing the MSIS-29v2. 
As a consequence of being a clinician-researcher using the MSIS-29v2 I am now much 
more aware of the impact that MS is having on the lives of people with MS. My 
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empathy has increased, and I find the consultation is more focused on how MS impacts 
on patients. The structure created as a consequence of using the MSIS-29v2 has helped 
me maintain different habits and practice. Indeed, through being an insider-researcher 
I believe I am able to make a difference in the work place. 
Finally, I acknowledge that as an insider-research and clinician-researcher, I found 
that I could not adopt a wholly non-clinical research identity, reflecting the main 
finding of the work of Hay-Smith, et al. (2016). Unquestionably, as a nurse the phase 
of Hay-Smith, et al. (2016) ‘Once a clinician, always a clinician’ resonates very 
strongly with me. 
8.10 OVERALL CONCLUSION 
The key finding of this two-phase study is that assessment of HRQoL does make a 
difference to patients who live with the incurable condition of MS which is known to 
reduce HRQoL in many domains. This research adds to the body of literature 
concerning the issues in measuring HRQoL demonstrating that assessment of HRQoL 
is of value to people with MS when used in the outpatient setting. Although the 
evidence for statistically-detected improvement in HRQoL was minimal, there was 
evidence from patients regarding detection of change when comparing questionnaires 
and response to individual changes as part of the longitudinal aspect of this study, 
particularly when the HTQ responses were evaluated. The health transition question 
was considered to be a valuable addition to the MSIS-29v2 by all involved in the 
project. 
My research has explored the effect of assessing QoL in MS care management as 
suggested by Baumstarck, et al. (2013), the findings indicating that such an assessment 
should become embedded in everyday clinical practice. The findings suggest that care 
has improved as patients have been able to identify issues of particular concern to them 
and then discuss these issues and make decisions using a shared decision-making 
approach. At times HRQoL improved although this does not appear to be of major 
concern to patients. Rather they appear are more concerned with resolving their issues 
and reducing the impact of MS. 
In response to the question: ‘Is there a role for the assessment of health-related quality 
of life in patients with multiple sclerosis in daily clinical practice?’ I would conclude 
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‘yes’. Measurement of HRQoL of patients with MS provides a valuable insight into 
the overall impact of the condition on the everyday life of the patient, from both the 
patient and HCP perspective, thereby aiding in selection of effective treatment regimes 
that satisfy the therapeutic goals of the patient. 
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HRQoL Measure Evaluation Criteria 
Psychometric 
Property 
Ruta, et al. (1994) Fitzpatrick, et al. 
(1998) 
Higginson and Carr (2001) 
Appropriateness Describes the effect of 
the condition on those 
aspects of patients’ lives 
that they consider to be 
of great importance. 
Allows patients to rate 
the extent to which those 
aspects of life are 
affected by the 
condition. 
Suitable for a wide 
variety of patients in 
different settings 
Is the content of the 
instrument 
appropriate to the 
questions which the 
clinical trial is 
intended to address? 
(appropriateness) 
Are the domains covered relevant? (appropriateness) 
In what population and setting was it developed and tested, and 
are these similar to those situations in which it is planned to be 
used? 
Reproducible 
Reliable 
Should be reproducible Does the instrument 
produce results that 
are reproducible and 
internally consistent? 
(reliability) 
Is the measure valid, reliable, responsive, and appropriate? 
Validity Does the instrument 
measure what it 
claims to measure? 
(validity) 
What were the assumptions of the assessors when determining 
validity? 
Responsiveness Would be sensitive to 
changes in health over 
Does the instrument 
detect changes over 
Will it measure differences between patients or over time and at 
what power? (responsiveness) 
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Psychometric 
Property 
Ruta, et al. (1994) Fitzpatrick, et al. 
(1998) 
Higginson and Carr (2001) 
time (responsive), and 
also allow patients to 
judge the values of those 
changes 
time that matter to 
patients? 
(responsiveness) 
Precision How precise are the 
scores of the 
instrument?  
Interpretability How interpretable 
are the scores of the 
instrument? 
(interpretability) 
Acceptability 
Respondent 
burden 
Should be brief and 
simple for patients to 
complete (acceptability). 
Is the instrument 
acceptable to 
patients? 
(acceptability) 
Are there floor and ceiling effects-that is, does the measure fail to 
identify deterioration in patients who already have a poor quality 
of life (floor effect) or improvement in patients who already have 
a good quality of life (ceiling effect)? 
How long does the measure take to complete? (acceptability, 
respondent burden) 
Who completes the measure: patients, their family, or a 
professional? 
What effect will this have-that is, will they complete it? 
Feasibility Is the instrument 
easy to administer 
and process? 
(feasibility) 
Do staff and patients find it easy to use? (feasibility) 
Who will need to be trained and informed about the measure? 
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Phase 1-Participant
Information Sheet 
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Phase 1 Consent Form 
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Collection Tool 
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Interventions Offered 
Appoints attended One Two Three Four Five 
No of participants 72 172 58 18 2 
Intervention T1 T1 T2 T1 T2 T3 T1 T2 T3 T4 T1 T2 T3 T4 T5 Total 
Reassurance 37 85 94 26 24 31 7 7 6 8 1 0 0 0 1 327 
Refer for 
counselling 
0 5 3 3 1 0 2 0 0 0 0 0 0 0 0 15 
Refer to wheelchair 
services 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Refer for hospital 
physiotherapy 
3 9 4 0 4 0 0 0 0 0 0 0 0 0 0 20 
Refer for home 
physiotherapy 
1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 2 
Refer to 
occupational 
therapy- home 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Refer to 
occupational 
therapy- social 
services 
1 4 1 0 0 0 0 0 0 0 0 0 0 0 0 6 
Refer to consultant 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 
Refer for MRI 2 12 12 6 6 3 1 4 1 0 0 1 0 0 0 44 
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Appoints attended One Two Three Four Five 
No of participants 72 172 58 18 2 
Intervention T1 T1 T2 T1 T2 T3 T1 T2 T3 T4 T1 T2 T3 T4 T5 Total 
Refer for visual 
evoked responses 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Refer for cognitive 
assessment 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Refer to continence 
service for bladder 
1 15 5 4 2 2 2 1 0 0 0 0 0 0 0 32 
Refer to continence 
service for bowels 
0 2 0 1 1 0 0 0 0 0 0 0 0 0 0 4 
Steroids 3 7 7 6 4 0 2 1 2 0 0 0 0 0 0 32 
Dietician 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 
Other 15 22 23 12 12 10 4 5 3 0 0 1 0 0 2 109 
Medications, 
started, altered or 
stopped 
17 70 52 33 22 19 14 11 1 6 2 1 2 2 3 255 
Total interventions 68 0 0 0 0 0 0 0 0 0 0 0 0 0 0 812 
Intervention 
declined 
3 6 6 5 1 1 0 1 1 1 0 0 0 0 0 25 
Nil 29 59 79 9 20 0 3 1 7 10 0 0 0 1 0 218 
Appendices 
320 
Referral Reasons 
Bladder and Bowels 
Advised to see GP re prostate as bladder issues GP asked to prescribe Vesicare. 
Suggested decaffeinated drinks GP for urinalysis 
Advised to discuss catheter change with GP 
surgery 
Urinalysis as possible urine infection 
Sent off urine sample as possible urine 
infection 
GP- regular urine checks and for regular 
Movicol to be prescribed 
Advised to get urine checked in 10 days for 
UTI 
Referred to GP for long-term antibiotics for 
recurrent UTI's 
MSU at GP 
Dietician 
Advise on weight loss 
GP referrals 
Referred back to GP for recurrent chest 
problems and feeling unwell. Also depressed 
Suggested see GP re L knee pain, ? arthritis. 
GP called to arrange an urgent appointment re 
hip 
Medication 
Discussed oral DMT's Fampyra trial 
Vitamin D3 suggested Discussed using stress ball for stress ball for 
stiff hands 
Discussed plegridy Advised to consider medication for stiff heavy 
legs and poor balance 
Mental health 
Advised to peak to GP re depression and 
mental health issues 
Chase up local mental health team review 
GP asked to increase antidepressants for low 
mood 
Mobility issues 
Functional Electrical Stimulation machine 
chased up 
Letter for DVLA 
Discussion about mobility scooter or 
wheelchair use as mobility deteriorating 
Letter to wheelchair services to chase up chair 
Suggested using a tri-walker 
Other referrals 
Neuropsychometry testing Surgical appliances for a foot up 
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Referred to surgical appliances Surgical appliances for ankle support 
Referred to podiatry for toe orthotic. refer to 
surgical appliances for ankle support 
Other 
Suggested vibro-plate Discussed finding a cleaner 
Pain clinic 
Pain clinic for back pain Referred to Royal London pain clinic 
Chase up pain clinic referral 
Social services 
REMAP contact details given and social 
services number for a ramp 
Wife advised to call social services re stair lift 
Social services chased about wet room Advised to contact social services for raised 
toilet seat 
Support 
Expert patient programme Recommended MS-UK 
Local MS Society for support Details given of local MS society branch 
Hospice referral for day care- cognitively well 
and feels under used and redundant 
TGN support details 
Information given on MS society re exercise 
group as socially isolated 
Work and benefits 
Advice given about returning to work Advice given about MSUK and Job Centre 
Advice given on benefits Advised to apply for PIP 
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Item Non-Response 
Frequency missed Frequency missed 
Question 
number 
Appt. 1 
(T1) 
Appt. 2 
(T2) 
Appt. 3 
(T3) 
Appt. 4 
(T4) 
Appt. 5 
(T5) 
Question 
number 
Appt. 1 
(T1) 
Appt. 2 
(T2) 
Appt. 3 
(T3) 
Appt. 4 
(T4) 
Appt. 5 
(T5) 
1 1 0 0 0 0 16 1 0 0 1 0 
2 1 0 0 0 0 17 3 0 0 0 0 
3 1 1 0 0 0 18 2 2 0 0 0 
4 0 0 0 0 0 19 4 0 0 0 0 
5 2 1 0 0 0 20 3 2 0 0 0 
6 2 0 0 0 0 21 4 1 1 0 0 
7 1 3 0 0 0 22 2 1 0 0 0 
8 3 2 0 0 0 23 8 0 0 0 0 
9 1 1 0 0 0 24 5 2 0 0 0 
10 3 1 0 0 0 25 4 0 0 1 0 
11 0 2 0 2 0 26 3 4 0 0 0 
12 0 0 0 0 0 27 3 0 0 1 0 
13 2 1 0 0 0 28 3 0 1 0 0 
14 1 1 0 0 0 29 4 1 0 0 0 
15 2 3 0 0 0 Total 69 29 2 5 0 
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Phase 2- Ethical Approval 
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 Phase 2- Participant
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Phase 2- Participant
Information Sheet 
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Phase 2- Participant Consent 
Form 
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Phase 2 Participant Interview 
Schedule 
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Phase 2- Health Professional 
Introduction Letter 
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Phase 2-Health Professional 
Information Sheet 
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Phase 2- Health Professional 
Consent Form 
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Phase 2 Healthcare 
Professional Interview Schedule 
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Reasons for Patient-Participant Selection 
Interview 
number 
Reason selected 
Appointment types, 
numbers and sites 
Treatments/ 
Interventions offered 
Impact scores 
Health transition question response 
Interview 1 DMT- oral 
Relapse during 
research period 
Predicted changes in 
HRQoL fairly well 
Ringed between 
response boxes 
Three multi-
professional clinic 
appointments  
Acute Trust 
T1- Nil 
T2- MRI due to 
relapse 
T3- Reassurance 
T1 Physical 20.00 
T2 Physical 21.67 
T1 Psychological 33.00 
T2 Psychological 30.00 
Slightly deteriorated 
T3 Physical 18.33 T3 Psychological 30.00 
No change 
Interview 2 No DMT 
Gradual 
deterioration in MS 
Predicted changes in 
HRQoL fairly well 
Multi-professional 
clinic appointment, 
nurse-led 
appointment, multi-
professional clinic 
appointment 
Acute Trust 
T1-Referral in 
progress for 
physiotherapy and 
wheelchair, 
Reassurance offered, 
T2- Reassurance 
T3- Pain relief 
changed 
T1 Physical 91.67 
T2 Physical 95.00 
T1 Psychological 48.00 
T2 Psychological 56.00 
Slightly deteriorated 
T3 Physical 93.33 T3 Psychological 63.00 
Slightly deteriorated 
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Interview 
number 
Reason selected 
Appointment types, 
numbers and sites 
Treatments/ 
Interventions offered  
Impact scores 
Health transition question response 
Interview 3 DMT- injectable 
HTQ response 
correlates with 
changes in impact 
scores 
Two multi-
professional clinic 
appointments 
Acute Trust 
T1 and T2 –No 
treatments offered at 
either appointment 
T1 Physical 23.33. 
T2 Physical 21.67 
T1 Psychological 7.00 
T2 Psychological 7.00 
No change 
Interview 4 Started oral DMT 
during research 
period as unstable 
MS 
HTQ response 
correlates with 
changes in impact 
scores 
One nurse-led and 
the two multi-
professional clinic 
appointments 
Acute Trust 
T1- Steroids given for 
relapse 
T2- Offered DMT-
Gilenya 
T3 Reassurance 
T1 Physical 100.00 
T2 Forms not given 
as only three weeks 
between 
appointments- 
urgent consultant 
review 
T1 Psychological 96.00 
T2 Forms not given as 
only three weeks between 
appointments- urgent 
consultant review 
T3 Physical 86.67 T3 Psychological 85.00 
Slightly improved 
Interview 5 Started oral DMT 
during research 
period as relapsing 
One nurse-led and 
then two multi-
professional clinic 
appointments 
Acute Trust 
T1- MRI 
T2- Steroids and 
DMT-Gilenya 
T3- Reassurance and 
change in neuropathic 
pain relief regime 
T1 Physical 80.00 
T2 Physical 78.33 
T1 Psychological 96.00 
T2 Psychological 93.00 
Stated had slightly deteriorated 
T3 Physical 23.33 T3 Psychological 22.00 
Significantly improved 
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Interview 
number 
Reason selected 
Appointment types, 
numbers and sites 
Treatments/ 
Interventions offered  
Impact scores 
Health transition question response 
Interview 6 No DMT Two nurse-led clinic 
appointments 
Outlying Hospital 
and Acute Trust 
T1- Reassurance and 
steroids 
T2- Neuropathic pain 
relief commenced for 
spasms and restless 
legs. Baclofen stopped 
as not tolerated 
T1 Physical 30.00 
T2 Physical 26.67 
T1 Psychological 44.00 
T2 Psychological 33.00 
Stated had significantly improved. ‘Leaving job 
that caused me a great deal of stress has resulted 
in improvement in quality of life. New job 
challenging but not stressful- helping build my 
confidence and self-esteem. Steroids resulted in 
overall improvement of symptoms (MS) 
Interview 7 Changed from 
injectable DMT to 
infusion as MS 
unstable 
Nurse-led 
appointment, then 
two multi-
professional clinic 
appointments 
Acute Trust 
T1- MRI and 
continence referral. 
Tysabri commenced, 
copaxone stopped 
T2- Reassurance, MRI 
(DMT-Tysabri 
monitoring), reduction 
of neuropathic pain 
relief 
T3- MRI (Tysabri 
monitoring) 
T1 Physical 31.67 
T2 Physical 23.33 
T1 Psychological 63.00 
T2 Psychological 30.00 
No change 
T3 Physical 21.67 T3 Psychological 30.00 
No change 
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Interview 
number 
Reason selected 
Appointment types, 
numbers and sites 
Treatments/ 
Interventions offered  
Impact scores 
Health transition question response 
Interview 8 Infusion DMT 
Diagnosed in 2014 
Selected as newly 
diagnosed and 
earlier interviewee 
thought 
questionnaire would 
be ‘too scary’ for 
newly diagnosed 
patients. 
HTQ response 
correlates with 
changes in impact 
scores 
Two multi-
professional clinic 
appointments 
Acute Trust 
T1- Neuropathic pain 
relief 
T2- Reassurance, 
steroids 
T1 Physical 55.00 
T2 Physical 48.33 
T1 Psychological 48.00 
T2 Psychological 33.00 
Stated had slightly improved 
Interview 9 Oral DMT 
HTQ response 
correlates with 
changes in impact 
scores 
Two multi-
professional clinic 
appointments, then 
nurse-led clinic 
appointment, multi-
professional clinic 
appointment 
Acute Trust 
T1-reassurance, 
counselling, MRI, 
continence referral 
T2- neuropathic pain 
relief dose increased 
T3- Reassurance 
T4- Reassurance 
T1 Physical 83.33 
T2 Physical 78.33 
T1 Psychological 89.00 
T2 Psychological 96.00 
Slightly deteriorated 
T3 Physical 81.67 T3 Psychological 89.00 
Significantly deteriorated 
T4 Physical 93.33 T4 Psychological 93.00 
Significantly deteriorated 
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Interview 
number 
Reason selected 
Appointment types, 
numbers and sites 
Treatments/ 
Interventions offered  
Impact scores 
Health transition question response 
Interview 
10 
Injectable DMT 
Accurately detected 
change in both 
impact scores at 
each appointment 
Multi-professional 
clinic appointment, 
nurse-led 
appointment, multi-
professional clinic 
appointment 
Acute Trust 
T1- Steroids given, 
FES machine chased, 
reassurance 
T2-Reassurance 
T3-Reassurance 
T1 Physical 58.33 
T2 Physical 55.00 
T1 Psychological 48.00 
T2 Psychological 33.00 
Slightly improved 
T3 Physical 46.67 T3 Psychological 22.00 
Slightly improved 
Interview 
11 
Injectable DMT 
Stated No change 
yet scores were 
worse 
Multi-professional 
clinic appointment, 
then nurse-led 
appointment 
Acute Trust 
T1- Reassurance and 
physiotherapy 
T2- Considered 
changing DMT due to 
increasing efficacy 
T1 Physical 46.67 
T2 Physical 66.67 
T1 Psychological 33.00 
T2 Psychological 48.00 
No change 
Interview 
12 
No DMT 
HTQ response 
correlates with 
changes in impact 
scores  
Pain was better with 
neuropathic pain but 
not reflected in 
scores. 
Three nurse-led 
appointments 
Outlying Hospital 
T1- Reassurance and 
neuropathic pain relief 
T2- Reassurance and 
falls prevention  
T3- Reassurance 
T1 Physical 55.00 
T2 Physical 61.67 
T1 Psychological 15.00 
T2 Psychological 19.00 
Slightly deteriorated 
T3 Physical 53.33 T3 Psychological 22.00 
Slightly deteriorated 
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Interview 
number 
Reason selected 
Appointment types, 
numbers and sites 
Treatments/ 
Interventions offered  
Impact scores 
Health transition question response 
Interview 
13 
No DMT 
HTQ response 
correlates with 
changes in impact 
scores- deterioration 
Nurse-led 
appointment, then 
two multi-
professional clinic 
appointments 
Acute Trust 
T1- Steroids, in 
relapse 
T2- Reassurance 
T3- Medication to 
help sleep 
T1 Physical 46.67 
T2 Physical 51.67 
T1 Psychological 59.00 
T2 Psychological 15.00 
Slightly deteriorated 
T3 Physical 65.00 T3 Psychological 74.00 
Significantly deteriorated 
Interview 
14 
Injectable DMT 
Scores improved but 
not reflected in 
participant 
comments 
Two multi-
professional clinic 
appointments 
Acute Trust 
T1- Reassurance, 
physiotherapy offered 
T2- nil 
T1 Physical 86.67 
T2 Physical 63.33 
T1 Psychological 89.00 
T2 Psychological 41.00 
Stated no change 
Interview 
15 
Switched for 
injectable to oral 
DMT 
HTQ response 
correlates with 
changes in impact 
scores 
Missed at least one 
question on each 
questionnaire 
Nurse-led 
appointment, then 
three multi-
professional clinic 
appointments 
Acute Trust 
T1- One neuropathic 
pain relief medication 
increased, and another 
stopped 
T2- MRI, anti-
spasmodic medication 
commenced 
T3- Switched DMT 
(injectable to oral) 
T1 Physical 58.33 
T2 Physical 66.67 
T1 Psychological 67.00 
T2 Psychological 67.00 
Slightly deteriorated 
T3 Physical 30.00 T3 Psychological 37.00 
Significantly improved (new medication had 
stopped spasms) 
T4 Physical 68.33 T4 Psychological 44.00 
Slightly deteriorated 
 
